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Abstract: BACKGROUND: The projected rise in the incidence of type 2 diabetes mellitus (T2DM) could
develop into a substantial health problem worldwide. Whether metformin can prevent or delay T2DM
and its complications in people with increased risk of developing T2DM is unknown. OBJECTIVES: To
assess the effects of metformin for the prevention or delay of T2DM and its associated complications in
persons at increased risk for the T2DM. SEARCH METHODS: We searched the Cochrane Central Reg-
ister of Controlled Trials, MEDLINE, Scopus, ClinicalTrials.gov, the World Health Organization (WHO)
International Clinical Trials Registry Platform and the reference lists of systematic reviews, articles and
health technology assessment reports. We asked investigators of the included trials for information about
additional trials. The date of the last search of all databases was March 2019. SELECTION CRITERIA:
We included randomised controlled trials (RCTs) with a duration of one year or more comparing met-
formin with any pharmacological glucose-lowering intervention, behaviour-changing intervention, placebo
or standard care in people with impaired glucose tolerance, impaired fasting glucose, moderately elevated
glycosylated haemoglobin A1c (HbA1c) or combinations of these. DATA COLLECTION AND ANAL-
YSIS: Two review authors read all abstracts and full-text articles and records, assessed risk of bias and
extracted outcome data independently. We used a random-effects model to perform meta-analysis and cal-
culated risk ratios (RRs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes,
using 95% confidence intervals (CIs) for effect estimates. We assessed the certainty of the evidence using
GRADE. MAIN RESULTS: We included 20 RCTs randomising 6774 participants. One trial contributed
48% of all participants. The duration of intervention in the trials varied from one to five years. We judged
none of the trials to be at low risk of bias in all ’Risk of bias’ domains. Our main outcome measures
were all-cause mortality, incidence of T2DM, serious adverse events (SAEs), cardiovascular mortality,
non-fatal myocardial infarction or stroke, health-related quality of life and socioeconomic effects.The fol-
lowing comparisons mostly reported only a fraction of our main outcome set. Fifteen RCTs compared
metformin with diet and exercise with or without placebo: all-cause mortality was 7/1353 versus 7/1480
(RR 1.11, 95% CI 0.41 to 3.01; P = 0.83; 2833 participants, 5 trials; very low-quality evidence); incidence
of T2DM was 324/1751 versus 529/1881 participants (RR 0.50, 95% CI 0.38 to 0.65; P < 0.001; 3632
participants, 12 trials; moderate-quality evidence); the reporting of SAEs was insufficient and diverse and
meta-analysis could not be performed (reported numbers were 4/118 versus 2/191; 309 participants; 4
trials; very low-quality evidence); cardiovascular mortality was 1/1073 versus 4/1082 (2416 participants;
2 trials; very low-quality evidence). One trial reported no clear difference in health-related quality of life
after 3.2 years of follow-up (very low-quality evidence). Two trials estimated the direct medical costs
(DMC) per participant for metformin varying from 220to1177 versus 61to184 in the comparator group
(2416 participants; 2 trials; low-quality evidence). Eight RCTs compared metformin with intensive diet
and exercise: all-cause mortality was 7/1278 versus 4/1272 (RR 1.61, 95% CI 0.50 to 5.23; P = 0.43;
2550 participants, 4 trials; very low-quality evidence); incidence of T2DM was 304/1455 versus 251/1505
(RR 0.80, 95% CI 0.47 to 1.37; P = 0.42; 2960 participants, 7 trials; moderate-quality evidence); the
reporting of SAEs was sparse and meta-analysis could not be performed (one trial reported 1/44 in the
metformin group versus 0/36 in the intensive exercise and diet group with SAEs). One trial reported
that 1/1073 participants in the metformin group compared with 2/1079 participants in the comparator
group died from cardiovascular causes. One trial reported that no participant died due to cardiovascular
causes (very low-quality evidence). Two trials estimated the DMC per participant for metformin varying
from 220to1177 versus 225to3628 in the comparator group (2400 participants; 2 trials; very low-quality
evidence). Three RCTs compared metformin with acarbose: all-cause mortality was 1/44 versus 0/45 (89
participants; 1 trial; very low-quality evidence); incidence of T2DM was 12/147 versus 7/148 (RR 1.72,
95% CI 0.72 to 4.14; P = 0.22; 295 participants; 3 trials; low-quality evidence); SAEs were 1/51 versus
2/50 (101 participants; 1 trial; very low-quality evidence). Three RCTs compared metformin with thia-
zolidinediones: incidence of T2DM was 9/161 versus 9/159 (RR 0.99, 95% CI 0.41 to 2.40; P = 0.98; 320
participants; 3 trials; low-quality evidence). SAEs were 3/45 versus 0/41 (86 participants; 1 trial; very
low-quality evidence). Three RCTs compared metformin plus intensive diet and exercise with identical
intensive diet and exercise: all-cause mortality was 1/121 versus 1/120 participants (450 participants; 2
trials; very low-quality evidence); incidence of T2DM was 48/166 versus 53/166 (RR 0.55, 95% CI 0.10
to 2.92; P = 0.49; 332 participants; 2 trials; very low-quality evidence). One trial estimated the DMC of
metformin plus intensive diet and exercise to be 270perparticipantcomparedwith225 in the comparator
group (94 participants; 1 trial; very-low quality evidence). One trial in 45 participants compared met-
formin with a sulphonylurea. The trial reported no patient-important outcomes. For all comparisons
there were no data on non-fatal myocardial infarction, non-fatal stroke or microvascular complications.
We identified 11 ongoing trials which potentially could provide data of interest for this review. These
trials will add a total of 17,853 participants in future updates of this review. AUTHORS’ CONCLU-
SIONS: Metformin compared with placebo or diet and exercise reduced or delayed the risk of T2DM in
people at increased risk for the development of T2DM (moderate-quality evidence). However, metformin
compared to intensive diet and exercise did not reduce or delay the risk of T2DM (moderate-quality
evidence). Likewise, the combination of metformin and intensive diet and exercise compared to intensive
diet and exercise only neither showed an advantage or disadvantage regarding the development of T2DM
(very low-quality evidence). Data on patient-important outcomes such as mortality, macrovascular and
microvascular diabetic complications and health-related quality of life were sparse or missing.
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A B S T R A C T
Background
The projected rise in the incidence of type 2 diabetes mellitus (T2DM) could develop into a substantial health problem worldwide. Whether
metformin can prevent or delay T2DM and its complications in people with increased risk of developing T2DM is unknown.
Objectives
To assess the effects of metformin for the prevention or delay of T2DM and its associated complications in persons at increased risk for
the T2DM.
Search methods
We searched the Cochrane Central Register of Controlled Trials, MEDLINE, Scopus, ClinicalTrials.gov, the World Health Organization (WHO)
International Clinical Trials Registry Platform and the reference lists of systematic reviews, articles and health technology assessment
reports. We asked investigators of the included trials for information about additional trials. The date of the last search of all databases
was March 2019.
Selection criteria
We included randomised controlled trials (RCTs) with a duration of one year or more comparing metformin with any pharmacological
glucose-lowering intervention, behaviour-changing intervention, placebo or standard care in people with impaired glucose tolerance,
impaired fasting glucose, moderately elevated glycosylated haemoglobin A1c (HbA1c) or combinations of these.
Data collection and analysis
Two review authors read all abstracts and full-text articles and records, assessed risk of bias and extracted outcome data independently.
We used a random-effects model to perform meta-analysis and calculated risk ratios (RRs) for dichotomous outcomes and mean differ-
ences (MDs) for continuous outcomes, using 95% confidence intervals (CIs) for effect estimates. We assessed the certainty of the evidence
using GRADE.
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Main results
We included 20 RCTs randomising 6774 participants. One trial contributed 48% of all participants. The duration of intervention in the trials
varied from one to five years. We judged none of the trials to be at low risk of bias in all 'Risk of bias' domains.
Our main outcome measures were all-cause mortality, incidence of T2DM, serious adverse events (SAEs), cardiovascular mortality, non-
fatal myocardial infarction or stroke, health-related quality of life and socioeconomic effects.The following comparisons mostly reported
only a fraction of our main outcome set.
Fifteen RCTs compared metformin with diet and exercise with or without placebo: all-cause mortality was 7/1353 versus 7/1480 (RR 1.11,
95% CI 0.41 to 3.01; P = 0.83; 2833 participants, 5 trials; very low-quality evidence); incidence of T2DM was 324/1751 versus 529/1881
participants (RR 0.50, 95% CI 0.38 to 0.65; P < 0.001; 3632 participants, 12 trials; moderate-quality evidence); the reporting of SAEs was
insufficient and diverse and meta-analysis could not be performed (reported numbers were 4/118 versus 2/191; 309 participants; 4 trials;
very low-quality evidence); cardiovascular mortality was 1/1073 versus 4/1082 (2416 participants; 2 trials; very low-quality evidence). One
trial reported no clear difference in health-related quality of life after 3.2 years of follow-up (very low-quality evidence). Two trials estimated
the direct medical costs (DMC) per participant for metformin varying from $220 to $1177 versus $61 to $184 in the comparator group (2416
participants; 2 trials; low-quality evidence).
Eight RCTs compared metformin with intensive diet and exercise: all-cause mortality was 7/1278 versus 4/1272 (RR 1.61, 95% CI 0.50 to
5.23; P = 0.43; 2550 participants, 4 trials; very low-quality evidence); incidence of T2DM was 304/1455 versus 251/1505 (RR 0.80, 95% CI
0.47 to 1.37; P = 0.42; 2960 participants, 7 trials; moderate-quality evidence); the reporting of SAEs was sparse and meta-analysis could
not be performed (one trial reported 1/44 in the metformin group versus 0/36 in the intensive exercise and diet group with SAEs). One trial
reported that 1/1073 participants in the metformin group compared with 2/1079 participants in the comparator group died from cardio-
vascular causes. One trial reported that no participant died due to cardiovascular causes (very low-quality evidence). Two trials estimated
the DMC per participant for metformin varying from $220 to $1177 versus $225 to $3628 in the comparator group (2400 participants; 2
trials; very low-quality evidence).
Three RCTs compared metformin with acarbose: all-cause mortality was 1/44 versus 0/45 (89 participants; 1 trial; very low-quality evi-
dence); incidence of T2DM was 12/147 versus 7/148 (RR 1.72, 95% CI 0.72 to 4.14; P = 0.22; 295 participants; 3 trials; low-quality evidence);
SAEs were 1/51 versus 2/50 (101 participants; 1 trial; very low-quality evidence).
Three RCTs compared metformin with thiazolidinediones: incidence of T2DM was 9/161 versus 9/159 (RR 0.99, 95% CI 0.41 to 2.40; P = 0.98;
320 participants; 3 trials; low-quality evidence). SAEs were 3/45 versus 0/41 (86 participants; 1 trial; very low-quality evidence).
Three RCTs compared metformin plus intensive diet and exercise with identical intensive diet and exercise: all-cause mortality was 1/121
versus 1/120 participants (450 participants; 2 trials; very low-quality evidence); incidence of T2DM was 48/166 versus 53/166 (RR 0.55, 95%
CI 0.10 to 2.92; P = 0.49; 332 participants; 2 trials; very low-quality evidence). One trial estimated the DMC of metformin plus intensive diet
and exercise to be $270 per participant compared with $225 in the comparator group (94 participants; 1 trial; very-low quality evidence).
One trial in 45 participants compared metformin with a sulphonylurea. The trial reported no patient-important outcomes.
For all comparisons there were no data on non-fatal myocardial infarction, non-fatal stroke or microvascular complications.
We identified 11 ongoing trials which potentially could provide data of interest for this review. These trials will add a total of 17,853 par-
ticipants in future updates of this review.
Authors' conclusions
Metformin compared with placebo or diet and exercise reduced or delayed the risk of T2DM in people at increased risk for the development
of T2DM (moderate-quality evidence). However, metformin compared to intensive diet and exercise did not reduce or delay the risk of
T2DM (moderate-quality evidence). Likewise, the combination of metformin and intensive diet and exercise compared to intensive diet
and exercise only neither showed an advantage or disadvantage regarding the development of T2DM (very low-quality evidence). Data
on patient-important outcomes such as mortality, macrovascular and microvascular diabetic complications and health-related quality of
life were sparse or missing.
P L A I N   L A N G U A G E   S U M M A R Y
Metformin for prevention/delay of type 2 diabetes mellitus (T2DM) and associated complications in persons at increased risk for
development of T2DM
Review question
Is the antidiabetic drug metformin able to prevent or delay the development of type 2 diabetes and its associated complications in people
with moderately elevated blood sugar levels?
Background
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People with moderately elevated blood sugar levels (often referred to as 'prediabetes') are said to have an increased risk for developing
diabetes. Metformin is a blood sugar-lowering medicine which has been used for a long time to treat people with type 2 diabetes. Type
2 diabetes, also known as adult-onset diabetes, is the most common type of diabetes and prevents the body from using insulin properly
(insulin resistance). Type 2 diabetes can have bad effects on health in the long term (diabetic complications), such as severe eye or kidney
disease or 'diabetic feet', eventually resulting in foot ulcers.
We investigated whether metformin can also be used to prevent or delay type 2 diabetes in people at increased risk. We examined the
effects of metformin on patient-important outcomes, such as complications of diabetes, death from any cause, health-related quality of
life and side effects of the drug.
Study characteristics
To be included, people had to have blood sugar levels higher than normal, but below the levels that are used to diagnose diabetes. We
found 20 randomised controlled trials (clinical studies where people are randomly put into one of two or more treatment groups) with a
total of 6774 participants. The comparator group consisted of diet and exercise, intensive diet and exercise or another blood sugar-low-
ering drug. One study dominated the evidence (48% of the total number of all participants). Twelve studies were performed in China. We
only included studies with a treatment duration of one year or more. The treatment duration in the included studies varied from one to
five years.
This evidence is up to date as of March 2019.
Key results
Fifteen studies compared metformin against diet and exercise. Eight studies compared metformin against intensive diet and exercise and
three studies compared metformin plus intensive diet and exercise against intensive diet and exercise only. When compared to standard
diet and exercise metformin slightly reduces or delays development of diabetes. However, when compared to intensive diet and exercise,
metformin does not provide an additional benefit in reducing or delaying development of diabetes.
Seven studies compared metformin with another glucose-lowering drug: three studies compared metformin with acarbose. Three studies
compared metformin with a thiazolidinedione (such as pioglitazone). There was neither an advantage or disadvantage when comparing
metformin with these drugs with respect to the development of diabetes. One study compared metformin with a sulphonylurea (glimepiri-
de). The trial did not report patient-important outcomes.
In general, the reporting of serious side effects was sparse. Few participants died and we did not detect a clear difference between the
intervention and comparator groups. We also did not detect an advantage or disadvantage of metformin in relation to health-related
quality of life. Our included studies did not report on non-fatal heart attacks, strokes or complications of diabetes such as kidney or eye
disease. Few studies estimated the direct medical costs. When compared to diet and exercise, metformin was more expensive. When
compared to intensive diet and exercise, metformin was less expensive.
We identified 11 ongoing studies which potentially could provide data for this review. These studies will add a total of 17,853 participants
in future updates of our review.
Future studies should investigate more patient-important outcomes such as complications of diabetes and especially the side effects of
the drugs. We do not know whether 'prediabetes' is just a condition defined by laboratory measurements, or whether it is in fact a real risk
factor for diabetes. It is also unknown whether treatment of this condition translates into better patient-important outcomes.
Certainty of the evidence
All included studies had problems in the way they were conduced or reported.
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.   Summary of findings table for metformin compared with diet and exercise or another antidiabetic
drug
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk
Population: people at increased risk for developing type 2 diabetes
Settings: outpatients
Intervention: metformin
Comparison: diet and exercise or a non-metformin blood glucose-lowering drug

















Placebo or diet and exercise
Follow-up: 1 to 5 years







Intensive diet plus exercise
Follow-up: 1 to 5 years







Sulphonylurea Not reported  
Acarbose
Follow-up: 5 years
See comment 89 (1) ⊕⊝⊝⊝
very lowb
1/44 participants in the metformin
group compared with 0/45 in the acar-
bose group died (Fang 2004)
Thiazolidinediones Not reported  
Incidence of type 2 diabetes mellitus (N)
Placebo or diet and exercise
Diagnostic criteria:



















































































































































• 3 trials applied the WHO 1985 criteria
(FPG <7.8 mmol/L and 2-hour glucose
≥7.8 mmol/L and <11.1 mmol/L after
a 75 g OGTT) (Fang 2004; Li 1999; Lu
2002).
• 5 trials applied the WHO 1999 criteria
(FPG ≥7.0 mmol/L and/or a 2-hour glu-
cose ≥11.1 mmol/L after a 75 g OGTT)
(Chen 2009; IDPP-1 2006; Ji 2011; Jin
2009; Zeng 2013).
• 2 trials applied the ADA 1997 criteria
(FPG ≥7.0 mmol/L or 2-hour glucose
≥11.1 mmol/L after a 75 g OGTT (i.e.
identical to WHO 1999 criteria) (DPP/
DPPOS 2002; Wang 2009).
• 1 trial applied the ADA 2009 crite-
ria (FPG 5.6 mmol/L to 6.9 mmol/L
or 2-hour glucose 7.8 mmol/L to 11.1
mmol/L) (Lu 2010).
• 1 trial applied the IFG criteria of ADA
2009 (FPG 5.6 mmol/L to 6.9 mmol/
L) or a HbA1c of 5.7% to 6.4% (PRE-
VENT-DM 2017)
Follow-up: 1 to 5 years
Intensive diet plus exercise
Diagnostic criteria:
• 1 trial applied the WHO 1985 crite-
ria (FPG < 7.8 mmol/L and 2-hour glu-
cose ≥ 7.8 mmol/L and < 11.1 mmol/L)
(Fang 2004)
• 3 trials applied the WHO 1999 crite-
ria (FPG ≥ 7.0 mmol/L and/or a 2-hour
glucose ≥ 11.1 mmol/L after a 75 g
OGTT) (IDPP-1 2006; Ji 2011; Li 2009).
• 1 trial applied the ADA 1997 criteria
(FPG ≥ 7.0 mmol/L or 2-hour glucose
≥ 11.1 mmol/L after a 75 g OGTT (i.e.
identical to WHO 1999 criteria) (DPP/
DPPOS 2002).
• 1 trial applied the IFG criteria of ADA
2009 (FPG 5.6 mmol/L to 6.9 mmol/



















































































































































L) or a HbA1c 5.7% to 6.4% (PRE-
VENT-DM 2017)
• No medical association recommend-
ed the cut-off points applied in Maji
2005 to diagnose intermediate hyper-
glycaemia.
Follow-up: 1 to 5 years
Sulphonylurea Not reported  
Acarbose
Diagnostic criteria:
• 1 trial applied the WHO 1985 crite-
ria (FPG < 7.8 mmol/L and 2-hour glu-
cose ≥ 7.8 mmol/L and < 11.1 mmol/L)
(Fang 2004).
• 1 trial applied the WHO 1999 criteria
(FPG ≥ 7.0 mmol/L and/or a 2-hpur
glucose ≥ 11.1 mmol/L after a 75 g
OGTT) (Liao 2012).
• No medical association recommend-
ed the cut-off points applied in Maji
2005 to diagnose intermediate hyper-
glycaemia.
Follow-up: 1 to 5 years









• 2 trials applied the WHO 1999 crite-
ria (FPG ≥ 7.0 mmol/L and/or a 2-hour
glucose ≥ 11.1 mmol/L after a 75 g
OGTT) (Jin 2009; Zeng 2013).
• No medical association recommend-
ed the cut-off points applied in Maji
2005 to diagnose intermediate hyper-
glycaemia.
Follow-up: 2 to 3 years






1 trial reported that no participant de-
veloped T2DM (Maji 2005)













































































































































Placebo or diet and exercise
Follow-up: 1 to 5 years
See comment 309 (4) ⊕⊝⊝⊝
very lowe
The reporting of SAE was insufficient
1 trial reported no SAE in 29 participants
in the metformin group and 30 partici-
pants in the standard care group (PRE-
VENT-DM 2017)
In 1 trial 3/45 participants in the met-
formin group experienced severe gas-
trointestinal reactions (Jin 2009)
In 1 trial 1/44 participants died due to
liver cancer in the metformin group
compared to 0/35 participants in the
standard care group (Fang 2004)
In 1 trial 1/75 participants in the stan-
dard care group died due to cerebral
thrombosis with pulmonary infection
and 1/51 participants in the standard
care plus fibre diet group experienced
stomach cancer (Lu 2002)
Intensive diet plus exercises
Follow-up: 1 to 5 years
See comment 139 (2) ⊕⊝⊝⊝
very lowe
The reporting of SAE was sparse
1 trial reported no SAE in 29 participants
in the metformin group and 30 partici-
pants in the standard care group (PRE-
VENT-DM 2017)
In 1 trial 1/44 participants died due to
liver cancer in the metformin group
compared to 0/36 participants in the in-





See comment 101 (1) ⊕⊝⊝⊝
very lowe
In 1 trial 1/51 participants in the met-
formin group experienced cerebral
haemorrhage, whereas 2/50 participants
in the acarbose group experienced lung
cancer and hepatitis, respectively (Liao
2012)
Thiazolidinediones See comments 86 (1) ⊕⊝⊝⊝
very lowe
In 1 trial 3/45 participants in the met-













































































































































Follow-up: 3 years trointestinal reactions (Jin 2009). No
severe reactions were reported in the
41 participants in the thiazolinedione
group
Cardiovascular mortality
Placebo or diet and exercise
Follow-up: 2.8 to 3 years
See comment 2416 (2) ⊕⊝⊝⊝
very lowf
1 trial reported that no participant died
due to cardiovascular causes (IDPP-1
2006)
1 trial reported that 1/1073 participants
in the metformin group compared with
4/1082 participants in the control group
died (DPP/DPPOS 2002)
Intensive diet plus exercise
Follow-up: 2.8 to 3 years
See comment 2400 (2) ⊕⊝⊝⊝
very lowf
1 trial reported that no participants died
due to cardiovascular causes (IDPP-1
2006)
1 trial reported that 1/1073 participants
in the metformin group compared with
2/1079 participants in the intensive diet
plus exercise group died from cardiovas-
cular causes (DPP/DPPOS 2002)
Sulphonylurea Not reported  
Acarbose Not reported  
Thiazolidinediones Not reported  
Non-fatal myocardial infarction/stroke
Placebo or diet and exercise
Follow-up: 2.8 to 3 years
See comments 2416 (2) ⊕⊝⊝⊝
very lowf
No trial reported data exclusively on
non-fatal myocardial infarction or stroke
Non-fatal cardiovascular events oc-
curred in 1.7% of the participants in the
control group compared with 1.5% of
the participants in the metformin group
(DPP/DPPOS 2002)
In the IDPP 2/133 participants in the diet













































































































































pants in the metformin group had a car-
diovascular event (IDPP-1 2006)
Intensive diet plus exercise
Follow-up: 2.8 to 3 years
See comments 2400 (2) ⊕⊝⊝⊝
very lowf
No trial reported data exclusively on
non-fatal myocardial infarction or stroke
1 trial reported that non-fatal cardiovas-
cular events occurred in 1.7% of the par-
ticipants in the control group compared
with 1.5% of the participants in the met-
formin group (DPP/DPPOS 2002)
1 trial reported that 0/128 participants
in the metformin group compared to
4/120 participants in the compara-
tor group experienced cardiovascular
events (IDPP-1 2006)
Sulphonylurea Not reported  
Acarbose Not reported  
Thiazolidinediones Not reported  
Health-related quality of life
Placebo or diet and exercise
Description: SF-36 to evaluate the health
utility index SF-6D (physical compo-
nent summaries and mental component
summaries)
Minimal important difference: difference
in scores between groups of at least 3%
Follow-up: 3.2 years
See comment 2144 (1) ⊕⊝⊝⊝
very lowg
After a mean of 3.2 years of follow-up
there was no clear difference in any of
the health-related quality of life scores
between the metformin group com-
pared with the placebo group (DPP/DP-
POS 2002)
Intensive diet plus exercise Not reported  
Sulphonylurea Not reported  
Acarbose Not reported  















































































































































Placebo or diet and exercise
Description: direct medical costs















- 2416 (2) ⊕⊕⊝⊝
lowh
DPP: $1177 for the metformin interven-
tion versus $184 for the placebo group
(DPP/DPPOS 2002)
IDPP: $220 for metformin group ver-
sus $61 in the diet and exercise group
(IDPP-1 2006)
Intensive diet plus exercise
Description: direct medical costs per
participant















- 2400 (2) ⊕⊕⊝⊝
lowh
DPP: $1177 for the metformin interven-
tion versus $3628 for the intensive diet
plus exercise group (DPP/DPPOS 2002)
IDPP: $220 for the metformin group
compared with $225 in the intensive diet
plus exercise group (IDPP-1 2006)
Sulphonylurea Not reported  
Acarbose Not reported  
Thiazolidinediones Not reported  
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
ADA: American Diabetes Association; CI: confidence interval; DPP: Diabetes Prevention Program; FPG: fasting plasma glucose; IDDP: Indian Diabetes Prevention Program;
OGTT: oral glucose tolerance test; RR: risk ratio; SAE: serious adverse event; SF-36: Short Form 36 items questionnaire; T2DM: type 2 diabetes mellitus.
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
*Assumed risk was derived from the event rates in the comparator groups
aDowngraded by three levels because of risk of bias including possible publication and other bias (early termination of studies due to benefit providing the majority of data),
inconsistency and imprecision - see Appendix 15; Appendix 16
bDowngraded by three levels because of risk of bias and serious risk of imprecision - see Appendix 17
cDowngraded by one level because of other bias (early termination of studies due to benefit providing the majority of data) - see Appendix 15
d Downgraded by two levels because of risk of bias and imprecision - see Appendix 17; Appendix 18
eDowngraded by three levels because of risk of bias including very high risk of publication and other bias and imprecision - see Appendix 15; Appendix 16
fDowngraded by three levels because of risk of bias including risk of publication and other bias - see Appendix 15; Appendix 16














































































































































hDowngraded by two levels because of risk of bias (trial stopped early for benefit providing the majority of data) and imprecision - see Appendix 15; Appendix 16
 
 
Summary of findings 2.   Summary of findings table for metformin plus intensive diet and exercise compared with intensive diet and exercise
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk
Population: people at increased risk for developing type 2 diabetes
Settings: outpatients
Intervention: metformin plus intensive diet and exercise


















Follow-up: 1.5 to 3 years
See comment 450 (2) ⊕⊝⊝⊝
very lowa
1 trial reported that 1/121
participants died in the
metformin plus intensive
diet plus exercise group
compared to 1/120 par-
ticipants in the intensive
diet plus exercise group
(IDPP-1 2006)
1 trial reported that 0/95
participants died in the
metformin intensive diet
plus exercise group com-
pared with 0/114 partici-
pants in the intensive diet
plus exercise group (Iqbal
Hydrie 2012).
Incidence of type 2 diabetes mellitus (N)
Diagnostic criteria:
• 2 trials applied the WHO 1999 criteria (FPG ≥7.0
mmol/L and/or a 2-hour glucose ≥11.1 mmol/L af-
ter a 75 g OGTT) (IDPP-1 2006; Zhao 2013)
Follow-up: 1 to 3 years




















































































































































Serious adverse events Not reported  
Cardiovascular mortality See comment 1 trial reported that no
participant (47 partici-
pants in each intervention
group) died due to cardio-
vascular causes (IDPP-1
2006).
Non-fatal myocardial infarction/stroke Not reported  
Health-related quality of life Not reported  
Socioeconomic effects
















- 94 (1) ⊕⊝⊝⊝
very lowc
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
*Assumed risk was derived from the event rates in the comparator groups
aDowngraded by three levels because of risk of bias and serious risk of imprecision - see Appendix 19
bDowngraded by three levels because of risk of bias, inconsistency and imprecision - see Appendix 19
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B A C K G R O U N D
Description of the condition
'Prediabetes', 'borderline diabetes', the 'prediabetic stage', 'high
risk of diabetes' or 'intermediate hyperglycaemia' (WHO/IDF 2006)
are often characterised by various measurements of elevated
blood glucose concentrations (such as isolated impaired fasting
glucose (IFG), isolated impaired glucose tolerance (IGT), isolated
elevated glycosylated haemoglobin A1c (HbA1c) or combinations
thereof). These elevated blood glucose levels indicating hypergly-
caemia are considered too high to be normal but below the diag-
nostic threshold for type 2 diabetes mellitus (T2DM). Therefore, be-
cause of the continuous spectrum from the normal to the diabet-
ic stage a sound evidence base is needed to define thresholds for
conditions of 'sub-diabetes'. It is obvious that the different terms
used to describe various stages of hyperglycaemia might induce
different emotional reactions, e.g. the term 'prediabetes' may im-
ply (at least for lay persons) that the disease diabetes is unavoid-
able whereas (high) risk of diabetes has the positive connotation
to maybe avoid the disease altogether. All of the above mentioned
terms will be used throughout this systematic review, however a fo-
cus will be set on 'prediabetes' because this labelling is associated
by many persons with dire consequences - despite the disputable
construct of intermediate health states termed prediseases (Viera
2011). On the other side, any diagnosis of 'prediabetes' might be
an opportunity to review for example eating habits and physical ac-
tivity levels, thus enabling 'affected' individuals to actively change
their way of life.
The most commonly used criteria to define people with a high risk
of developing T2DM were established by the American Diabetes As-
sociation (ADA) and the World Health Organization (WHO). The first
glycaemic measurement used to define the prediabetic stage by the
US National Diabetes Data Group was IGT (NDDG 1979). IGT is based
on the measurement of plasma glucose two hours after ingestion of
75 g glucose. The prediabetic range is defined as a plasma glucose
level between 7.8 mmol/L to 11.1 mmol/L (140 mg/dL to 200 mg/dL)
two hours after the glucose load. Studies have indicated that IGT
is caused by insulin resistance and defective insulin secretion (Ab-
dul-Ghani 2006). In 1997, the ADA and later on the WHO introduced
the IFG concept to define 'prediabetes' (ADA 1997; WHO 1999). The
initial definition of IFG was 6.1 mmol/L to 6.9 mmol/L (110 125 mg/
dLto 125 mg/dL). Later on, the ADA reduced the lower threshold for
defining IFG to 5.6 mmol/L (100 mg/dL) (ADA 2003). However, this
lower cut-off point for IFG to define 'prediabetes' was not endorsed
by the WHO (WHO/IDF 2006). IFG seems to be associated with ß-
cell dysfunction (impaired insulin secretion) and an increase of the
hepatic glucose output (DeFronzo 1989). More recently, HbA1c has
been introduced for identifying people with a high risk of develop-
ing T2DM. In 2009, the International Expert Committee (IEC) sug-
gested the HbA1c to identify people with a high risk of T2DM. People
with HbA1c measurements between 6.0% to 6.4% fulfilled this cri-
terion (IEC 2009). Shortly after, the ADA re-defined this HbA1c lev-
el as 5.7% to 6.4% to identify people with a high risk of developing
T2DM (ADA 2010). Unlike IFG and IGT, HbA1c reflects longer-term
glycaemic control, i.e. how the blood glucose levels have been dur-
ing the previous two to three months (Inzucchi 2012).
In 2010, the International Diabetes Federation (IDF) estimated the
prevalence of IGT to be 343 million, and this number is predicted to
increase to 471 million by 2035 (IDF 2013). Studies have shown poor
correlations between HbA1c and IFG/IGT (Gosmanov 2014; Selvin
2011). Besides, the various glycaemic tests do not seem to identi-
fy the same people (Gosmanov 2014; Selvin 2011). The risk of pro-
gression from 'prediabetes' to T2DM depends on the diagnostic cri-
teria used to identify 'prediabetes'. Some people diagnosed with
'prediabetes' will never develop T2DM, and some will return to nor-
moglycaemia. IGT is often accepted as the best glycaemic variable
for 'prediabetes' to predict progression to T2DM. However, studies
indicate that less than half of the people defined as prediabetic by
means of IGT will develop T2DM in the following 10 years. IFG and
HbA1c are both thought to predict a different risk spectrum for de-
veloping T2DM (Cheng 2006; Morris 2013). Most importantly, 'pre-
diabetes' is commonly an asymptomatic condition, and naturally
often remains 'undiagnosed' (Centers for Disease Control and Pre-
vention 2015). Consequently, 'prediabetes' may exist before the di-
agnosis of T2DM is established.
It is still not clarified if any particular intervention, especially glu-
cose-lowering drugs, should be recommended for people with 'pre-
diabetes' (Yudkin 2014). Studies have indicated that the progres-
sion from 'prediabetes' to T2DM is reduced, or maybe just de-
layed with 'lifestyle' interventions (increased physical activity, di-
etary changes or both) (Diabetes Prevention Program 2002; Dia-
betes Prevention Program FU 2009; Finnish Diabetes Prevention
Study Group 2001). A recent meta-analysis of 22 trials with lifestyle
interventions in people with high risk of T2DM concluded that the
effect of lifestyle interventions on longer-term diabetes prevention
is not clarified (Dunkley 2014).
The prescription of pharmacological glucose-lowering interven-
tions for the prevention of T2DM is not generally accepted among
international diabetes associations and clinicians. Several groups
of pharmacological glucose-lowering interventions have been in-
vestigated in people with 'prediabetes'. Some findings indicate
that the progression from 'prediabetes' to T2DM is reduced or
maybe just delayed (Diabetes Prevention Program 2002; Diabetes
Prevention Program FU 2009). However, the ADA recommends met-
formin for people with 'prediabetes' and a body mass index (BMI)
> 35 kg/m2, aged < 60 years, and women with prior gestational dia-
betes mellitus (ADA 2015).
Description of the intervention
Metformin is a biguanide originating from the plant Galega offic-
inalis (Witters 2001). First described in 1922, it was administered
to humans for the first time in France in 1957. In 1972, Canada ap-
proved its use for T2DM and later, in 1994, it received approval for
use in T2DM by the US Food and Drug Administration (FDA) (Corey
2007; FDA 1994).
People with T2DM are initially advised to follow behaviour-chang-
ing ('lifestyle') interventions including weight loss and increased
physical activity (ADA 2019a). However, over time the majori-
ty of people with T2DM will require additional glucose-lowering
pharmacological interventions. Currently, metformin is the recom-
mended first-line, glucose-lowering medication (ADA 2019a).
The glucose-lowering effect increases with increasing doses of met-
formin, whether by the immediate-release or prolonged-release
formulations. The maximal recommended dose of metformin is
2000 mg daily in the USA. However, the maximum recommended
daily dose of metformin in Europe and in other regions is 3000 mg.
The landmark study, UK Prospective Diabetes Study (UKPDS) ap-
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
development of type 2 diabetes mellitus (Review)









Cochrane Database of Systematic Reviews
plied a median daily dose of 2550 mg/day in people with newly di-
agnosed T2DM (UKPDS 1998).
Adverse effects of the intervention
The most common adverse effects of metformin are gastrointesti-
nal disturbances, which are reported in 20% to 30% of people using
this drug. However, the gastrointestinal disturbances only necessi-
tate discontinuation of the drug in less than 5% of the affected in-
dividuals (DeFronzo 1999).
A potential complication of metformin use is lactic acidosis, a rare,
but potentially fatal, metabolic condition that can occur whenev-
er substantial tissue hypoxia exists (Kreisberg 1980). Lactic acido-
sis is characterised by elevated blood lactate concentrations (ex-
ceeding 5.0 mmol/L) and decreased blood pH (less than 7.35). The
mortality is estimated to be about 50% (Huang 2016). A Cochrane
Review found no firm evidence of metformin being associated with
an increased risk of lactic acidosis or elevated lactate levels when
compared to other glucose-lowering drugs (Salpeter 2010). Howev-
er, several case reports of lactic acidosis in metformin-treated peo-
ple have been published subsequently (Kalantar-Zadeh 2013; Sc-
housboe 2012).
How the intervention might work
The exact mechanism(s) of action of metformin are not clearly
elucidated. However, metformin is known to alter carbohydrate
metabolism by reducing basal hepatic glucose production (gluco-
neogenesis), improving insulin sensitivity in the liver and periph-
eral tissues, as well as increasing insulin-stimulated glucose up-
take and utilisation in peripheral tissues (AHFS 1999). It has been
proposed that its prime mode of action is via activation of the
5' adenosine monophosphate-activated protein kinase (AMPK) en-
zyme (Cho 2015; Duca 2015).
Why it is important to do this review
There has been an increased focus on the prevention or delay of
T2DM with non-pharmacological interventions and glucose-lower-
ing medications. Recently, one literature review (Moin 2018) and
several systematic reviews (Haw 2017; Lily 2009; Moelands 2018;
Pang 2018; Salpeter 2008) have been performed in people with el-
evated risk of T2DM. All these reviews have methodological short
comings and applied limited search strategies. As the prevalence of
intermediate hyperglycaemia is increasing, an updated review with
comprehensive search and updated methodology is needed.
O B J E C T I V E S
To assess the effects of metformin for the prevention or delay of
type 2 diabetes mellitus (T2DM) and its associated complications in
persons at increased risk for the development of T2DM.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs).
Types of participants
Nondiabetic individuals at increased risk of developing T2DM, that
is, diagnosed with intermediate hyperglycaemia or 'prediabetes'.
Diagnostic criteria for 'prediabetes'
To be consistent with changes in the classification of and diag-
nostic criteria for 'prediabetes' (impaired fasting glucose (IFG), im-
paired glucose tolerance (IGT) and elevated glycosylated haemo-
globin A1c (HbA1c)) over the years, the diagnosis had to be estab-
lished using the standard criteria valid at the time of the trial com-
mencing (for example ADA 1997; ADA 2010; NDDG 1979; WHO 1999).
Ideally, the diagnostic criteria should have been described. If nec-
essary, we used the trial authors' definition of 'prediabetes' but
contacted trial authors for additional information. Differences of
glycaemic measurements used to define 'prediabetes' may intro-
duce substantial heterogeneity. We therefore planned to subject
diagnostic criteria to a subgroup analysis.
Types of interventions
We planned to investigate the following comparisons of interven-
tion versus control/comparator.
Intervention
• Metformin monotherapy (with or without diet, exercise or both).
Comparator
• Placebo.
• Non-pharmacological interventions (for example diet, exercise).
• Sulfonylureas (for example glibenclamide).
• α-glucosidase inhibitors (for example acarbose).
• Thiazolidinediones (for example pioglitazone).
• Meglitinides (for example repaglinide).
• Sodium-glucose co-transporter 2 inhibitors (for example em-
pagliflozin)
• Glucagon-like peptide-1 analogues (for example liraglutide).
• Dipeptidyl peptidase-4 inhibitors (for example sitagliptin).
• Insulin.
Concomitant interventions had to be the same in intervention and
control groups to establish fair comparisons.
Minimum duration of intervention
We included trials with a minimum duration of intervention of one
year.
Exclusion criteria
• People diagnosed with the 'metabolic syndrome' because this
is a special cohort of doubtful clinical usefulness and uncertain
distinct disease entity (a composite of risk indicators such as el-
evated blood lipids, insulin resistance, obesity, high blood pres-
sure).
We did not exclude trials because one or several of our primary
or secondary outcome measures were not reported in the publica-
tion. In case none of our primary or secondary outcomes was re-
ported, we included the trial and contacted the corresponding au-
thor for supplementary data. If no additional data were available,
we planned to show these trials a supplementary table.
Types of outcome measures
Primary outcomes
• All-cause mortality.
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• Incidence of type 2 diabetes (T2DM).
• Serious adverse events.
Secondary outcomes
• Cardiovascular mortality.
• Non-fatal myocardial infarction.
• Non-fatal stroke.
• Amputation of lower extremity.
• Blindness or severe vision loss.
• End-stage renal disease.
• Non-serious adverse events.
• Hypoglycaemia.
• Health-related quality of life.
• Time to progression to T2DM.
• Measures of blood glucose control.
• Socioeconomic effects.
Method and timing of outcome measurement
• All-cause mortality: defined as death from any cause. Measured
at the end of the intervention and the end of follow-up.
• Incidence of T2DM and time to progression to T2DM: defined ac-
cording to diagnostic criteria valid at the time the diagnosis was
established using the standard criteria valid at the time of the
trial commencing (e.g. ADA 2008; WHO 1998). If necessary, we
used the trial authors' definition of T2DM. Measured at the end
of the intervention and the longest reported end of follow-up.
• Serious adverse events: defined according to the Internation-
al Conference on Harmonization Guidelines as any event that
leads to death, that is life-threatening, required in-patient hos-
pitalisation or prolongation of existing hospitalisation, resulted
in persistent or significant disability, and any important medical
event which may have had jeopardised the patient or required
intervention to prevent it (ICH 1997) or as reported in trials. Mea-
sured at any time of the intervention and during follow-up.
• Cardiovascular mortality, non-fatal myocardial infarction, non-
fatal stroke, amputation of lower extremity, blindness or se-
vere vision loss, hypoglycaemia (mild, moderate, severe/seri-
ous): defined as reported in trials. Measured at the end of the in-
tervention and at the end of follow-up.
• End-stage renal disease: defined as dialysis, renal transplanta-
tion or death due to renal disease. Measured at the end of the
intervention and at the end of follow-up.
• Non-serious adverse events: defined as number of participants
with any untoward medical occurrence not necessarily having a
causal relationship with the intervention. Measured at the end
of the intervention and at the end of follow-up.
• Health-related quality of life: defined as mental and physical
health-related quality of life as separate and combined, evaluat-
ed by a validated instrument such as Short-Form 36. Measured
at the end of the intervention and at the end of follow-up.
• Measures of blood glucose control: fasting blood glucose, blood
glucose two hours after ingestion of 75 g glucose and HbA1c
measurements. Measured at the end of the intervention and at
the end of follow-up.
• Socioeconomic effects: for example costs of the intervention,
absence from work, medication consumption. Measured at the
end of the intervention and at the end of follow-up.
Search methods for identification of studies
Electronic searches
We searched the following sources from inception of each database
to 7 March 2019.
• Cochrane Central Register of Controlled Trials (CENTRAL) via the
Cochrane Register of Studies Online (CRSO) (searched 7 March
2019).
• Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Oth-
er Non-Indexed Citations and Daily 1946 to March 06, 2019
(searched 7 March 2019).
• Scopus (searched 7 March 2019).
• ClinicalTrials.gov (searched 7 March 2019).
• World Health Organization (WHO) International Clinical Tri-
als Registry Platform (ICTRP) Search Portal (http://app-
s.who.int/trialsearch/) (searched 7 March 2019).
For detailed search strategies, see Appendix 1. We continuously ap-
plied an email alert service for MEDLINE via OvidSP to identify new-
ly published trials using the search strategy detailed in Appendix
1. We placed no restrictions on the language of publication when
searching the electronic databases or reviewing reference lists of
identified trials.
Searching other resources
We tried to identify additional trials by searching the reference lists
of included trials, (systematic) reviews, meta-analyses and health
technology assessment reports. Additionally, we attempted to ob-
tain additional trials by handsearching the most recent journal is-
sues in print that were not indexed in the electronic databases as
well. We also searched grey literature sources, which included in-
ternal reports and conference proceedings.
Data collection and analysis
Selection of studies
Two review authors independently scanned the abstract or title,
or both, of records retrieved, to determine which trials should be
assessed further (BR and BH). We investigated the full-text articles
of all potentially relevant trials. We resolved discrepancies through
consensus or by recourse to another review author (MIM). If we
could not resolve a disagreement, we categorised the trial as a
'study awaiting classification' and contact the trial authors for clar-
ification. We prepared a flow diagram of the number of trials iden-
tified and excluded at each stage in accordance with the PRISMA
flow diagram of trial selection (Liberati 2009; Figure 1).
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Figure 1.   Trial flow diagram (as of 29.05.2017, Mim)
 
Data extraction and management
For trials that fulfilled inclusion criteria, two review authors (KSM
and BH or YC) independently extracted key participant and inter-
vention characteristics. We reported data on efficacy outcomes
and adverse events using standard data extraction sheets from the
CMED Group. We resolved any disagreements by discussion or, if re-
quired, by consultation with another review author (BR) (for details
see Characteristics of included studies; Table 1; Appendix 2; Appen-
dix 3; Appendix 4; Appendix 5; Appendix 6; Appendix 7; Appendix 8;
Appendix 9; Appendix 10; Appendix 11; Appendix 12; Appendix 13).
We provided information about potentially relevant ongoing trials
including trial identifier in the Characteristics of ongoing studies ta-
ble and in Appendix 7 'Matrix of trial endpoint (publications and tri-
al documents)'. For each included trial, we tried to retrieve the pro-
tocol. If not available from the search of the databases, reference
screening or Internet searches, we asked authors to provide a copy
of the protocol. Predefined outcomes were entered in Appendix 7.
We emailed all authors of the included trials to enquire whether
they were willing to answer questions regarding their trials. We pre-
sented the results of this survey in 'Survey of trial investigators pro-
viding information on included trials' (see Appendix 14). We sought
relevant missing information on the trial from the primary author(s)
of the articles, if possible.
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
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Dealing with duplicate and companion publications
In the event of duplicate publications, companion documents or
multiple reports of a primary trial, we maximised the information
yield by collating all available data and used the most complete da-
ta set aggregated across all known publications. Duplicate publica-
tions, companion documents or multiple reports of a primary trial
were listed as secondary references under the primary reference of
the included, excluded trial or ongoing trial.
Assessment of risk of bias in included studies
Review authors (KS and BH) independently assessed the risk of bias
of the included trials. Studies in Chinese were assessed by one au-
thor (YC). We resolved any disagreements by consensus, or by con-
sultation with a third review author (BH or BR). If adequate infor-
mation was not available from the trial publication, trial protocol
or both, we contacted trial authors for missing data on 'Risk of bias'
items.
We used the Cochrane 'Risk of bias' assessment tool (Higgins 2017)
assigning assessments of low, high, or unclear risk of bias (for de-
tails, see Appendix 2; Appendix 3). We evaluated individual bias
items as described in the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011 according to the criteria and as-
sociated categorisations contained therein(Higgins 2017).
Summary assessment of risk of bias
We presented a 'Risk of bias' graph and a 'Risk of bias' summary
figure.
For risk of bias evaluation we grouped outcome measures as fol-
lows:
• Health-related quality of life.
• Incidence of T2DM.
• Macrovascular complications: non-fatal myocardial infarction,
non-fatal stroke.
• Measures of blood glucose control.
• Microvascular complications: amputation of lower extremity,
blindness/severe vision loss, end-stage renal disease
• Mortality: all-cause mortality, cardiovascular mortality.
• Non-seroius adverse events (including hypoglycaemic episodes,
depending on measurement).
• Serious hypoglycaemic episodes (including hypoglycaemic
episodes, depending on measurement).
• Socioeconomic effects.
• Time to progression to 2DM.
We distinguished between self-reported, investigator-assessed
and adjudicated outcome measures.
We defined the following outcomes as self-reported.
• Non-serious adverse events.
• Hypoglycaemia, if reported by participants.
• Health-related quality of life.
• Blood glucose control, if measured by trial participants.
We defined the following outcomes as investigator-assessed:
• All-cause mortality.
• Incidence of T2DM.
• Time to progression to T2DM.
• Serious adverse events.
• Cardiovascular mortality.
• Non-fatal myocardial infarction.
• Non-fatal stroke.
• Amputation of lower extremity.
• Blindness or severe vision loss.
• End-stage renal disease.
• Hypoglycaemia, if measured by trial personnel.
• Blood glucose control, if measured by trial personnel.
• Socioeconomic effects.
Summary assessment of risk of bias
Risk of bias for a trial across outcomes: some risk of bias do-
mains, such as selection bias (sequence generation and allocation
sequence concealment), affected the risk of bias across all outcome
measures in a trial. Otherwise, we did not perform a summary as-
sessment of the risk of bias across all outcomes for a trial. In case
of high risk of selection bias, we excluded the trial.
Risk of bias for an outcome within a trial and across domains:
we assessed the risk of bias for an outcome measure by including
all entries relevant to that outcome (i.e. both trial-level entries and
outcome-specific entries). 'Low' risk of bias was defined as low risk
of bias for all key domains, 'unclear' risk of bias as unclear risk of
bias for one or more key domains and 'high' risk as high risk of bias
for one or more key domains.
Risk of bias for an outcome across trials and across domains:
these were our main summary assessments that were incorporated
in our judgements about the quality of evidence in the 'Summary
of findings' tables. 'Low' risk of bias was defined as most informa-
tion coming from trials at low risk of bias, 'unclear' risk of bias as
most information coming from trials at low or unclear risk of bias
and 'high' risk of bias as sufficient proportion of information com-
ing from trials at high risk of bias.
Measures of treatment effect
For trials addressing the same outcome but using different out-
come measure scales we planned to use standardised mean differ-
ences (SMD) with 95% CI. We planned to calculate time-to-event da-
ta as hazard ratio (HR) with 95% CI with the generic inverse variance
method. Unadjusted hazard ratios were planned to be preferred, as
adjustment could differ among the included trials.
The scales measuring health-related quality of life may go in dif-
ferent directions. Some scales increase in values with improved
health-related quality of life, whereas other scales decrease in val-
ues with improved health-related quality of life. To adjust for the
different directions of the scales, scales reporting better health-re-
lated quality of life with decreasing values were planned to be mul-
tiplied by –1.
Unit of analysis issues
We took into account the level at which randomisation occurred,
such as cross-over trials, cluster-randomised trials and multiple ob-
servations for the same outcome. If more than one comparison
from the same trial was eligible for inclusion in the same meta-
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analysis, we either combined groups to create a single pair-wise
comparison or appropriately reduced the sample size so that the
same participants did not contribute multiply (splitting the 'shared'
group into two or more groups). While the latter approach offers
some solution to adjusting the precision of the comparison, it does
not account for correlation arising from the same set of participants
being in multiple comparisons (Higgins 2011c).
We planned to reanalyse cluster randomised trials that did not ap-
propriately adjust for potential clustering of participants within
clusters in their analysis. The variance of the intervention effects
would have been inflated by a design effect (DEFF). Calculation
of a DEFF involves estimation of an intra-cluster correlation (ICC).
Estimates of ICCs were planned to be obtained through contact
with authors, or imputed using estimates from other included stud-
ies that report ICCs, or using external estimates from empirical re-
search (e.g. Bell 2013). We planned to examine the impact of clus-
tering using sensitivity analyses.
Dealing with missing data
If possible, we obtained missing data from trial authors and careful-
ly evaluated important numerical data such as screened, random-
ly assigned participants as well as intention-to-treat (ITT), and as-
treated and per-protocol populations.
We investigated attrition rates (e.g. drop-outs, losses to follow-up,
withdrawals), and critically appraised issues concerning missing
data and imputation methods (e.g. last observation carried forward
(LOCF)).
Where means and standard deviations (SDs) for outcomes were not
reported and we could not receive the needed information from tri-
al authors, we planned to impute these values by assuming the SDs
of the missing outcome to be the average of the SDs from those tri-
als in which this information was reported.
We planned to investigate the impact of imputation on meta-analy-
ses by performing sensitivity analyses.
Assessment of heterogeneity
We identified heterogeneity (inconsistency) by visually inspecting
the forest plots and by using a standard Chi2 test with a significance
level of α = 0.1 (Deeks 2017). In view of the low power of this test,
we also considered the I2 statistic, which quantifies inconsistency
across trials, to assess the impact of heterogeneity on the meta-
analysis (Higgins 2002; Higgins 2003).
When we found heterogeneity, we attempted to determine pos-
sible reasons for this by examining individual trial and subgroup
characteristics.
Assessment of reporting biases
Had we included 10 or more trials investigating a particular out-
come, we planned to use funnel plots to assess small-trial effects.
Several explanations may account for funnel plot asymmetry, in-
cluding true heterogeneity of effect with respect to trial size, poor
methodological design (and hence bias of small trials) and publica-
tion bias (Sterne 2017). Therefore, we planned to interpret results
carefully (Sterne 2011).
Data synthesis
We planned to undertake (or display) a meta-analysis only if we
judged participants, interventions, comparisons, and outcomes to
be sufficiently similar to ensure an answer that was clinically mean-
ingful. Unless good evidence showed homogeneous effects across
trials of different methodological quality, we primarily summarised
low risk of bias data using a random-effects model (Wood 2008).
We interpreted random-effects meta-analyses with due consider-
ation for the whole distribution of effects and presented a predic-
tion interval (Borenstein 2017a; Borenstein 2017b; Higgins 2011)
for the outcome measures reported in the 'Summary of findings'
tables. A prediction interval requires at least three trials to be cal-
culated and specifies a predicted range for the true treatment ef-
fect in an individual trial (Riley 2011). For rare events such as event
rates below 1%, we planned to use the Peto odds ratio method,
provided there was no substantial imbalance between interven-
tion and comparator group sizes, and intervention effects were not
exceptionally large. In addition, we performed statistical analyses
according to the statistical guidelines presented in the Cochrane
Handbook for Systematic Reviews of Interventions (Deeks 2017).
Subgroup analysis and investigation of heterogeneity
We expected the following characteristics to introduce clinical het-
erogeneity, and planned to carry out subgroup analyses including
investigation of interactions (Altman 2003).
• Trials designed to blind participants and investigators versus
open-label trials.
• Trials with long duration (≥ 2 years) versus trials with short du-
ration (< 2 years).
• Diagnostic 'prediabetes' criteria (IFG, IGT, HbA1c).
• Age, depending on data.
• Sex.
• Ethnicity, depending on data.
• Comorbid conditions, such as hypertension or obesity.
• Participants with previous gestational diabetes mellitus.
Sensitivity analysis
We planned to perform sensitivity analyses to explore the influence
of the following factors (when applicable) on effect sizes by restrict-
ing the analysis to:
• published trials;
• taking into account risk of bias, as specified in the Assessment
of risk of bias in included studies section;
• trials using the following filters: imputation, language of publi-
cation, source of funding (industry versus other), or country.
We also planned to test the robustness of results by repeating the
analysis using different measures of effect size (RR, OR, etc) and dif-
ferent statistical models (fixed-effect and random-effects models).
Certainty of the evidence
We presented the overall quality of the certainty for each outcome
specified below, according to the GRADE approach, which takes in-
to account issues related to internal validity (risk of bias, inconsis-
tency, imprecision, publication bias) and also to external validity,
such as directness of results. Two review authors (BH and BR) inde-
pendently rated the certainty of evidence for each outcome.
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We included five appendices entitled 'Checklist to aid consistency
and reproducibility of GRADE assessments', to help with standard-
isation of the 'Summary of findings' tables (Meader 2014). Alterna-
tively, we would have used the GRADEpro Guideline Development
Tool (GDT) software and presented evidence profile tables as an ap-
pendix (GRADEpro GDT 2015). We presented results for outcomes as
described in the Types of outcome measures section. When meta-
analysis was not possible, we presented the results in a narrative
format in the 'Summary of findings' tables. We justified all decisions
to downgrade the quality of trials by using footnotes, and we made
comments to aid the reader's understanding of the Cochrane Re-
view when necessary.
'Summary of findings' tables
We presented a summary of the evidence in the Summary of find-
ings for the main comparison and the Summary of findings 2. This
provides key information about the best estimate of the magnitude
of effect, in relative terms and as absolute differences for each rel-
evant comparison of alternative management strategies, numbers
of participants and trials addressing each important outcome, and
a rating of overall confidence in effect estimates for each outcome.
We created the 'Summary of findings' table using the methods de-
scribed in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Schünemann 2011) along with Review Manager (RevMan
5.3) table editor (RevMan 2014).
Interventions presented in the 'Summary of findings' tables were
metformin and metformin plus intensive diet plus exercise and
comparators were diet and exercise, another blood glucose lower-
ing drug or intensive diet plus exercise.
We reported the following outcomes, listed according to priority.
1. All-cause mortality.
2. Incidence of T2DM.
3. Serious adverse events.
4. Cardiovascular mortality.
5. Non-fatal myocardial infarction/stroke.
6. Health-related quality of life.
7. Socioeconomic effects.
R E S U L T S
Description of studies
For a detailed description of studies, see the 'Characteristics of in-
cluded studies', 'Characteristics of excluded studies, and 'Charac-
teristics of ongoing studies' sections.
Results of the search
The search resulted in 4289 records, which after deduplication were
reduced to 3249 records. A total of 170 references were identified
as potentially eligible after screening title and abstract. Of these,
49 were excluded after checking full text. Furthermore, one pub-
lication was excluded after contact with the main author (dura-
tion of intervention less than one year) (ChiCTR-TRC-09000548),
one Japanese publication was excluded after translation (not a ran-
domised controlled trial (RCT)) (Ishida 2005) and one Chinese pub-
lication was excluded after translation (wrong intervention) (Chen
2013). Of the remaining eligible 118 records, there were 11 ongo-
ing trials and five trials awaiting assessment. Cross-checking four
systematic reviews (Haw 2017; Lily 2009; Moelands 2018; Salpeter
2008) revealed three additional references to already included tri-
als. One systematic review (Pang 2018) revealed a further 10 Chi-
nese trials to be included. At the end of the process we identified 20
trials (102 records) meeting our inclusion criteria. The flowchart of
records throughout the screening process is presented in Figure 1.
Included studies
A detailed description of the characteristics of included trials is pre-
sented elsewhere (see Characteristics of included studies and Ap-
pendix 4; Appendix 5; Appendix 6; Appendix 7; Appendix 8; Appen-
dix 9; Appendix 10; Appendix 11; Appendix 12; Appendix 13). The
following is a succinct overview.
Source of data
All but one trial reported data published in medical journals (Wang
2009). One trial was published as a conference proceeding (Wang
2009). One trial reported additional data in trial registers (DPP/DP-
POS 2002). We contacted all authors or investigators of included tri-
als by email (see Appendix 15). No additional data were provided.
Comparisons
Fifteen trials compared metformin with placebo or diet and exer-
cise (Alfawaz 2018; BIGPRO1 2009; Chen 2009; DPP/DPPOS 2002;
Fang 2004; IDPP-1 2006; Ji 2011; Jin 2009; Li 1999; Lu 2002; Lu 2010;
Papoz 1978; PREVENT-DM 2017; Wang 2009; Zeng 2013). One trial
compared metformin with a sulphonylurea (Papoz 1978). Three tri-
als compared metformin with acarbose (Fang 2004; Liao 2012; Maji
2005). Three trials compared metformin with a thiazolidinediones
(Jin 2009; Maji 2005; Zeng 2013). Eight trials compared metformin
with intensive diet and exercise (Alfawaz 2018; DPP/DPPOS 2002;
Fang 2004; IDPP-1 2006; Ji 2011; Li 2009; Maji 2005; PREVENT-DM
2017). Three trials compared metformin plus intensive diet and ex-
ercise with intensive diet and exercise (IDPP-1 2006; Iqbal Hydrie
2012; Zhao 2013). Ten trials had more than two comparison groups
of relevance for this review (Alfawaz 2018; DPP/DPPOS 2002; Fang
2004; IDPP-1 2006; Ji 2011; Jin 2009; Maji 2005; Papoz 1978; PRE-
VENT-DM 2017; Zeng 2013).
Overview of trial populations
Five trials provided information on sample size calculation (BIG-
PRO1 2009; DPP/DPPOS 2002; IDPP-1 2006; Iqbal Hydrie 2012; PRE-
VENT-DM 2017). Eight of the included trials reported the total num-
ber of participants screened (BIGPRO1 2009; DPP/DPPOS 2002;
Fang 2004; IDPP-1 2006; Iqbal Hydrie 2012; Li 1999; Maji 2005; PRE-
VENT-DM 2017). A total of 2426 participants were randomised to
metformin. A total of 4348 participants were randomised to a com-
parator group. The number of randomised participants ranged
from 28 to 1073 in the metformin groups and from 23 to 1082 in the
comparator groups.
Trial design
All of the 20 included trials were parallel RCTs. Four trials performed
blinding of the participants and investigators for one or more com-
parators (BIGPRO1 2009; DPP/DPPOS 2002; Li 1999; Papoz 1978),
the same four trials applied placebo. Three trials reported a run-
in period (DPP/DPPOS 2002; Liao 2012; Maji 2005). Two trials were
terminated (DPP/DPPOS 2002; IDPP-1 2006). The duration of the in-
tervention in the included trials varied from one year to five years.
The trials were performed between the years 1969 and 2017. One
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trial had an extended follow-up period after the intervention period
had stopped (DPP/DPPOS 2002). Four trials were multicentre trials,
defined as two or more trial centres (Alfawaz 2018; BIGPRO1 2009;
DPP/DPPOS 2002; Iqbal Hydrie 2012). Twelve trials were single-cen-
tre trials (Chen 2009; Fang 2004; Ji 2011; Jin 2009; Li 2009; Liao 2012;
Lu 2010; Papoz 1978; PREVENT-DM 2017; Wang 2009; Zeng 2013;
Zhao 2013), and four trials did not provide the number of trial cen-
tres (IDPP-1 2006; Li 1999; Lu 2002; Maji 2005). Two trials were per-
formed in the USA ( DPP/DPPOS 2002; PREVENT-DM 2017), two tri-
als were performed in France (BIGPRO1 2009; Papoz 1978), two tri-
als were performed in the Middle-east (Alfawaz 2018; Iqbal Hydrie
2012), the remaining trials were performed in Asia. Three of the
included trials stated that they had received commercial funding
(BIGPRO1 2009; DPP/DPPOS 2002; IDPP-1 2006). Six trials had re-
ceived non-commercial funding (Alfawaz 2018; Iqbal Hydrie 2012;
Ji 2011; Jin 2009; Papoz 1978; PREVENT-DM 2017). One trial stated
that they had received military funding (Lu 2002). Eight trials did
not report the funding source (Li 1999; Li 2009; Liao 2012; Lu 2010;
Maji 2005; Wang 2009; Zeng 2013; Zhao 2013).
Settings
All included trials were performed in an outpatient setting.
Participants
Fifteen trials included only people from Asia; 12 of these Chinese
(Chen 2009; Fang 2004; Ji 2011; Jin 2009; Li 1999; Li 2009; Liao 2012;
Lu 2002; Lu 2010; Wang 2009; Zeng 2013; Zhao 2013); two Indian
(IDPP-1 2006; Maji 2005); one Pakistini (Iqbal Hydrie 2012). One trial
included only Saudi Arabians (Alfawaz 2018). One trial only includ-
ed Hispanic participants (PREVENT-DM 2017). One trial included
mainly White participants (DPP/DPPOS 2002). Two trials did not re-
port information about ethnicity (BIGPRO1 2009; Papoz 1978) (see
Appendix 5). Five trials did not report the gender of the participants
in each intervention group (Iqbal Hydrie 2012; Jin 2009; Li 2009; Ma-
ji 2005; Wang 2009). One trial included only females (PREVENT-DM
2017), and one trial included only males (Papoz 1978). For the re-
maining trials authors provided gender information, and both men
and women were included. Four trials did not report the age of the
participants (Jin 2009; Li 2009; Maji 2005; Zhao 2013). The age of the
included participants varied from 41 to 65 years (see Appendix 8).
All, but five trials reported baseline fasting glucose (Iqbal Hydrie
2012; Lu 2002; Lu 2010; Wang 2009; Zhao 2013). The reported fasting
glucose values at baseline varied from 5.3 mmol/L to 7.3 mmol/L.
All, but four trials reported 2-hour plasma glucose after an oral glu-
cose tolerance test (OGTT) at baseline (Alfawaz 2018; Iqbal Hydrie
2012; Lu 2010; PREVENT-DM 2017). The 2-hour plasma glucose val-
ues varied from 6.4 mmol/L to 10.4 mmol/L. Seven trials reported
HbA1c values at baseline (Alfawaz 2018; DPP/DPPOS 2002; IDPP-1
2006; Li 1999; Lu 2010; Maji 2005; PREVENT-DM 2017). HbA1c varied
from 5.6% to 7.6%. One trial did not report any glycaemic variables
at baseline (Iqbal Hydrie 2012). All, but three trials reported body
mass index (BMI) at baseline (Chen 2009; Liao 2012; Papoz 1978).
BMI varied from 24 kg/m2 to 35.6 kg/m2.
Six trials did not report exclusion criteria (Iqbal Hydrie 2012; Ji
2011; Li 2009; Lu 2002; Maji 2005; Papoz 1978). Major exclusion cri-
teria were diagnosis of diabetes; receiving glucose-lowering inter-
ventions and taking medications known to alter glucose tolerance;
pregnant or lactating women; known renal, hepatic, pulmonary,
cardiac, cerebral, mental or endocrine disease; heavy alcohol con-
sumption.
Diagnosis
The diagnosis applied in the included trials for identifying interme-
diate hyperglycaemia varied. Three trials applied the World Health
Organization (WHO) 1985 diagnostic criteria for the definition of im-
paired fasting glucose (IFG) and impaired glucose tolerance (IGT)
(fasting plasma glucose < 7.8 mmol/L and 2-hour plasma glucose
after (OGTT) ≥ 7.8 mmol/L and < 11.1 mmol/L) (Fang 2004; Li 1999;
Lu 2002). Ten trials applied the WHO 1999 criteria for the defini-
tion of IFG and/or IGT (fasting plasma glucose < 7.0 mmol/L and 2-
hour plasma glucose after OGTT ≥ 7.8 mmol/L and < 11.1 mmol/
L) (BIGPRO1 2009; Chen 2009; IDPP-1 2006; Iqbal Hydrie 2012; Ji
2011; Jin 2009; Li 2009; Liao 2012; Zeng 2013; Zhao 2013). Two tri-
als applied the diagnostic criteria for impaired glucose defined by
American Diabetes Association (ADA) 1997 (fasting plasma glucose
concentration of 5.3 mmol/L to 6.9 mmol/L and 2-hour plasma glu-
cose after OGTT ≥ 7.8 mmol/L to 11.0 mmol/L) (ADA 1997) (DPP/DP-
POS 2002; Wang 2009). For the American Indian clinics in the Dia-
betes Prevention Program (DPP), fasting plasma glucose less then
6.9 mmol/L with no lower limit applied. Before June 1997, the cri-
terion for plasma fasting glucose was 5.6 mmol/L to 7.7 mmol/L,
or less than 7.7 mmol/L in the American Indian clinics (DPP/DP-
POS 2002). A total of the 54 participants (total in all three inter-
vention groups) included in the DPP had fasting plasma glucose
above 7.0 mmol/L at baseline (DPP/DPPOS 2002). Thirteen per cent
of the participants included in the DPP trial had HbA1c ≥ 6.5% at
baseline (DPP/DPPOS 2002). One trial applied the diagnostic crite-
ria for impaired glucose defined by ADA 2009 (fasting plasma glu-
cose 5.6 mmol/L to 6.9 mmol/L or 2-hour plasma glucose 7.8 mmol/
L to 11.1 mmol/L) (Lu 2010). One trial only applied the IFG crite-
ria defined by ADA 2009 (fasting plasma glucose 5.6 mmol/L to 6.9
mmol/L) or a HbA1c 5.7% to 6.4% (PREVENT-DM 2017). Most of the
participants were included based on an elevated HbA1c only (67%);
13% of the participants fulfilled the inclusion criteria by IFG only;
the remaining participants had both IFG and intermediate elevated
HbA1c (PREVENT-DM 2017). One trial applied the diagnostic crite-
ria for IFG defined by ADA 2017 (fasting plasma glucose 5.6 mmol/L
to 6.9 mmol/L) (Alfawaz 2018). One trial applied the diagnostic cri-
teria for impaired glucose defined by the European Diabetes Epi-
demiology Study Group 1970 (fasting blood glucose ≥ 5.6 mmol/L
and < 7.2 mmol/L or 2-hour blood glucose after OGTT ≥ 6.7 mmol/
L and < 8.3 mmol/L; when these criteria for intermediate hypergly-
caemia were fulfilled, a second test was performed: blood glucose
concentrations were determined fasting at 15, 30, 60, 120, 80, 240
and 300 minutes after an oral glucose load. Eligible individuals had
2-hour blood glucose concentrations ≥ 6.7 mmol/L but < 8.3 mmol/
L or fasting blood glucose concentrations ≥ 5.6 mmol/L and < 7.2
mmol/L; blood glucose after 30 minutes ≥ 8.9 mmol/L and < 12.2
mmol/L; blood glucose after 60 minutes ≥ 8.9 mmol/L and < 12.2
mmol/L) (Papoz 1978). Another trial defined IGT as 2-hour plasma
glucose after OGTT ≥ 6.1 mmol/L and < 11.1 mmol/L and fasting
plasma glucose < 6.1 mmol/L (Maji 2005). No medical associations
recommend the cut-off points applied in the study by Maji and col-
leagues to diagnose intermediate hyperglycaemia (Maji 2005).
In one trial, the people with IFG and IGT were only a subset of the
total randomised participants (101 out of 457 (22.1%)) (BIGPRO1
2009).
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Interventions
The metformin intervention varied among the included trials; one
trial applied metformin 38 mg once daily with standard diet and
physical activity (Zeng 2013); one trial applied metformin 375 mg to
750 mg three times a day with no concomitant intervention (Fang
2004); one trial applied metformin 250 mg twice daily with stan-
dard diet, physical activity and education (Wang 2009); two trials
applied metformin 250 mg three times a day with no concomitant
intervention (Li 1999; Liao 2012); three trials applied metformin 500
mg daily with standard diet and physical activity (Alfawaz 2018; Li
2009; Maji 2005); one trial randomised the participants into two dif-
ferent metformin groups; one metformin group receiving 500 mg
twice daily with concomitant standard diet and physical activity
and one metformin group receiving 500 mg twice daily with inten-
sive diet and physical activity (IDPP-1 2006); one trial applied met-
formin 500 mg twice daily with intensive diet and physical activity
(Iqbal Hydrie 2012); one trial applied metformin 500 mg twice dai-
ly with standard diet, physical activity and education (Zhao 2013);
two trials applied metformin 500 mg three times a day with stan-
dard diet, physical activity and education (Ji 2011; Lu 2010); one tri-
al applied metformin 750 mg three times a day with standard diet
and physical activity (Chen 2009); one trial applied metformin 750
mg three times a day with education (Lu 2002); four trials applied
metformin 850 mg twice daily with standard diet and physical ac-
tivity (BIGPRO1 2009; DPP/DPPOS 2002; Papoz 1978; PREVENT-DM
2017); and one trial applied metformin 1000 mg twice or three times
a day with standard diet and physical activity (Jin 2009). For details
see 'Description of interventions' Appendix 4
Outcomes
Three trials had specified primary outcomes (DPP/DPPOS 2002;
IDPP-1 2006; PREVENT-DM 2017), all of these trials were registered
at ClinicalTrials.gov (Appendix 7).
Sixteen trials reported the incidence of type 2 diabetes mellitus
(T2DM) (Chen 2009; DPP/DPPOS 2002; Fang 2004; IDPP-1 2006; Ji
2011; Jin 2009; Li 1999; Li 2009; Liao 2012; Lu 2002; Lu 2010; Maji
2005; PREVENT-DM 2017; Wang 2009; Zeng 2013; Zhao 2013). Five
trials reported all-cause mortality (DPP/DPPOS 2002; Fang 2004;
IDPP-1 2006; Lu 2002; PREVENT-DM 2017). Sixteen trials reported 2-
hour glucose values (BIGPRO1 2009; Chen 2009; DPP/DPPOS 2002;
Fang 2004; IDPP-1 2006; Ji 2011; Jin 2009; Li 1999; Li 2009; Liao 2012;
Lu 2002; Lu 2010; Papoz 1978; Wang 2009; Zeng 2013; Zhao 2013).
Six trials reported HbA1c (Alfawaz 2018; DPP/DPPOS 2002; Ji 2011;
Li 1999; Lu 2010; PREVENT-DM 2017). Eighteen trials reported fast-
ing glucose values (Alfawaz 2018; BIGPRO1 2009; Chen 2009; DPP/
DPPOS 2002; Fang 2004; IDPP-1 2006; Ji 2011; Jin 2009; Li 1999; Li
2009; Liao 2012; Lu 2002; Lu 2010; Papoz 1978; PREVENT-DM 2017;
Wang 2009; Zeng 2013; Zhao 2013).
The reporting of adverse events was lacking in most trials (see Ap-
pendix 11; Appendix 12; Appendix 13).
Source of data
Where possible, we contacted all trial authors or investigators
through email. If an email address was not provided in the publica-
tion we tried to contact authors by phone (see Appendix 14).
Excluded studies
We excluded 53 articles or records after full-text evaluation (Fig-
ure 1). These references are listed in Characteristics of excluded
studies. We excluded 30 trials published in 31 references as they
had a duration of the intervention less than one year (Acbay 1996;
Ballon 2011; Biarnés 2005; Bulcão 2007; Caballero 2004; Chazova
2006; ChiCTR-TRC-09000548; Eguchi 2007; Esteghamati 2013; Flo-
res-Saenz 2003; Gómez-Díaz 2012; Gore 2005; Kelly 2012; Kendall
2013; Kilic 2011; Koev 2004; Krysiak 2012; Lehtovirta 2001; Li 2009b;
LIMIT-1; Malin 2013; Morel 1999; NCT00108615; NCT02338193;
RESIST; Retnakaran 2012; SLCTR/2016/026; Stroup 2013; Sultana
2012; Wan 2010). Ten trials published in 10 references were exclud-
ed due to wrong population (Celik 2012; Fleming 2002; Gram 2011;
Haukeland 2008; Kato 2009; NCT03258723; Rodríguez-Moctezuma
2005; Scheen 2009; Schuster 2004; UKPDS). Six trials published
in six references were excluded due to wrong intervention (Chen
2013; Guardado-Mendoza R 2018; Lu 2011; Pre-DICTED; STOP-NID-
DM; Zinman 2010). Four trials, one medical letter and one narrative
review published in a total of six references were excluded as they
were not RCTs (CTRI/2013/02/003417; EUCTR-000650-21-ES; EUC-
TR2008-004497-40-GB; Ishida 2005; Medical letter; Vitolins 2017).
Risk of bias in included studies
For details on the risk of bias of the included trials see Characteris-
tics of included studies.
For an overview of review authors' judgements about each risk of
bias item for individual trials and across all trials see Figure 2 and
Figure 3.
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Figure 2.   'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies (blank cells indicate that the particular outcome was not measured in some trials).
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Figure 3.   'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study
(blank cells indicate that the trial did not measure that particular outcome).
 
Allocation
We judged three trials to be at low risk of selection bias regard-
ing the method of randomisation and allocation concealment (Al-
fawaz 2018; DPP/DPPOS 2002; PREVENT-DM 2017). Three trials on-
ly reported the method of randomisation but not how allocation
concealment was achieved (BIGPRO1 2009; Fang 2004; Zeng 2013).
The remaining trials only reported that the participants were ran-
domised but did not provide any further description. Therefore,
these trials were judged as unclear risk of bias regarding randomi-
sation and allocation concealment.
We evaluated trial baseline data for our predefined prognostic
baseline variables. None of the trials reporting one or more key
prognostic variables showed important differences between the in-
tervention groups (see Appendix 5; Appendix 6)
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
development of type 2 diabetes mellitus (Review)









Cochrane Database of Systematic Reviews
Blinding
Four trials explicitly reported blinding of participants and investiga-
tors (BIGPRO1 2009; DPP/DPPOS 2002; Li 1999; Papoz 1978). How-
ever, one trial had a comparator group receiving placebo, which
was blinded and an intensive diet and exercise group which was not
blinded for the investigators and participants (DPP/DPPOS 2002).
When measured, all primary outcomes of this review were investi-
gator-assessed and we judged these at low risk of performance and
detection bias. The trials reporting blood glucose measurements
were all performed by the investigators and we judged these out-
comes measures at low risk of performance and detection bias.
Incomplete outcome data
All, but two trials reported the complete number of participants
randomised and completing the trial (DPP/DPPOS 2002; Maji 2005).
We judged five trials to have low risk of incomplete outcome data
for all outcomes reported with relevance of our review (BIGPRO1
2009; DPP/DPPOS 2002; Ji 2011; Lu 2010; PREVENT-DM 2017). We
judged seven trials to have unclear risk of attrition bias for one or
more outcomes (Fang 2004; IDPP-1 2006; Iqbal Hydrie 2012; Li 1999;
Maji 2005; Papoz 1978; Zeng 2013). The reason for unclear risk of at-
trition bias were unclear or missing description of how missing da-
ta were handled, unclear whether mortality status was investigat-
ed in the people lost to follow-up and reasons for dropout were not
reported. We judged eight trials to have high risk of attrition bias for
one or more of the outcomes (Alfawaz 2018; Chen 2009; Jin 2009;
Li 2009; Liao 2012; Lu 2002; Wang 2009; Zhao 2013). The reason for
high risk of attrition bias were high dropout rate, dropout rates not
balanced, reasons for dropouts not balanced, missing information
on dropouts or per protocol analysis applied.
Selective reporting
We judged 15 trials as high risk of selective outcome reporting
mainly because one or more outcomes of relevance for our review
were likely assessed but not reported and/or the protocol were un-
available. For more details, see Figure 3, Appendix 7 and Appendix
8.
Other potential sources of bias
Seven trials appeared to be free of other potential sources of bias
(Alfawaz 2018; Iqbal Hydrie 2012; Ji 2011; Jin 2009; Lu 2002; Papoz
1978; PREVENT-DM 2017). Three of the included trials stated that
they had received support from a pharmaceutical company (BIG-
PRO1 2009; DPP/DPPOS 2002; IDPP-1 2006). Nine trials did not re-
port the funding source (Chen 2009; Fang 2004; Li 1999; Li 2009; Lu
2010; Maji 2005; Wang 2009; Zeng 2013; Zhao 2013). It is known that
trials receiving funding or provision of free drug or devices from
a pharmaceutical company lead to more favourable results and
conclusions than trials sponsored by other sources (Lundh 2017).
Therefore, these trials were judged at unclear risk of bias in the 'oth-
er sources' bias-domain.
Effects of interventions
See: Summary of findings for the main comparison Summary of
findings table for metformin compared with diet and exercise or an-
other antidiabetic drug; Summary of findings 2 Summary of find-
ings table for metformin plus intensive diet and exercise compared
with intensive diet and exercise
Baseline characteristics
For details of baseline characteristics, see Appendix 5 and Appendix
6.
Metformin versus placebo or diet and exercise
Fifteen trials compared metformin with diet and exercise in com-
bination with placebo (BIGPRO1 2009; DPP/DPPOS 2002; Li 1999;
Papoz 1978) or without concomitant placebo (Alfawaz 2018; Chen
2009; Fang 2004; IDPP-1 2006; Ji 2011; Jin 2009; Lu 2002; Lu 2010;
PREVENT-DM 2017; Wang 2009; Zeng 2013). One trial administered
metformin in doses of 38 mg/day (Zeng 2013). One trial admin-
istered metformin in doses up to 500 mg/day. One trial admin-
istered metformin in doses up to 750 mg/day (Li 1999); two tri-
als administered metformin in doses up to 1000 mg/day (Alfawaz
2018; IDPP-1 2006); two trials administered metformin in doses up
to 1500 mg/day (Ji 2011; Lu 2010); three trials administered met-
formin in doses up to 1700 mg/day (BIGPRO1 2009; DPP/DPPOS
2002; Papoz 1978); three trials administered metformin in doses up
to 2250 mg/day (Chen 2009; Fang 2004; Lu 2002); one trial adminis-
tered metformin in doses up to 2550 mg/day (PREVENT-DM 2017);
and one trial administered metformin in doses up to 3000 mg/day
(Jin 2009). One trial had an extended follow-up period (DPP/DPPOS
2002). Ten trials stated that the metformin group also received con-
comitant standard diet plus exercise (Alfawaz 2018; BIGPRO1 2009;
Chen 2009; DPP/DPPOS 2002; Ji 2011; Jin 2009; Lu 2002; Lu 2010;
Wang 2009; Zeng 2013). Nine trials included people of Chinese eth-
nicity (Chen 2009; Fang 2004; Ji 2011; Jin 2009; Li 1999; Lu 2002; Lu
2010; Wang 2009; Zeng 2013); one trial included mainly White peo-
ple (DPP/DPPOS 2002); one trial included people of Saudi Arabian
ethnicity (Alfawaz 2018); one trial included people of Indian ethnic-
ity (IDPP-1 2006); one trial included Hispanic people (PREVENT-DM




Five trials reported data on all-cause mortality (DPP/DPPOS 2002;
Fang 2004; IDPP-1 2006; Lu 2002; PREVENT-DM 2017).
A total of seven deaths were reported in 1353 participants in the
metformin group versus seven out of 1480 participants in the com-
parator group (risk ratio (RR) 1.11, 95% confidence interval (CI) 0.41
to 3.01; P = 0.83; 2833 participants, 5 trials; very low-quality evi-
dence; Analysis 1.1). Calculation of a 95% prediction interval was
not meaningful. We did not perform subgroup analyses and sensi-
tivity analyses due to lack of data.
Incidence of type 2 diabetes (T2DM)
Twelve trials reported data on the incidence of T2DM. The defini-
tion of T2DM varied among the included trials (see Appendix 9 and
Appendix 10).
A total of 324 out of 1751 participants developed T2DM in the met-
formin group versus 529 out of 1881 participants in the comparator
group (RR 0.50, 95% CI 0.38 to 0.65; P < 0.001; 3632 participants, 12
trials; moderate-quality evidence; Analysis 1.2). The 95% prediction
interval ranged between 0.26 and 0.97.
One trial reported the incidence of T2DM after an extended fol-
low-up period (DPP/DPPOS 2002). At year 15, the cumulative inci-
dence of T2DM was 560 participants (62%) in the former control
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group versus 499 participants (56%) in the former metformin group
(DPP/DPPOS 2002).
The funnel plot did not show small trial effect (data not shown).
Subgroup analysis: analysing trials according to blinded versus
open-label trials showed interaction between subgroups indicat-
ing smaller effect sizes with blinded trials (P = 0.003; Analysis 1.3).
Subgroup analysis according to duration of the intervention did not
show interaction between subgroups (P = 0.18; Analysis 1.4). Sub-
group analysis according to ethnicity showed interaction between
subgroups indicating smaller effect sizes in White people (P = 0.01;
Analysis 1.5). Subgroup analysis according to diagnostic criteria,
age, gender, comorbid condition and previous gestational diabetes
could not be performed.
Sensitivity analysis: sensitivity analysis according to publication
status could not be performed as all included trials were published.
Sensitivity analysis restricted to only trials with low risk of selec-
tion bias did not substantially change the effect estimate: RR 0.75,
95% CI 0.65 to 0.87; P < 0.001; 2155 participants, 1 trial (DPP/DP-
POS 2002). Eight trials were only published in Chinese. Sensitivi-
ty analysis restricted to trials published in English did not substan-
tially change the direction of the effect estimate: RR 0.74, 95% CI
0.65 to 0.84; P < 0.001; 2560 participants; 4 trials (DPP/DPPOS 2002;
IDPP-1 2006; Li 1999; PREVENT-DM 2017). Sensitivity analysis ex-
cluding trials funded by a pharmaceutical company did not sub-
stantially change the direction of the effect estimate: RR 0.36, 95%
CI 0.26 to 0.49; P < 0.001; 1216 participants; 10 trials (Chen 2009;
Fang 2004; Ji 2011; Jin 2009; Li 1999; Lu 2002; Lu 2010; PREVENT-DM
2017; Wang 2009; Zeng 2013).
Serious adverse events
The reporting of serious adverse events was insufficient and di-
verse (very low-quality evidence). One trial reported no serious ad-
verse events in both the intervention and comparator groups (PRE-
VENT-DM 2017). In one trial three out of 45 participants in the met-
formin group experienced severe gastrointestinal reactions (Jin
2009). In one study one out of 44 participants died due to liver can-
cer in the metformin group compared to 0/35 participants in the
standard care group (Fang 2004). In one study one out of 75 par-
ticipants in the standard care group died due to cerebral thrombo-
sis with pulmonary infection and one out of 51 participants in the




Two trials reported cardiovascular mortality (DPP/DPPOS 2002;
IDPP-1 2006; very low-quality evidence). One trial reported that no
participant died due to cardiovascular causes (IDPP-1 2006). One
trial reported that one out of 1073 participants in the metformin
group compared with four out of 1082 participants in the control
group died due to cardiovascular causes (DPP/DPPOS 2002).
Non-fatal myocardial infarction
No trial reported data exclusively on non-fatal myocardial infarc-
tion (very low-quality evidence). In the DPP trial non-fatal cardio-
vascular events occurred in 1.7% of the participants in the control
group compared with 1.5% of the participants in the metformin
group (DPP/DPPOS 2002). In the Indian Diabetes Prevention Pro-
gram (IDPP) trial, two out of 133 participants in the diet and exercise
group versus none out of 128 participants in the metformin group
had a cardiovascular event (IDPP-1 2006).
Non-fatal stroke
None of the trials reported on non-fatal stroke (very low-quality ev-
idence).
Amputation of lower extremity
None of the trials reported on amputation of lower extremity.
Blindness or severe vision loss
None of the trials reported on blindness or severe vision loss.
End-stage renal disease
None of the trials reported on end-stage renal disease.
Non-serious adverse events
Two trials reported on all non-serious adverse events (Lu 2010; PRE-
VENT-DM 2017). A total of 31 out of 144 participants experienced a
non-serious adverse event in the metformin group versus 17 out of
141 participants in the comparator group (RR 3.86, 95% CI 0.18 to
83.36; P = 0.39; 285 participants, 2 trials; Analysis 1.6). Seven trials
reported partially on adverse effects (DPP/DPPOS 2002; Fang 2004;
IDPP-1 2006; Jin 2009; Li 1999; Lu 2010; Wang 2009), see Appendix
11; Appendix 12; Appendix 13.
Hypoglycaemia
Three trials reported data on hypoglycaemia (IDPP-1 2006; Lu 2010;
Jin 2009). One trial had two intervention arms applying metformin
(metformin monotherapy and metformin plus intensive diet and
exercise) (IDPP-1 2006). The number of participants with hypogly-
caemia was not reported separately for each metformin group. A
total of 22 out of 248 participants reported symptoms of mild hypo-
glycaemia. None experienced symptoms of hypoglycaemia in the
comparator group (IDPP-1 2006). One trial reported that no partici-
pant experienced hypoglycaemia (Jin 2009). One trial reported that
four out of 115 participants in the metformin group experienced
low blood glucose compared to two out of 111 participants in the
comparator group (Lu 2010).
Health-related quality of life
The DPP trial applied the Short Form (SF)-36 to evaluate the health
utility index (SF-6D), physical component summaries (PCS) and
mental component summaries (MCS). Minimal important differ-
ence (MID) was defined as difference in scores between groups of at
least 3% (DPP/DPPOS 2002). After a mean of 3.2 years of follow-up
there was no clear difference in any of the health-related quality of
life scores between the metformin group compared with the place-
bo group (very low-quality evidence).
Time to progression to T2DM
After a median of 10 years follow-up in the DPP trial, the onset of
diagnosis of T2DM was delayed by two years with metformin com-
pared with placebo (DPP/DPPOS 2002).
Measures of blood glucose control
2-hour glucose
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Thirteen trials reported data on 2-hour glucose after an oral glucose
tolerance test (OGTT) (BIGPRO1 2009; Chen 2009; DPP/DPPOS 2002;
Fang 2004; IDPP-1 2006; Ji 2011; Jin 2009; Li 1999; Lu 2002; Lu 2010;
Papoz 1978; Wang 2009; Zeng 2013). The effect estimate showed
benefit in favour of metformin (mean difference (MD) -0.86 mmol/L;
95% CI -1.26 to -0.46; P < 0.001; 3346 participants; 13 trials; Analysis
1.7).
Subgroup analysis: analysing trials according to blinded versus
open-label trials showed interaction between subgroups (P = 0.03;
Analysis 1.8), however CIs overlapped. Subgroup analysis accord-
ing to duration of the intervention did not indicate interaction be-
tween subgroups (P = 0.08; Analysis 1.9). Subgroup analysis accord-
ing to ethnicity showed interaction between subgroups indicating
greater effect sizes for Asian people (P < 0.001; Analysis 1.10). Sub-
group analysis according to diagnostic criteria, age, gender, comor-
bid condition and previous gestational diabetes could not be per-
formed.
Sensitivity analysis: sensitivity analysis according to publication
status could not be performed as all included trials were published.
Sensitivity analysis restricted to only trials with low risk of selection
bias changed the direction of the effects estimate: MD 0.00 mmol/
L, 95% CI -0.17 to 0.17; P = 1.0; 1856 participants, 1 trial (DPP/DP-
POS 2002). Eight trials were only published in Chinese. Sensitivi-
ty analysis restricted to trials published in English changed the di-
rection of the effect estimate: MD -0.48 mmol/L; 95% CI -1.11 to
0.16; P = 0.14; 2279 participants; 5 trials (BIGPRO1 2009; DPP/DPPOS
2002; IDPP-1 2006; Li 1999; PREVENT-DM 2017). Sensitivity analy-
sis excluding trials funded by a pharmaceutical company did not
substantially change the direction of the effect estimate: MD -0.99
mmol/L, 95% CI -1.34 to -0.64; P < 0.001; 1179 participants; 10 trials
(Chen 2009; Fang 2004; Ji 2011; Jin 2009; Li 1999; Lu 2002; Lu 2010;
Papoz 1978; Wang 2009; Zeng 2013).
HbA1c
Six trials reported data on HbA1c (Alfawaz 2018; DPP/DPPOS 2002;
Ji 2011; Li 1999; Lu 2010; PREVENT-DM 2017) showing a MD of
-0.08%; 95% CI -0.22 to 0.05; P = 0.04; 2467 participants; 6 trials;
Analysis 1.11.
Subgroup analysis: analysing trials according to blinded versus
open-label trials did not show interaction between subgroups (P =
0.11; Analysis 1.11 ). Subgroup analysis according to duration of the
intervention did not show interaction between subgroups (P = 0.71;
Analysis 1.12). Subgroup analysis according to ethnicity showed
interaction between subgroups indicating greater effect sizes for
Asian people (P = 0.01; Analysis 1.13). Subgroup analysis according
to diagnostic criteria, age, gender, comorbid condition and previ-
ous gestational diabetes could not be performed.
Sensitivity analysis: sensitivity analysis according to publication
status could not be performed as all included trials were published.
Sensitivity analysis restricted to only trials with low risk of selec-
tion bias changed the direction of the effect estimate: MD 0.00%,
95% CI -0.04 to 0.04; P = 1.0; 1856 participants; 1 trial (DPP/DPPOS
2002). Two trials were only published in Chinese. Sensitivity analy-
sis restricted to trials published in English changed the direction
of the effect estimate: MD -0.01 %; 95% CI -0.13 to 0.07; P = 0.74;
2125 participants; 4 trials (Alfawaz 2018; DPP/DPPOS 2002; Li 1999;
PREVENT-DM 2017). Sensitivity analysis excluding trials funded by
a pharmaceutical company did not substantially change the direc-
tion of the effect estimate: MD -0.29 %, 95% CI -0.57 to -0.02; P = 0.04;
611 participants; 5 trials (Alfawaz 2018; Ji 2011; Li 1999; Lu 2010;
PREVENT-DM 2017).
Fasting plasma glucose
Fifteen trials reported data on fasting plasma glucose (Alfawaz
2018; BIGPRO1 2009; Chen 2009; DPP/DPPOS 2002; Fang 2004;
IDPP-1 2006; Ji 2011; Jin 2009; Li 1999; Lu 2002; Lu 2010; Papoz
1978; PREVENT-DM 2017; Wang 2009; Zeng 2013); random-effects
MD -0.28 mmol/L; 95% CI -0.42 to -0.13; P = 0.0002; 3546 partici-
pants; 15 trials; Analysis 1.14. Heterogeneity was substantial (I2 =
82%; P < 0.0001).
Subgroup analysis: analysing trials according to blinded versus
open-label trials did not show interaction between subgroups (P
= 0.22; Analysis 1.15). Subgroup analysis according to duration of
the intervention did not show interaction between subgroups (P =
0.13; Analysis 1.16). Subgroup analysis according to ethnicity did
not show any interaction between subgroups (P = 0.67; Analysis
1.17). Subgroup analysis according to diagnostic criteria, age, gen-
der, comorbid condition and previous gestational diabetes could
not be performed.
Sensitivity analysis: sensitivity analysis according to publication
status could not be performed as all included trials were published.
Sensitivity analysis restricted to only trials with low risk of selection
bias changed the direction of the effect estimate; random-effects
MD -0.30, 95% CI -0.39 to -0.21; P < 0.001; 1861 participants; 1 tri-
al (DPP/DPPOS 2002). Eight trials were published in Chinese. Sensi-
tivity analysis restricted to trials published in English changed the
direction of the effect estimate random-effects MD -0.31 mmol/L;
95% CI -0.55 to -0.08; P = 0.009; 2483 participants; 7 trials (Alfawaz
2018; BIGPRO1 2009; DPP/DPPOS 2002; IDPP-1 2006; Li 1999; Papoz
1978; PREVENT-DM 2017). Sensitivity analysis excluding trials fund-
ed by a pharmaceutical company did not change the direction of
the effect estimate random-effects MD -0.27 mmol/L, 95% CI -0.48
to -0.06; P = 0.0002; 1374 participants; 12 trials (Alfawaz 2018; Chen
2009; Fang 2004; Ji 2011; Jin 2009; Li 1999; Lu 2002; Lu 2010; Papoz
1978; PREVENT-DM 2017; Wang 2009; Zeng 2013).
Socioeconomic effects
During the DPP trial the metformin intervention was substantially
more expensive than the placebo intervention (DPP/DPPOS 2002).
Direct medical costs of the interventions during the DPP were es-
timated to be $1177 for the metformin intervention versus $184
for the placebo group (low-quality evidence). By year 10, the di-
rect medical costs of the intervention and non-intervention-related
medical costs were lower for the metformin group than for the con-
trol group ($27,915 versus $28,237).
From the perspective of a health system (direct medical costs of
the interventions plus direct medical costs of care outside the tri-
al) costs were $99,600 per quality adjusted life years (QALY)-gained
with metformin compared with placebo. From the perspective of
society (direct medical costs plus non medical costs (expenditures
from medical treatments, but not involving purchase of medical
services or products) plus indirect costs (costs to the society due
to morbidity and mortality, e.g. absence from work due to medical
treatment)) the costs were $99,200 per QALY-gained with metformin
compared with placebo (DPP/DPPOS 2002).
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The IDPP trial estimated the direct medical costs of interventions
over the three-year trial period to be $220 per participant in the
metformin group compared with $61 in the standard diet and phys-
ical activity group (IDPP-1 2006).
Metformin versus intensive diet plus exercise
Eight trials compared metformin with intensive diet and exercise
(Alfawaz 2018; DPP/DPPOS 2002; Fang 2004; IDPP-1 2006; Ji 2011; Li
2009; Maji 2005; PREVENT-DM 2017). Two trials applied metformin
in doses up to 500 mg/day (Li 2009; Maji 2005); two trials applied
metformin in doses up to 1000 mg/day (Alfawaz 2018; IDPP-1 2006);
one trial applied metformin in doses up to 1500 mg/day (Ji 2011);
one trial applied metformin in doses up to 1700 mg/day (DPP/DP-
POS 2002); one trial applied metformin in doses up to 2250 mg/
day (Fang 2004); and one trial administered metformin in doses
up to 2550 mg/day (PREVENT-DM 2017). Five trials stated that the
metformin group received concomitant diet and exercise (Alfawaz
2018; DPP/DPPOS 2002; Ji 2011; Jin 2009; Maji 2005).
Primary outcomes
All-cause mortality
Four trials reported data on all-cause mortality (DPP/DPPOS 2002;
Fang 2004; IDPP-1 2006; PREVENT-DM 2017).
A total of seven deaths were reported in 1278 participants in the
metformin group versus four out of 1272 participants in the com-
parator group (RR 1.61, 95% CI 0.50 to 5.23; P = 0.43; 2550 partici-
pants, 4 trials; very low-quality of the evidence; Analysis 2.1).
We did not perform subgroup analyses and sensitivity analyses due
to lack of data.
Incidence of type 2 diabetes (T2DM)
Seven trials reported the incidence of T2DM (DPP/DPPOS 2002;
Fang 2004; IDPP-1 2006; Ji 2011; Li 2009; Maji 2005; PREVENT-DM
2017). The definition of T2DM varied among the included trials (see
Appendix 9 and Appendix 10). Calculation of a 95% prediction in-
terval was not meaningful.
A total of 304 out of 1455 participants developed T2DM in the met-
formin group versus 251 out of 1505 participants in the compara-
tor group (RR 0.80, 95% CI 0.47 to 1.37; P = 0.42; 2960 participants,
7 trials; moderate-quality of the evidence; Analysis 2.2). The 95%
prediction interval ranged between 0.18 and 3.62.
One trial reported the incidence of T2DM after an extended fol-
low-up period (DPP/DPPOS 2002). At year 15 the cumulative inci-
dence of T2DM was 480 participants (55%) in the former intensive
diet plus physical activity group versus 499 participants (56%) in
the former metformin group (DPP/DPPOS 2002).
Subgroup analysis: analysing trials according to blinded versus
open-label trials could not be performed as all participants were
aware of randomising to intensive diet plus exercise. Subgroup
analysis according to duration of the intervention could not be
performed as only one trial (without any participants developing
T2DM) had a duration of intervention of less than two years (PRE-
VENT-DM 2017). Subgroup analysis according to ethnicity showed
interaction between subgroups (P = 0.02; Analysis 2.4), however
CIs overlapped. Subgroup analysis according to diagnostic criteria,
age, gender, comorbid condition and previous gestational diabetes
could not be performed.
Sensitivity analysis: sensitivity analysis according to publication
status could not be performed as all included trials were published.
Sensitivity analysis restricted to only trials with low risk of selection
bias changed the direction of the effect estimate: RR 1.51, 95% CI
1.25 to 1.81; P < 0.001; 2152 participants; 1 trial (DPP/DPPOS 2002).
Three trials were published in Chinese. Sensitivity analysis restrict-
ed to trials published in English did not substantially change the
direction of the effect estimate: RR 1.26, 95% CI 0.86 to 1.86; P =
0.24; 2600 participants; 4 trials (DPP/DPPOS 2002; IDPP-1 2006; Maji
2005; PREVENT-DM 2017). Sensitivity analysis excluding trials fund-
ed by a pharmaceutical company changed the direction of the ef-
fect estimate towards benefit of metformin therapy: RR 0.47, 95%
CI 0.25 to 0.87; P = 0.02; 560 participants; 5 trials (Fang 2004; Ji 2011;
Li 2009; Maji 2005; PREVENT-DM 2017).
Serious adverse events
The reporting of serious adverse events was sparse and meta-
analysis could not be performed. One trial reported no serious ad-
verse events in 29 participants in the metformin group and 30 par-
ticipants in the standard care group (PREVENT-DM 2017). In one tri-
al, one out of 44 participants died due to liver cancer in the met-
formin group compared to zero out of 36 participants in the stan-
dard care group (Fang 2004).
Secondary outcomes
Cardiovascular mortality
Two trials reported cardiovascular mortality (DPP/DPPOS 2002;
IDPP-1 2006). One trial reported that no participants died due to
cardiovascular causes (IDPP-1 2006). One trial reported that one
out of 1073 participants in the metformin group compared with two
out of 1079 participants in the intensive diet plus exercise group
died from cardiovascular causes (DPP/DPPOS 2002).
Non-fatal myocardial infarction
No trial reported data exclusively on non-fatal myocardial infarc-
tion. One trial reported that non-fatal cardiovascular events oc-
curred in 1.7% of the participants in the control group compared
with 1.5% of the participants in the metformin group (DPP/DP-
POS 2002). One trial reported that zero out of 128 participants in
the metformin group compared to four out of 120 participants in
the comparator group experienced cardiovascular events (IDPP-1
2006).
Non-fatal stroke
No trial reported data exclusively on non-fatal stroke.
Amputation of lower extremity
None of the trials reported on amputation of lower extremity.
Blindness or severe vision loss
None of the trials reported on blindness or severe vision loss.
End-stage renal disease
None of the trials reported on end-stage renal disease
Non-serious adverse events
One trial reported on all non-serious adverse events (PREVENT-DM
2017). Ten (34.5%) out of 29 participants in the metformin group
compared with zero out of 33 participants in the comparator group
experienced a non-serious adverse event (PREVENT-DM 2017).
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Three trials reported on some adverse effects (DPP/DPPOS 2002;
Fang 2004; IDPP-1 2006). In one trial, three out of 44 participants
had diarrhoea in the metformin group compared to zero out of 36
participants in the comparator group (Fang 2004). One trial had two
metformin groups (metformin monotherapy and metformin plus
intensive diet and exercise), which were reported together. The tri-
al reported that five out of 248 participants in the combined met-
formin groups experienced gastrointestinal symptoms compared
to zero out of 120 participants in the comparator group (IDPP-1
2006). In one trial, 20 events of musculoskeletal symptoms per 100
person years and 78 events of gastrointestinal symptoms per 100
person years were experienced in the metformin group compared
with 24 events of musculoskeletal symptoms per 100 person years
and 13 events of gastrointestinal symptoms per 100 person years in
the comparator group (DPP/DPPOS 2002).
Hypoglycaemia
One trial reported data on hypoglycaemia (IDPP-1 2006). In the
two metformin groups (metformin monotherapy and metformin
plus intensive diet and exercise), 22 out of 248 participants report-
ed symptoms of mild hypoglycaemia; it was not possible to sepa-
rate these data. No participant experienced symptoms of hypogly-
caemia in the intensive diet plus exercise group (IDPP-1 2006).
Health-related quality of life
The DPP trial applied the SF-36 to evaluate the health utility index
(SF-6D), physical component summaries (PCS) and mental compo-
nent summaries (MCS). Minimal important difference (MID) was de-
fined as scores between groups of at least 3% (DPP/DPPOS 2002).
After a mean of 3.2 years of follow-up trial authors only reported the
comparison metformin versus placebo, not metformin versus diet
plus exercise (DPP/DPPOS 2002).
Time to progression to T2DM
After a median of 10 years follow-up in the DPP trial, the onset of
diagnosis of T2DM was delayed by two years with metformin and
four years with intensive diet and exercise compared with placebo
(DPP/DPPOS 2002).
Measures of blood glucose control
2-hour glucose
Five trials reported data on 2-hour glucose (DPP/DPPOS 2002; Fang
2004; IDPP-1 2006; Ji 2011; Li 2009): MD -0.03 mmol/L, 95% CI -0.26
to 0.20; P = 0.81; 2417 participants; 5 trials; Analysis 2.5.
Subgroup analysis: analysing trials according to blinded versus
open-label trials could not be performed as all participants were
aware of randomising to intensive diet plus exercise. Subgroup
analysis according to duration of the intervention could not be per-
formed as all trials reporting this outcome had a duration of in-
tervention of two years or more. Subgroup analysis according to
ethnicity did not show interaction between subgroups (P = 0.06;
Analysis 2.6). Subgroup analysis according to diagnostic criteria,
age, gender, comorbid condition and previous gestational diabetes
could not be performed.
Sensitivity analysis: sensitivity analysis according to publication
status could not be performed as all included trials were published.
Sensitivity analysis restricted to only trials with low risk of selection
bias changed the direction of the effect estimate: MD 0.20 mmol/
L, 95% CI 0.02 to 0.38; P = 0.03; 1834 participants; 1 trial (DPP/DP-
POS 2002). Three trials were only published in Chinese. Sensitivity
analysis restricted to trials published in English changed the direc-
tion of the effect estimate favouring intensive diet plus exercise: MD
0.20 mmol/L, 95% CI 0.02 to 0.37; P = 0.03; 2065 participants; 2 trials
(DPP/DPPOS 2002; IDPP-1 2006). Sensitivity analysis excluding tri-
als funded by a pharmaceutical company did not change the direc-
tion of the effect estimate: MD -0.32, 95% CI -0.83 to 0.19; P = 0.22;
352 participants; 3 trials (Fang 2004; Ji 2011; Li 2009).
HbA1c
Four trials reported data on HbA1c (Alfawaz 2018; DPP/DPPOS
2002; Ji 2011; PREVENT-DM 2017): MD 0.01% mmol/L, 95% CI -0.12
to 0.14; P = 0.93; 2135 participants; 4 trials; Analysis 2.7.
Subgroup analysis: analysing trials according to blinded versus
open-label trials could not be performed as all participants were
aware of randomising to intensive diet plus exercise. Subgroup
analysis according to duration of the intervention did not show
interaction between subgroups (P = 0.65; Analysis 2.8). Subgroup
analysis according to ethnicity showed interaction between sub-
groups (P = 0.04; Analysis 2.9). Subgroup analysis according to diag-
nostic criteria, age, gender, comorbid condition and previous ges-
tational diabetes could not be performed.
Sensitivity analysis: sensitivity analysis according to publication
status could not be performed as all included trials were published.
Sensitivity analysis restricted to only trials with low risk of selec-
tion bias did not substantially change the direction of the effect es-
timate: MD 0.00%, 95% CI -0.04 to 0.04; P = 1.0; 1834 participants;
1 trial (DPP/DPPOS 2002). One trial was only published in Chinese.
Sensitivity analysis restricted to trials published in English did not
change the direction of the effect estimate: MD 0.01%, 95% CI -0.13
to 0.16; P = 0.87; 2023 participants; 3 trials (Alfawaz 2018; DPP/DP-
POS 2002; PREVENT-DM 2017). Sensitivity analysis excluding trials
funded by a pharmaceutical company did not change the direction
of the effect estimate: MD -0.10%, 95% CI -0.44 to 0.25; P = 0.59; 301
participants; 3 trials (Alfawaz 2018; Ji 2011; PREVENT-DM 2017).
Fasting plasma glucose
Seven trials reported data on fasting plasma glucose (Alfawaz 2018;
DPP/DPPOS 2002; Fang 2004; IDPP-1 2006; Ji 2011; Li 2009; PRE-
VENT-DM 2017). The MD was -0.26 mmol/L, 95% CI -0.59 to 0.07; P =
0.12; 2603 participants; 7 trials; Analysis 2.10.
Subgroup analysis: analysing trials according to blinded versus
open-label trials could not be performed as all participants were
aware of randomising to intensive diet plus exercise. Subgroup
analysis according to duration of the intervention did not show in-
teraction between subgroups (P = 0.09; Analysis 2.11). Subgroup
analysis according to ethnicity did not show interaction between
subgroups (P = 0.10; Analysis 2.12). Subgroup analysis according to
diagnostic criteria, age, gender, comorbid condition and previous
gestational diabetes could not be performed.
Sensitivity analysis: sensitivity analysis according to publication
status could not be performed as all included trials were published.
Sensitivity analysis restricted to only trials with low risk of selection
bias changed the direction of the effect estimate: MD 0.00 mmol/
L, 95% CI -0.07 to 0.07; P = 1.0; 1831 participants; 1 trial (DPP/DP-
POS 2002). Three trials were only published in Chinese. Sensitivity
analysis restricted to trials published in English changed the direc-
tion of the effect estimate: MD 0.0 mmol/L, 95% CI -0.07 to 0.07; P
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= 0.95; 2251 participants; 4 trials (Alfawaz 2018; DPP/DPPOS 2002;
IDPP-1 2006; PREVENT-DM 2017). Sensitivity analysis excluding tri-
als funded by a pharmaceutical company changed the direction of
the effect estimate towards benefit of metformin: MD -0.37 mmol/
L, 95% CI -0.65 to -0.09; P = 0.009; 541 participants; 5 trials (Alfawaz
2018; Fang 2004; Ji 2011; Li 2009; PREVENT-DM 2017).
Socioeconomic effects
Direct medical costs of the interventions during the DPP were es-
timated to be $1177 for the metformin intervention versus $3628
for the intensive diet plus physical activity group (DPP/DPPOS
2002). By year 10, the direct medical costs of the interventions
and non-intervention-related medical costs were lower for the met-
formin group than for the intensive diet plus physical activity group
($27,915 versus $29,164).
The IDPP estimated direct medical costs of interventions over the
3-year trial period to be $220 per participant in the metformin
group compared with $225 in the intensive diet and physical activ-
ity group (IDPP-1 2006).
Metformin versus insulin secretagogues
One trial compared metformin with a sulphonylurea (Papoz 1978).
Metformin was administered in doses of 1700 mg/day with con-
comitant placebo. Glibenclamide was administered in doses of 4
mg/day with concomitant placebo. For both groups, overweight
participants were recommended calorie restriction. The ethnicity
of the included participants was not reported.
The trial reported 2-hour blood glucose and fasting blood glucose
in mg/100 mL. The results were converted to plasma glucose mea-
sured in mmol/L and standard errors were converted to standard
deviations (SDs). For the metformin group the 2-hour plasma glu-
cose at the end of intervention was 7.2 mmol/L (SD 1.3) measured
in 23 participants compared to 7.1 mmol/L (SD 1.3) measured in 22
participants in the glibenclamide group. For the metformin group
the fasting plasma glucose at the end of intervention was 5.9 mmol/
L (SD 0.5) measured in 23 participants compared to 5.6 mmol/L (SD
0.6) measured in 22 participants in the glibenclamide group.
Metformin versus acarbose
Three trials compared metformin with acarbose (Fang 2004; Liao
2012; Maji 2005). Several differences existed between these three
trials. Two trials did not specify the concomitant intervention with
diet and physical activity (Fang 2004; Liao 2012); the other tri-
al specified that diet and physical activity was provided in both
the metformin and the acarbose intervention groups (Maji 2005).
Two trials included people with Chinese ethnicity (Fang 2004; Liao
2012), one trial included people with Indian ethnicity (Maji 2005).
One trial administered metformin in doses up to 500 mg/day and
acarbose in doses up to 50 mg/day (Maji 2005). One trial adminis-
tered metformin in doses up to 1500 mg/day and acarbose in doses
up to 300 mg/day (Liao 2012). One trial administered metformin in




One trial reported data on all-cause mortality (Fang 2004). One par-
ticipant out of 44 in the metformin group compared with zero out
of 45 in the acarbose group died (Fang 2004).
Incidence of type 2 diabetes (T2DM)
All included trials reported data on the incidence of T2DM. A total of
12 out of 147 participants developed T2DM in the metformin group
versus seven out of 148 participants in the comparator group (RR
1.72; 95% CI 0.72 to 4.14; P = 0.22; 295 participants; 3 trials; low-
quality evidence; Analysis 4.2). Calculation of a 95% prediction in-
terval was not meaningful.
Serious adverse events
In one trial one out of 51 participants in the metformin group expe-
rienced cerebral haemorrhage, whereas two out of 50 participants




None of the trials reported on cardiovascular mortality.
Non-fatal myocardial infarction
None of the trials reported on non-fatal myocardial infarction.
Non-fatal stroke
None of the trials reported on non-fatal stroke.
Amputation of lower extremity
None of the trials reported on amputation of lower extremity.
Blindness or severe vision loss
None of the trials reported on blindness or severe vision loss.
End-stage renal disease
None of the trials reported on end-stage renal disease
Non-serious adverse events
One trial reported that in the metformin group three out of 44 par-
ticipants experienced diarrhoea (Fang 2004). In the acarbose group
one out of 45 participants experienced rash and one out of 45 par-
ticipants experienced frequent venting (Fang 2004).
Hypoglycaemia
None of the trials reported on hypoglycaemia.
Health-related quality of life
None of the trials reported on health-related quality of life.
Time to progression to T2DM
None of the trials reported on time to progression to T2DM.
Measures of blood glucose control
2-hour glucose
Both included trials reported data on 2-hour glucose. Effects of in-
tervention showed benefit in favour of acarbose: MD 0.49 mmol/L,
95% CI 0.09 to 0.88; P = 0.02; 190 participants; 2 trials; Analysis 4.3.
One trial reported a mean 2-hour glucose of 5.9 mmol/L (SD 0.9)
in the metformin group (unknown how many of the 48 initially ran-
domised participants were included in the analysis) compared with
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6.0 mmol/L (SD 0.5) in the acarbose group (unknown how many of
the 48 initially randomised participants were included in the analy-
sis) (Maji 2005).
HbA1c
One trial reported a mean HbA1c of 6.96% (SD 0.43) in the met-
formin group (unknown how many of the 48 initially randomised
participants were included in the analysis) compared with 6.96%
(SD 0.16) in the acarbose group (unknown how many of the 48 ini-
tially randomised participants were included in the analysis) (Maji
2005).
Fasting plasma glucose
Both included trials reported data on fasting plasma glucose. The
MD was 0.00 mmol/L, 95% CI -0.35 to 0.35; P = 0.99; 190 participants;
2 trials; Analysis 4.4.
One trial reported a mean fasting plasma glucose of 5.4 mmol/L
(SD 0.3) in the metformin group (unknown how many of the 48 ini-
tially randomised participants were included in the analysis) com-
pared with 5.5 mmol/L (SD 0.4) in the acarbose group (unknown
how many of the 48 initially randomised participants were includ-
ed in the analysis) (Maji 2005).
Socioeconomic effects
None of the trials reported on socioeconomic effects.
Metformin versus thiazolidinediones
Three trials compared metformin with a thiazolidinediones (Jin
2009; Maji 2005; Zeng 2013). One trial administered metformin in
doses up to 38 mg/day and pioglitazone in doses up to 38 mg/
day (Zeng 2013); one trial administered metformin in doses up to
500 mg/day and rosiglitazone in doses up to 2 mg/day (Maji 2005);
and one trial administered metformin in doses up to 3000 mg/day
and rosiglitazone in doses up to 4 mg/day (Jin 2009). All trials stat-
ed that both the intervention and comparator group received diet
and exercise. Two trials included people with Chinese ethnicity (Jin




None of the trials reported on all-cause mortality..
Incidence of type 2 diabetes (T2DM)
All included trials reported data on incidence of T2DM. A total of
nine out of 161 participants developed T2DM in the metformin
group versus nine out of 159 participants in the comparator group
(RR 0.99, 95% CI 0.41 to 2.40; P = 0.98; 320 participants; 3 trials; low-
quality evidence; Analysis 5.1). Calculation of a 95% prediction in-
terval was not meaningful.
Serious adverse events
In one trial, three out of 45 participants in the metformin group ex-
perienced severe gastrointestinal reactions and no serious adverse




None of the trials reported on cardiovascular mortality.
Non-fatal myocardial infarction
None of the trials reported on non-fatal myocardial infarction.
Non-fatal stroke
None of the trials reported on non-fatal stroke.
Amputation of lower extremity
None of the trials reported on amputation of lower extremity.
Blindness or severe vision loss
None of the trials reported on blindness or severe vision loss.
End-stage renal disease
None of the trials reported on end-stage renal disease.
Non-serious adverse events
One trial reported that in the rosiglitazone group one out of 41 par-
ticipants experienced facial oedema and two out of 41 participants
experienced intolerance of both lower limbs (Jin 2009).
Hypoglycaemia
One trial reported that no participant in any of the treatment arms
experienced hypoglycaemia (Jin 2009).
Health-related quality of life
None of the trials reported on health-related quality of life.
Time to progression to T2DM
None of the trials reported on time to progression to T2DM.
Measures of blood glucose control
2-hour glucose
All included trials reported on 2-hour glucose. The MD was -0.54
mmol/L, 95% CI -1.80 to 0.73; P = 0.41; 224 participants; 2 trials;
Analysis 5.2.
One trial reported a mean 2-hour plasma glucose of 5.9 mmol/L (SD
0.9) in the metformin group (unknown how many of the 48 initially
randomised participants were included in the analysis) compared
with 5.8 mmol/L (SD 0.5) in the rosiglitazone group (unknown how
many of the 48 initially randomised participants were included in
the analysis) (Maji 2005).
HbA1c
One trial reported a mean HbA1c of 6.96% (SD 0.43) in the met-
formin group (unknown how many of the 48 initially randomised
participants were included in the analysis) compared with 6.96%
(SD 0.48) in the rosiglitazone group (unknown how many of the
48 initially randomised participants were included in the analysis)
(Maji 2005).
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
development of type 2 diabetes mellitus (Review)









Cochrane Database of Systematic Reviews
Fasting plasma glucose
All included trials reported on fasting plasma glucose. The MD was
-0.13 mmol/L, 95% CI -0.32 to 0.07; P = 0.20; 224 participants; 2 tri-
als; Analysis 5.3.
One trial reported a mean fasting plasma glucose of 5.4 mmol/L (SD
0.3) in the metformin group (unknown how many of the 48 initially
randomised participants were included in the analysis) compared
with 5.2 mmol/L (SD 0.4) in the rosiglitazone group (unknown how
many of the 48 initially randomised participants were included in
the analysis) (Maji 2005).
Socioeconomic effects
None of the trials reported on socioeconomic effects.
Metformin plus intensive diet and exercise versus intensive
diet and exercise
Three trials compared metformin plus intensive diet and exercise
with identical intensive diet and exercise (IDPP-1 2006; Iqbal Hydrie
2012; Zhao 2013). All the trials administered metformin in doses
up to 1000 mg/day. The ethnicity of the included people were Indi-




IDPP-1 2006 reported that one out of 121 participants died in the
metformin group compared to one out of 120 participants in the
comparator group (very low-quality evidence). Iqbal Hydrie 2012
trial reported that zero out of 95 participants died in the metformin
group compared with zero out of 114 participants in the compara-
tor group (Analysis 6.1).
Incidence of type 2 diabetes (T2DM)
Two trials reported incidence of T2DM (IDPP-1 2006; Zhao 2013). A
total of 48 out of 166 participants developed T2DM in the metformin
plus intensive diet and exercise compared with 53 out of 166 par-
ticipants in the comparator group (RR 0.55, 95% CI 0.10 to 2.92; P =
0.49; 332 participants; 2 trials; very low-quality evidence; Analysis
6.2). Calculation of a 95% prediction interval was not meaningful.
Serious adverse events
None of the trials reported on serious adverse events. All included




One trial reported that no participant died due to cardiovascular
causes (IDPP-1 2006).
Non-fatal myocardial infarction
None of the trials reported on non-fatal myocardial infarction.
Non-fatal stroke
None of the trials reported on non-fatal stroke.
Amputation of lower extremity
None of the trials reported on amputation of lower extremity.
Blindness or severe vision loss
None of the trials reported on blindness or severe vision loss.
End-stage renal disease
None of the trials reported on end-stage renal disease.
Non-serious adverse events
One trial had two metformin groups (metformin monotherapy and
metformin plus intensive diet and exercise) and reported that five
out of 248 participants in both metformin groups experienced gas-
trointestinal symptoms compared to zero out of 120 participants
in the comparator group (IDPP-1 2006). One trial reported that one
out of 45 participants in the metformin group experienced gastroin-
testinal symptoms compared with zero out of 46 participants in the
comparator group (Zhao 2013).
Hypoglycaemia
One trial reported data on hypoglycaemia (IDPP-1 2006). In the two
metformin groups (metformin monotherapy and metformin plus
intensive diet and exercise), 22 out of 248 participants reported
symptoms of mild hypoglycaemia; it was not possible to separate
these data. None experienced symptoms of hypoglycaemia in the
intensive diet plus exercise group (IDPP-1 2006).
Health-related quality of life
None of the trials reported on health-related quality of life.
Time to progression to T2DM
None of the trials reported on time to progression to T2DM.
Measures of blood glucose control
2-hour glucose
Two included trials reported on 2-hour glucose (IDPP-1 2006; Zhao
2013). The MD was -0.52 mmol/L, 95% CI -2.08 to 1.04; P = 0.51; 316
participants; 2 trials; Analysis 6.6).
HbA1c
None of the trials reported on HbA1c.
Fasting plasma glucose
Two trials reported data on fasting plasma glucose (IDPP-1 2006;
Zhao 2013). The MD was -0.26 mmol/L, 95% CI -0.94 to 0.43; P = 0,46;
316 participants; 2 trials; Analysis 6.7.
Socioeconomic effects
The IDPP estimated direct medical costs of interventions over the
three-year trial period to be $270 per participant in the metformin
plus intensive diet and physical activity group compared with $225
in the intensive diet and physical activity group (IDPP-1 2006).
Ongoing trials
We identified 11 ongoing trials which potentially could pro-
vide data of interest for this review (CTRI/2017/09/009635; JPRN-
UMIN000018995; Nadeau 2014; NCT01804049; Espinoza 2019;
NCT02915198; NCT02969798; Rhee 2019; NCT03194009; ePRECIDE
2017; Ji 2019). The trials will enrol a total of 17,853 participants. All
but three ongoing trials explicitly stated that they assessed one or
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more of the primary or secondary outcomes of interest of this re-
view (NCT01804049; Espinoza 2019; ePRECIDE 2017). Allthough not
stated in the protocol, it is very likely that the remaining trials will
assess one or more outcomes of interest for this review. Two tri-
als did not report the trial completion date (CTRI/2017/09/009635;
JPRN-UMIN000018995). One trial stated the trial completion date
to be August 2018, but no trial results are available (NCT01804049).
Two trials estimated the completion date to be in the year 2019
(Nadeau 2014; ePRECIDE 2017); two trials estimated the comple-
tion date to be in the year 2020 (NCT02969798; Rhee 2019)' three tri-
als estimated the completion date to be in the year 2022 (Espinoza
2019; NCT03194009; Ji 2019); and one trial estimated the comple-
tion date to be in the year 2024 (NCT02915198).
Studies awaiting assessment
One trial was published as an abstract only; the trial concluded
"No differences were seen in relative risk for diabetes by 6 years
with acarbose (1.04, P = 0.81), Metformin (0.99, P = 0.94) or combi-
nation therapy (1.02, P = 0.91). In those with IGT at baseline, rela-
tive risk was reduced significantly with acarbose (0.66, P = 0.046)
but not Metformin (1.09, P = 0.70) or combination therapy (0.72,
P = 0.27)" (EDIT 1997). For one trial it is unclear if the trial could
be included, the principal investigator was contacted and replied
that the trial is neither finished nor published (NCT02409238). For
two trials, it is unclear if the trials could be included: one trial
we contacted the author but we did not receive a reply (ChiC-
TR-IPR-17012309), and for the other trial we could not contact the
author due to lack of contact information (Polanco 2015).
D I S C U S S I O N
Summary of main results
This Cochrane Review investigated the effects of metformin in peo-
ple at increased risk of developing type 2 diabetes mellitus (T2DM).
We included 20 trials with a total of 6774 participants. We judged all
trials to be unclear or high risk of bias in one or more 'Risk of bias'
domains. Metformin compared with placebo or diet and exercise
reduced or delayed the risk of T2DM in people at increased risk for
the development of T2DM (moderate-quality evidence). However,
metformin compared to intensive diet and exercise did not reduce
or delay the risk of T2DM (very low-quality evidence). Likewise, for
the combination of metformin and intensive diet and exercise com-
pared to intensive diet and exercise only neither showed an advan-
tage or disadvantage regarding the development of T2DM. The re-
porting of the incidence of T2DM for the remaining comparisons
were sparse. The reporting of mortality and macrovascular and mi-
crovascular complications were sparse for all comparisons. Socioe-
conomic effects showed that metformin was more expensive than
no treatment, however, assessment of the costs was not identical in
the included trials reporting this outcome. The data on health-re-
lated quality of life were sparse. When reported, no firm influence of
metformin was found. The certainty of the evidence for these out-
come measures was low or very low.
Overall completeness and applicability of evidence
The diagnosis of intermediate hyperglycaemia varied among the
trials and some trials used a definition that may have included par-
ticipants judged to be euglycaemic or having T2DM. Most of the
trials applied the criteria established by the World Health Orga-
nization (WHO) or American Diabetes Association (ADA) (impaired
fasting glucose (IFG) or impaired glucose tolerance (IGT), or both)
to define intermediate hyperglycaemia. One trial applied the defi-
nition established by the European Diabetes Epidemiology Study
Group 1970 (Papoz 1978). One trial applied cut-off points not rec-
ommended by any medical association (Maji 2005). This trial de-
fined IGT with 2-hour plasma glucose after an oral glucose toler-
ance test (OGTT) ≥ 6.1 mmol/L and < 11.1 mmol/L and fasting plas-
ma glucose < 6.1 mmol/L (Maji 2005).
Not all ethnicities were represented in the included trials; most of
the trials included participants from Asia. One trial included main-
ly White people (DPP/DPPOS 2002) and one trial included Hispan-
ic people only (PREVENT-DM 2017). Two trials were performed in
France, but did not report the ethnicity of the included people (BIG-
PRO1 2009; Papoz 1978).
Detailed information about the participants was lacking in most tri-
als. The included trials applied different doses of metformin. A po-
tential selection bias might exist as more healthy and motivated
people may participate in a clinical trial. However, a Cochrane Re-
view observed that clinical outcomes in people participating in ran-
domised controlled trials (RCTs) are comparable to similar people
outside trials (Vist 2008).
One of the included trials contributed with about 48% of the includ-
ed participants (DPP/DPPOS 2002). Reporting of complications as-
sociated with T2DM during the intervention period was lacking.
The number of participants diagnosed with T2DM in the control
groups of the included trials was higher than that estimated from
observational trials (Cheng 2006; Morris 2013). This might be ex-
plained by the regular glycaemic testing of people participating in
a RCT. Therefore, many of those diagnosed with T2DM in a RCT may
not be diagnosed in a 'real-world' setting.
We conducted an extensive search for trials, including publication
in all languages. In total, 11 trials were published in Chinese on-
ly. We tried to contact all authors to obtain additional data, how-
ever, only two authors replied (BIGPRO1 2009; DPP/DPPOS 2002).
No additional data were provided. We looked for additional data
and cross-checked our data with systematic reviews of relevance.
Examination of four systematic reviews (Haw 2017; Lily 2009; Moe-
lands 2018; Salpeter 2008) revealed three additional references.
One systematic review (Pang 2018) revealed a further 10 Chinese
trials to be included.
Quality of the evidence
None of the 20 included trials in our review was classified as hav-
ing low risk of bias in all 'Risk of bias' domains. Only three out of 20
trials provided sufficient information on the method of randomisa-
tion and allocation concealment (Alfawaz 2018; DPP/DPPOS 2002;
PREVENT-DM 2017). Four trials explicitly reported blinding of par-
ticipants and investigators (BIGPRO1 2009; DPP/DPPOS 2002; Li
1999; Papoz 1978). In all the included trials the assessment of the
primary outcomes of this review and measurement of glucose val-
ues were performed by the investigators. We judged these out-
comes as objective and unlikely to be influenced by lack of blinding.
Only five trials provided sufficient information on incomplete out-
come data (BIGPRO1 2009; DPP/DPPOS 2002; Ji 2011; Lu 2010; PRE-
VENT-DM 2017). Most of the trials were judged to have high risk of
selective outcome reporting because one or more outcomes of rel-
evance for our review were likely assessed but not reported and/or
the protocol could not be retrieved. Three of the included trials stat-
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ed that they had received funding from a pharmaceutical compa-
ny (BIGPRO1 2009; DPP/DPPOS 2002; IDPP-1 2006). It is known that
trials receiving funding or provision of free drug or devices from
a pharmaceutical company leads to more favourable results and
conclusions than trials sponsored by other sources (Lundh 2017).
For the comparisons 'metformin versus placebo or diet and exer-
cise' and 'metformin versus intensive diet plus exercise' outcomes
were judged to be of very low, low or moderate quality of the evi-
dence. For the remaining comparisons, outcomes were judged to
be of very low- or low-quality evidence.
We included trials with an intervention duration of one year or
more. Trials with shorter duration could have been included, but
as we were focusing on patient-important outcomes we did not in-
clude such short-term trials.
Potential biases in the review process
Many of the included trials were not designed or powered to detect
our predefined patient-important outcomes. For the performed
meta-analyses we investigated heterogeneity and the potential
reasons for it through subgroup and sensitivity analyses. We were
dealing with a substantially heterogeneous group of trials. Our
meta-analyses were limited by the inability to use individual par-
ticipant data to assess whether distinct clinical characteristics may
have influenced the effect estimates of the interventions. We tried
to contact all trial authors for clarification if one of the bias domains
was not adequately reported, however, most of the authors did not
reply. We included trials with a minimum duration of one year in or-
der to detect clinically relevant differences for the predefined out-
comes. Even though we focused on long-term trials, the reporting
of clinical outcomes in the included trials was sparse. Two review
authors carried out data extraction. However, the review authors
extracting the data were not blinded as to which trial they were ex-
tracting data from.
Agreements and disagreements with other studies or
reviews
Recently, several systematic reviews (Haw 2017; Lily 2009; Moe-
lands 2018; Pang 2018; Salpeter 2008) have investigated strate-
gies to prevent or delay T2DM in people at increased risk of T2DM.
However, only a few of the systematic reviews have focused on
metformin for prevention of T2DM in people at risk for T2DM (Lily
2009; Salpeter 2008). Both of these publications performed a search
with no language restriction. One systematic review included three
RCT's with a follow-up time of at least six months investigating
people with IGT or IFG (Lily 2009). This review only included trials
that focused on the development of T2DM as the primary outcome
and thus could have missed potential relevant data if incidence of
T2DM was reported as a secondary or other outcome. The review
found that metformin was effective in reducing the incidence of
T2DM (fixed odds ratio (OR) 0.65, 95% confidence interval (CI) 0.55
to 0.78). Another trial included 31 RCT's with a duration of at least
eight weeks (Salpeter 2008). The review included trials with peo-
ple at increased risk for T2DM defined as people with obesity, poly-
cystic ovary syndrome (PCOS), insulin resistance, impaired glucose
tolerance, family history of diabetes, peripheral vascular disease or
metabolic syndrome. Due to the wide inclusion criteria, the review
possibly included normoglycaemic people and is therefore difficult
to compare with our review. Our search did not provide any other
relevant systematic review.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
There is moderate-quality evidence that metformin compared with
placebo or diet and exercise reduced or delayed the risk of type 2
diabetes mellitus (T2DM) in people with impaired glucose tolerance
(IGT) and/or impaired fasting glucose (IFG). Following diet and ex-
ercise or a non-metformin antidiabetic drug 281 per 1000 partici-
pants developed T2DM compared with 141 per 1000 participants
(95% confidence interval (CI) 107 to 183) after metformin therapy.
However, metformin compared to intensive diet and exercise did
not reduce or delay the risk of T2DM (moderate-quality evidence).
Following intensive diet and exercise 167 per 1000 participants de-
veloped T2DM compared with 133 per 1000 participants (95% CI 78
to 228) after metformin therapy.
Likewise, the combination of metformin and intensive diet and ex-
ercise compared to intensive diet and exercise only neither showed
an advantage or disadvantage regarding the development of T2DM
(very low-quality evidence). Following intensive diet and exercise
289 per 1000 participants developed T2DM compared with 159 per
1000 participants (CI 29 to 844) after metformin combined with in-
tensive diet and exercise.
It needs to be clarified, whether there is the same metformin effect
in people with increased risk defined by other glycaemic variables,
such as elevated glycosylated haemoglobin A1c (HbA1c) levels.
Data on patient-important outcomes such as mortality, macrovas-
cular and microvascular diabetic complications and health-related
quality of life were sparse or missing.
Implications for research
It remains to be clarified whether the reduction or delay in the in-
cidence of type 2 diabetes mellitus with metformin in people with
IGT and/or IFG can decrease the long-term risk of complications as-
sociated with T2DM. Future trials should also investigate the effect
of metformin in people with moderately elevated HbA1c and focus
on patient-important outcomes.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Parallel randomised controlled trial, randomisation ratio 1:1:1
Participants Inclusion criteria: fasting glucose level of 5.6 mmol/L to 6.9 mmol/L; the participants were identified
through screening as recommended in guidelines by ADA 2017
Exclusion criteria: receiving glucose-lowering intervention; pregnant or lactating women; renal, he-
patic, pulmonary, cardiac complications
Diagnostic criteria: ADA 2017 criteria for IFG (fasting glucose 5.6 mmol/Lto 6.9 mmol/L)
Interventions Number of study centres: 2
Run-in period: none
Administration-free period before testing during trial: not reported
Extension period: none
Outcomes Composite outcome measures reported: metabolic syndrome (primary outcome)
Alfawaz 2018 
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Study details Trial terminated early: no
Publication details Language of publication: English
Funding: non-commercial funding
Publication status: peer-reviewed journal
Stated aim of study Quote from publication: "... aimed to determine the differences in the effects of general advice (GA) on
lifestyle change, intensive lifestyle modification programme (ILMP) and GA + metformin (GA + Met) in
reducing the prevalence of full metabolic syndrome (MetS) in subjects with prediabetes"
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from publication: "A computer-generated serial number, randomly as-
signed..."
Comment: adequate description of the sequence generation
Allocation concealment
(selection bias)
Low risk Quote from publication: "True allocation concealment was done since the re-
search personnel involved cannot adjust randomization"




measures of blood glucose
control
Low risk Comment: investigator-assessed outcome measure, unclear if this outcome
also was assessed by the blinded independent outcome committee. The out-
come is not likely to be influenced by lack of blinding
Blinding of outcome as-
sessment (detection bias) 
measures of blood glucose
control
Low risk Comment: investigator-assessed outcome measure, unclear if this outcome
also was assessed by the blinded independent outcome committee. The out-
come is not likely to be influenced by lack of blinding
Incomplete outcome data
(attrition bias) 
measures of blood glucose
control
High risk Quote from publication: "Hence, the missing data (<5% of the total data
points in any variable) was dealt with the last observation carried forward
(LOCF) method. However, as much as possible, the LOCF was minimized by re-
moving the data of the subjects lost to follow up at 6-month or 12-month and
also by removing ones with >5% missing data in any variable"
Comment: in metformin plus general advise on diet and exercise group 60.2%
of randomised participants were analysed. In intensive lifestyle modification
programme group and general advise on diet and exercise group 74.5% and
86.7% of randomised participants were analysed, respectively. Drop-out rates
were not balanced (69.4 to 95.9% of randomised participants finished the
trial). Reasons for drop-outs were not balanced. Plausible effect size among




High risk Comment: no trial protocol available. Likely that the incidence of T2DM as
well as adverse events has been collected during the trial, but not reported
Other bias Low risk Comment: the trial appeared to be free of other sources of bias
Alfawaz 2018  (Continued)
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Methods Parallel randomised controlled trial, randomisation ratio 1:1
Participants Inclusion criteria: participants with a high waist-to-hip ratio ( ≥ 0.95 in men; ≥ 0.80 in women), who
were considered to be non-diabetic. Other trial inclusion criteria were age (35 to 60 years for men, 40
to 65 years for women), absence of cardiovascular diseases and no contraindications to the use of met-
formin
Exclusion criteria: participants with Ischaemic cardiovascular disease, diabetes, psychiatric disorders,
heavy chronic medical treatment, serious life-threatening medical conditions, impaired renal function
and lactic acidosis were excluded
Diagnostic criteria: WHO 1999 (IFG is defined as a FPG of 110 mg/dL to 125 mg/dL (6.1 mmol/L to 6.9
mmol/L) and IGT as a 2hPG of 140 mg/dLto 199 mg/dL (7.8 mmol/L to11.0 mmol/L))
Interventions Number of study centres: 33
Run-in period: none
Administration-free period before testing during trial: NR
Extension period: no
Outcomes Composite outcome measures reported: no
Study details Trial terminated early: no
Publication details Language of publication: English
Funding: both commercial funding (Lipha Pharmaceuticals Ltd) and non-commercial funding (INSERM,
CNAMts)
Publication status: peer-reviewed journal
Stated aim of study Quote from publication: "To study the effects of 1 year of treatment with metformin versus placebo on
the clinical and metabolic parameters described as part of the metabolic syndrome"
Notes Data on the people with IFG and IGT were only a subset of participants 101 out of 457 (22.1%) and re-
ported in a post hoc analysis.
Quote from publication: "Analyses were performed in the subset of trial patients who had impaired
fasting glucose (IFG) or impaired glucose tolerance (IGT), or both, according to the 1999 WHO definition
[13], wherein IFG is defined as a FPG of 110–125 mg/dL (6.1–6.9 mmol/L) and IGT as a 2hPG of 140–199
mg/dL (7.8–11.0 mmol/L). In addition, these analyses were repeated in another subset of subjects, de-
fined according to inclusion criteria of the DPP [5]—namely, body mass index (BMI)≥24 kg/m2, FPG of
95–125 mg/dL (5.3–6.9 mmol/L) and 2hPG of 140–199 mg/dL (7.8–11.0 mmol/L)."
"Of the 457 subjects included in the BIGPRO1 trial, 101 (22%; 49 in the metformin group and 52 in the
placebo group) had IFG or IGT at baseline, with eight subjects in the metformin group and 11 in the
placebo group having isolated IFG; and 51 (11%; 28 in the metformin group and 23 in the placebo
group) met the DPP inclusion criteria."
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from publication: "Confidential balanced random lists are used to allo-
cate to every patient's number metformin or placebo,..."
BIGPRO1 2009 
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Comment: adequate description of the sequence generation
Allocation concealment
(selection bias)




measures of blood glucose
control
Low risk Quote from publication: "..., in double-blind fashion, i.e. packages. are similar
whatever their content and only identified by the patient' trial number."
Comment: blinding of participants and key study personnel ensured
Blinding of outcome as-
sessment (detection bias) 
measures of blood glucose
control
Low risk Quote from publication: "..., in double-blind fashion, i.e. packages. are similar
whatever their content and only identified by the patient' trial number."








measures of blood glucose
control
Low risk Quote from publication: "All patient who definitively stop the trial treatment
for any reason continue to be followed up and examined a scheduled" and "At
12 months, 37 subjects (21 metformin, 16 placebo) in the IFG/IGT subset and
19 (10 metformin, 9 placebo) in the DPP subset had dropped out. The reasons
for the subjects’ absence at 12 months were roughly similar between treat-
ment groups, with only a slight tendency to a greater influence of side effects
in the metformin group and a lack of motivation in the placebo
group. To assess whether this dropout rate had any effect on the initial compa-
rability of the two treatment groups, baseline characteristics were compared
between those who missed the last visit and the remaining subjects. The only
difference found was that those remaining in the trial were more often treated
for hypertension than the dropouts (45% and 16%, respectively, in the IFG/IGT
subset, P < 0.003; 47% and 21%, respectively, in the DPP subset, P = 0.07)."
Comment: it is predefined to include all randomised participants. In the post
hoc analysis of the participants with IFG and/or IGT only 63% of the partici-




High risk Comment: adverse events and incidence of T2DM were assessed in the total
population, but not reported in the subset with IGT and/or IFG. However, these
analyses were not predefined in the protocol.





Methods Parallel randomised controlled trial, randomisation ratio 1:1
Participants Inclusion criteria: IGT
Exclusion criteria: liver and kidney dysfunction
Diagnostic criteria: WHO 1999 (2hPG of 140 mg/dL to 199 mg/dL (7.8 mmol/L to 11.0 mmol/L))
Interventions Number of trial centres: 1
Chen 2009 
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Run-in period: not reported
Administration-free period before testing during trial: not specified if any study drug was taken on
the testing day at the end of the intervention. However, for participants who did not convert to dia-
betes, the fasting and 2-hour 75g-OGTT blood glucose was detected at 1-year follow-up after drug with-
drawal.
Extension period: none
Outcomes Composite outcome measures reported: none
Study details Trial terminated early: no
Publication details Language of publication: Chinese
Funding: not reported
Publication status: peer-reviewed journal, full article
Stated aim of study Quote from publication: "To observe the effect of Shenqi Jiangtang capsule on preventing type 2 dia-
betes in IGT patients."
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from publication: "randomised"
Comment: insufficient information about the sequence generation process
Allocation concealment
(selection bias)





Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to





measures of blood glucose
control
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding. (investigator-assessed outcome measure-
ment)
Blinding of outcome as-
sessment (detection bias) 
incidence of T2DM
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding. (investigator-assessed outcome measure-
ment)
Blinding of outcome as-
sessment (detection bias) 
measures of blood glucose
control
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to





High risk Quote from publication: "A total of 17 patients withdrew during the observa-
tion period, including 6 in the Shenqi Jiangtang capsule group, 6 in the general
life intervention group and 5 in the metformin group."
Comment: no reason given and PP analysis used (only reported)
Chen 2009  (Continued)
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Incomplete outcome data
(attrition bias) 
measures of blood glucose
control
High risk Quote from publication: "A total of 17 patients withdrew during the observa-
tion period, including 6 in the Shenqi Jiangtang capsule group, 6 in the general
life intervention group and 5 in the metformin group."
Comment: no reason given and PP analysis used (only reported)
Selective reporting (re-
porting bias)
High risk Comment: protocol unavailable, non-SAE likely to have been analysed but not
reported. Outcomes stated in the methods were reported in the results (BMI,
liver and kidney function)




Methods Parallel randomised controlled trial, randomisation ratio 1:1:1
Participants Inclusion criteria: ≥ 25 years, BMI ≥ 24 kg/m2 in Asians BMI ≥ 22 kg/m2, FPG 95 mg/dL to 125 mg/dL (5.3
mmol/L to 6. 9 mmol/L) and 2-hour OGTT 140 mg/dL to 199 mg/dL (7.8 mmol/L to 11.0 mmol/L). Be-
cause of the relative higher rate of progression from IGT to diabetes in Native Americans and the small
size of the population, the glucose requirement for eligibility in the Southwest American Indian Center
will be fasting glucose < 126 mg/dL (7.0 mmol/L) and 2-hour plasma glucose 140 mg/dL to 199 mg/dL
(7.8 mmol/L to 11.0 mmol/L).
Exclusion criteria: T2DM, participants taking medicines known to alter glucose tolerance, ever used
glucose-lowering drugs during pregnancy, illnesses that could seriously reduce their life expectancy or
their ability to participate in the trial, cardiovascular disease (hospitalisation for treatment of heart dis-
ease in past 6 months; NYHA class > 2; leN bundle branch block or third degree atrioventricular block;
aortic stenosis; SBP > 180 mmHg or DBP > 105 mmHg); cancer requiring treatment in the past five years
(unless prognosis is considered good); renal disease; gastrointestinal disease; anaemia (haematocrit <
36.0% in men or < 33.0% in women); electrolyte abnormality (serum potassium < 3.2 or > 5.5 mmol/L).
Diagnostic criteria: IGT (2-hour OGTT 140 mg/dL to 199 mg/dL (7.8 mmol/L to 11.0 mmol/L)) and ele-
vated fasting glucose (FPG 95 mg/dL to 125 mg/dL (5.3 mmol/L to 6.9 mmol/L)) (ADA 1997).
Interventions Number of study centres: 27
Treatment before study: none
Run-in period: 3 weeks; during the run-in period the participants had to fill out a daily diary and place-
bo pills according to a schedule
Extension period: yes, an additional follow-up with a median of 5.7 years (IQR 5.5 to 5.8) after end of
the intervention period
Outcomes Composite outcome measures reported: yes (Quote from publication: ".....a composite microvascu-
lar-neuropathic outcome for diabetic retinopathy, nephropathy, or reduced light touch sensation in
the feet. Secondary outcomes include the individual components of the composite primary outcome,
cardiovascular disease, further development of diabetes, measures of glycaemia, insulin secretion, in-
sulin sensitivity, cardiovascular disease risk factors, physical activity, nutrition, bodyweight, health-re-
lated quality of life, and economic assessments.")
Study details Trial terminated before regular end (for benefit/because of adverse events): the trial was stopped
one year earlier than originally planned due to larger intervention effect of diet and physical activity
than anticipated.
Taking trial drug on glycaemic testing days: placebo and metformin was not taken on the morning of
glycaemic testing
DPP/DPPOS 2002 
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Publication details Language of publication: English
Funding: commercial funding (Lipha (Merck-Sante) provided medicines, and LifeScan donated mate-
rials) / non-commercial funding (the National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), National Institute of Child Health and Human Development, the National Institute on Aging,
the National Eye Institute, the National Heart Lung and Blood Institute, the Office of Women’s Health,
the National Center for Minority Health and Human Disease, the Centers for Disease Control and Pre-
vention, and the American Diabetes Association)
Publication status: peer-reviewed journal
Stated aim of study Quote from publication: "The principal objective of the DPP is to prevent or delay the development of
NIDDM in those persons who are at high risk for its development by virtue of having impaired glucose
tolerance"
Notes Individuals who meet only one of the glucose inclusion criteria was rescreened after 6 months.
Because of the relative higher rate of progression from IGT to T2DM in Native Americans and the small
size of the population, the glucose requirement for eligibility in the Southwest American Indian Center
differed (see above).
The trial included initially four intervention groups. The troglitazone group was discontinued in 1998
because of potential liver toxicity.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from publication: "A sequence of randomization numbers within a
clinical center will be constructed of the form XXYZZZ, where XX is the clinical
center number, Y is a number that indicates assignment to either the intensive
lifestyle intervention or pharmacological treatment, and ZZZ is a three digit se-
quence number within each XXY combination. The DPP Coordinating Center
will prepare the master randomization list with assignments to the three treat-
ment groups within a clinical center using the standard urn design.
The sequence of pharmacological randomization numbers within a clinical
center with the specific pharmacological treatment assignment (i.e., met-
formin or placebo) will be forwarded, in confidence, to the drug distribution
center for drug labelling and distribution. Pharmacological treatment assign-
ment to the sequence of pharmacological randomization numbers will be
known only by the staff of the DPP Coordinating Center and the drug distribu-
tion center."
Comment: adequate description of the sequence generation
Allocation concealment
(selection bias)
Low risk Quote from publication: "A sequence of randomization numbers within a
clinical center will be constructed of the form XXYZZZ, where XX is the clinical
center number, Y is a number that indicates assignment to either the intensive
lifestyle intervention or pharmacological treatment, and ZZZ is a three digit se-
quence number within each XXY combination. The DPP Coordinating Center
will prepare the master randomization list with assignments to the three treat-
ment groups within a clinical center using the standard urn design.
The sequence of pharmacological randomization numbers within a clinical
center with the specific pharmacological treatment assignment (i.e., met-
formin or placebo) will be forwarded, in confidence, to the drug distribution
center for drug labeling and distribution. Pharmacological treatment assign-
ment to the sequence of pharmacological randomization numbers will be
known only by the staff of the DPP Coordinating Center and the drug distribu-
tion center."
DPP/DPPOS 2002  (Continued)
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Low risk Quote from publication: "Masking intensive lifestyle intervention assignment
to the participants is not possible and masking the investigators is not practi-
cal." and "Assignments to metformin and placebo were double-blinded."
Comment: no blinding for the comparison of metformin with intensive di-
et and physical activity, but judged that the outcome is not likely to be influ-





Low risk Quote from publication: "Masking intensive lifestyle intervention assignment
to the participants is not possible and masking the investigators is not practi-
cal." and "Assignments to metformin and placebo were double-blinded." and
"Primary outcome data (OGTT and FPG results) measured centrally will remain
masked to the investigators and to the participants until confirmed progres-
sion from IGT to diabetes"
Comment: assessed centrally unblinded, the outcome is not likely to be influ-





measures of blood glucose
control
Low risk Quote from publication: "Masking intensive lifestyle intervention assignment
to the participants is not possible and masking the investigators is not practi-
cal." and "Assignments to metformin and placebo were double-blinded." and
"Primary outcome data (OGTT and FPG results) measured centrally will remain
masked to the investigators and to the participants until confirmed progres-
sion from IGT to diabetes" and Plasma lipid levels and HbA1c measured
centrally will remain masked to the investigators and to the participants dur-
ing the study."
Comment: assessed centrally unblinded, the outcome is not likely to be influ-






Low risk Quote from publication: "Masking intensive lifestyle intervention assignment
to the participants is not possible and masking the investigators is not practi-
cal." and "Assignments to metformin and placebo were double-blinded."
Comment: no blinding for the comparison of metformin with intensive di-
et and physical activity, but judged that the outcome is not likely to be influ-






High risk Quote from publication: "Masking intensive lifestyle intervention assignment
to the participants is not possible and masking the investigators is not practi-
cal." and "Assignments to metformin and placebo were double-blinded."
Comment: no blinding for the comparison of metformin with intensive di-
et and physical activity and the outcome is likely to be influenced by lack of
blinding
Blinding of outcome as-
sessment (detection bias) 
incidence of T2DM
Low risk Quote from publication: "Masking intensive lifestyle intervention assignment
to the participants is not possible and masking the investigators is not practi-
cal." and "Assignments to metformin and placebo were double-blinded." and
"Primary outcome data (OGTT and FPG results) measured centrally will remain
masked to the investigators and to the participants until confirmed progres-
sion from IGT to diabetes"
Comment: assessed centrally unblinded, the outcome is not likely to be influ-
enced by lack of blinding
DPP/DPPOS 2002  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
measures of blood glucose
control
Low risk Quote from publication: "Masking intensive lifestyle intervention assignment
to the participants is not possible and masking the investigators is not practi-
cal." and "Assignments to metformin and placebo were double-blinded." and
"Primary outcome data (OGTT and FPG results) measured centrally will remain
masked to the investigators and to the participants until confirmed progres-
sion from IGT to diabetes" and "Plasma lipid levels and HbA1c measured cen-
trally will remain masked to the investigators and to the participants during
the study."
Comment: assessed centrally unblinded, the outcome is not likely to be influ-
enced by lack of blinding
Blinding of outcome as-
sessment (detection bias) 
socioeconomic effects
Low risk Quote from publication: "Masking intensive lifestyle intervention assignment
to the participants is not possible and masking the investigators is not practi-
cal." and "Assignments to metformin and placebo were double-blinded."
Comment: no blinding for the comparison of metformin with intensive diet
and physical activity but judged that the outcome is not likely to be influenced
by lack of blinding, investigator-assessed outcome measurement
Blinding of outcome as-
sessment (detection bias) 
health-related quality of
life
High risk Quote from publication: "Masking intensive lifestyle intervention assignment
to the participants is not possible and masking the investigators is not practi-
cal." and "Assignments to metformin and placebo were double-blinded."
Comment: no blinding for the comparison of metformin with intensive di-
et and physical activity and the outcome is likely to be influenced by lack of





Low risk Quote from publication: "At the close of the study, 99.6 percent of the partici-
pants were alive, of whom 92.5 percent had attended a scheduled visit within
the previous five months"
Comment: not stated how many participants who had known vital status in
each intervention group at the end of follow-up for the DPP trial. However, at
inception of the number with unknown mortality status are relatively low. At





Low risk Quote from publication: "At the close of the study, 99.6 percent of the partici-
pants were alive, of whom 92.5 percent had attended a scheduled visit within
the previous five months"
Comment: not stated how many participants who had known vital status at
the end of follow-up for the DPP trial. However, at inception of the DPPOS a
relatively low and balanced number of participants in the intervention groups
could not be included.
Incomplete outcome data
(attrition bias) 
measures of blood glucose
control
Low risk Comment: not stated how many participants who had known vital status at
the end of follow-up for the DPP trial. However, at inception of the DPPOS a




time to progression to
T2DM
Low risk Comment: "At the close of the study, 99.6 percent of the participants were





Low risk Comment: not clearly described how many participants included in the costs
analyses, but as the study have a high follow-up rate, we assume that nearly all
participants are included.
DPP/DPPOS 2002  (Continued)
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Low risk Quote from publication: " the current reports and analyses includes 3,234
participants seen at baseline, who were randomly assigned to one of the three
treatment arms investigated."
Comment: article reporting health related quality of life do not report the
number of participants with available data at follow-up
Selective reporting (re-
porting bias)
High risk Comment: several outcome are likely to be measured and analysed, but not
reported, e.g. hypoglycaemia, non-serious adverse events. Outcomes pub-
lished in many different publications. Several outcomes are reported incom-
pletely so that they cannot be included in meta-analysis




Methods Parallel randomised controlled trial, randomisation ratio 1:1:1:1
Participants Inclusion criteria: participants in accordance with the diagnostic criteria of IGT
Exclusion criteria: participants with severe somatological disease, mental disease or history of mental
disease, severe intellectual or cognitive disorders, drug or alcohol dependence
Diagnostic criteria: IGT
Interventions Number of study centres: 1
Run-in period: not described
Administration-free period before testing during trial: not reported
Extension period: none
Outcomes Composite outcome measures reported: none
Study details Trial terminated before regular end (for benefit/because of adverse events): no
Taking trial drug on glycaemic testing days: not specified if any study drug was taken on the testing
day at the end of the intervention.
Publication details Language of publication: Chinese
Funding: not described
Publication status: full article (Chinese Journal of Clinical Rehabilitation)
Stated aim of study Quote from publication: "To observe influence of medicine intervention and non-medicine interven-
tion on the outcomes of the crowd with IGT and explore which intervention can prevent IGT from devel-
oping to diabetes mellitus more effectively."
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from publication: "Patients were randomly allocated by random num-
ber table."
Fang 2004 
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Comment: adequate description of the sequence generation
Allocation concealment
(selection bias)






Low risk Comment: no description of blinding, but according to the intervention arms
in the trial, neither the participants or the personnel were blinded. The out-





Low risk Comment: no description of blinding, but according to the intervention arms
in the trial, neither the participants or the personnel were blinded. The out-




measures of blood glucose
control
Low risk Comment: no description of blinding, but according to the intervention arms
in the trial, neither the participants or the personnel were blinded. The out-
come is not likely to be influenced by lack of blinding
Blinding of outcome as-
sessment (detection bias) 
all-cause mortality/cardio-
vascular mortality
Low risk Comment: unclear whether outcome assessors were blinded, but the out-
come is not likely to be influenced by lack of blinding
Blinding of outcome as-
sessment (detection bias) 
incidence of T2DM
Low risk Comment: unclear whether outcome assessors were blinded, but the out-
come is not likely to be influenced by lack of blinding
Blinding of outcome as-
sessment (detection bias) 
measures of blood glucose
control
Low risk Comment: unclear whether outcome assessors were blinded, but the out-





Unclear risk Quote from publication: "160/178 (90%) were analysed"




Unclear risk Quote from publication: "160/178 (90%) were analysed"
Comment: unclear description on how missing data were handled
Incomplete outcome data
(attrition bias) 
measures of blood glucose
control
Unclear risk Quote from publication: "160/178 (90%) were analysed"
Comment: unclear description on how missing data were handled
Selective reporting (re-
porting bias)
Unclear risk Comment: no trial protocol available
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Methods Parallel randomised controlled trial, randomisation ratio 1:1:1:1
Participants Inclusion criteria: IGT (mean 2-hour plasma glucose after OGTT 140 mg/dL to 199 mg/dL (7.8 mmol/L
to 11.0 mmol/L) and FPG < 126 mg/dL (7.0 mmol/L)) (WHO 1999); no major illness; 35 to 55 years
Exclusion criteria: diagnosis of T2DM during recruitment; pregnancy
Diagnostic criteria: IGT (WHO 1999)
Interventions Number of study centres: -
Run-in period: none
Administration-free period before testing during trial: not reported
Titration period: none
Outcomes Composite outcome measures reported: yes (cardiovascular disease)
Study details Trial terminated before regular end (for benefit/because of adverse events): yes; Quote from pub-
lication: "After a median follow-up period of 30 months, because there were
significant differences in the outcome measure between the control and intervention groups, the com-
mittee recommended the termination of the study in December 2004"
Taking trial drug on glycaemic testing days: not specified
Publication details Language of publication: English
Funding: commercial (M/S US Vitamins)
Publication status: peer-reviewed journal
Stated aim of study Quote from publication: "In a prospective community-based study, we tested whether the pro-
gression to diabetes could be influenced by interventions in native Asian Indians with IGT who were
younger, leaner and more insulin resistant than the above populations"
Notes Two more intervention groups existed that were not included in this review; 1) metformin and 2) diet
plus physical activity combined with metformin
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from publication: "A randomised, controlled clinical trial was per-
formed in subjects who were......"
Comment: insufficient information about the sequence generation process
Allocation concealment
(selection bias)






Low risk Quote from publication: "Masking: Open Label" and "However, the principal
investigators were blinded to the outcome until they were asked to close the
study by the international data monitoring committee."
Comment: outcome evaluated by an independent outcome committee. Out-




Low risk Quote from publication: "Masking: Open Label" "However, the principal in-
vestigators were blinded to the outcome until they were asked to close the
study by the international data monitoring committee."
IDPP-1 2006 
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measures of blood glucose
control
Low risk Quote from publication: "Masking: Open Label" and ""However, the principal
investigators were blinded to the outcome until they were asked to close the
study by the international data monitoring committee."
Comment: investigator-assessed outcome measure, unclear if this outcome
also was assessed by the blinded independent outcome committee. The out-
come is not likely to be influenced by lack of blinding
Blinding of outcome as-
sessment (detection bias) 
all-cause mortality/cardio-
vascular mortality
Low risk Quote from publication: "However, the principal investigators were blinded
to the outcome until they were asked to close the study by the international
data monitoring committee."
Comment: outcome evaluated by an independent outcome committee
Blinding of outcome as-
sessment (detection bias) 
incidence of T2DM
Low risk Quote from publication: "However, the principal investigators were blinded
to the outcome until they were asked to close the study by the international
data monitoring committee."
Comment: outcome evaluated by an independent outcome committee and
investigator-assessed outcome measure
Blinding of outcome as-
sessment (detection bias) 
measures of blood glucose
control
Low risk Quote from publication: "However, the principal investigators were blinded
to the outcome until they were asked to close the study by the international
data monitoring committee."
Comment: investigator-assessed outcome measure, unclear if this outcome
also was assessed by the blinded independent outcome committee. The out-
come is not likely to be influenced by lack of blinding
Blinding of outcome as-








Unclear risk Comment: unknown whether mortality status was known on the participants
lost to follow-up. The proportion of missing outcomes compared with ob-





Unclear risk Comment: the proportion of missing outcomes compared with observed




measures of blood glucose
control
Unclear risk Comment: Insufficient information to assess whether missing data in combi-
nation with the method used to handle missing data were likely to induce bias
Selective reporting (re-
porting bias)
High risk Quote from publication: "An internal safety committee monitored the ad-
verse events and safety of study protocol. The data and final outcome mea-
sures were monitored by the international monitoring committee who had
looked at the results three times, i.e. when 500 subjects had completed the fol-
low-up assessments at 12, 24 and 30 months. The principal investigators were
blinded to the interim results."
IDPP-1 2006  (Continued)
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Comment: several outcomes with relevance for this review are not reported or
only reported in a format which makes them unsuitable for meta-analyses, e.g.
adverse events




Methods Parallel randomised controlled trial, randomisation ratio 1:1:1
Participants Inclusion criteria: IGT, > 30 years
Exclusion criteria: NS
Diagnostic criteria: WHO 1999 criteria (FPG < 7.0 mmol/L and 2-hour plasma glucose after OGTT ≥ 7.8
mmol/L and < 11.1 mmol/L)
Interventions Number of study centres: multicentre, but number of centres not reported
Run-in period: none
Administration-free period before testing during trial: not reported
Extension period: no
Outcomes Composite outcome measures reported: no
Study details Trial terminated before regular end (for benefit/because of adverse events): no
Taking trial drug on glycaemic testing days: not specified
Publication details Language of publication: English
Funding: non-commercial funding
Publication status: peer-reviewed journal
Stated aim of study Quote from publication: "To observe the rate of conversion from impaired glucose tolerance (IGT) to
diabetes following lifestyle modification (LSM) or a combination of lifestyle and metformin compared
to a control population with 18-month followup"
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from publication: "After taking informed consent, the participants
were randomized by age strata (31–40 years, 41–50 years, 51–60 years, and >60
years) into three different arms"
Comment: insufficient information about the sequence generation
Allocation concealment
(selection bias)
Unclear risk Comment: no description of allocation concealment
Iqbal Hydrie 2012 
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Low risk Comment: no blinding, but the outcome is not likely to be influenced by lack
of blinding
Blinding of outcome as-
sessment (detection bias) 
all-cause mortality/cardio-
vascular mortality
Low risk Comment: no blinding of outcome assessment, but the outcome is not likely
to be influenced by lack of blinding
Blinding of outcome as-
sessment (detection bias) 
incidence of T2DM
Low risk Comment: no blinding of outcome assessment, but the outcome is not likely





Unclear risk Quote from publication: "Overall 44 subjects dropped out or were lost to fol-
lowup. In the control group there were 2 deaths while 24 subjects dropped out
during the study. In the lifestyle modification group 8 subjects refused to con-
tinue the study and dropped out. In the LSM + drug group 5 subjects stopped
taking the drug either due to side effects of the drug such as gastrointestinal
problems or complaining of weakness probably due to hypoglycemia while 5
subjects refused to follow due to personal reasons and were lost to followup."





Unclear risk Quote from publication: "Overall 44 subjects dropped out or were lost to fol-
lowup. In the control group there were 2 deaths while 24 subjects dropped out
during the study. In the lifestyle modification group 8 subjects refused to con-
tinue the study and dropped out. In the LSM + drug group 5 subjects stopped
taking the drug either due to side effects of the drug such as gastrointestinal
problems or complaining of weakness probably due to hypoglycemia while 5
subjects refused to follow due to personal reasons and were lost to followup."
Comment: large difference in missingness among the intervention groups. No
description of how to handle missing data.
Selective reporting (re-
porting bias)
High risk No trial protocol available. Glycaemic measures not reported, hypoglycaemia
and adverse events reported in a format that make them unsuitable for meta-
analysis.




Methods Parallel randomised controlled trial, randomisation ratio 1:1:1
Participants Inclusion criteria: no history of diabetes or autoimmune disease, and no acute or chronic infection
within 2 weeks before enrolment, IFG and/or IGT.
Exclusion criteria: not reported
Ji 2011 
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Diagnostic criteria: WHO 1999 (IGT (2hPG between 7.8 mmol/L and 11.0 mmol/L); or IFG (FPG between
6.1 mmoL/L and 6.9 mmol/L))
Interventions Number of study centres: 1
Run-in period: not reported
Administration-free period before testing during trial: not specified if any study drug was taken on
the testing day at the end of intervention
Extension period: none
Outcomes Composite outcome measures reported: none
Study details Trial terminated early: no
Publication details Language of publication: Chinese
Funding: non-commercial funding (governmental funding)
Publication status: peer-reviewed journal, full-article
Stated aim of study Quote from publication: "To observe the changes of serum, hs-crp and insulin sensitivity index before
and after metformin treatment or intensive lifestyle intervention in patients with prediabetes."
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from publication: "randomised"
Comment: insufficient information about the sequence generation process
Allocation concealment
(selection bias)





Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to





measures of blood glucose
control
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding. (investigator-assessed outcome measure-
ment)
Blinding of outcome as-
sessment (detection bias) 
incidence of T2DM
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding. (investigator-assessed outcome measure-
ment)
Blinding of outcome as-
sessment (detection bias) 
measures of blood glucose
control
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to




Low risk Quote from publication: "No patients were discontinued due to adverse drug
reactions."
Ji 2011  (Continued)
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incidence of T2DM Comment: reported (no missing data)
Incomplete outcome data
(attrition bias) 
measures of blood glucose
control
Low risk Quote from publication: "No patients were discontinued due to adverse drug
reactions."
Comment: reported (no missing data)
Selective reporting (re-
porting bias)
High risk Comment: protocol unavailable. Adverse events not reported. Likely to have
been assessed and evaluated during the study




Methods Parallel randomised controlled trial, randomisation ratio 1:1:1
Participants Inclusion criteria: IFG
Exclusion criteria: severe cardiovascular and cerebrovascular diseases and obvious abnormal liver
and kidney functions
Diagnostic criteria: IFG diagnosed from WHO 1999 criteria (FPG between 6.1 mmol/L to 6.9 mmol /L, 2-
hour postprandial blood glucose (2hPG) < 7.8 mmol/L)
Interventions Number of study centres: 1
Run-in period: not reported
Administration-free period before testing during trial: not specified if any study drug was taken on
the testing day at the end of intervention
Extension period: none
Outcomes Composite outcomes measures reported: none
Study details Trial terminated early (for benefit/because of adverse events): no
Publication details Language of publication: Chinese
Funding: non-commercial (government funding)
Publication status: peer-reviewed, full-article
Stated aim of study Quote from publication: "To observe the changes of islet cell function and insulin resistance (IR) in pa-
tients with impaired fasting glucose after different methods of intervention, and to explore the patho-
genesis and intervention pathway of IFG."
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from publication: "randomised"
Comment: insufficient information about the sequence generation process
Jin 2009 
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Allocation concealment
(selection bias)





Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to





measures of blood glucose
control
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding (investigator-assessed outcome measure-
ment)
Blinding of outcome as-
sessment (detection bias) 
incidence of T2DM
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding (investigator-assessed outcome measure-
ment)
Blinding of outcome as-
sessment (detection bias) 
measures of blood glucose
control
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to





High risk Quote from publication: "During the treatment, 1 patient in the rosiglitazone
group had facial edema and 2 patients in the rosiglitazone group had intoler-
ance of both lower limbs and withdrew from the study. Three patients in the
metformin group were withdrawn from the study due to severe gastrointesti-
nal reactions. No significant adverse reactions or hypoglycemia were observed
in other patients."
Comment: PP analysis was used (reported and reasons explained)
Incomplete outcome data
(attrition bias) 
measures of blood glucose
control
High risk Quote from publication: "During the treatment, 1 patient in the rosiglitazone
group had facial edema and 2 patients in the rosiglitazone group had intoler-
ance of both lower limbs and withdrew from the study. Three patients in the
metformin group were withdrawn from the study due to severe gastrointesti-
nal reactions. No significant adverse reactions or hypoglycemia were observed
in other patients."
Comment: PP analysis was used (reported and reasons explained)
Selective reporting (re-
porting bias)
Unclear risk Comment: protocol unavailable




Methods Parallel randomised controlled trial, randomisation ratio 1:1
Participants Inclusion criteria: participants aged 30 years to 60 years with IGT
Exclusion criteria: diabetes, a history of ischaemic heart disease or renal or hepatic disorders, and
previous treatment with metformin
Diagnostic criteria: WHO 1985 (IGT (2hPG 140 mg/dL to 200 mg/dL [7.8 mmol/L to 11.0 mmol/L]) and
FPG <140 mg/dL (7.8 mmol/L))
Li 1999 
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Interventions Number of study centres: -
Run-in period: not described
Administration-free period before testing during trial: not reported
Extension period: no
Outcomes Composite outcome measures reported: none
Study details Trial terminated early: no
Taking trial drug on glycaemic testing days: not specified
Publication details Language of publication: English
Funding: not described
Publication status: peer-reviewed journal
Stated aim of study Quote from publication: "To evaluate the effect of metformin on glucose metabolism, insulin sensitivi-
ty and rate of conversion diabetes in people with impaired glucose tolerance (IGT)."
Notes The placebo was provided by the manufacturer of metformin, Beijing Tian-An United Pharmaceutical
Co. Ltd. (Tokyo, Japan)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from publication: "People meeting the entry criteria were random-
ized under double-blind conditions to receive either placebo or metformin at a
dosage of 250 mg three times daily for a duration of 12 months."
Comment: insufficient information about the sequence generation
Allocation concealment
(selection bias)





Low risk Quote from publication: "People meeting the entry criteria were random-
ized under double-blind conditions to receive either placebo or metformin at a
dosage of 250 mg three times daily for a duration of 12 months."




measures of blood glucose
control
Low risk Quote from publication: "People meeting the entry criteria were random-
ized under double-blind conditions to receive either placebo or metformin at a
dosage of 250 mg three times daily for a duration of 12 months."
Comment: blinding of participants and key study personnel ensured
Blinding of outcome as-
sessment (detection bias) 
incidence of T2DM
Low risk Quote from publication: "People meeting the entry criteria were random-
ized under double-blind conditions to receive either placebo or metformin at a
dosage of 250 mg three times daily for a duration of 12 months."
Comment: possible blinding of outcome assessment, but the outcome is not
likely to be influenced by lack of blinding.
Li 1999  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
measures of blood glucose
control
Low risk Quote from publication: "People meeting the entry criteria were random-
ized under double-blind conditions to receive either placebo or metformin at a
dosage of 250 mg three times daily for a duration of 12 months."
Comment: possible blinding of outcome assessment, but the outcome is not




Low risk Quote from publication: "On an intention-to-treat basis, excluding only five
patients lost to follow-up, 32 of the metformin treated subjects became nor-
mally glucose tolerant (76.2%) compared to 23 (53.5%) for placebo patients.
Six patients on placebo converted to frank diabetes (14.0%) and this com-
pared to three patients (7.1%) on metformin, P = 0.091, Table 3."
Comment: the proportion of missing outcomes compared with observed




measures of blood glucose
control
Unclear risk Quote from publication: "Twelve subjects were excluded from the metformin
group for the following reasons: tablet noncompliance, seven; loss to fol-
low-up, three; and gastrointestinal side-effects, two. Eight subjects were ex-
cluded from the placebo group as follows: tablet noncompliance, five; loss to
follow-up, two;.and raised liver enzymes, one."
Comment: insufficient information to assess whether missing data in combi-
nation with the method used to handle missing data were likely to induce bias
Selective reporting (re-
porting bias)
High risk Comment: no trial protocol available. Likely that hypoglycaemia is measured
but not reported.




Methods Parallel randomised controlled trial, randomisation ratio 1:1
Participants Inclusion criteria: obesity (BMI of 25 kg/m2 or more) and impaired regulation of glucose
Exclusion criteria: not reported
Diagnostic criteria: WHO 1999 (FPG between 6.1 mmol/L to 6.9 mmol/L, 2-hour glucose (2hPG) be-
tween 7.8 mmol/Lto 11.0 mmol/L)
Interventions Number of study centres: 1
Run-in period: not reported
Administration-free period before testing during trial: not specified if any study drug was taken on
the testing day at the end of intervention
Extension period: none
Outcomes Composite outcome measures reported: none
Study details Trial terminated early (for benefit/because of adverse events): no
Publication details Language of publication: Chinese
Funding: not reported
Li 2009 
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Publication status: peer-reviewed journal, full article
Stated aim of study Quote from publication: "In this study, metformin was used to treat obese people with impaired regu-
lation of mixed sugars, so as to explore the methods of diabetes intervention."
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from publication: "randomised"
Comment: insufficient information about the sequence generation process
Allocation concealment
(selection bias)





Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to





measures of blood glucose
control
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding (investigator-assessed outcome measure-
ment)
Blinding of outcome as-
sessment (detection bias) 
incidence of T2DM
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding (investigator-assessed outcome measure-
ment)
Blinding of outcome as-
sessment (detection bias) 
measures of blood glucose
control
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to





High risk Comment: a total of 7 participants (3:4) lost to follow-up, no explanation pro-
vided, PP analysis was used (only reported)
Incomplete outcome data
(attrition bias) 
measures of blood glucose
control
Low risk Comment: a total of 7 participants (3:4) lost to follow-up, no explanation pro-
vided, ITT analysis was used (only reported)
Selective reporting (re-
porting bias)
Unclear risk Comment: protocol unavailable




Methods Parallel randomised controlled trial, randomisation ratio 1:1
Liao 2012 
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Participants Inclusion criteria: IGT. All participants were not treated with any glucose-lowering drugs before inclu-
sion, and were treated with simple diet and exercise for 3 months, with unsatisfactory results and no
obvious adverse reactions. All participants had no serious diseases of gastrointestinal tract, heart, liver,
kidney and other important organs
Exclusion criteria: blood glucose abnormalities caused by other diseases
Diagnostic criteria: WHO 1999 (FPG between 6.1 mmol/L to 6.9 mmol/L, 2hPG between 7.8 mmol/L to
11.0 mmol/L)
Interventions Number of study centres: 1
Run-in period: 3 months
Administration-free period before testing during trial: not specified if any study drug was taken on
the testing day at the end of intervention
Extension period: none
Outcomes Composite outcome measures reported: none
Study details Trial terminated early (for benefit/because of adverse events): no
Publication details Language of publication: Chinese
Funding: not reported
Publication status: peer-reviewed journal, full-article
Stated aim of study Quote from publication: "To compare the effectiveness and security of acarbose and metformin in the
treatment for impaired glucose tolerance"
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from publication: "randomised"
Comment: insufficient information about the sequence generation process
Allocation concealment
(selection bias)





Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to





measures of blood glucose
control
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding. (investigator-assessed outcome measure-
ment)
Blinding of outcome as-
sessment (detection bias) 
incidence of T2DM
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding. (investigator-assessed outcome measure-
ment)
Liao 2012  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
measures of blood glucose
control
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to





High risk Quote from publication: "In the acarbose group, 2 cases were lost after 1 year
of follow-up, 1 case of lung cancer and 1 case of hepatitis. In the metformin
group, 1 case of cerebral hemorrhage was lost after 1 year of follow-up."
Comment: PP analysis was used (reported and reasons explained)
Incomplete outcome data
(attrition bias) 
measures of blood glucose
control
High risk Quote from publication: "In the acarbose group, 2 cases were lost after 1 year
of follow-up, 1 case of lung cancer and 1 case of hepatitis. In the metformin
group, 1 case of cerebral hemorrhage was lost after 1 year of follow-up."
Comment: PP analysis was used (reported and reasons explained)
Selective reporting (re-
porting bias)
High risk Comment: protocol unavailable. Outcomes that were not mentioned in the
method section were reported in the result section (e.g. adverse events)




Methods Parallel randomised controlled trial, randomisation ratio 1:1:1:1
Participants Inclusion criteria: IGT
Exclusion criteria: not reported
Diagnostic criteria: WHO 1985 (IGT 2hPG of 140 mg/dL to 199 mg/dL (7.8 mmol/L to 11.0 mmol/L))
Interventions Number of study centres: not reported (12 authors from 5 departments in 2 hospitals)
Run-in period: not reported
Administration-free period before testing during trial: did not take study-drug on the morning of the
OGTT retest
Extension period: none
Outcomes Composite outcome measures reported: none
Study details Trial terminated early (for benefit/because of adverse events): no
Publication details Language of publication: Chinese
Funding: military funding
Publication status: peer-reviewed journal, full-article
Stated aim of study Quote from publication: "To evaluate the efficacy of metformin and diet fibre intervention in prevent-
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from publication: "randomised"
Comment: insufficient information about the sequence generation process
Allocation concealment
(selection bias)






Low risk Comment: no blinding reported, however, mortality is unlikely to be influ-





Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to





measures of blood glucose
control
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding. (investigator-assessed outcome measure-
ment)
Blinding of outcome as-
sessment (detection bias) 
all-cause mortality/cardio-
vascular mortality
Low risk Comment: no blinding reported, however, mortality is unlikely to be influ-
enced by lack of blinding. (adjudicated outcome measurement)
Blinding of outcome as-
sessment (detection bias) 
incidence of T2DM
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding. (investigator-assessed outcome measure-
ment)
Blinding of outcome as-
sessment (detection bias) 
measures of blood glucose
control
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to





High risk Quote from publication: "A total of 23 patients withdrew, and the withdraw-
al rate was 7.8%. Among the 72 cases in the education group, 7 cases quit with-
out definite reason, and 1 case died of cerebral thrombosis complicated with
pulmonary infection. Six cases in the education + diet instruction group were
lost to follow-up. In the dietary fiber group, 3 patients lost follow-up and 1 pa-
tient withdrew from gastric cancer. In the metformin group, 3 patients were
lost to follow-up, and 2 patients withdrew due to going abroad."




measures of blood glucose
control
High risk Quote from publication: "A total of 23 patients withdrew, and the withdraw-
al rate was 7.8%. Among the 72 cases in the education group, 7 cases quit with-
out definite reason, and 1 case died of cerebral thrombosis complicated with
pulmonary infection. Six cases in the education + diet instruction group were
lost to follow-up. In the dietary fiber group, 3 patients lost follow-up and 1 pa-
tient withdrew from gastric cancer. In the metformin group, 3 patients were
lost to follow-up, and 2 patients withdrew due to going abroad."
Lu 2002  (Continued)
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High risk Comment: protocol unavailable. Outcomes not described in the method sec-
tion were reported in the results (adverse events)




Methods Parallel randomised controlled trial, randomisation ratio 1:1
Participants Inclusion criteria: (1) participants with pre-diabetes; (2) 25 to 80 years old; (3) twice increased fasting
blood glucose (fasting blood glucose 5.6 mmol/L to 6.9 mmol/L); (4) postprandial blood glucose was in-
creased (OGTT 2-hour blood glucose 7.8 mmol/L to 11.1 mmol/L).
Exclusion criteria: (1) participants with cardiovascular diseases, hepatitis, kidney diseases and other
basic diseases that may increase the risk of intervention; (2) participants who may affect the process
of the experiment: inability to follow up, refusal of random grouping, pregnancy and lactation, etc., (3)
participants were taking drugs that could interfere with the test results, such as diuretics, beta-blockers
13 and glucocorticoids.
Diagnostic criteria: ADA 2009 (fasting blood glucose 5.6 mmol/L to 6.9 mmol/L or 2-hour blood glucose
7.8 mmol/L to 11.1 mmol/L).
Interventions Number of study centres: 1
Run-in period: not reported
Administration-free period before testing during trial: not specified if any study drug was taken on
the testing day at the end of intervention
Extension period: none
Outcomes Composite outcome measures reported: none
Study details Trial identifier: unregistered
Trial terminated early (for benefit/because of adverse events): no
Publication details Language of publication: Chinese
Funding: not reported
Publication status: peer-reviewed journal, full article
Stated aim of study Quote from publication: "This study is a clinical demonstration study on lifestyle adjustment and met-
formin intervention, two commonly used measures to prevent or delay diabetes. Through the compar-
ison and analysis of the blood glucose index changes after the implementation, the compliance of the
two kinds of intervention measures, weight changes, the incidence of adverse events and other indica-
tors, the efficacy and safety were reasonably evaluated, and the most reasonable, effective and practi-
cal measures for preventing or delaying diabetes were finally determined."
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Lu 2010 
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Random sequence genera-
tion (selection bias)
Unclear risk Quote from publication: "randomised"
Comment: insufficient information about the sequence generation process
Allocation concealment
(selection bias)





Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to





measures of blood glucose
control
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding. (investigator-assessed outcome measure-
ment)
Blinding of outcome as-
sessment (detection bias) 
incidence of T2DM
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding. (investigator-assessed outcome measure-
ment)
Blinding of outcome as-
sessment (detection bias) 
measures of blood glucose
control
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to





Low risk Quote from publication: "A total of 100 patients in the lifestyle intervention
group completed the study, 17 patients withdrew from the study (2 patients
went abroad, 15 patients for personal reasons), and the baseline characteris-
tics of those who did not complete the study were the same as those who com-
pleted the study. 111 patients (6 without follow-up) entered the primary and
secondary endpoint analysis. In the metformin group, 21 patients withdrew
from the study (6 with gastrointestinal reactions, lO with personal reasons, 5
with other reasons), and 115 patients entered the primary and secondary end-
point analysis (2 without follow-up)."; "last observation carried forward (LOCF)
was used"; "Since our study included observational studies of compliance, our
analysis showed that the LOCF did not affect the interpretation of the results
of this study."
Comment: reported, acceptable reason, and appropriate imputation of data
(reported and reasons explained)
Incomplete outcome data
(attrition bias) 
measures of blood glucose
control
Low risk Quote from publication: "A total of 100 patients in the lifestyle intervention
group completed the study, 17 patients withdrew from the study (2 patients
went abroad, 15 patients for personal reasons), and the baseline characteris-
tics of those who did not complete the study were the same as those who com-
pleted the study. 111 patients (6 without follow-up) entered the primary and
secondary endpoint analysis. In the metformin group, 21 patients withdrew
from the study (6 with gastrointestinal reactions, lO with personal reasons, 5
with other reasons), and 115 patients entered the primary and secondary end-
point analysis (2 without follow-up)."; "last observation carried forward (LOCF)
was used"; "Since our study included observational studies of compliance, our
analysis showed that the LOCF did not affect the interpretation of the results
of this study."
Comment: reported, acceptable reason, and appropriate imputation of data
(reported and reasons explained)
Lu 2010  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk Comment: protocol unavailable




Methods Parallel randomised controlled trial, randomisation ratio 1:1:1:1
Participants Inclusion criteria: IGT
Exclusion criteria: NR
Diagnostic criteria: IGT (2hPG 110 to 200 mg/dL [6.1 mmol/L to 11.0 mmol/L]) and FPG <1 10mg/dL
(6.1 mmol/L))
Interventions Number of study centres: NR
Run-in period: participants with IGT were selected and given diet and lifestyle advice for three months.
The participants who still had IGT were thereafter randomised
Administration-free period before testing during trial: not reported
Extension period: no
Outcomes Composite outcome measures reported: no
Study details Trial terminated before regular end (for benefit/because of adverse events): no
Taking trial drug on glycaemic testing days: NR
Publication details Language of publication: English
Funding: NR
Publication status: peer-reviewed journal
Stated aim of study Quote from publication: "The present study of diabetes prevention programme has been started in
2001 at Ramakrishna Mission Seva Pratishthan to assess the nature and extent if interventional thera-
pies regarding prevention of type 2 diabetes"
Notes 2-hour OGTT; HbA1c; FPG were reported as per cent change from baseline; not possible to include data
in the meta-analysis. There were no significant change in the percent reduction of glycaemic parame-
ters in between the three groups receiving a pharmacological intervention
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from publication: "Those who still had their blood sugar at the IGT
range were randomised into 3 groups to receive either metformin or rosiglita-
zone or acarbose."
Comment: insufficient information about the sequence generation
Allocation concealment
(selection bias)
Unclear risk Comment: no description of allocation concealment
Maji 2005 
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Low risk Quote from publication: "..no person in the study group developed diabetes
during this period of three years, ..""





measures of blood glucose
control
Low risk Comment: no blinding, the outcome is not likely to be influenced by lack of
blinding
Blinding of outcome as-
sessment (detection bias) 
incidence of T2DM
Low risk Quote from publication: "..no person in the study group developed diabetes
during this period of three years, ..""
Comment: no blinding, the outcome is not likely to be influenced by lack of
blinding
Blinding of outcome as-
sessment (detection bias) 
measures of blood glucose
control





Unclear risk Comment: not mentioned in the publication how missing data were handled
Incomplete outcome data
(attrition bias) 
measures of blood glucose
control
Unclear risk Comment: not mentioned in the publication how missing data were handled
or how many included in the analyses
Selective reporting (re-
porting bias)
High risk No trial protocol available. Glycaemic parameters reported in a format that
made them unsuitable for meta-analysis. Data on hypoglycaemia and adverse
events were not reported




Methods Parallel randomised controlled clinical trial, randomisation ratio 1:1
Participants Inclusion criteria: male, 25 to 55 years, 'borderline' diabetes (see criteria in the section 'diagnostic cri-
teria')
Exclusion criteria: NR
Diagnostic criteria: fasting blood glucose ≥ 5.6 mmol/L and < 7.2 mmol/L or 2-hour blood glucose af-
ter a 75 g oral glucose challenge ≥ 6.7 mmol/L and < 8.3 mmol/L; when these criteria for intermediate
hyperglycaemia were fulfilled, a second test was performed: blood glucose concentrations were deter-
mined fasting at 15, 30, 60, 120, 80, 240 and 300 minutes after an oral glucose load. Eligible individu-
als had 2-hour blood glucose concentrations ≥ 6.7 mmol/L but < 8.3 mmol/L or fasting blood glucose
concentrations ≥ 5.6 mmol/L and < 7.2 mmol/L; blood glucose after 30 minutes ≥ 8.9 mmol/L and < 12.2
mmol/L; blood glucose after 60 minutes ≥ 8.9 mmol/L and < 12.2 mmol/L (the European Diabetes Epi-
demiology Study Group 1970 criteria)
Interventions Number of study centres: 1
Papoz 1978 
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Run-in period: none
Administration-free period before testing during trial: participants received study-drug on the day
of testing blood glucose at 2 months and 14 months. However, the last glycaemic measurements were
performed 15 days after the study drug was stopped
Extension period: none
Outcomes Composite outcome measures reported: no
Study details Trial terminated early: no
Publication details Language of publication: English
Funding: non-commercial funding
Publication status: peer-reviewed journal
Stated aim of study Quote from publication: "A double blind controlled clinical trial was undertaken to test the effective-
ness of oral hypoglycaemic drugs in improving blood glucose and plasma insulin levels of borderline
diabetic patients"
Notes Blood glucose values in this trial were reported as whole blood glucose. In the tables and result section
all values are converted to plasma glucose values (diabetes.co.uk)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from publication: "They were randomized into 4 groups according..."
Comment: method of randomisation not described
Allocation concealment
(selection bias)




measures of blood glucose
control
Low risk Quote from publication: "A double blind controlled clinical trial was under-
taken..."
Comment: investigator-assessed, double-blinding
Blinding of outcome as-
sessment (detection bias) 
measures of blood glucose
control





measures of blood glucose
control
Unclear risk Quote from publication: "Thirty four patients (24 during the first year, 10 dur-
ing the second year of the study) were lost to follow-up; they came equally
from the four different treatment groups and exhibited similar baseline char-
acteristics to the follow-up patients. Their removal from the trial did not intro-
duce any bias into the study"




High risk Comment: likely that adverse events have been evaluated, but not reported
(see Appendix 8)
Other bias Low risk Comment: the trial appeared to be free of other sources of bias
Papoz 1978  (Continued)
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Methods Parallel randomised controlled trial, randomisation ratio 1:1:1
Participants Inclusion criteria: Latinas aged 20 years or more, IFG (FPG of 100 to 125 mg/dL) and/or elevated HbA1c
of 5.7% to 6.4% (39 mmol/mol to 46 mmol/mol), BMI at 23 kg/m2 or more
Exclusion criteria: diabetes at baseline, were currently pregnant or planned to become pregnant, or
were participating in a supervised weight loss program. Blood pressure at or above 160 mmHg/100
mmHg, contraindication to metformin, chronic conditions that could affect a participant’s ability to
participate (e.g. severe osteoarthritis), medical co morbidities that could influence body weight (e.g.
uncontrolled thyroid disease), or medications that could affect weight or glucose metabolism (e.g., oral
corticosteroids).
Diagnostic criteria: IFG (FPG of 100 mg/dL to 125 mg/dL (5.6 mmol/L to 6.9 mmol/L) and/or intermedi-
ate elevated HbA1c of 5.7% to 6.4% (39 mmol/mol to 46 mmol/mol))
Interventions Number of study centres: one
Run-in period: none
Administration-free period before testing during trial: not reported
Extension period: no
Outcomes Composite outcome measures reported: no
Study details Trial terminated before regular end (for benefit/because of adverse events): no
Publication details Language of publication: English
Funding: non-commercial funding
Publication status: peer-reviewed journal
Stated aim of study Quote from publication: "This study was designed to compare the real-world effectiveness of ILI, met-
formin, and standard care among Hispanic women (Latinas) with prediabetes"
Notes Quote from publication: "Though all participants had prediabetes by HbA1c or fasting plasma glucose
criteria, more participants qualified for the study based on elevated HbA1c alone (n=53, 57.6% of to-
tal participants). Among the remaining 39 participants, 12 (13.0%) qualified by having impaired fasting
glucose alone, and 27 (29.3%) met both glycemic criteria for prediabetes"
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from publication: "The random allocation sequence was generated in-
dependently by a statistician and concealed in individually sealed envelopes
accessible only to the research coordinator, who ultimately assigned partici-
pants to the study interventions."
Comment: adequate description of the sequence generation
Allocation concealment
(selection bias)
Low risk Quote from publication: "The assignment for each randomized group was
concealed in individually-sealed, opaque envelopes kept in a locked filing cab-
inet accessible only to the research coordinator, who ultimately assigned par-
ticipants to the study interventions."
Comment: adequate description of the allocation concealment
PREVENT-DM 2017 
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Low risk Quote from publication: "The nature of the study interventions precludes
blinding participants, promotoras, or the research coordinator to treatment
assignments."






Low risk Quote from publication: "The nature of the study interventions precludes
blinding participants, promotoras, or the research coordinator to treatment
assignments."
Comment: no blinding, the outcome is not likely to be influenced by lack of
blinding
Blinding of outcome as-
sessment (detection bias) 
all-cause mortality/cardio-
vascular mortality
Low risk Quote from publication: "The nature of the study interventions precludes
blinding participants, promotoras, or the research coordinator to treatment
assignments."
Comment: no blinding, the outcome is not likely to be influenced by lack of
blinding
Blinding of outcome as-
sessment (detection bias) 
incidence of T2DM
Low risk Quote from publication: "The nature of the study interventions precludes
blinding participants, promotoras, or the research coordinator to treatment
assignments."
Comment: no blinding, the outcome is not likely to be influenced by lack of
blinding
Blinding of outcome as-
sessment (detection bias) 







Low risk Quote from publication: "Data will be analyzed assuming an intent-to-treat
approach where all randomized subjects are analyzed according to their treat-
ment assignment, regardless of adherence."
Comment: the number of participants who were lost to follow-up or excluded
due to pregnancy were low (2 in metformin and standard care; three in inten-




Low risk Quote from publication: "Data will be analyzed assuming an intent-to-treat
approach where all randomized subjects are analyzed according to their treat-
ment assignment, regardless of adherence."
Comment: the numbers of participants who were lost to follow-up or exclud-
ed due to pregnancy were low (2 in metformin and standard care; three in in-
tensive diet plus exercise group
Selective reporting (re-
porting bias)
High risk Likely hypoglycaemia was evaluated, but no data provided




Methods Parallel randomised controlled trial, randomisation ratio 1:1
Wang 2009 
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Participants Inclusion criteria: IGT and/or IFG
Exclusion criteria: hyperthyroidism, hypercortisolism and acromegaly; blood glucose abnormalities
caused by pancreatic exocrine gland dysfunction and liver function damage
Diagnostic criteria: ADA 1997 (FPG 5.6 mmol/L to 6.9 mmol/L, and/or 2hPG 7.8 mmol/L to 11.0 mmol/
L)
Interventions Number of study centres: 1
Run-in period: not reported
Administration-free period before testing during trial: not specified if any study drug was taken on
the testing day at the end of intervention
Extension period: none
Outcomes Composite outcome measures reported: none
Study details Trial terminated early (for benefit/because of adverse events): no
Publication details Language of publication: Chinese
Funding: not reported
Publication status: conference proceedings
Stated aim of study Quote from publication: "To observe the effect of metformin on 30 patients with impaired glucose reg-
ulation (IGR), and to explore the intervention method in the prediabetes stage."
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from publication: "randomised"
Comment: insufficient information about the sequence generation process
Allocation concealment
(selection bias)





Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to





measures of blood glucose
control
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding (investigator-assessed outcome measure-
ment)
Blinding of outcome as-
sessment (detection bias) 
incidence of T2DM
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding (investigator-assessed outcome measure-
ment)
Wang 2009  (Continued)
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Blinding of outcome as-
sessment (detection bias) 
measures of blood glucose
control
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to





High risk Quote from publication: "In the treatment group, 2 patients showed gastroin-
testinal reactions after taking the medicine, and the discomfort symptoms dis-
appeared after stopping the medicine, which was considered as adverse drug
reactions, so they were withdrawn from the study."
Comment: PP analysis was used (2/30 = 6.7%); however, if the two who were
absent from analysis had developed T2DM the incidence would have been
doubled (4/32 = 12.5%)
Incomplete outcome data
(attrition bias) 
measures of blood glucose
control
High risk Quote from publication: "In the treatment group, 2 patients showed gastroin-
testinal reactions after taking the medicine, and the discomfort symptoms dis-
appeared after stopping the medicine, which was considered as adverse drug
reactions, so they were withdrawn from the study."
Comment: the author did not report the number of participants included in
the FBG and 2hPG analyses, possibly PP analyses were applied
Selective reporting (re-
porting bias)
Unclear risk Comment: protocol unavailable




Methods Parallel randomised controlled trial, randomisation ratio 1:1:1
Participants Inclusion criteria: impaired fasting glucose with or without IGT
Exclusion criteria: liver and kidney dysfunction; severe cardiovascular and cerebrovascular diseases
Diagnostic criteria: WHO 1999 (IFG FPG 6.1 to 6.9 mmol/L; IGT 2hPG ≥7.8 mmol/L to <11.1 mmol/L)
Interventions Number of study centres: 1
Run-in period: NR
Administration-free period before testing during trial: not specified if any study drug was taken on
the testing day at the end of intervention
Extension period: none
Outcomes Composite outcome measures reported: none
Study details Trial terminated early (for benefit/because of adverse events): no
Publication details Language of publication: Chinese
Funding: not reported
Publication status: peer-reviewed journal, full-article
Stated aim of study Quote from publication: "To evaluate the clinical effects of different interventions on impaired glu-
cose regulation."
Zeng 2013 
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Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote from publication: "random number table"
Comment: adequate description of the sequence generation
Allocation concealment
(selection bias)





Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to





measures of blood glucose
control
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding (investigator-assessed outcome measure-
ment)
Blinding of outcome as-
sessment (detection bias) 
incidence of T2DM
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding (investigator-assessed outcome measure-
ment)
Blinding of outcome as-
sessment (detection bias) 
measures of blood glucose
control
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to









measures of blood glucose
control




High risk Comment: protocol unavailable. Adverse events not reported- likely this out-
come has been evaluated




Methods Parallel randomised controlled trial, randomisation ratio 1:1
Participants Inclusion criteria: IGT, IFG, BMI > 25 kg /m2, waist to hip ratio ≥ 0.9 for males and ≥ 0.85 for females
Exclusion criteria: impaired liver and kidney function, severe heart and lung disease, infection, surgery
and heavy alcohol consumption
Zhao 2013 
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Diagnostic criteria: WHO 1999 (FPG between 5.6 mmol /L ˜ 6.9 mmol /L, 2hPG 7.8 mmol /L ˜ 11.0
mmol/L)
Interventions Number of study centres: 1
Run-in period: not reported
Administration-free period before testing during trial: not specified if any study drug was taken on
the testing day at the end of intervention
Extension period: none
Outcomes Composite outcome measures reported: none
Study details Trial terminated early (for benefit/because of adverse events): no
Publication details Language of publication: Chinese
Funding: not reported
Publication status: peer-reviewed journal, full-article




Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote from publication: "randomised"
Comment: insufficient information about the sequence generation process
Allocation concealment
(selection bias)





Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to





measures of blood glucose
control
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding. (investigator-assessed outcome measure-
ment)
Blinding of outcome as-
sessment (detection bias) 
incidence of T2DM
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding (investigator-assessed outcome measure-
ment)
Blinding of outcome as-
sessment (detection bias) 
measures of blood glucose
control
Low risk Comment: no blinding reported, however, laboratory indexes are unlikely to
be influenced by lack of blinding (investigator-assessed outcome measure-
ment)
Zhao 2013  (Continued)
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High risk Quote from publication: "In the treatment group, 1 patient withdrew due
to gastrointestinal reaction (diarrhea); no case was lost to follow-up in both
groups."
Comment: PP analysis was used (reported and reasons explained)
Incomplete outcome data
(attrition bias) 
measures of blood glucose
control
High risk Quote from publication: "In the treatment group, 1 patient withdrew due
to gastrointestinal reaction (diarrhea); no case was lost to follow-up in both
groups."
Comment: PP analysis was applied (reported and reasons explained)
Selective reporting (re-
porting bias)
High risk Comment: protocol unavailable. Have only reported non-serious adverse ef-
fects. It is likely that serious adverse effect have been collected as well, but not
reported
Other bias Unclear risk Comment: funding source not reported
Zhao 2013  (Continued)
2hPG: 2-hour plasma glucose value after glucose tolerance test; ADA: American Diabetes Association; BMI: body mass index;DBP: diastolic
blood pressure; FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c;IGT: impaired glucose tolerance; IFG: impaired fasting
glucose; ITT: intention to treat; NIDDM: non-insulin-dependent diabetes mellitus; NR: not reported; NYHA: New York Heart Association;
OGTT: oral glucose tolerance test; PP: per protocol; RCT: randomised controlled trial; SAE: serious adverse events; SBP: systolic blood
pressure; T2DM: type 2 diabetes mellitus; WHO: World Health Organization.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Acbay 1996 Duration of the intervention less than one year
Ballon 2011 Duration of the intervention less than one year
Biarnés 2005 Duration of the intervention less than one year
Bulcão 2007 Duration of the intervention less than one year
Caballero 2004 Duration of the intervention less than one year
Celik 2012 Wrong population
Chazova 2006 Duration of the intervention less than one year
Chen 2013 Translated from Chinese: wrong intervention. Co-intervention not identical.
ChiCTR-TRC-09000548 Duration of intervention less than one year (information provided by author)
CTRI/2013/02/003417 Study protocol for non-randomised study
Eguchi 2007 Duration of the intervention less than one year
Esteghamati 2013 Duration of the intervention less than one year
EUCTR-000650-21-ES Not a RCT
EUCTR2008-004497-40-GB Not a RCT
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Study Reason for exclusion
Fleming 2002 Wrong population
Flores-Saenz 2003 Duration of the intervention less than one year
Gore 2005 Duration of the intervention less than one year
Gram 2011 Wrong population
Guardado-Mendoza R 2018 Wrong intervention/comparator
Gómez-Díaz 2012 Duration of the intervention less than one year
Haukeland 2008 Wrong population
Ishida 2005 Not a RCT (translated from Japanese: narrative review explaining the history, mechanism and side
effects of metformin)
Kato 2009 Wrong population
Kelly 2012 Duration of the intervention less than one year
Kendall 2013 Duration of the intervention less than one year
Kilic 2011 Duration of the intervention less than one year
Koev 2004 Duration of the intervention less than one year
Krysiak 2012 Duration of the intervention less than one year
Lehtovirta 2001 Duration of the intervention less than one year
Li 2009b Duration of the intervention less than one year
LIMIT-1 Duration of the intervention less than one year
Lu 2011 Wrong intervention/comparator (not identical concomitant intervention)
Malin 2013 Duration of the intervention less than one year
Medical letter Not a RCT
Morel 1999 Duration of the intervention less than one year
NCT00108615 Duration of the intervention less than one year
NCT02338193 Duration of the intervention less than one year
NCT03258723 Wrong population
Pre-DICTED Wrong intervention/comparator
RESIST Duration of the intervention less than one year
Retnakaran 2012 Duration of the intervention less than one year
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Study Reason for exclusion
Rodríguez-Moctezuma 2005 Wrong population
Scheen 2009 Wrong population
Schuster 2004 Non-prediabetic population
SLCTR/2016/026 Duration of the intervention less than one year
STOP-NIDDM Wrong intervention (does not randomise to metformin)
Stroup 2013 Duration of the intervention less than one year
Sultana 2012 Duration of the intervention less than one year
UKPDS Wrong population
Vitolins 2017 Not a RCT
Wan 2010 Duration of intervention less than one year
Zinman 2010 Wrong intervention/comparator
RCT: randomised clinical trial
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Randomised, parallel, interventional study
Participants Inclusion criteria: according to the classification standard of WHO glucose metabolism status
(1999), IGR was diagnosed two weeks before randomisation; aged 35 to 60 years; no use of glu-
cose-lowering drugs (including herbal medicine for lowering blood glucose); women who are male
or non-pregnant, non-lactating, and have no family planning for the next three years; BMI 24 kg/m2
to < 32 kg/m2
Interventions Metformin plus lifestyle intervention versus lifestyle intervention
Outcomes Height, weight, blood pressure, fat, blood glucose, insulin, endothelial progenitor cells
Publicaton details Trial register record: ChiCTR-IPR-17012309
Notes Not clarified if study can be included, duration of intervention? Author (Ping Yu) contacted for fur-




Methods Randomised, parallel, interventional study
Participants Participants 'at risk' for developing diabetes, fasting BG 5.5 to 7.7 mmol/L
EDIT 1997 
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Interventions Metformin 500 mg three times daily plus placebo three times daily versus acarbose 50 mg three
times daily plus placebo three times daily versus placebo three times daily plus placebo three
times daily
One of the intervention groups will not to be included in review (metformin 500 mg three times dai-
ly + acarbose 50 mg three times daily)
Outcomes Incidence of T2DM, glycaemic variables
Publicaton details Trial register record: ISRCTN96631607
The study is only published as abstracts
Notes Conlcusion of the trial in published abstract": "No differences were seen in relative risk for diabetes
by 6 years with acarbose (1.04, P = 0.81), Metformin (0.99, P = 0.94) or combination therapy (1.02, P
= 0.91). In those with IGT at baseline, relative risk was reduced significantly with acarbose (0.66, P =
0.046) but not Metformin (1.09, P = 0.70) or combination therapy (0.72, P = 0.27)." The reviewers of




Methods Randomised, parallel, interventional study
Participants Prediabetes (if not diabetic):
IFG: ADA criteria: fasting plasma glucose level from 5.6 mmol/L (100 mg/dL) to 6.9 mmol/L (125
mg/dL), and/or IGT (WHO and ADA criteria: two-hour glucose levels of 140 mg/dL to 199 mg/dL (7.8
mmol to 11.0 mmol) on the 75 g oral glucose tolerance test and/or HbA1C: 5.7% to 6.4% (ADA crite-
ria)
People with type 2 diabetes
Interventions Metformin plus lifestyle interventions versus standard care
Outcomes Primary efficacy endpoint: change in cerebral glucose metabolic rate
Primary cognitive endpoint: change in composite z-score of memory and multi-domain non-
amnestic cognitive test performance using a neuropsychological assessment
Secondary outcome measures: change in subjective memory and cognitive complaint, change in
basic activities of daily living (ADL), change in cognitive instrumental ADL scale, change in glob-
al clinical dementia rating sum of boxes, change in mini-mental state examination, change in the
Montreal cognitive assessment scale, change in fasting plasma insulin, change in homeostatic
model assessment, change in weight, change in BMI, change in waist circumference, change in FPG,
change in HbA1c, change in fasting lipids
Publicaton details Trial register record: NCT02409238
Notes The study includes prediabetic and diabetic people and data need to be separated for use in this
review. Not clarified if study can be included. Authors (Wee Kien Han Andrew and Tan Kee Tung)
contacted for information about if study are finished and published (30.03.2019). Answer: study




Methods Randomised, open-label clinical trial
Participants People with prediabetes
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Interventions Metformin 850 mg twice daily plus lifestyle changes versus change in lifestyle
Outcomes Quote: "The study was divided into two phases, with 2 intervention groups. In the first phase group
1 (52 patients) was treated with metformin 850 mg. 2 times a day, as well as changes in lifestyle
and group 2 (50 subjects) only changes in lifestyle, were evaluated clinically and biochemically
for a period of six years. In the second phase intervention was similar for all participants receiv-
ing combined treatment for 4 years, with an average follow-up of 120 months (+/- 3.5). First phase:
Group one, 75% of the subjects remained with PD; 21% developed T2DM and 3.8% showed normo-
glycemia with a 3.5% annual T2DM conversion. In group two, 62% remained with PD and 38% de-
veloped T2DM, with an annual incidence of 6.2%. Second phase: Group one, 57% had PD, 8 sub-
jects developed T2DM (15.8%), with an overall incidence of 22 cases (42.3%), 4.2% cases per year.
While in group two, 40% continued with PD and 22% were categorized as having T2DM, with an
overall prevalence of 30 cases (60% of the population), with an annual rate of development of
T2DM 6%. In the analysis of all subjects an incidence of 52 cases of T2DM (50.9%) was obtained,
while the rest population remained with PD. The variables that were associated with the devel-
opment of T2DM were fasting glucose levels and post challenge, HbA1c, insulin levels, HOMA IR,
HOMA B, HOMA S and waist circumference (p <0.001). Early intervention with changes in lifestyle
concomitant use of metformin prevents more effectively the development of T2DM in high risk sub-
jects of Western Mexico"
Publicaton details Only abstract available
Notes Not possible to clarify if study meets inclusion criteria (definition of prediabetes? study pub-
lished?). No contact information
Polanco 2015  (Continued)
ADA: American Diabetes Association; ADL: activities of daily living; BG: blood glucose; BMI: body mass index; HbA1c: glycosylated haemo-
globin A1c; IFG: impaired fasting glucose; IGR: impaired glucose regulation; IGT: impaired glucose tolerance; T2D: type 2 diabetes melli-
tus; WHO: World Health Organization.
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title A study of life style modification with and without metformin in prediabetic participants




Primary purpose: not reported
Participants Condition: IFG, IGT or HbA1c 5.7% to 6.4%
Enrollment: 90
Inclusion criteria: BMI 18.5 to 29.9 kg/m2. Non diabetic individuals with either IFG (FPG > 100 mg/
dL < 126 mg/dL (> 5.6 mmol/L < 7.0 mmol/L), IGT (2hPG > 140 < 200 mg/dL) (> 7.8 mmol/L < 11.1
mmol/L), HbA1c 5.7% to 6.4%
Exclusion criteria: type 1 or type 2 diabetes (FPG > 126 mg/dL (7.0 mmol/L), 2hPG > 200 mg/dL
(11.1 mmol/L) and HbA1c > 6.5%); contraindications to metformin (chronic kidney failure, hepatic
dysfunction, renal impairment) and hypersensitivity; pregnant and lactating women
Interventions Intervention: metformin 250 mg twice daily plus life style modification
Comparator: life style modification
CTRI/2017/09/009635 
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Duration of intervention: two years and six months
Outcomes Primary outcomes: conversion to normoglycaemia, IGT or IFG or intermediate elevated HbA1c,
and T2DM
Secondary outcomes: antioxidants
Other outcomes: not reported
Starting date Study start date: 08/09/2016
Study completion date: not reported






Trial name or title Acronym: ePREDICE
Methods Type of trial: efficacy trial
Allocation: randomised
Intervention model: parallel assignment
Masking: double-blind
Primary purpose: not specified in protocol
Participants Condition: IGT or IFG, or both
Enrolment: 3000
Inclusion criteria: age 45 to 74 years; IFG (FPG 6.1-6.9 mmol/L and 2hPG < 7.8 mmol/L) or IGT (FPG
< 7.0 mmol/L and 2hPG ≥ 7.8 to < 11.1 mmol/L) or both conditions; informed consent given
Exclusion criteria: T1DM; known or unknown T2DM (including screen-detected T2DM) with or
without pharmacological treatment; use of a GLP-1 receptor agonist (exenatide or other) or pram-
lintide or any DPP-4 inhibitor or metformin within the 3 months prior to enrolment; use of insulin
or long-acting insulin analogue within 3 months prior to enrolment; any previous cardiovascular or
cerebrovascular clinically documented event or revascularisation procedure; clinical evidence of
macrovascular complications (overt clinical cardiovascular disease) at enrolment, including angina
(stable or unstable) and evidence of previous myocardial infarction in baseline electrocardiogram;
current renal replacement therapy; previous diagnosis of liver cirrhosis or chronic hepatitis, or an
elevation of liver enzymes (AST and or ALT) > 3 times normal ranges; previous diagnosis of chron-
ic heart failure (NYHA class III or higher); prior solid organ transplant or awaiting solid organ trans-
plant; malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy in the
previous 5 years. Participants with intraepithelial squamous cell carcinoma of the skin (Bowen's
disease) treated with topical 5-fluorouracil and people with basal cell skin cancer allowed to enter
trial; any acute condition or exacerbation of chronic condition that would, in investigator's opin-
ion, interfere with the initial trial visit schedule and procedures; known or suspected hypersensitiv-
ity to trial products or related products; known use of non-prescribed narcotics or illicit drugs; si-
multaneous participation in any other clinical trial of an investigational agent; women of childbear-
ing potential who are pregnant (all fertile women will be tested for before randomisation), breast-
feeding or intend to become pregnant; presence of cataract that impedes the retinal evaluation of
ePRECIDE 2017 
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both eyes; other previously diagnosed retinal diseases; any diseases that would prevent the mea-
surement of primary endpoints; dementia, mental disorder or evident cognitive impairment un-
able to give informed consent; end-stage or metastatic cancer; institutionalisation; renal function
impairment: GFR < 60 mL/minute/1.73 m2.; contraindication to any of the study drugs (metformin
or linagliptin). This includes: ALT > 3 times the upper limit of normal, history of cirrhosis or hepati-
tis, suspected renal artery stenosis, recent gastrointestinal bleeding (within last year), pregnant,
breastfeeding or a female of childbearing potential not on reliable contraception and also any cir-
cumstance where ongoing medication might lead to potential adverse drug interaction with com-
ponents of the trial medications; any other reason, medical condition, ongoing medication or sig-
nificant disability that would prevent the participant complying with trial consent, treatment and
follow-up procedures or potentially jeopardise her/his medical care
Interventions Intervention: 2 tablets of linagliptin 5 mg + diet and physical activity
Comparator (1): 2 tablets of metformin 850 mg/day + diet and physical activity
Comparator (2): 2 tablets of linagliptin 2.5 mg + metformin 850 mg plus diet and physical activity
Comparator (3): 2 tablets of placebo + diet and physical activity
Duration of intervention: at least 3 years, and additional follow-up to 5 years
Outcomes Primary outcome: a combined continuous variable, "the microvascular complication índex" (M-
CI), composed of linear combination of ETDRS score, the level of urinary albumin to creatinine ra-
tio, and sudomotor test (SUDOSCAN) score, measured during the 36th and 60th month visits.
From email correspondence: primary purpose: prevention of complications of hypergly-
caemia/prevention of progression to diabetes
Secondary outcomes: retinopathy score at last visit defined as 2-steps' progression on ETDRS
scale between baseline and visits at months 36 and 60; 1 SD increase in level of urinary albumin
to creatinine ratio between baseline and visits at months 36 and 60; 1 SD decrease change in lev-
el of hands and feet conductance in SUDOSCAN between baseline and visits at months 36 and 60;
change in microvascular endothelial function measured by EndoPAT method (in a subset); change
in the Non-Alcoholic Fatty Liver Index (in a subset); change in biomarkers of microvascular dam-
age, endothelial function, per-oxidation, inflammation and metabolomics (in a subset); change in
the insulin secretion and β-cell function; change in self-perceived quality of life; change in symp-
toms of peripheral neuropathy; change in neuropsychological parameters: cognitive function, anx-
iety and depressive symptoms and indices; changes in obstructive sleep apnoea indices as mea-
sured by Somnomedics (in a subset); changes in ambulatory blood pressure monitoring (in a sub-
set); change in the mean common carotid intimae-media thickness (in a subset); incidence of ma-
jor cardiovascular events, defined as an expanded composite of total coronary events, total stroke
events, revascularisation procedures (coronary artery bypass graN, percutaneous coronary angio-
plasty and peripheral revascularisation), hospitalisation for heart failure, TIA and cardiovascular or
cerebrovascular death. Secondary outcomes will be evaluated at 36 and 60 months
Other outcome: none
Starting date Trial start date: 2015
Trial completion date: December 2019
Contact information Responsible party/principal investigator: Prof Jaakko Tuomilehto; Prof Rafael Gabriel (co-princi-
pal investigators)
Trial identifier NCT03222765; EUCTR2013-000418-39-AT
Notes Multinational trial with 15 clinical centres from 12 countries: Australia, Austria, Bulgaria, Germany,
Greece, Italy, Lithuania, Poland, Serbia, Spain, Switzerland and Turkey.
ePRECIDE 2017  (Continued)
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Trial name or title Metformin for preventing frailty in high-risk older adults
Methods Type of trial: interventional
Allocation: randomised
Intervention model: parallel assignment
Masking: quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose: prevention
Participants Condition: older prediabetic people
Enrollment: 120
Inclusion criteria: men and women; all ethnic groups; age 65 and older; community-dwelling; 2-
hour values of 140 mg/dL to 199 mg/dL after an oral glucose load, and no diagnosis of diabetes in
the past 12 months; participants must have the following laboratory values: haematocrit ≥ 33%,
AST < 2 X upper limit of normal,ALT < 2 X upper limit of normal, alkaline phosphatase < 2 X upper
limit of normal, normal urinalysis, normal electrolytes, normal platelets, prothrombin time and
partial thromboplastin time, and normal renal function for the participant´s age (defined by a
serum creatinine < 1.5 mg/dL (132.6 mmol/L) in males or < 1.4 mg/dL (123.8 mmol/L) in females
and creatinine clearance ≥ 60 mL/min)
Exclusion criteria: characteriSed as frail, defined as the presence of 3 or more of: 1) weak hand
grip strength, 2) slow walking speed, 3) low physical activity, 4) unintentional weight loss of ≥ 10
pounds over the past year, 5) self-reported exhaustion; resident of nursing home or long-term care
facility; T2DM; taking drugs known to affect glucose sensitivity; untreated depression or geriatric
depression scale score on 15-item scale >7; diagnosis of any disabling neurologic disease Parkin-
son's disease, amyotrophic lateral sclerosis, multiple sclerosis, cerebrovascular accident with
residual deficits (muscle weakness or gait disorder), diagnosis of dementia or mini-mental state ex-
am score < 18; history of moderate-severe heart disease (NYHA Classification greater than grade
II) or pulmonary disease (dyspnoea on exertion upon climbing one flight of stairs or less; abnor-
mal breath sounds on auscultation); poorly controlled hypertension (SBP >170 mmHg, DBP >105
mmHg); systemic steroids, anabolic steroids, growth hormone or immunosuppressants within 6
months; chronic inflammatory condition, autoimmune disease, or infectious processes (e.g., active
tuberculosis, human immunodeficiency virus, rheumatoid arthritis, systemic lupus erythematosus,
hepatitis B or C); active tobacco use (within 6 months); active malignancy, non-skin; disease or con-
dition likely to cause death within 5 years; hypersensitivity to metformin or pioglitazone; donated
blood within the last 2 months
Interventions Intervention: metformin up to 2000 mg
Comparator: placebo
Duration of intervention: two years
Outcomes Primary outcomes: frailty composite measure
Secondary outcomes: gait speed, grip strength, six minute walk, short physical performance bat-
tery, body composition, frailty as defined by a deficit accumulation index
Other outcomes: not reported
Espinoza 2019 
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Starting date Study start date: April 2016
Study completion date: October 2022






Trial name or title Efficacy of metformin in preventing diabetes in China (ChinaDPP)
Methods Type of trial: interventional
Allocation: randomised
Intervention model: parallel assignment
Masking: open-label
Primary purpose: prevention
Participants Condition: diagnosis of IGR before the randomisation based on the 1999 WHO diagnostic and clas-
sification criteria
Enrollment: 1674
Inclusion criteria: diagnosis of IGR before the randomisation based on the 1999 WHO diagnostic
and classification criteria; 18 ≤age ≤70 years old; not on a treatment of anti-diabetic agents, includ-
ing Chinese traditional herbs lowering blood glucose for at least six months before screening; male
or non-pregnant, non-breastfeeding females, females without birthing plan in next three years; BMI
21 kg/m2 ≤ BM I＜32 kg/m2; written informed consent given before any trial-related activities are
carried out
Exclusion criteria: administration with medications for pre-existed diseases affect glucose me-
tabolism (except thiazide diuretics when its daily dose ≤12.5mg); administration with anti-obesity
agents (including Chinese traditional medicine) within six months of enrolment and during inter-
vention; administration with three or more than three types antihypertensive drugs; diabetes peo-
ple (prior history of gestational diabetes will not be excluded); have any of the following cardiovas-
cular conditions within three months prior to the screening visit: acute myocardial infarction, con-
gestive heart failure defined as NYHA class III/IV or leN ventricular ejection fraction ≤ 40%) or cere-
brovascular accident; persistent uncontrolled hypertension (SBP ≥160mmHg, or DBP ≥ 100 mmHg);
impaired liver function, have obvious clinical signs or symptoms of liver disease, acute or chron-
ic hepatitis, ALT or AST levels ≥3 times the upper limit of the reference range at the screening visit;
renal dysfunction (GFR < 45mL/minute); people ventilated by ventilator; hypersensitivity to met-
formin or to any of the excipients such as povidone K 30, magnesium stearate and hypromellose;
disease which may cause tissue hypoxia (especially acute disease, or worsening of chronic respi-
ratory disease); acute alcohol intoxication, alcoholism; severe chronic gastrointestinal disease;
severe psychiatric illness; cancer requiring treatment in past five years; uncontrolled thyroid dis-
eases; women who are pregnant or breastfeeding; participation in another clinical trial within the
past 30 days; other significant disease that in the Investigator's opinion would exclude the person
from the trial
Interventions Intervention: metformin 850 mg twice daily plus standard lifestyle intervention
Comparator: standard lifestyle intervention
Ji 2019 
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Duration of intervention: 2 years
Outcomes Primary outcomes: development of T2DM
Secondary outcomes: not reported
Other outcomes: not reported
Starting date Study start date: April 25, 2017
Study completion date: December 31, 2022






Trial name or title Metformin therapy for East Asian women with recent gestational diabetes mellitus and glucose ab-
normalities: a multicenter, randomised, open-label trial




Primary purpose: not reported
Participants Condition: women with recent GDM and glucose abnormalities, including IFG, or IGT, or both (IFG,
IGT) postpartum
Enrollment: 210
Inclusion criteria: women who experienced GDM in a previous singleton pregnancy in the past 5
years; postpartum metabolic abnormalities determined by a 75 g OGTT, inclusive of prior GDM with
IFG, IGT, or both (IFG, IGT) postpartum; can respond to the questionnaire in Japanese; over 20 years
of age; have a record of clinical data during pregnancy; own the Maternal and Child Health Hand-
book.
Exclusion criteria: currently lactating; planning to conceive in the next two years; a history of dia-
betes and prior use of metformin or insulin to treat diabetes; a history of lactic acidosis; renal im-
pairment (serum creatinine level >= 1.2 mg/dL (106 µmol/L), including dialysis patients); severe liv-
er dysfunction (serum AST and/or ALT level exceeding more than a threefold increase in normal lab
values); cardiac failure, cardiac infarction, pulmonary embolism, a high degree of failure in lung
function, and hypoxaemia; excessive alcohol intake; malnutrition, or are in a state of starvation or
debility, or have pituitary malfunction or adrenal insufficiency; a history of hypersensitivity reac-
tion to metformin or other biguanides; thyroid function that is not controlled by hyperthyroidism
(serum free thyroxine levels exceed normal lab values within three months); autoantibody-positive
status (e.g. GAD, IA-2), or suspected diabetes mellitus associated with a mutation of mitochondri-
al DNA, maternally inherited diabetes and deafness , or maturity-onset diabetes of the young; not
considered eligible to participate in this study by the attending doctor due to other reasons.
Interventions Intervention: standard lifestyle intervention
JPRN-UMIN000018995 
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Comparator: standard lifestyle intervention plus metformin up to 1500 mg per day
Duration of intervention: 24 months
Outcomes Primary outcomes: period of progression to type 2 diabetes mellitus
Secondary outcomes: change in blood glucose and serum insulin levels determined by a 75 g oral
glucose tolerance test (OGTT); change in index of insulin sensitivity (Matsuda index) from baseline
and at study end (24 months after initiation of therapy, or the final point to be observed); change in
index of insulin resistance (HOMA-IR) from baseline and at study end (24 months after initiation of
therapy, or the final point to be observed); change in index of beta-cell function (Disposition index,
Insulinogenic index) from baseline and at study end (24 months after initiation of therapy, or the fi-
nal point to be observed); change in blood pressure, lipid metabolism, and body weight from base-
line; improvement to normal glucose tolerance; incidence rate of adverse events
Other outcomes: not stated
Starting date Study start date: November 2015
Study completion date: not stated







Trial name or title RISE adult medication study (RISE adult)





Participants Condition: people with prediabetes and early type 2 diabetes
Enrollment: 267
Inclusion criteria: fasting plasma glucose 95 mg/dL to 125 mg/dL (5.3 mmol/L to 6.9 mmol/L) plus
2-hour glucose ≥140 mg/dL (7.8 mmol/L) on 75 g OGTT plus HbA1c ≤7.0%. There is no upper limit
for the 2-hour glucose on OGTT; age 20 to 65 years; BMI ≥25 kg/m2 but ≤50 kg/m2; self-reported di-
abetes < 1 year in duration; drug naive (no prior to oral glucose lowering agent(s), insulin or other
injectable glucose lowering agents)
Exclusion criteria: underlying disease likely to limit life span and/or increase risk of intervention
or an underlying condition that is likely to limit ability to participate in outcomes assessment; an
underlying disease that affects glucose metabolism other than type 2 diabetes; medications that
affect glucose metabolism, or has an underlying condition that is likely to require such medica-
tions; active infections; renal disease (serum creatinine >1.4 mg/dL (123.8 µmol/L) for men; >1.3
mg/dL (114.9 µmol/L) for women) or serum potassium abnormality (<3.4 or >5.5 mmol/L); anaemia
(haemoglobin <11 g/dL (6.8 mmol/L) in women, < 12 g/dL (7.4 mmol/L) in men) or known coagu-
lopathy; cardiovascular disease, including uncontrolled hypertension; participants must be able to
Nadeau 2014 
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safely tolerate administration of intravenous fluids required during clamp studies; history of condi-
tions that may be precipitated or exacerbated by a study drug: pancreatitis, serum ALT more than
3 times the upper limit of normal, excessive alcohol intake, suboptimally-treated thyroid disease,
medullary carcinoma of the thyroid or MEN-2 (in participant or a family history), hypertriglyceri-
daemia (> 400 mg/dL despite treatment); conditions or behaviours likely to affect the conduct of
the RISE Study: unable or unwilling to give informed consent, unable to adequately communicate
with clinic staff, another household member is a participant or staff member in RISE, current, re-
cent or anticipated participation in another intervention research project that would interfere with
any of the interventions/outcomes in RISE, weight loss of > 5% in past three months for any reason
other than postpartum weight loss, participants taking weight loss drugs or using preparations tak-
en for intended weight loss are excluded, likely to move away from participating clinics in next two
years, women of childbearing potential who are unwilling to use adequate contraception, current
(or anticipated) pregnancy and lactation, major psychiatric disorder that, in the opinion of clinic
staff, would impede the conduct of RISE; additional conditions may serve as criteria for exclusion at
the discretion of the local site
Interventions Intervention: metformin up to 2000 mg per day
Comparator (1): basal insulin glargine for 3 months followed by open-label metformin for 9
months
Comparator (2): placebo, masked to metformin alone
Comparator (3): liraglutide + open-label metformin
Duration of intervention: 12 months
Outcomes Primary outcomes: ß-cell function measured by hyperglycaemic clamp techniques
Secondary outcomes: hyperglycaemic clamp and OGTT measures of ß-cell function and glucose
tolerance
Other outcomes: hyperglycaemic clamp and OGTT measures of ß-cell function and glucose toler-
ance
Starting date Study start date: April 2013
Study completion date: August 2019
Contact information Contact: Jesse Brown VA medical center, Chicago, Illinois, United States, 60612
Trial identifier NCT01779362
Notes Includes people with prediabetes and early type 2 diabetes. Only interesting if af subgroup analysis




Trial name or title Metformin and muscle in insulin-resistant older veterans
Methods Type of study: efficacy study
Allocation: randomised
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Participants Condition: prediabetes
Enrollment: 120
Inclusion criteria: participants with sedentary, weight-stable, ambulatory veterans aged 65 years
and older with prediabetes identified with fasting glucose values 100 mg/dL (5.6 mmol/L) or
greater but under 126 mg/dL (7.0 mmol/L) with no use of diabetes medications
Exclusion criteria: chronic medical conditions affecting muscle mass or function like active non-
skin cancer and hypogonadism; Medications affecting muscle mass or function like glucocorticoids
and androgen/antiandrogens; contraindications to metformin
Interventions Intervention: metformin 850 mg orally twice daily
Comparator: one placebo capsule by mouth twice daily
Outcomes Primary outcomes: change in total and appendicular lean mass
Secondary outcomes: change in physical performance and muscle histologic characteristics
Starting date Study start date: February 28, 2013
Study completion date: August 2018
Contact information Michael P Davey, MD PhD








Trial name or title Investigation of metformin in prediabetes on atherosclerotic cardiovascular outcomes (VA-IMPACT)





Participants Condition: people with prediabetes and established atherosclerotic cardiovascular disease
Enrollment: 7868
Inclusion criteria: prediabetes: this condition is fulfilled by HbA1c of at least 5.7%, but less than
6.5%, or two measurements of fasting plasma glucose (on separate days) of 100 mg/dL to 125 mg/
dL (5.6 mmol/L to 6.9 mmol/L), or a 2-hour plasma glucose level of 140 mg/dLto 199 mg/dL (7.8
mmol/L to 11.1 mmol/L) following a 75 g glucose load OGTT. At least one of these criteria must be
met in the absence of diabetic treatment; established atherosclerotic cardiovascular disease: qual-
ifying participants must have evidence of atherosclerotic disease in at least one of the following
NCT02915198 
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vascular beds: coronary, cerebrovascular, or peripheral arterial circulation; renal function: esti-
mated GFR at least 45 mL/min/1.73 m2; informed consent has been fully executed, and participant
agrees to study procedures
Exclusion criteria: related to glucometabolic state: treatment with metformin or other antidiabet-
ic medication within 12 months of randomisation, treatment with systemic glucocorticoids with-
in 3 months of randomisation (due to potential effect on plasma glucose and HbA1c levels), fast-
ing plasma glucose 140 mg/dL (7.8 mmol/L) measured between screening and randomisation vis-
its, or any plasma glucose 200 mg/dL (11.1 mmol/L) or HbA1c 7.0% measured within 12 months of
randomisation; related to safety or tolerability: metabolic acidosis (total CO2 below the local labo-
ratory lower limit of normal on most recent blood chemistry panel), current treatment with cimeti-
dine, vandetanib, or a systemic carbonic anhydrase inhibitor (topiramate, acetazolamide, metha-
zolamide, dichlorphenamide, or zonisamide) (use of ophthalmic carbonic anhydrase inhibitors is
not exclusionary), cirrhosis, active hepatitis, or jaundice at time of randomisation, or total bilirubin
> 2 times upper limit of normal on most recent laboratory study, binge or heavy alcohol consump-
tion within 6 months of randomisation (binge drinking is defined by consumption of 5 or more al-
coholic drinks for men or 4 for women within 2 hours, heavy drinking is defined by consumption of
5 or more alcoholic drinks on one occasion, occurring 5 or more times in a month), severe anaemia
(haemoglobin < 10 g/dL (6.2 mmol/L)) on screening or most recent laboratory testing, prior history
of intolerance to metformin; related to likelihood of non-modifiable events: myocardial infarction,
coronary revascularisation procedure (PCI or CABG), or stroke within 1 month of randomisation,
uncontrolled hypertension at screening assessment (SBP 180 mm Hg or DBP 110 mm Hg), acute or
decompensated congestive heart failure; related to prognosis, reliability, ethics, or data validity:
expected survival less than study duration, participants considered to be unable, unwilling, or un-
reliable to meet protocol requirements, impaired decision-making capacity, defined by any histo-
ry of dementia or cognitive impairment, concurrent participation in another research study involv-
ing a randomised comparison of drug or device treatments, unless specifically excepted by CSP;
female participants: pregnant or intent to become pregnant during the trial, lactating, women of
childbearing potential who are not using a highly effective method of contraception
Interventions Intervention: metformin up to 2000 mg per day
Comparator: matching placebo
Outcomes Primary outcomes: time in days to death, non-fatal myocardial infarction, stroke, hospitalisation
for unstable angina, or symptom-driven coronary revascularisation
Secondary outcomes: time in days to cardiovascular outcomes, time in days to oncologic out-
come, time in days to diabetes outcome
Other outcomes: not stated
Starting date Study start date: February 2019
Study completion date: August 2024







Trial name or title Pre-diabetes in participants with impaired fasting glucose (IFG) and impaired glucose tolerance
(IGT)
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Methods Type of trial: efficacy trial
Allocation: randomised
Intervention model: cross-over assignment
Masking: open-label
Primary purpose: treatment
Participants Condition: IGT and IFG
NGT participants will serve as controls and will be matched in age, gender, ethnicity and BMI to IGT
and IFG participants
Enrolment: 700
Inclusion criteria: age 18 to 65 years; FPG < 100 mg/dL (5.6 mmol/L) and 2-h PG < 140 mg/dL (7.8
mmol/L); BMI 24 kg/m2; to 40 kg/m2; stable body weight (± 4 pounds (1.8 kg)) over the preceding 3
months; no evidence of major organ system disease as determined by physical examination, histo-
ry and screening laboratory data; women of childbearing potential with a negative pregnancy test
at screening and treatment visits, using contraception for the duration of participation in the study
(i.e. until follow-up 7 to 14 days after last dose) (oral contraceptive, injectable progesterone, sub-
dermal implant, spermicidal foam/gel/film/cream/suppository, diaphragm with spermicide, cop-
per or hormonal-containing IUD, vasectomised male partner > 6 month predosing); signed and dat-
ed informed consent document indicating that participant has been informed of all pertinent as-
pects of study; willing and able to comply with scheduled visits, treatment, laboratory tests and
study procedures
Exclusion criteria: recent (i.e. within 3 months prior to screening) evidence or medical history
of unstable concurrent disease such as: documented evidence or history of clinically significant
haematological, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, im-
munological or clinically significant neurological disease; family history of diabetes in a first-degree
relative; BMI < 24 or > 40 kg/m2; unstable body weight (change ± 4 pounds (1.8 kg) over the preced-
ing 3 months); participating in an excessively heavy exercise programme; feeding/sleeping sched-
ule different from a daytime feeding/night-time sleeping schedule; receiving medications known
to alter glucose metabolism (with the exception of metformin or pioglitazone, or both) or which ef-
fect brain neurosynaptic function; evidence of major organ system disease as determined by phys-
ical examination, history and screening laboratory data; pregnant or unwilling to use contracep-
tion during study; blood donation of approximately 1 pint (500 mL) within 8 weeks prior to screen-
ing; other severe acute or chronic medical or psychiatric condition or laboratory abnormality that
may increase risk associated with study participation or investigational product administration
or may interfere with the interpretation of study results and, in judgement of investigator, would
make participant inappropriate for entry into study; people haematuria; evidence or prior history
of heart failure; family history of pancreatic, bladder and breast cancer; history of pancreatitis; es-
timated GFR < 60 ± 5 mL/minute/1.73 m2; elevated serum creatinine (> 1.5 mg/dL for men/1.4 mg/
dL for women); history of orthostatic hypotension (> 15 mmHg/10 mmHg); liver enzymes > 3-fold
above upper normal limit; history of hypersensitivity to pioglitazone, dapagliflozin or saxagliptin.
Interventions Intervention: saxagliptin 5 mg/day
Comparator (1): dapagliflozin 100 mg/day
Comparator (2): pioglitazone 30 mg/day
Comparator (3): metformin 200 mg/day
The trial will randomise participants exclusively with IGT to 1 treatment group; participants exclu-
sively with IFG to 1 treatment group and participants with IGT plus IFG to 1 treatment group
Duration of intervention: 24 months
NCT02969798  (Continued)
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Outcomes Primary outcomes: β-cell function, insulin sensitivity and glucose tolerance status in people with
isolated IGT; β-cell function, insulin sensitivity and glucose tolerance status in people with isolated
IFG; β-cell function, insulin sensitivity and glucose tolerance status in people with IGT plus IFG
Secondary outcomes: not stated
Other outcomes: not stated
Starting date Trial start date: January 2014
Trial completion date: July 2020
Contact information Responsible party/principal investigator: Ralph A DeFronzo, The University of Texas Health
Science Center at San Antonio
Trial identifier NCT02969798





Trial name or title Diabetes prevention via exercise, nutrition and treatment (PRuDENTE)
Methods Type of trial: interventional
Allocation: randomised
Intervention model: parallel assignment
Masking: open-label
Primary purpose: prevention
Participants Condition: adults with FPG between 100 mg/dL and 125 mg/dL (5.6 mmol/L to 6.9 mmol/L)
Enrollment: 3060
Inclusion criteria: having received primary care in the chosen health centre (ideally two or more
visits to that clinic in the prior year); subscribers to "Seguro Popular" (Mexican national health in-
surance); BMI >= 30 kg/m2; results of FPG with values for prediabetes diagnosis (glucose between
100 mg/dL and 125 mg/dL (5.6 mmol/L to 6.9 mmol/L))
Exclusion criteria: renal insufficiency (GFR < 30 mL/minute); known hepatic impairment or altered
liver enzymes (AST or ALT three times above normal values; active alcoholism or drug addiction; al-
lergies or previous known intolerance to exercise or metformin; current pregnancy; plans to leave
the area in the next three years; previous diagnosis of T2DM
Interventions Intervention: metformin plus lifestyle modifications recommendations (physical activity and diet)
Comparator: lifestyle modifications recommendations (physical activity and diet)
Duration of intervention: three years
Outcomes Primary outcomes: diabetes measured by HbA1c and fasting blood glucose; lifestyle modifica-
tions by decreasing adiposity indicators; caloric intake; physical activity
Secondary outcomes: implementation process outcomes at the clinic level; implementation
process outcomes patient level; cost-utility of metformin
NCT03194009 
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Other outcomes: not reported
Starting date Study start date: August 10, 2017
Study completion date: December 31, 2022
Contact information Contact:
Luz María Sánchez-Romero, MD, PhD luz.sanchez@insp.mx






Trial name or title Hospital-based diabetes prevention study in Korea: A prospective, multicenter, randomised, open-
label, controlled study





Participants Condition: IFG, IGT
Enrollment: 744
Inclusion criteria: 30 < age < 71; BMI ≥ 23 kg/m2; 75 g OGTT 2 hours after the test blood glucose
140 mg/dL ˜ 199 mg/dL (7.8 mmol/L ˜ 11.1 mmol/L) or fasting blood sugar 110 mg/dL ˜ 125 mg/dL
(6.1 mmol/L ˜ 6.9 mmol/L) or HbA1c 5.7% ˜ 6.4%
Exclusion criteria: diagnosed with diabetes mellitus except for maternity period or having drugs
for diabetes mellitus; type 2 diabetes mellitus; fasting glucose ≥ 126 mg/dL (7.0 mmol/L); 75 g OGTT
2 hours after the blood glucose ≥ 200 mg/dL (11.1 mmol/L); HbA1c ≥ 6.5%; short life expectancy;
history of severe cardiovascular disease within the last 6 months (cerebral haemorrhage, stroke,
myocardial infarction, angina pectoris, heart failure, etc.); SBP >180 mmHg or DBP >105 mmHg;
aortic stenosis; leN bundle branch block or third degree AV block; diagnosed and treated for malig-
nant tumours including leukaemia and lymphoma within the last 5 years; abnormal renal function
(creatinine ≥ 1.4 mg/dL (123.8 mmol/L) (male) or ≥ 1.3 mg/dL (114.9 mmol/L) (female) or urine pro-
tein ≥ 2 +); anaemia (haematocrit < 36% ((male) or >< 33% (female)); cirrhosis or chronic active he-
patitis (AST/ALT>３UNL); acute gastrointestinal disease (pancreatitis, infectious intestinal disease);
surgery within the last 3 to 6 months or just after the surgery; chronic infection (HIV, active tuber-
culosis, etc.); pulmonary patients who rely on oxygen or daily bronchodilators; judged to be able
to influence the clinical trial by investigator; can not communicate; psychiatric or cognitive impair-
ment that may affect the compliance of the clinical trial; do not agree to the treatment group allo-
cation by random assignment; participate in other studies that may interfere with the clinical tri-
al; lost weight by more than 10% during the past 6 months, excluding weight loss after giving birth;
can not have normal walking or exercise; currently pregnant or who are within the last 3 months af-
ter giving birth; planning pregnancy during the clinical trial period; have a history of drug and alco-
hol abuse (acute, chronic) within the last 2 years; not appropriate or unreliable for clinical trials at
the discretion of the tester; taking medication or medical condition that may affect the diagnosis of
diabetes (thiazide diuretics, systemic beta blockers, taking Niacin for the treatment of neutropenic
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depression, possibility of taking or injecting a systemic steroid preparation, taking a serotonin re-
uptake inhibitor (SSRI) for weight loss purpose, taking medicine for weight loss; hormone status
is not appropriate during thyroid hormone replacement therapy (TSH abnormal range) (If thyroid
hormone therapy is stable for more than 3 months and TSH is normal, the participant can partici-
pate in); other endocrine diseases (e.g. Cushing's syndrome, acromegaly); during treatment, fast-
ing plasma triglyceride > 600 mg/dL (6.8 mmol/L)
Interventions Intervention: life style modification
Comparator (1): conventional management
Comparator (2): metformin up to 1000 mg per day
Duration of intervention: 36 months
Outcomes Primary outcomes: cumulative incidence of diabetes mellitus after randomisation
Secondary outcomes: change on HbA1c, fasting glucose and HOMA2%B
Other outcomes: not stated
Starting date Study start date: November 2016
Study completion date: November 2020





2hPG: 2-hour glucose after an OGTT; AST: aspartate amino transferase; ALT: alanine amino transferase; BMI: body mass index; CABG:
coronary artery bypass graN; DBP: diastolic blood pressure; DNA: deoxyribonucleic acid; ETDRS: Early Treatment Diabetic Retinopathy
Study; FPG: fasting plasma glucose; GAD: glutamate decarboxylase; GDM: gestational diabetes mellitus; GFR: glomerular filtration rate;
HbA1c: glycosylated haemoglobin A1c; IA-2: insulin antibodies - 2; IFG: impaired fasting glucose; IGR: impaired glucose regulation; IGT:
impaired glucose tolerance; NGT: normal glucose tolerance; NYHA: New York Heart Association; OGTT: oral glucose tolerance test; PCI:
percutaneous coronary intervention; SBP: systolic blood pressure; SD: standard deviation; TSH: thyroid stimulating hormonE; T2DM type
2 diabetes mellitus.
blood glucose mg/dL converted to mmol/L (via https://www.diabetes.co.uk/blood-sugar-converter.html)
creatinine mg/dL converted to µmol/L (via http://www.endmemo.com/medical/unitconvert/Creatinine.php)
haemoglobin g/dL converted to mmol/L (via http://unitslab.com/node/7)
pounds converted to kg (via https://www.convertunits.com/from/pounds/to/kg)
triglycerides mg/dL converted to mmol/L (via http://www.endmemo.com/medical/unitconvert/Triglycerides.php)
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Metformin versus placebo or diet and exercsie





Statistical method Effect size
1 All-cause mortality 5 2833 Risk Ratio (M-H, Random, 95%
CI)
1.11 [0.41, 3.01]
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Statistical method Effect size
2 Incidence of type 2 diabetes 12 3632 Risk Ratio (M-H, Random, 95%
CI)
0.50 [0.38, 0.65]
3 Incidence of type 2 diabetes (blinded vs
open-label)
12 3632 Risk Ratio (M-H, Random, 95%
CI)
0.50 [0.38, 0.65]
3.1 Participants blinded 2 2240 Risk Ratio (M-H, Random, 95%
CI)
0.74 [0.64, 0.86]
3.2 Open-label 10 1392 Risk Ratio (M-H, Random, 95%
CI)
0.40 [0.27, 0.59]
4 Incidence of type 2 diabetes (duration of
the intervention)
12 3632 Risk Ratio (M-H, Random, 95%
CI)
0.50 [0.38, 0.65]
4.1 Duration of the intervention less than 2
years
4 296 Risk Ratio (M-H, Random, 95%
CI)
0.30 [0.14, 0.66]
4.2 Duration of the intervention 2 years or
more
8 3336 Risk Ratio (M-H, Random, 95%
CI)
0.53 [0.40, 0.71]
5 Incidence of type 2 diabetes (ethnicity) 12 3632 Risk Ratio (M-H, Random, 95%
CI)
0.50 [0.38, 0.65]
5.1 mainly White 1 2155 Risk Ratio (M-H, Random, 95%
CI)
0.75 [0.65, 0.87]
5.2 mainly Asian 10 1418 Risk Ratio (M-H, Random, 95%
CI)
0.41 [0.28, 0.59]
5.3 Other 1 59 Risk Ratio (M-H, Random, 95%
CI)
0.34 [0.01, 8.13]
6 Non-serious adverse events 2 285 Risk Ratio (M-H, Random, 95%
CI)
3.86 [0.18, 83.36]
7 2-hr glucose values 13 3346 Mean Difference (IV, Random,
95% CI)
-0.86 [-1.26, -0.46]
8 2-hr glucose values (blinded vs open-la-
bel)
13 3346 Mean Difference (IV, Random,
95% CI)
-0.86 [-1.26, -0.46]
8.1 Participants blinded 4 2032 Mean Difference (IV, Random,
95% CI)
-0.26 [-0.86, 0.33]
8.2 Open-label 9 1314 Mean Difference (IV, Random,
95% CI)
-1.03 [-1.35, -0.71]
9 2-hr glucose values (duration of interven-
tion)
13 3346 Mean Difference (IV, Random,
95% CI)
-0.86 [-1.26, -0.46]
9.1 Duration of intervention less than 2
years
4 286 Mean Difference (IV, Random,
95% CI)
-1.37 [-1.91, -0.82]
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Statistical method Effect size
9.2 Duration of intervention 2 years or
more
9 3060 Mean Difference (IV, Random,
95% CI)
-0.75 [-1.18, -0.33]
10 2-r glucose values (ethnicity) 13 3346 Mean Difference (IV, Random,
95% CI)
-0.86 [-1.26, -0.46]
10.1 Mainly White 1 1856 Mean Difference (IV, Random,
95% CI)
0.0 [-0.17, 0.17]
10.2 Mainly Asian 10 1384 Mean Difference (IV, Random,
95% CI)
-1.05 [-1.35, -0.75]
10.3 Other 2 106 Mean Difference (IV, Random,
95% CI)
0.05 [-0.69, 0.79]
11 HbA1c (blinded vs open-label) 6 2467 Mean Difference (IV, Random,
95% CI)
-0.08 [-0.22, 0.05]
11.1 Participants blinded 2 1926 Mean Difference (IV, Random,
95% CI)
0.0 [-0.04, 0.04]
11.2 Open-label 4 541 Mean Difference (IV, Random,
95% CI)
-0.35 [-0.77, 0.08]
12 HbA1c (duration of intervention) 6 2467 Mean Difference (IV, Random,
95% CI)
-0.08 [-0.22, 0.05]
12.1 Duration of intervention less than 2
years
3 269 Mean Difference (IV, Random,
95% CI)
-0.15 [-0.50, 0.21]
12.2 Duration of intervention 2 years or
more
3 2198 Mean Difference (IV, Random,
95% CI)
-0.26 [-0.75, 0.22]
13 HbA1c (ethnicity) 6 2467 Mean Difference (IV, Random,
95% CI)
-0.08 [-0.22, 0.05]
13.1 Mainly White 1 1856 Mean Difference (IV, Random,
95% CI)
0.0 [-0.04, 0.04]
13.2 Mainly Asian 4 556 Mean Difference (IV, Random,
95% CI)
-0.45 [-0.74, -0.16]
13.3 Other 1 55 Mean Difference (IV, Random,
95% CI)
0.0 [-0.11, 0.11]
14 Fasting plasma glucose 15 3546 Mean Difference (IV, Random,
95% CI)
-0.28 [-0.42, -0.13]
15 Fasting plasma glucose (blinded vs
open-label)
15 3546 Mean Difference (IV, Random,
95% CI)
-0.28 [-0.42, -0.13]
15.1 Participants blinded 4 2037 Mean Difference (IV, Random,
95% CI)
-0.51 [-0.94, -0.09]
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Statistical method Effect size
15.2 Open-label 11 1509 Mean Difference (IV, Random,
95% CI)
-0.22 [-0.42, -0.03]
16 Fasting plasma glucose (duration of the
intervention)
15 3546 Mean Difference (IV, Random,
95% CI)
-0.28 [-0.42, -0.13]
16.1 Duration of the intervention less than
2 years
6 485 Mean Difference (IV, Random,
95% CI)
-0.51 [-0.89, -0.13]
16.2 Duration of the intervention 2 years or
more
9 3061 Mean Difference (IV, Random,
95% CI)
-0.19 [-0.35, -0.02]
17 Fasting plasma glucose (ethnicity) 15 3546 Mean Difference (IV, Random,
95% CI)
-0.28 [-0.42, -0.13]
17.1 Mainly White 1 1861 Mean Difference (IV, Random,
95% CI)
-0.30 [-0.39, -0.21]
17.2 Mainly Asian 11 1524 Mean Difference (IV, Random,
95% CI)
-0.31 [-0.51, -0.11]





Analysis 1.1.   Comparison 1 Metformin versus placebo or diet and exercsie, Outcome 1 All-cause mortality.
Study or subgroup Metformin Placebo or diet
and exercise
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
IDPP-1 2006 0/128 1/133 9.73% 0.35[0.01,8.42]
Lu 2002 0/75 1/195 9.74% 0.86[0.04,20.87]
DPP/DPPOS 2002 6/1073 5/1082 70.7% 1.21[0.37,3.95]
Fang 2004 1/48 0/40 9.84% 2.51[0.11,59.98]
PREVENT-DM 2017 0/29 0/30   Not estimable
   
Total (95% CI) 1353 1480 100% 1.11[0.41,3.01]
Total events: 7 (Metformin), 7 (Placebo or diet and exercise)  
Heterogeneity: Tau2=0; Chi2=0.81, df=3(P=0.85); I2=0%  
Test for overall effect: Z=0.21(P=0.83)  
Favours metformin 5000.002 100.1 1 Favours placebo or diet and exercise
 
 
Analysis 1.2.   Comparison 1 Metformin versus placebo or diet and exercsie, Outcome 2 Incidence of type 2 diabetes.
Study or subgroup Metformin Placebo or diet
and exercise
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Chen 2009 2/46 8/44 3.02% 0.24[0.05,1.06]
Favours metformin 1000.01 100.1 1 Favours placebo or diet and exercise
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Study or subgroup Metformin Placebo or diet
and exercise
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
DPP/DPPOS 2002 232/1073 313/1082 25.35% 0.75[0.65,0.87]
Fang 2004 9/48 15/40 9.65% 0.5[0.25,1.02]
IDPP-1 2006 51/128 73/133 21.88% 0.73[0.56,0.94]
Ji 2011 3/52 12/64 4.34% 0.31[0.09,1.03]
Jin 2009 3/45 11/41 4.38% 0.25[0.07,0.83]
Li 1999 3/42 6/43 3.75% 0.51[0.14,1.91]
Lu 2002 7/75 40/195 8.89% 0.46[0.21,0.97]
Lu 2010 6/115 15/111 6.85% 0.39[0.16,0.96]
PREVENT-DM 2017 0/29 1/30 0.74% 0.34[0.01,8.13]
Wang 2009 2/30 11/32 3.29% 0.19[0.05,0.8]
Zeng 2013 6/68 24/66 7.86% 0.24[0.11,0.56]
   
Total (95% CI) 1751 1881 100% 0.5[0.38,0.65]
Total events: 324 (Metformin), 529 (Placebo or diet and exercise)  
Heterogeneity: Tau2=0.07; Chi2=21.07, df=11(P=0.03); I2=47.8%  
Test for overall effect: Z=4.99(P<0.0001)  
Favours metformin 1000.01 100.1 1 Favours placebo or diet and exercise
 
 
Analysis 1.3.   Comparison 1 Metformin versus placebo or diet and
exercsie, Outcome 3 Incidence of type 2 diabetes (blinded vs open-label).
Study or subgroup Metformin Placebo or diet
and exercise
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.1 Participants blinded  
DPP/DPPOS 2002 232/1073 313/1082 25.35% 0.75[0.65,0.87]
Li 1999 3/42 6/43 3.75% 0.51[0.14,1.91]
Subtotal (95% CI) 1115 1125 29.1% 0.74[0.64,0.86]
Total events: 235 (Metformin), 319 (Placebo or diet and exercise)  
Heterogeneity: Tau2=0; Chi2=0.31, df=1(P=0.58); I2=0%  
Test for overall effect: Z=3.96(P<0.0001)  
   
1.3.2 Open-label  
Chen 2009 2/46 8/44 3.02% 0.24[0.05,1.06]
Fang 2004 9/48 15/40 9.65% 0.5[0.25,1.02]
IDPP-1 2006 51/128 73/133 21.88% 0.73[0.56,0.94]
Ji 2011 3/52 12/64 4.34% 0.31[0.09,1.03]
Jin 2009 3/45 11/41 4.38% 0.25[0.07,0.83]
Lu 2002 7/75 40/195 8.89% 0.46[0.21,0.97]
Lu 2010 6/115 15/111 6.85% 0.39[0.16,0.96]
PREVENT-DM 2017 0/29 1/30 0.74% 0.34[0.01,8.13]
Wang 2009 2/30 11/32 3.29% 0.19[0.05,0.8]
Zeng 2013 6/68 24/66 7.86% 0.24[0.11,0.56]
Subtotal (95% CI) 636 756 70.9% 0.4[0.27,0.59]
Total events: 89 (Metformin), 210 (Placebo or diet and exercise)  
Heterogeneity: Tau2=0.14; Chi2=16.37, df=9(P=0.06); I2=45.03%  
Test for overall effect: Z=4.7(P<0.0001)  
   
Total (95% CI) 1751 1881 100% 0.5[0.38,0.65]
Favours metformin 200.05 50.2 1 Favours placebo or diet and exercise
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Study or subgroup Metformin Placebo or diet
and exercise
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 324 (Metformin), 529 (Placebo or diet and exercise)  
Heterogeneity: Tau2=0.07; Chi2=21.07, df=11(P=0.03); I2=47.8%  
Test for overall effect: Z=4.99(P<0.0001)  
Test for subgroup differences: Chi2=8.8, df=1 (P=0), I2=88.64%  
Favours metformin 200.05 50.2 1 Favours placebo or diet and exercise
 
 
Analysis 1.4.   Comparison 1 Metformin versus placebo or diet and exercsie,
Outcome 4 Incidence of type 2 diabetes (duration of the intervention).
Study or subgroup Metformin Placebo or diet
and exercise
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.4.1 Duration of the intervention less than 2 years  
Chen 2009 2/46 8/44 3.02% 0.24[0.05,1.06]
Li 1999 3/42 6/43 3.75% 0.51[0.14,1.91]
PREVENT-DM 2017 0/29 1/30 0.74% 0.34[0.01,8.13]
Wang 2009 2/30 11/32 3.29% 0.19[0.05,0.8]
Subtotal (95% CI) 147 149 10.8% 0.3[0.14,0.66]
Total events: 7 (Metformin), 26 (Placebo or diet and exercise)  
Heterogeneity: Tau2=0; Chi2=1.1, df=3(P=0.78); I2=0%  
Test for overall effect: Z=3(P=0)  
   
1.4.2 Duration of the intervention 2 years or more  
DPP/DPPOS 2002 232/1073 313/1082 25.35% 0.75[0.65,0.87]
Fang 2004 9/48 15/40 9.65% 0.5[0.25,1.02]
IDPP-1 2006 51/128 73/133 21.88% 0.73[0.56,0.94]
Ji 2011 3/52 12/64 4.34% 0.31[0.09,1.03]
Jin 2009 3/45 11/41 4.38% 0.25[0.07,0.83]
Lu 2002 7/75 40/195 8.89% 0.46[0.21,0.97]
Lu 2010 6/115 15/111 6.85% 0.39[0.16,0.96]
Zeng 2013 6/68 24/66 7.86% 0.24[0.11,0.56]
Subtotal (95% CI) 1604 1732 89.2% 0.53[0.4,0.71]
Total events: 317 (Metformin), 503 (Placebo or diet and exercise)  
Heterogeneity: Tau2=0.07; Chi2=15.64, df=7(P=0.03); I2=55.24%  
Test for overall effect: Z=4.34(P<0.0001)  
   
Total (95% CI) 1751 1881 100% 0.5[0.38,0.65]
Total events: 324 (Metformin), 529 (Placebo or diet and exercise)  
Heterogeneity: Tau2=0.07; Chi2=21.07, df=11(P=0.03); I2=47.8%  
Test for overall effect: Z=4.99(P<0.0001)  
Test for subgroup differences: Chi2=1.8, df=1 (P=0.18), I2=44.59%  
Favours metformin 1000.01 100.1 1 Favours placebo or diet and exercise
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Analysis 1.5.   Comparison 1 Metformin versus placebo or diet
and exercsie, Outcome 5 Incidence of type 2 diabetes (ethnicity).
Study or subgroup Metformin Placebo or diet
and exercise
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.5.1 mainly White  
DPP/DPPOS 2002 232/1073 313/1082 25.35% 0.75[0.65,0.87]
Subtotal (95% CI) 1073 1082 25.35% 0.75[0.65,0.87]
Total events: 232 (Metformin), 313 (Placebo or diet and exercise)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.87(P=0)  
   
1.5.2 mainly Asian  
Chen 2009 2/46 8/44 3.02% 0.24[0.05,1.06]
Fang 2004 9/48 15/40 9.65% 0.5[0.25,1.02]
IDPP-1 2006 51/128 73/133 21.88% 0.73[0.56,0.94]
Ji 2011 3/52 12/64 4.34% 0.31[0.09,1.03]
Jin 2009 3/45 11/41 4.38% 0.25[0.07,0.83]
Li 1999 3/42 6/43 3.75% 0.51[0.14,1.91]
Lu 2002 7/75 40/195 8.89% 0.46[0.21,0.97]
Lu 2010 6/115 15/111 6.85% 0.39[0.16,0.96]
Wang 2009 2/30 11/32 3.29% 0.19[0.05,0.8]
Zeng 2013 6/68 24/66 7.86% 0.24[0.11,0.56]
Subtotal (95% CI) 649 769 73.91% 0.41[0.28,0.59]
Total events: 92 (Metformin), 215 (Placebo or diet and exercise)  
Heterogeneity: Tau2=0.13; Chi2=16.24, df=9(P=0.06); I2=44.59%  
Test for overall effect: Z=4.78(P<0.0001)  
   
1.5.3 Other  
PREVENT-DM 2017 0/29 1/30 0.74% 0.34[0.01,8.13]
Subtotal (95% CI) 29 30 0.74% 0.34[0.01,8.13]
Total events: 0 (Metformin), 1 (Placebo or diet and exercise)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.66(P=0.51)  
   
Total (95% CI) 1751 1881 100% 0.5[0.38,0.65]
Total events: 324 (Metformin), 529 (Placebo or diet and exercise)  
Heterogeneity: Tau2=0.07; Chi2=21.07, df=11(P=0.03); I2=47.8%  
Test for overall effect: Z=4.99(P<0.0001)  
Test for subgroup differences: Chi2=9.07, df=1 (P=0.01), I2=77.95%  
Favours metformin 2000.005 100.1 1 Favours placebo or diet and exercise
 
 
Analysis 1.6.   Comparison 1 Metformin versus placebo or diet and exercsie, Outcome 6 Non-serious adverse events.
Study or subgroup Metformin Placebo or diet
and exercise
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Lu 2010 21/115 17/111 59.51% 1.19[0.67,2.14]
PREVENT-DM 2017 10/29 0/30 40.49% 21.7[1.33,354.1]
   
Total (95% CI) 144 141 100% 3.86[0.18,83.36]
Favours metformin 1000.01 100.1 1 Favours placebo or diet and exercise
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
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Study or subgroup Metformin Placebo or diet
and exercise
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total events: 31 (Metformin), 17 (Placebo or diet and exercise)  
Heterogeneity: Tau2=4.04; Chi2=4.81, df=1(P=0.03); I2=79.23%  
Test for overall effect: Z=0.86(P=0.39)  
Favours metformin 1000.01 100.1 1 Favours placebo or diet and exercise
 
 
Analysis 1.7.   Comparison 1 Metformin versus placebo or diet and exercsie, Outcome 7 2-hr glucose values.
Study or subgroup Metformin Placebo or di-
et and exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
BIGPRO1 2009 28 0.2 (4.2) 36 0.5 (4.2) 2.75% -0.28[-2.35,1.79]
Chen 2009 44 8.7 (2.6) 46 9.3 (3.8) 4.9% -0.6[-1.94,0.74]
DPP/DPPOS 2002 924 8.2 (2) 932 8.2 (1.8) 10.86% 0[-0.17,0.17]
Fang 2004 44 7.5 (1.9) 35 9.5 (2.2) 6.95% -2[-2.92,-1.08]
IDPP-1 2006 123 9.8 (3.3) 124 11 (4.3) 6.75% -1.2[-2.16,-0.24]
Ji 2011 52 7.7 (1.3) 64 8.2 (1.3) 9.57% -0.5[-0.98,-0.02]
Jin 2009 45 0 (1.2) 45 0.6 (0.9) 9.8% -0.59[-1.02,-0.16]
Li 1999 33 6 (2) 37 7.4 (2.5) 6.21% -1.4[-2.46,-0.34]
Lu 2002 75 8.1 (2.4) 195 9 (2.9) 8.37% -0.85[-1.53,-0.17]
Lu 2010 115 7.2 (1.2) 111 8.2 (1.3) 10.34% -0.96[-1.28,-0.64]
Papoz 1978 23 7.2 (1.3) 19 7.1 (1.3) 7.7% 0.1[-0.69,0.89]
Wang 2009 30 7.2 (1) 32 8.9 (1.5) 8.66% -1.7[-2.33,-1.07]
Zeng 2013 68 7.3 (3.3) 66 8.8 (1.7) 7.14% -1.42[-2.31,-0.53]
   
Total *** 1604   1742   100% -0.86[-1.26,-0.46]
Heterogeneity: Tau2=0.37; Chi2=75.02, df=12(P<0.0001); I2=84%  
Test for overall effect: Z=4.25(P<0.0001)  
Favours metformin 105-10 -5 0 Favours placebo or diet and exercise
 
 
Analysis 1.8.   Comparison 1 Metformin versus placebo or diet and
exercsie, Outcome 8 2-hr glucose values (blinded vs open-label).
Study or subgroup Metformin Placebo or di-
et and exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.8.1 Participants blinded  
BIGPRO1 2009 28 0.2 (4.2) 36 0.5 (4.2) 2.75% -0.28[-2.35,1.79]
DPP/DPPOS 2002 924 8.2 (2) 932 8.2 (1.8) 10.86% 0[-0.17,0.17]
Li 1999 33 6 (2) 37 7.4 (2.5) 6.21% -1.4[-2.46,-0.34]
Papoz 1978 23 7.2 (1.3) 19 7.1 (1.3) 7.7% 0.1[-0.69,0.89]
Subtotal *** 1008   1024   27.53% -0.26[-0.86,0.33]
Heterogeneity: Tau2=0.19; Chi2=6.74, df=3(P=0.08); I2=55.5%  
Test for overall effect: Z=0.87(P=0.39)  
   
1.8.2 Open-label  
Chen 2009 44 8.7 (2.6) 46 9.3 (3.8) 4.9% -0.6[-1.94,0.74]
Favours metformin 52.5-5 -2.5 0 Favours placebo or diet and exercise
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
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Study or subgroup Metformin Placebo or di-
et and exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Fang 2004 44 7.5 (1.9) 35 9.5 (2.2) 6.95% -2[-2.92,-1.08]
IDPP-1 2006 123 9.8 (3.3) 124 11 (4.3) 6.75% -1.2[-2.16,-0.24]
Ji 2011 52 7.7 (1.3) 64 8.2 (1.3) 9.57% -0.5[-0.98,-0.02]
Jin 2009 45 0 (1.2) 45 0.6 (0.9) 9.8% -0.59[-1.02,-0.16]
Lu 2002 75 8.1 (2.4) 195 9 (2.9) 8.37% -0.85[-1.53,-0.17]
Lu 2010 115 7.2 (1.2) 111 8.2 (1.3) 10.34% -0.96[-1.28,-0.64]
Wang 2009 30 7.2 (1) 32 8.9 (1.5) 8.66% -1.7[-2.33,-1.07]
Zeng 2013 68 7.3 (3.3) 66 8.8 (1.7) 7.14% -1.42[-2.31,-0.53]
Subtotal *** 596   718   72.47% -1.03[-1.35,-0.71]
Heterogeneity: Tau2=0.12; Chi2=18.22, df=8(P=0.02); I2=56.1%  
Test for overall effect: Z=6.34(P<0.0001)  
   
Total *** 1604   1742   100% -0.86[-1.26,-0.46]
Heterogeneity: Tau2=0.37; Chi2=75.02, df=12(P<0.0001); I2=84%  
Test for overall effect: Z=4.25(P<0.0001)  
Test for subgroup differences: Chi2=4.91, df=1 (P=0.03), I2=79.62%  
Favours metformin 52.5-5 -2.5 0 Favours placebo or diet and exercise
 
 
Analysis 1.9.   Comparison 1 Metformin versus placebo or diet and
exercsie, Outcome 9 2-hr glucose values (duration of intervention).
Study or subgroup Metformin Placebo or di-
et and exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.9.1 Duration of intervention less than 2 years  
BIGPRO1 2009 28 0.2 (4.2) 36 0.5 (4.2) 2.75% -0.28[-2.35,1.79]
Chen 2009 44 8.7 (2.6) 46 9.3 (3.8) 4.9% -0.6[-1.94,0.74]
Li 1999 33 6 (2) 37 7.4 (2.5) 6.21% -1.4[-2.46,-0.34]
Wang 2009 30 7.2 (1) 32 8.9 (1.5) 8.66% -1.7[-2.33,-1.07]
Subtotal *** 135   151   22.52% -1.37[-1.91,-0.82]
Heterogeneity: Tau2=0.04; Chi2=3.36, df=3(P=0.34); I2=10.58%  
Test for overall effect: Z=4.91(P<0.0001)  
   
1.9.2 Duration of intervention 2 years or more  
DPP/DPPOS 2002 924 8.2 (2) 932 8.2 (1.8) 10.86% 0[-0.17,0.17]
Fang 2004 44 7.5 (1.9) 35 9.5 (2.2) 6.95% -2[-2.92,-1.08]
IDPP-1 2006 123 9.8 (3.3) 124 11 (4.3) 6.75% -1.2[-2.16,-0.24]
Ji 2011 52 7.7 (1.3) 64 8.2 (1.3) 9.57% -0.5[-0.98,-0.02]
Jin 2009 45 0 (1.2) 45 0.6 (0.9) 9.8% -0.59[-1.02,-0.16]
Lu 2002 75 8.1 (2.4) 195 9 (2.9) 8.37% -0.85[-1.53,-0.17]
Lu 2010 115 7.2 (1.2) 111 8.2 (1.3) 10.34% -0.96[-1.28,-0.64]
Papoz 1978 23 7.2 (1.3) 19 7.1 (1.3) 7.7% 0.1[-0.69,0.89]
Zeng 2013 68 7.3 (3.3) 66 8.8 (1.7) 7.14% -1.42[-2.31,-0.53]
Subtotal *** 1469   1591   77.48% -0.75[-1.18,-0.33]
Heterogeneity: Tau2=0.32; Chi2=55.17, df=8(P<0.0001); I2=85.5%  
Test for overall effect: Z=3.49(P=0)  
   
Total *** 1604   1742   100% -0.86[-1.26,-0.46]
Heterogeneity: Tau2=0.37; Chi2=75.02, df=12(P<0.0001); I2=84%  
Favours metformin 105-10 -5 0 Favours placebo or diet and exercise
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
development of type 2 diabetes mellitus (Review)
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Study or subgroup Metformin Placebo or di-
et and exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=4.25(P<0.0001)  
Test for subgroup differences: Chi2=3.03, df=1 (P=0.08), I2=67.02%  
Favours metformin 105-10 -5 0 Favours placebo or diet and exercise
 
 
Analysis 1.10.   Comparison 1 Metformin versus placebo or
diet and exercsie, Outcome 10 2-r glucose values (ethnicity).
Study or subgroup Metformin Placebo or di-
et and exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.10.1 Mainly White  
DPP/DPPOS 2002 924 8.2 (2) 932 8.2 (1.8) 10.86% 0[-0.17,0.17]
Subtotal *** 924   932   10.86% 0[-0.17,0.17]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.10.2 Mainly Asian  
Chen 2009 44 8.7 (2.6) 46 9.3 (3.8) 4.9% -0.6[-1.94,0.74]
Fang 2004 44 7.5 (1.9) 35 9.5 (2.2) 6.95% -2[-2.92,-1.08]
IDPP-1 2006 123 9.8 (3.3) 124 11 (4.3) 6.75% -1.2[-2.16,-0.24]
Ji 2011 52 7.7 (1.3) 64 8.2 (1.3) 9.57% -0.5[-0.98,-0.02]
Jin 2009 45 0 (1.2) 45 0.6 (0.9) 9.8% -0.59[-1.02,-0.16]
Li 1999 33 6 (2) 37 7.4 (2.5) 6.21% -1.4[-2.46,-0.34]
Lu 2002 75 8.1 (2.4) 195 9 (2.9) 8.37% -0.85[-1.53,-0.17]
Lu 2010 115 7.2 (1.2) 111 8.2 (1.3) 10.34% -0.96[-1.28,-0.64]
Wang 2009 30 7.2 (1) 32 8.9 (1.5) 8.66% -1.7[-2.33,-1.07]
Zeng 2013 68 7.3 (3.3) 66 8.8 (1.7) 7.14% -1.42[-2.31,-0.53]
Subtotal *** 629   755   78.69% -1.05[-1.35,-0.75]
Heterogeneity: Tau2=0.11; Chi2=18.93, df=9(P=0.03); I2=52.44%  
Test for overall effect: Z=6.8(P<0.0001)  
   
1.10.3 Other  
BIGPRO1 2009 28 0.2 (4.2) 36 0.5 (4.2) 2.75% -0.28[-2.35,1.79]
Papoz 1978 23 7.2 (1.3) 19 7.1 (1.3) 7.7% 0.1[-0.69,0.89]
Subtotal *** 51   55   10.45% 0.05[-0.69,0.79]
Heterogeneity: Tau2=0; Chi2=0.11, df=1(P=0.74); I2=0%  
Test for overall effect: Z=0.14(P=0.89)  
   
Total *** 1604   1742   100% -0.86[-1.26,-0.46]
Heterogeneity: Tau2=0.37; Chi2=75.02, df=12(P<0.0001); I2=84%  
Test for overall effect: Z=4.25(P<0.0001)  
Test for subgroup differences: Chi2=35.36, df=1 (P<0.0001), I2=94.34%  
Favours metformin 52.5-5 -2.5 0 Favours placebo or diet and exercise
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Analysis 1.11.   Comparison 1 Metformin versus placebo or
diet and exercsie, Outcome 11 HbA1c (blinded vs open-label).
Study or subgroup Metformin Placebo or di-
et and exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.11.1 Participants blinded  
DPP/DPPOS 2002 924 5.8 (0.4) 932 5.8 (0.5) 45.17% 0[-0.04,0.04]
Li 1999 37 6.6 (1.3) 33 6.6 (1.3) 4.37% 0[-0.61,0.61]
Subtotal *** 961   965   49.54% 0[-0.04,0.04]
Heterogeneity: Tau2=0; Chi2=0, df=1(P=1); I2=0%  
Test for overall effect: Not applicable  
   
1.11.2 Open-label  
Alfawaz 2018 59 5 (1.7) 85 5.6 (1.5) 5.46% -0.6[-1.14,-0.06]
Ji 2011 52 5.6 (1.2) 64 6.2 (1.3) 7.29% -0.6[-1.06,-0.14]
Lu 2010 115 5.7 (4.4) 111 6.1 (4.6) 1.25% -0.38[-1.56,0.8]
PREVENT-DM 2017 27 0.1 (0.2) 28 0.1 (0.2) 36.45% 0[-0.11,0.11]
Subtotal *** 253   288   50.46% -0.35[-0.77,0.08]
Heterogeneity: Tau2=0.12; Chi2=10.76, df=3(P=0.01); I2=72.11%  
Test for overall effect: Z=1.59(P=0.11)  
   
Total *** 1214   1253   100% -0.08[-0.22,0.05]
Heterogeneity: Tau2=0.01; Chi2=11.67, df=5(P=0.04); I2=57.16%  
Test for overall effect: Z=1.19(P=0.23)  
Test for subgroup differences: Chi2=2.51, df=1 (P=0.11), I2=60.09%  
Favours metformin 21-2 -1 0 Favours placebo or diet and exercise
 
 
Analysis 1.12.   Comparison 1 Metformin versus placebo or diet
and exercsie, Outcome 12 HbA1c (duration of intervention).
Study or subgroup Metformin Placebo or di-
et and exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.12.1 Duration of intervention less than 2 years  
Alfawaz 2018 59 5 (1.7) 85 5.6 (1.5) 5.46% -0.6[-1.14,-0.06]
Li 1999 37 6.6 (1.3) 33 6.6 (1.3) 4.37% 0[-0.61,0.61]
PREVENT-DM 2017 27 0.1 (0.2) 28 0.1 (0.2) 36.45% 0[-0.11,0.11]
Subtotal *** 123   146   46.29% -0.15[-0.5,0.21]
Heterogeneity: Tau2=0.06; Chi2=4.6, df=2(P=0.1); I2=56.51%  
Test for overall effect: Z=0.82(P=0.41)  
   
1.12.2 Duration of intervention 2 years or more  
DPP/DPPOS 2002 924 5.8 (0.4) 932 5.8 (0.5) 45.17% 0[-0.04,0.04]
Ji 2011 52 5.6 (1.2) 64 6.2 (1.3) 7.29% -0.6[-1.06,-0.14]
Lu 2010 115 5.7 (4.4) 111 6.1 (4.6) 1.25% -0.38[-1.56,0.8]
Subtotal *** 1091   1107   53.71% -0.26[-0.75,0.22]
Heterogeneity: Tau2=0.12; Chi2=6.99, df=2(P=0.03); I2=71.38%  
Test for overall effect: Z=1.06(P=0.29)  
   
Total *** 1214   1253   100% -0.08[-0.22,0.05]
Heterogeneity: Tau2=0.01; Chi2=11.67, df=5(P=0.04); I2=57.16%  
Favours metformin 21-2 -1 0 Favours placebo or diet and exercise
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
development of type 2 diabetes mellitus (Review)
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Study or subgroup Metformin Placebo or di-
et and exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=1.19(P=0.23)  
Test for subgroup differences: Chi2=0.14, df=1 (P=0.71), I2=0%  
Favours metformin 21-2 -1 0 Favours placebo or diet and exercise
 
 
Analysis 1.13.   Comparison 1 Metformin versus placebo or diet and exercsie, Outcome 13 HbA1c (ethnicity).
Study or subgroup Metformin Placebo or di-
et and exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.13.1 Mainly White  
DPP/DPPOS 2002 924 5.8 (0.4) 932 5.8 (0.5) 45.17% 0[-0.04,0.04]
Subtotal *** 924   932   45.17% 0[-0.04,0.04]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.13.2 Mainly Asian  
Alfawaz 2018 59 5 (1.7) 85 5.6 (1.5) 5.46% -0.6[-1.14,-0.06]
Ji 2011 52 5.6 (1.2) 64 6.2 (1.3) 7.29% -0.6[-1.06,-0.14]
Li 1999 37 6.6 (1.3) 33 6.6 (1.3) 4.37% 0[-0.61,0.61]
Lu 2010 115 5.7 (4.4) 111 6.1 (4.6) 1.25% -0.38[-1.56,0.8]
Subtotal *** 263   293   18.37% -0.45[-0.74,-0.16]
Heterogeneity: Tau2=0; Chi2=2.82, df=3(P=0.42); I2=0%  
Test for overall effect: Z=3(P=0)  
   
1.13.3 Other  
PREVENT-DM 2017 27 0.1 (0.2) 28 0.1 (0.2) 36.45% 0[-0.11,0.11]
Subtotal *** 27   28   36.45% 0[-0.11,0.11]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total *** 1214   1253   100% -0.08[-0.22,0.05]
Heterogeneity: Tau2=0.01; Chi2=11.67, df=5(P=0.04); I2=57.16%  
Test for overall effect: Z=1.19(P=0.23)  
Test for subgroup differences: Chi2=8.85, df=1 (P=0.01), I2=77.41%  
Favours metformin 21-2 -1 0 Favours placebo or diet and exercise
 
 
Analysis 1.14.   Comparison 1 Metformin versus placebo or diet and exercsie, Outcome 14 Fasting plasma glucose.
Study or subgroup Metformin Placebo or di-
et and exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Alfawaz 2018 59 5.8 (1.7) 85 5.9 (0.9) 5.02% -0.1[-0.57,0.37]
BIGPRO1 2009 28 -0.3 (1.5) 36 0.7 (2) 2.3% -1.02[-1.88,-0.16]
Chen 2009 44 5.1 (0.9) 46 5.5 (1) 6% -0.4[-0.79,-0.01]
DPP/DPPOS 2002 926 5.9 (0.8) 935 6.2 (1.1) 10.12% -0.3[-0.39,-0.21]
Fang 2004 44 5.9 (0.7) 35 6.3 (1.2) 5.45% -0.4[-0.84,0.04]
Favours metformin 21-2 -1 0 Favours placebo or diet and exercise
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
development of type 2 diabetes mellitus (Review)
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Study or subgroup Metformin Placebo or di-
et and exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
IDPP-1 2006 123 6.1 (1.5) 124 6.5 (1.8) 5.74% -0.4[-0.81,0.01]
Ji 2011 52 6.3 (1.3) 64 6.4 (1.5) 4.64% -0.1[-0.61,0.41]
Jin 2009 45 0.6 (0.9) 41 0.2 (0.8) 6.6% 0.42[0.07,0.77]
Li 1999 33 5 (1.1) 37 6.2 (1.3) 4.14% -1.2[-1.76,-0.64]
Lu 2002 75 5.3 (0.8) 195 5.4 (1) 8.4% -0.13[-0.36,0.1]
Lu 2010 115 5.6 (0.3) 111 6.1 (0.3) 10.21% -0.5[-0.58,-0.42]
Papoz 1978 23 5.9 (0.5) 19 5.9 (0.6) 6.75% 0[-0.34,0.34]
PREVENT-DM 2017 27 -0.2 (0.4) 28 -0.2 (0.4) 8.63% 0[-0.21,0.21]
Wang 2009 30 5.6 (0.6) 32 6.3 (0.5) 7.67% -0.7[-0.98,-0.42]
Zeng 2013 68 5.3 (0.7) 66 5.4 (0.6) 8.34% -0.08[-0.31,0.15]
   
Total *** 1692   1854   100% -0.28[-0.42,-0.13]
Heterogeneity: Tau2=0.05; Chi2=77.84, df=14(P<0.0001); I2=82.01%  
Test for overall effect: Z=3.69(P=0)  
Favours metformin 21-2 -1 0 Favours placebo or diet and exercise
 
 
Analysis 1.15.   Comparison 1 Metformin versus placebo or diet and
exercsie, Outcome 15 Fasting plasma glucose (blinded vs open-label).
Study or subgroup Metformin Placebo or di-
et and exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.15.1 Participants blinded  
BIGPRO1 2009 28 -0.3 (1.5) 36 0.7 (2) 2.3% -1.02[-1.88,-0.16]
DPP/DPPOS 2002 926 5.9 (0.8) 935 6.2 (1.1) 10.12% -0.3[-0.39,-0.21]
Li 1999 33 5 (1.1) 37 6.2 (1.3) 4.14% -1.2[-1.76,-0.64]
Papoz 1978 23 5.9 (0.5) 19 5.9 (0.6) 6.75% 0[-0.34,0.34]
Subtotal *** 1010   1027   23.31% -0.51[-0.94,-0.09]
Heterogeneity: Tau2=0.13; Chi2=15.52, df=3(P=0); I2=80.68%  
Test for overall effect: Z=2.38(P=0.02)  
   
1.15.2 Open-label  
Alfawaz 2018 59 5.8 (1.7) 85 5.9 (0.9) 5.02% -0.1[-0.57,0.37]
Chen 2009 44 5.1 (0.9) 46 5.5 (1) 6% -0.4[-0.79,-0.01]
Fang 2004 44 5.9 (0.7) 35 6.3 (1.2) 5.45% -0.4[-0.84,0.04]
IDPP-1 2006 123 6.1 (1.5) 124 6.5 (1.8) 5.74% -0.4[-0.81,0.01]
Ji 2011 52 6.3 (1.3) 64 6.4 (1.5) 4.64% -0.1[-0.61,0.41]
Jin 2009 45 0.6 (0.9) 41 0.2 (0.8) 6.6% 0.42[0.07,0.77]
Lu 2002 75 5.3 (0.8) 195 5.4 (1) 8.4% -0.13[-0.36,0.1]
Lu 2010 115 5.6 (0.3) 111 6.1 (0.3) 10.21% -0.5[-0.58,-0.42]
PREVENT-DM 2017 27 -0.2 (0.4) 28 -0.2 (0.4) 8.63% 0[-0.21,0.21]
Wang 2009 30 5.6 (0.6) 32 6.3 (0.5) 7.67% -0.7[-0.98,-0.42]
Zeng 2013 68 5.3 (0.7) 66 5.4 (0.6) 8.34% -0.08[-0.31,0.15]
Subtotal *** 682   827   76.69% -0.22[-0.42,-0.03]
Heterogeneity: Tau2=0.08; Chi2=60.9, df=10(P<0.0001); I2=83.58%  
Test for overall effect: Z=2.26(P=0.02)  
   
Total *** 1692   1854   100% -0.28[-0.42,-0.13]
Heterogeneity: Tau2=0.05; Chi2=77.84, df=14(P<0.0001); I2=82.01%  
Favours metformin 52.5-5 -2.5 0 Favours placebo or diet and exercise
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
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Study or subgroup Metformin Placebo or di-
et and exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=3.69(P=0)  
Test for subgroup differences: Chi2=1.49, df=1 (P=0.22), I2=33.07%  
Favours metformin 52.5-5 -2.5 0 Favours placebo or diet and exercise
 
 
Analysis 1.16.   Comparison 1 Metformin versus placebo or diet and
exercsie, Outcome 16 Fasting plasma glucose (duration of the intervention).
Study or subgroup Metformin Placebo or di-
et and exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.16.1 Duration of the intervention less than 2 years  
Alfawaz 2018 59 5.8 (1.7) 85 5.9 (0.9) 5.02% -0.1[-0.57,0.37]
BIGPRO1 2009 28 -0.3 (1.5) 36 0.7 (2) 2.3% -1.02[-1.88,-0.16]
Chen 2009 44 5.1 (0.9) 46 5.5 (1) 6% -0.4[-0.79,-0.01]
Li 1999 33 5 (1.1) 37 6.2 (1.3) 4.14% -1.2[-1.76,-0.64]
PREVENT-DM 2017 27 -0.2 (0.4) 28 -0.2 (0.4) 8.63% 0[-0.21,0.21]
Wang 2009 30 5.6 (0.6) 32 6.3 (0.5) 7.67% -0.7[-0.98,-0.42]
Subtotal *** 221   264   33.75% -0.51[-0.89,-0.13]
Heterogeneity: Tau2=0.17; Chi2=28.94, df=5(P<0.0001); I2=82.72%  
Test for overall effect: Z=2.63(P=0.01)  
   
1.16.2 Duration of the intervention 2 years or more  
DPP/DPPOS 2002 926 5.9 (0.8) 935 6.2 (1.1) 10.12% -0.3[-0.39,-0.21]
Fang 2004 44 5.9 (0.7) 35 6.3 (1.2) 5.45% -0.4[-0.84,0.04]
IDPP-1 2006 123 6.1 (1.5) 124 6.5 (1.8) 5.74% -0.4[-0.81,0.01]
Ji 2011 52 6.3 (1.3) 64 6.4 (1.5) 4.64% -0.1[-0.61,0.41]
Jin 2009 45 0.6 (0.9) 41 0.2 (0.8) 6.6% 0.42[0.07,0.77]
Lu 2002 75 5.3 (0.8) 195 5.4 (1) 8.4% -0.13[-0.36,0.1]
Lu 2010 115 5.6 (0.3) 111 6.1 (0.3) 10.21% -0.5[-0.58,-0.42]
Papoz 1978 23 5.9 (0.5) 19 5.9 (0.6) 6.75% 0[-0.34,0.34]
Zeng 2013 68 5.3 (0.7) 66 5.4 (0.6) 8.34% -0.08[-0.31,0.15]
Subtotal *** 1471   1590   66.25% -0.19[-0.35,-0.02]
Heterogeneity: Tau2=0.04; Chi2=48.88, df=8(P<0.0001); I2=83.63%  
Test for overall effect: Z=2.18(P=0.03)  
   
Total *** 1692   1854   100% -0.28[-0.42,-0.13]
Heterogeneity: Tau2=0.05; Chi2=77.84, df=14(P<0.0001); I2=82.01%  
Test for overall effect: Z=3.69(P=0)  
Test for subgroup differences: Chi2=2.34, df=1 (P=0.13), I2=57.31%  
Favours metformin 52.5-5 -2.5 0 Favours placebo or diet and exercise
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Analysis 1.17.   Comparison 1 Metformin versus placebo or diet
and exercsie, Outcome 17 Fasting plasma glucose (ethnicity).
Study or subgroup Metformin Placebo or di-
et and exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.17.1 Mainly White  
DPP/DPPOS 2002 926 5.9 (0.8) 935 6.2 (1.1) 10.12% -0.3[-0.39,-0.21]
Subtotal *** 926   935   10.12% -0.3[-0.39,-0.21]
Heterogeneity: Not applicable  
Test for overall effect: Z=6.73(P<0.0001)  
   
1.17.2 Mainly Asian  
Alfawaz 2018 59 5.8 (1.7) 85 5.9 (0.9) 5.02% -0.1[-0.57,0.37]
Chen 2009 44 5.1 (0.9) 46 5.5 (1) 6% -0.4[-0.79,-0.01]
Fang 2004 44 5.9 (0.7) 35 6.3 (1.2) 5.45% -0.4[-0.84,0.04]
IDPP-1 2006 123 6.1 (1.5) 124 6.5 (1.8) 5.74% -0.4[-0.81,0.01]
Ji 2011 52 6.3 (1.3) 64 6.4 (1.5) 4.64% -0.1[-0.61,0.41]
Jin 2009 45 0.6 (0.9) 41 0.2 (0.8) 6.6% 0.42[0.07,0.77]
Li 1999 33 5 (1.1) 37 6.2 (1.3) 4.14% -1.2[-1.76,-0.64]
Lu 2002 75 5.3 (0.8) 195 5.4 (1) 8.4% -0.13[-0.36,0.1]
Lu 2010 115 5.6 (0.3) 111 6.1 (0.3) 10.21% -0.5[-0.58,-0.42]
Wang 2009 30 5.6 (0.6) 32 6.3 (0.5) 7.67% -0.7[-0.98,-0.42]
Zeng 2013 68 5.3 (0.7) 66 5.4 (0.6) 8.34% -0.08[-0.31,0.15]
Subtotal *** 688   836   72.21% -0.31[-0.51,-0.11]
Heterogeneity: Tau2=0.08; Chi2=55.71, df=10(P<0.0001); I2=82.05%  
Test for overall effect: Z=3.01(P=0)  
   
1.17.3 Other  
BIGPRO1 2009 28 -0.3 (1.5) 36 0.7 (2) 2.3% -1.02[-1.88,-0.16]
Papoz 1978 23 5.9 (0.5) 19 5.9 (0.6) 6.75% 0[-0.34,0.34]
PREVENT-DM 2017 27 -0.2 (0.4) 28 -0.2 (0.4) 8.63% 0[-0.21,0.21]
Subtotal *** 78   83   17.67% -0.14[-0.49,0.22]
Heterogeneity: Tau2=0.06; Chi2=5.21, df=2(P=0.07); I2=61.58%  
Test for overall effect: Z=0.75(P=0.45)  
   
Total *** 1692   1854   100% -0.28[-0.42,-0.13]
Heterogeneity: Tau2=0.05; Chi2=77.84, df=14(P<0.0001); I2=82.01%  
Test for overall effect: Z=3.69(P=0)  
Test for subgroup differences: Chi2=0.79, df=1 (P=0.67), I2=0%  
Favours metformin 21-2 -1 0 Favours placebo or diet and exercise
 
 
Comparison 2.   Metformin versus intensive diet plus exercise





Statistical method Effect size
1 All-cause mortality 4 2550 Risk Ratio (M-H, Random, 95% CI) 1.61 [0.50, 5.23]
2 Incidence of type 2 diabetes 7 2960 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.47, 1.37]
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Statistical method Effect size
3 Incidence of type 2 diabetes (duration
of intervention)
7 2960 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.47, 1.37]
3.1 Duration of intervention less than 2
years
1 62 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Duration of intervention 2 years or
more
6 2898 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.47, 1.37]
4 Incidence of type 2 diabetes (ethnicity) 7 2960 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.47, 1.37]
4.1 Mainly White 1 2152 Risk Ratio (M-H, Random, 95% CI) 1.51 [1.25, 1.81]
4.2 Mainly Asian 5 746 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.32, 1.24]
4.3 Other 1 62 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5 2-hr plasma glucose 5 2417 Mean Difference (IV, Random,
95% CI)
-0.03 [-0.26, 0.20]
6 2-hr plasma glucose (ethnicity) 5 2417 Mean Difference (IV, Random,
95% CI)
-0.03 [-0.26, 0.20]
6.1 Mainly White 1 1834 Mean Difference (IV, Random,
95% CI)
0.20 [0.02, 0.38]
6.2 Mainly Asian 4 583 Mean Difference (IV, Random,
95% CI)
-0.21 [-0.59, 0.17]
6.3 Other 0 0 Mean Difference (IV, Random,
95% CI)
0.0 [0.0, 0.0]
7 HbA1c 4 2135 Mean Difference (IV, Random,
95% CI)
0.01 [-0.12, 0.14]
8 HbA1c (duration of intervention) 4 2135 Mean Difference (IV, Random,
95% CI)
0.01 [-0.12, 0.14]
8.1 Duration of intervention less than 2
years
2 189 Mean Difference (IV, Random,
95% CI)
-0.14 [-0.74, 0.46]
8.2 Duration of intervention 2 years or
more
2 1946 Mean Difference (IV, Random,
95% CI)
-0.00 [-0.04, 0.04]
9 HbA1c (ethnicity) 4 2135 Mean Difference (IV, Random,
95% CI)
0.01 [-0.12, 0.14]
9.1 Mainly White 1 1834 Mean Difference (IV, Random,
95% CI)
0.0 [-0.04, 0.04]
9.2 Mainly Asian 2 244 Mean Difference (IV, Random,
95% CI)
-0.27 [-0.66, 0.12]
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Statistical method Effect size
9.3 Other 1 57 Mean Difference (IV, Random,
95% CI)
0.12 [0.02, 0.22]
10 Fasting plasma glucose 7 2603 Mean Difference (IV, Random,
95% CI)
-0.26 [-0.59, 0.07]
11 Fasting plasma glucose (duration of
intervention)
7 2603 Mean Difference (IV, Random,
95% CI)
-0.26 [-0.59, 0.07]
11.1 Duration of intervention less than 2
years
2 189 Mean Difference (IV, Random,
95% CI)
0.02 [-0.17, 0.21]
11.2 Duration of intervention 2 years or
more
5 2414 Mean Difference (IV, Random,
95% CI)
-0.38 [-0.79, 0.04]
12 Fasting plasma glucose (ethnicity) 7 2603 Mean Difference (IV, Random,
95% CI)
-0.26 [-0.59, 0.07]
12.1 Mainly White 1 1831 Mean Difference (IV, Random,
95% CI)
0.0 [-0.07, 0.07]
12.2 Mainly Asian 5 715 Mean Difference (IV, Random,
95% CI)
-0.38 [-0.73, -0.04]





Analysis 2.1.   Comparison 2 Metformin versus intensive diet plus exercise, Outcome 1 All-cause mortality.
Study or subgroup Metformin Intensive diet
plus exercise
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
DPP/DPPOS 2002 6/1073 3/1079 72.57% 2.01[0.5,8.02]
Fang 2004 1/48 0/40 13.79% 2.51[0.11,59.98]
IDPP-1 2006 0/128 1/120 13.64% 0.31[0.01,7.6]
PREVENT-DM 2017 0/29 0/33   Not estimable
   
Total (95% CI) 1278 1272 100% 1.61[0.5,5.23]
Total events: 7 (Metformin), 4 (Intensive diet plus exercise)  
Heterogeneity: Tau2=0; Chi2=1.19, df=2(P=0.55); I2=0%  
Test for overall effect: Z=0.79(P=0.43)  
Favours metformin 5000.002 100.1 1 Favours intensive diet plus exercise
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Analysis 2.2.   Comparison 2 Metformin versus intensive diet plus exercise, Outcome 2 Incidence of type 2 diabetes.
Study or subgroup Metformin Intensive diet
plus exercise
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
DPP/DPPOS 2002 232/1073 155/1079 27.23% 1.51[1.25,1.81]
Fang 2004 9/48 12/40 18.11% 0.63[0.29,1.33]
IDPP-1 2006 51/128 47/120 25.76% 1.02[0.75,1.38]
Ji 2011 3/52 4/60 9.26% 0.87[0.2,3.69]
Li 2009 9/77 33/83 19.63% 0.29[0.15,0.57]
Maji 2005 0/48 0/90   Not estimable
PREVENT-DM 2017 0/29 0/33   Not estimable
   
Total (95% CI) 1455 1505 100% 0.8[0.47,1.37]
Total events: 304 (Metformin), 251 (Intensive diet plus exercise)  
Heterogeneity: Tau2=0.27; Chi2=26.92, df=4(P<0.0001); I2=85.14%  
Test for overall effect: Z=0.81(P=0.42)  
Favours metformin 5000.002 100.1 1 Favours intensive diet plus exercise
 
 
Analysis 2.3.   Comparison 2 Metformin versus intensive diet plus exercise,
Outcome 3 Incidence of type 2 diabetes (duration of intervention).
Study or subgroup Metformin Intensive diet
plus exercise
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.3.1 Duration of intervention less than 2 years  
PREVENT-DM 2017 0/29 0/33   Not estimable
Subtotal (95% CI) 29 33 Not estimable
Total events: 0 (Metformin), 0 (Intensive diet plus exercise)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.3.2 Duration of intervention 2 years or more  
DPP/DPPOS 2002 232/1073 155/1079 27.23% 1.51[1.25,1.81]
Fang 2004 9/48 12/40 18.11% 0.63[0.29,1.33]
IDPP-1 2006 51/128 47/120 25.76% 1.02[0.75,1.38]
Ji 2011 3/52 4/60 9.26% 0.87[0.2,3.69]
Li 2009 9/77 33/83 19.63% 0.29[0.15,0.57]
Maji 2005 0/48 0/90   Not estimable
Subtotal (95% CI) 1426 1472 100% 0.8[0.47,1.37]
Total events: 304 (Metformin), 251 (Intensive diet plus exercise)  
Heterogeneity: Tau2=0.27; Chi2=26.92, df=4(P<0.0001); I2=85.14%  
Test for overall effect: Z=0.81(P=0.42)  
   
Total (95% CI) 1455 1505 100% 0.8[0.47,1.37]
Total events: 304 (Metformin), 251 (Intensive diet plus exercise)  
Heterogeneity: Tau2=0.27; Chi2=26.92, df=4(P<0.0001); I2=85.14%  
Test for overall effect: Z=0.81(P=0.42)  
Test for subgroup differences: Not applicable  
Favours metformin 1000.01 100.1 1 Favours intensive diet plus exercise
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Analysis 2.4.   Comparison 2 Metformin versus intensive diet plus
exercise, Outcome 4 Incidence of type 2 diabetes (ethnicity).
Study or subgroup Metformin Intensive diet
plus exercise
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
2.4.1 Mainly White  
DPP/DPPOS 2002 232/1073 155/1079 27.23% 1.51[1.25,1.81]
Subtotal (95% CI) 1073 1079 27.23% 1.51[1.25,1.81]
Total events: 232 (Metformin), 155 (Intensive diet plus exercise)  
Heterogeneity: Not applicable  
Test for overall effect: Z=4.33(P<0.0001)  
   
2.4.2 Mainly Asian  
Fang 2004 9/48 12/40 18.11% 0.63[0.29,1.33]
IDPP-1 2006 51/128 47/120 25.76% 1.02[0.75,1.38]
Ji 2011 3/52 4/60 9.26% 0.87[0.2,3.69]
Li 2009 9/77 33/83 19.63% 0.29[0.15,0.57]
Maji 2005 0/48 0/90   Not estimable
Subtotal (95% CI) 353 393 72.77% 0.63[0.32,1.24]
Total events: 72 (Metformin), 96 (Intensive diet plus exercise)  
Heterogeneity: Tau2=0.33; Chi2=11.89, df=3(P=0.01); I2=74.77%  
Test for overall effect: Z=1.34(P=0.18)  
   
2.4.3 Other  
PREVENT-DM 2017 0/29 0/33   Not estimable
Subtotal (95% CI) 29 33 Not estimable
Total events: 0 (Metformin), 0 (Intensive diet plus exercise)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 1455 1505 100% 0.8[0.47,1.37]
Total events: 304 (Metformin), 251 (Intensive diet plus exercise)  
Heterogeneity: Tau2=0.27; Chi2=26.92, df=4(P<0.0001); I2=85.14%  
Test for overall effect: Z=0.81(P=0.42)  
Test for subgroup differences: Chi2=5.89, df=1 (P=0.02), I2=83.02%  
Favours metformin 5000.002 100.1 1 Favours intensive diet plus exercise
 
 
Analysis 2.5.   Comparison 2 Metformin versus intensive diet plus exercise, Outcome 5 2-hr plasma glucose.
Study or subgroup Metformin Intensive diet
plus exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
DPP/DPPOS 2002 924 8.2 (2) 910 8 (1.9) 35.3% 0.2[0.02,0.38]
Fang 2004 44 7.5 (1.9) 36 8.4 (2.4) 5.18% -0.9[-1.86,0.06]
IDPP-1 2006 123 9.8 (3.3) 108 9.7 (3) 6.97% 0.1[-0.71,0.91]
Ji 2011 52 7.7 (1.3) 60 8.2 (1.8) 11.99% -0.5[-1.08,0.08]
Li 2009 77 10.3 (0.4) 83 10.3 (0.3) 40.56% 0[-0.11,0.11]
   
Total *** 1220   1197   100% -0.03[-0.26,0.2]
Heterogeneity: Tau2=0.03; Chi2=10.58, df=4(P=0.03); I2=62.19%  
Test for overall effect: Z=0.24(P=0.81)  
Favours metformin 52.5-5 -2.5 0 Favours intensive diet plus exercise
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Analysis 2.6.   Comparison 2 Metformin versus intensive diet
plus exercise, Outcome 6 2-hr plasma glucose (ethnicity).
Study or subgroup Metformin Intensive diet
plus exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.6.1 Mainly White  
DPP/DPPOS 2002 924 8.2 (2) 910 8 (1.9) 35.3% 0.2[0.02,0.38]
Subtotal *** 924   910   35.3% 0.2[0.02,0.38]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.18(P=0.03)  
   
2.6.2 Mainly Asian  
Fang 2004 44 7.5 (1.9) 36 8.4 (2.4) 5.18% -0.9[-1.86,0.06]
IDPP-1 2006 123 9.8 (3.3) 108 9.7 (3) 6.97% 0.1[-0.71,0.91]
Ji 2011 52 7.7 (1.3) 60 8.2 (1.8) 11.99% -0.5[-1.08,0.08]
Li 2009 77 10.3 (0.4) 83 10.3 (0.3) 40.56% 0[-0.11,0.11]
Subtotal *** 296   287   64.7% -0.21[-0.59,0.17]
Heterogeneity: Tau2=0.07; Chi2=6.06, df=3(P=0.11); I2=50.49%  
Test for overall effect: Z=1.08(P=0.28)  
   
2.6.3 Other  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total *** 1220   1197   100% -0.03[-0.26,0.2]
Heterogeneity: Tau2=0.03; Chi2=10.58, df=4(P=0.03); I2=62.19%  
Test for overall effect: Z=0.24(P=0.81)  
Test for subgroup differences: Chi2=3.64, df=1 (P=0.06), I2=72.5%  
Favours metformin 52.5-5 -2.5 0 Favours intensive diet plus exercise
 
 
Analysis 2.7.   Comparison 2 Metformin versus intensive diet plus exercise, Outcome 7 HbA1c.
Study or subgroup Metformin Intensive diet
plus exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Alfawaz 2018 59 5 (1.7) 73 5.5 (1) 6.09% -0.5[-0.99,-0.01]
DPP/DPPOS 2002 924 5.8 (0.4) 910 5.8 (0.5) 47.47% 0[-0.04,0.04]
Ji 2011 52 5.6 (1.2) 60 5.7 (0.9) 8.71% -0.1[-0.5,0.3]
PREVENT-DM 2017 27 0.1 (0.2) 30 -0.1 (0.2) 37.72% 0.12[0.02,0.22]
   
Total *** 1062   1073   100% 0.01[-0.12,0.14]
Heterogeneity: Tau2=0.01; Chi2=8.95, df=3(P=0.03); I2=66.49%  
Test for overall effect: Z=0.09(P=0.93)  
Favours metformin 10.5-1 -0.5 0 Favours intensive diet plus exercise
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Analysis 2.8.   Comparison 2 Metformin versus intensive diet
plus exercise, Outcome 8 HbA1c (duration of intervention).
Study or subgroup Metformin Intensive diet
plus exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.8.1 Duration of intervention less than 2 years  
Alfawaz 2018 59 5 (1.7) 73 5.5 (1) 6.09% -0.5[-0.99,-0.01]
PREVENT-DM 2017 27 0.1 (0.2) 30 -0.1 (0.2) 37.72% 0.12[0.02,0.22]
Subtotal *** 86   103   43.81% -0.14[-0.74,0.46]
Heterogeneity: Tau2=0.16; Chi2=5.87, df=1(P=0.02); I2=82.96%  
Test for overall effect: Z=0.46(P=0.64)  
   
2.8.2 Duration of intervention 2 years or more  
DPP/DPPOS 2002 924 5.8 (0.4) 910 5.8 (0.5) 47.47% 0[-0.04,0.04]
Ji 2011 52 5.6 (1.2) 60 5.7 (0.9) 8.71% -0.1[-0.5,0.3]
Subtotal *** 976   970   56.19% -0[-0.04,0.04]
Heterogeneity: Tau2=0; Chi2=0.24, df=1(P=0.62); I2=0%  
Test for overall effect: Z=0.05(P=0.96)  
   
Total *** 1062   1073   100% 0.01[-0.12,0.14]
Heterogeneity: Tau2=0.01; Chi2=8.95, df=3(P=0.03); I2=66.49%  
Test for overall effect: Z=0.09(P=0.93)  
Test for subgroup differences: Chi2=0.21, df=1 (P=0.65), I2=0%  
Favours metformin 42-4 -2 0 Favours intensive diet plus exercise
 
 
Analysis 2.9.   Comparison 2 Metformin versus intensive diet plus exercise, Outcome 9 HbA1c (ethnicity).
Study or subgroup Metformin Intensive diet
plus exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.9.1 Mainly White  
DPP/DPPOS 2002 924 5.8 (0.4) 910 5.8 (0.5) 47.47% 0[-0.04,0.04]
Subtotal *** 924   910   47.47% 0[-0.04,0.04]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.9.2 Mainly Asian  
Alfawaz 2018 59 5 (1.7) 73 5.5 (1) 6.09% -0.5[-0.99,-0.01]
Ji 2011 52 5.6 (1.2) 60 5.7 (0.9) 8.71% -0.1[-0.5,0.3]
Subtotal *** 111   133   14.8% -0.27[-0.66,0.12]
Heterogeneity: Tau2=0.03; Chi2=1.54, df=1(P=0.21); I2=35.08%  
Test for overall effect: Z=1.38(P=0.17)  
   
2.9.3 Other  
PREVENT-DM 2017 27 0.1 (0.2) 30 -0.1 (0.2) 37.72% 0.12[0.02,0.22]
Subtotal *** 27   30   37.72% 0.12[0.02,0.22]
Heterogeneity: Not applicable  
Test for overall effect: Z=2.26(P=0.02)  
   
Total *** 1062   1073   100% 0.01[-0.12,0.14]
Heterogeneity: Tau2=0.01; Chi2=8.95, df=3(P=0.03); I2=66.49%  
Favours metformin 10.5-1 -0.5 0 Favours intensive diet plus exercise
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Study or subgroup Metformin Intensive diet
plus exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=0.09(P=0.93)  
Test for subgroup differences: Chi2=6.53, df=1 (P=0.04), I2=69.36%  
Favours metformin 10.5-1 -0.5 0 Favours intensive diet plus exercise
 
 
Analysis 2.10.   Comparison 2 Metformin versus intensive diet plus exercise, Outcome 10 Fasting plasma glucose.
Study or subgroup Metformin Intensive diet
plus exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Alfawaz 2018 59 5.8 (1.7) 73 5.7 (0.8) 12.13% 0.1[-0.37,0.57]
DPP/DPPOS 2002 916 5.9 (0.8) 915 5.9 (0.8) 15.97% 0[-0.07,0.07]
Fang 2004 44 5.9 (0.7) 36 6.2 (0.6) 14.46% -0.3[-0.58,-0.02]
IDPP-1 2006 123 6.1 (1.5) 108 6.1 (1.4) 13.34% 0[-0.37,0.37]
Ji 2011 52 6.3 (1.3) 60 7.2 (0.7) 13.08% -0.9[-1.3,-0.5]
Li 2009 77 5.8 (0.3) 83 6.5 (0.3) 15.89% -0.7[-0.79,-0.61]
PREVENT-DM 2017 27 -0.2 (0.4) 30 -0.2 (0.4) 15.13% 0[-0.21,0.21]
   
Total *** 1298   1305   100% -0.26[-0.59,0.07]
Heterogeneity: Tau2=0.18; Chi2=154.46, df=6(P<0.0001); I2=96.12%  
Test for overall effect: Z=1.54(P=0.12)  
Favours metformin 52.5-5 -2.5 0 Favours intensive diet plus exercise
 
 
Analysis 2.11.   Comparison 2 Metformin versus intensive diet plus
exercise, Outcome 11 Fasting plasma glucose (duration of intervention).
Study or subgroup Metformin Intensive diet
plus exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.11.1 Duration of intervention less than 2 years  
Alfawaz 2018 59 5.8 (1.7) 73 5.7 (0.8) 12.13% 0.1[-0.37,0.57]
PREVENT-DM 2017 27 -0.2 (0.4) 30 -0.2 (0.4) 15.13% 0[-0.21,0.21]
Subtotal *** 86   103   27.26% 0.02[-0.17,0.21]
Heterogeneity: Tau2=0; Chi2=0.14, df=1(P=0.7); I2=0%  
Test for overall effect: Z=0.17(P=0.87)  
   
2.11.2 Duration of intervention 2 years or more  
DPP/DPPOS 2002 916 5.9 (0.8) 915 5.9 (0.8) 15.97% 0[-0.07,0.07]
Fang 2004 44 5.9 (0.7) 36 6.2 (0.6) 14.46% -0.3[-0.58,-0.02]
IDPP-1 2006 123 6.1 (1.5) 108 6.1 (1.4) 13.34% 0[-0.37,0.37]
Ji 2011 52 6.3 (1.3) 60 7.2 (0.7) 13.08% -0.9[-1.3,-0.5]
Li 2009 77 5.8 (0.3) 83 6.5 (0.3) 15.89% -0.7[-0.79,-0.61]
Subtotal *** 1212   1202   72.74% -0.38[-0.79,0.04]
Heterogeneity: Tau2=0.2; Chi2=145.97, df=4(P<0.0001); I2=97.26%  
Test for overall effect: Z=1.78(P=0.08)  
   
Total *** 1298   1305   100% -0.26[-0.59,0.07]
Favours metformin 52.5-5 -2.5 0 Favours intensive diet plus exercise
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Study or subgroup Metformin Intensive diet
plus exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Heterogeneity: Tau2=0.18; Chi2=154.46, df=6(P<0.0001); I2=96.12%  
Test for overall effect: Z=1.54(P=0.12)  
Test for subgroup differences: Chi2=2.84, df=1 (P=0.09), I2=64.76%  
Favours metformin 52.5-5 -2.5 0 Favours intensive diet plus exercise
 
 
Analysis 2.12.   Comparison 2 Metformin versus intensive diet
plus exercise, Outcome 12 Fasting plasma glucose (ethnicity).
Study or subgroup Metformin Intensive diet
plus exercise
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
2.12.1 Mainly White  
DPP/DPPOS 2002 916 5.9 (0.8) 915 5.9 (0.8) 15.97% 0[-0.07,0.07]
Subtotal *** 916   915   15.97% 0[-0.07,0.07]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
2.12.2 Mainly Asian  
Alfawaz 2018 59 5.8 (1.7) 73 5.7 (0.8) 12.13% 0.1[-0.37,0.57]
Fang 2004 44 5.9 (0.7) 36 6.2 (0.6) 14.46% -0.3[-0.58,-0.02]
IDPP-1 2006 123 6.1 (1.5) 108 6.1 (1.4) 13.34% 0[-0.37,0.37]
Ji 2011 52 6.3 (1.3) 60 7.2 (0.7) 13.08% -0.9[-1.3,-0.5]
Li 2009 77 5.8 (0.3) 83 6.5 (0.3) 15.89% -0.7[-0.79,-0.61]
Subtotal *** 355   360   68.9% -0.38[-0.73,-0.04]
Heterogeneity: Tau2=0.12; Chi2=29.42, df=4(P<0.0001); I2=86.4%  
Test for overall effect: Z=2.2(P=0.03)  
   
2.12.3 Other  
PREVENT-DM 2017 27 -0.2 (0.4) 30 -0.2 (0.4) 15.13% 0[-0.21,0.21]
Subtotal *** 27   30   15.13% 0[-0.21,0.21]
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total *** 1298   1305   100% -0.26[-0.59,0.07]
Heterogeneity: Tau2=0.18; Chi2=154.46, df=6(P<0.0001); I2=96.12%  
Test for overall effect: Z=1.54(P=0.12)  
Test for subgroup differences: Chi2=4.66, df=1 (P=0.1), I2=57.04%  
Favours metformin 21-2 -1 0 Favours intensive diet plus exercise
 
 
Comparison 3.   Metformin versus sulphonylurea





Statistical method Effect size
1 2-hr plasma glucose 1 45 Mean Difference (IV, Random, 95% CI) 0.10 [-0.66, 0.86]
2 Fasting plasma glucose 1 45 Mean Difference (IV, Random, 95% CI) 0.30 [-0.02, 0.62]
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Analysis 3.1.   Comparison 3 Metformin versus sulphonylurea, Outcome 1 2-hr plasma glucose.
Study or subgroup Metformin Sulphonylurea Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Papoz 1978 23 7.2 (1.3) 22 7.1 (1.3) 100% 0.1[-0.66,0.86]
   
Total *** 23   22   100% 0.1[-0.66,0.86]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.26(P=0.8)  
Favours metformin 52.5-5 -2.5 0 Favours sulphonylurea
 
 
Analysis 3.2.   Comparison 3 Metformin versus sulphonylurea, Outcome 2 Fasting plasma glucose.
Study or subgroup Metformin Sulphonylurea Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Papoz 1978 23 5.9 (0.5) 22 5.6 (0.6) 100% 0.3[-0.02,0.62]
   
Total *** 23   22   100% 0.3[-0.02,0.62]
Heterogeneity: Not applicable  
Test for overall effect: Z=1.82(P=0.07)  
Favours metformin 21-2 -1 0 Favours sulphonylurea
 
 
Comparison 4.   Metformin versus acarbose





Statistical method Effect size
1 All-cause mortality 1   Risk Ratio (M-H, Random, 95% CI) Subtotals only
2 Incidence of type 2 diabetes 3 295 Risk Ratio (M-H, Random, 95% CI) 1.72 [0.72, 4.14]
3 2-hr plasma glucose 2 190 Mean Difference (IV, Random, 95% CI) 0.49 [0.09, 0.88]
4 Fasting plasma glucose 2 190 Mean Difference (IV, Random, 95% CI) 0.00 [-0.35, 0.35]
 
 
Analysis 4.1.   Comparison 4 Metformin versus acarbose, Outcome 1 All-cause mortality.
Study or subgroup Metformin Acarbose Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Fang 2004 1/44 0/45 0% 3.07[0.13,73.31]
Favours metformin 5000.002 100.1 1 Favours acarbose
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Analysis 4.2.   Comparison 4 Metformin versus acarbose, Outcome 2 Incidence of type 2 diabetes.
Study or subgroup Metformin Acarbose Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Fang 2004 9/48 6/50 84.52% 1.56[0.6,4.06]
Liao 2012 3/51 1/50 15.48% 2.94[0.32,27.33]
Maji 2005 0/48 0/48   Not estimable
   
Total (95% CI) 147 148 100% 1.72[0.72,4.14]
Total events: 12 (Metformin), 7 (Acarbose)  
Heterogeneity: Tau2=0; Chi2=0.26, df=1(P=0.61); I2=0%  
Test for overall effect: Z=1.22(P=0.22)  
Favours metformin 5000.002 100.1 1 Favours acarbose
 
 
Analysis 4.3.   Comparison 4 Metformin versus acarbose, Outcome 3 2-hr plasma glucose.
Study or subgroup Metformin Acarbose Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Fang 2004 44 7.5 (1.9) 45 7 (1.8) 26.53% 0.5[-0.27,1.27]
Liao 2012 51 7.7 (1.2) 50 7.2 (1.2) 73.47% 0.48[0.02,0.94]
   
Total *** 95   95   100% 0.49[0.09,0.88]
Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.97); I2=0%  
Test for overall effect: Z=2.4(P=0.02)  
Favours metformin 52.5-5 -2.5 0 Favours acarbose
 
 
Analysis 4.4.   Comparison 4 Metformin versus acarbose, Outcome 4 Fasting plasma glucose.
Study or subgroup Metformin Acarbose Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Fang 2004 44 5.9 (0.7) 45 5.7 (0.7) 45.29% 0.2[-0.08,0.48]
Liao 2012 51 5.5 (0.4) 50 5.7 (0.4) 54.71% -0.16[-0.33,0.01]
   
Total *** 95   95   100% 0[-0.35,0.35]
Heterogeneity: Tau2=0.05; Chi2=4.71, df=1(P=0.03); I2=78.75%  
Test for overall effect: Z=0.02(P=0.99)  
Favours metformin 21-2 -1 0 Favours acarbose
 
 
Comparison 5.   Metformin versus thiazolidinediones





Statistical method Effect size
1 Incidence of type 2 diabetes 3 320 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.41, 2.40]
2 2-hr plasma glucose 2 224 Mean Difference (IV, Random, 95% CI) -0.54 [-1.80, 0.73]
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Statistical method Effect size
3 Fasting plasma glucose 2 224 Mean Difference (IV, Random, 95% CI) -0.13 [-0.32, 0.07]
 
 
Analysis 5.1.   Comparison 5 Metformin versus thiazolidinediones, Outcome 1 Incidence of type 2 diabetes.
Study or subgroup Metformin Thiazo-
lidinediones
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Jin 2009 3/45 3/41 32.92% 0.91[0.19,4.26]
Maji 2005 0/48 0/48   Not estimable
Zeng 2013 6/68 6/70 67.08% 1.03[0.35,3.04]
   
Total (95% CI) 161 159 100% 0.99[0.41,2.4]
Total events: 9 (Metformin), 9 (Thiazolidinediones)  
Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.9); I2=0%  
Test for overall effect: Z=0.02(P=0.98)  
Favours metformin 1000.01 100.1 1 Favours thiazolidinediones
 
 
Analysis 5.2.   Comparison 5 Metformin versus thiazolidinediones, Outcome 2 2-hr plasma glucose.
Study or subgroup Metformin Thiazolidinediones Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Jin 2009 45 0 (1.2) 41 1.2 (2.8) 50.07% -1.18[-2.09,-0.27]
Zeng 2013 68 7.3 (3.3) 70 7.2 (2) 49.93% 0.11[-0.8,1.02]
   
Total *** 113   111   100% -0.54[-1.8,0.73]
Heterogeneity: Tau2=0.62; Chi2=3.84, df=1(P=0.05); I2=73.96%  
Test for overall effect: Z=0.83(P=0.41)  
Favours metformin 105-10 -5 0 Favours thiazolidinediones
 
 
Analysis 5.3.   Comparison 5 Metformin versus thiazolidinediones, Outcome 3 Fasting plasma glucose.
Study or subgroup Metformin Thiazolidinediones Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Jin 2009 45 0.6 (0.9) 41 0.8 (1) 25.23% -0.21[-0.6,0.18]
Zeng 2013 68 5.3 (0.7) 70 5.4 (0.6) 74.77% -0.1[-0.33,0.13]
   
Total *** 113   111   100% -0.13[-0.32,0.07]
Heterogeneity: Tau2=0; Chi2=0.23, df=1(P=0.63); I2=0%  
Test for overall effect: Z=1.28(P=0.2)  
Favours metformin 21-2 -1 0 Favours thiazolidinediones
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Comparison 6.   Metformin + intensive diet and exercise versus intensive diet and exercise





Statistical method Effect size
1 All-cause mortality 2   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Incidence of type 2 diabetes 2 332 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.10, 2.92]
3 Incidence of type 2 diabetes (blind-
ed vs open-label)
3 524 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.53, 1.58]
3.1 Participants blinded 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Open-label 3 524 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.53, 1.58]
4 Incidence of type 2 diabetes (dura-
tion of the intervention)
3 524 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.53, 1.58]
4.1 Duration of the intervention less
than 2 years
2 283 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.09, 3.42]
4.2 Duration of the intervention 2
years or more
1 241 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.72, 1.36]
5 Incidence of type 2 diabetes (ethnic-
ity)
3 524 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.53, 1.58]
5.1 mainly White 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 mainly Asian 3 524 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.53, 1.58]
5.3 Other 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
6 2-hr glucose values 2 316 Mean Difference (IV, Random, 95% CI) -0.52 [-2.08, 1.04]
7 Fasting plasma glucose 2 316 Mean Difference (IV, Random, 95% CI) -0.26 [-0.94, 0.43]
8 Fasting plasma glucose (blinded vs
open-label)
2 316 Mean Difference (IV, Random, 95% CI) -0.26 [-0.94, 0.43]
8.1 Participants blinded 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8.2 Open-label 2 316 Mean Difference (IV, Random, 95% CI) -0.26 [-0.94, 0.43]
9 Fasting plasma glucose (duration of
the intervention)
2 316 Mean Difference (IV, Random, 95% CI) -0.26 [-0.94, 0.43]
9.1 Duration of the intervention less
than 2 years
1 91 Mean Difference (IV, Random, 95% CI) -0.60 [-0.97, -0.23]
9.2 Duration of the intervention 2
years or more
1 225 Mean Difference (IV, Random, 95% CI) 0.10 [-0.32, 0.52]
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Analysis 6.1.   Comparison 6 Metformin + intensive diet and exercise
versus intensive diet and exercise, Outcome 1 All-cause mortality.





Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
IDPP-1 2006 1/121 1/120 0% 0.99[0.06,15.67]
Iqbal Hydrie 2012 0/95 0/114   Not estimable
Favours metformin + intensive diet and exercise 10000.001 100.1 1 Favours intensive diet and exercise
 
 
Analysis 6.2.   Comparison 6 Metformin + intensive diet and exercise versus
intensive diet and exercise, Outcome 2 Incidence of type 2 diabetes.





Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
IDPP-1 2006 47/121 47/120 66.87% 0.99[0.72,1.36]
Zhao 2013 1/45 6/46 33.13% 0.17[0.02,1.36]
   
Total (95% CI) 166 166 100% 0.55[0.1,2.92]
Total events: 48 (Metformin + intensive diet and exercise]), 53 (Intensive
diet and exercise)
 
Heterogeneity: Tau2=1.05; Chi2=2.83, df=1(P=0.09); I2=64.67%  
Test for overall effect: Z=0.7(P=0.49)  
Favours metformin + intensive diet and exercise 10000.001 100.1 1 Favours intensive diet and exercise
 
 
Analysis 6.3.   Comparison 6 Metformin + intensive diet and exercise versus intensive
diet and exercise, Outcome 3 Incidence of type 2 diabetes (blinded vs open-label).





Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.3.1 Participants blinded  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Metformin + intensive diet and exercise]), 0 (Intensive diet
and exercise)
 
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
6.3.2 Open-label  
IDPP-1 2006 47/121 47/120 67.75% 0.99[0.72,1.36]
Iqbal Hydrie 2012 8/85 9/107 25.77% 1.12[0.45,2.78]
Zhao 2013 1/45 6/46 6.48% 0.17[0.02,1.36]
Subtotal (95% CI) 251 273 100% 0.91[0.53,1.58]
Total events: 56 (Metformin + intensive diet and exercise]), 62 (Intensive
diet and exercise)
 
Heterogeneity: Tau2=0.09; Chi2=2.89, df=2(P=0.24); I2=30.79%  
Test for overall effect: Z=0.33(P=0.74)  
   
Favours metformin + intensive diet and exercise 1000.01 100.1 1 Favours intensive diet and exercise
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Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Total (95% CI) 251 273 100% 0.91[0.53,1.58]
Total events: 56 (Metformin + intensive diet and exercise]), 62 (Intensive
diet and exercise)
 
Heterogeneity: Tau2=0.09; Chi2=2.89, df=2(P=0.24); I2=30.79%  
Test for overall effect: Z=0.33(P=0.74)  
Test for subgroup differences: Not applicable  
Favours metformin + intensive diet and exercise 1000.01 100.1 1 Favours intensive diet and exercise
 
 
Analysis 6.4.   Comparison 6 Metformin + intensive diet and exercise versus intensive
diet and exercise, Outcome 4 Incidence of type 2 diabetes (duration of the intervention).





Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.4.1 Duration of the intervention less than 2 years  
Iqbal Hydrie 2012 8/85 9/107 25.77% 1.12[0.45,2.78]
Zhao 2013 1/45 6/46 6.48% 0.17[0.02,1.36]
Subtotal (95% CI) 130 153 32.25% 0.55[0.09,3.42]
Total events: 9 (Metformin + intensive diet and exercise]), 15 (Intensive di-
et and exercise)
 
Heterogeneity: Tau2=1.18; Chi2=2.77, df=1(P=0.1); I2=63.87%  
Test for overall effect: Z=0.64(P=0.52)  
   
6.4.2 Duration of the intervention 2 years or more  
IDPP-1 2006 47/121 47/120 67.75% 0.99[0.72,1.36]
Subtotal (95% CI) 121 120 67.75% 0.99[0.72,1.36]
Total events: 47 (Metformin + intensive diet and exercise]), 47 (Intensive
diet and exercise)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.05(P=0.96)  
   
Total (95% CI) 251 273 100% 0.91[0.53,1.58]
Total events: 56 (Metformin + intensive diet and exercise]), 62 (Intensive
diet and exercise)
 
Heterogeneity: Tau2=0.09; Chi2=2.89, df=2(P=0.24); I2=30.79%  
Test for overall effect: Z=0.33(P=0.74)  
Test for subgroup differences: Chi2=0.39, df=1 (P=0.53), I2=0%  
Favours metformin + intensive diet and exercise 1000.01 100.1 1 Favours intensive diet and exercise
 
 
Analysis 6.5.   Comparison 6 Metformin + intensive diet and exercise versus
intensive diet and exercise, Outcome 5 Incidence of type 2 diabetes (ethnicity).





Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
6.5.1 mainly White  
Favours metformin + intensive diet and exercise 1000.01 100.1 1 Favours intensive diet and exercise
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Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Metformin + intensive diet and exercise]), 0 (Intensive diet
and exercise)
 
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
6.5.2 mainly Asian  
IDPP-1 2006 47/121 47/120 67.75% 0.99[0.72,1.36]
Iqbal Hydrie 2012 8/85 9/107 25.77% 1.12[0.45,2.78]
Zhao 2013 1/45 6/46 6.48% 0.17[0.02,1.36]
Subtotal (95% CI) 251 273 100% 0.91[0.53,1.58]
Total events: 56 (Metformin + intensive diet and exercise]), 62 (Intensive
diet and exercise)
 
Heterogeneity: Tau2=0.09; Chi2=2.89, df=2(P=0.24); I2=30.79%  
Test for overall effect: Z=0.33(P=0.74)  
   
6.5.3 Other  
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Metformin + intensive diet and exercise]), 0 (Intensive diet
and exercise)
 
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 251 273 100% 0.91[0.53,1.58]
Total events: 56 (Metformin + intensive diet and exercise]), 62 (Intensive
diet and exercise)
 
Heterogeneity: Tau2=0.09; Chi2=2.89, df=2(P=0.24); I2=30.79%  
Test for overall effect: Z=0.33(P=0.74)  
Test for subgroup differences: Not applicable  
Favours metformin + intensive diet and exercise 1000.01 100.1 1 Favours intensive diet and exercise
 
 
Analysis 6.6.   Comparison 6 Metformin + intensive diet and exercise
versus intensive diet and exercise, Outcome 6 2-hr glucose values.





Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
IDPP-1 2006 117 10 (3.8) 108 9.7 (3) 48.46% 0.3[-0.59,1.19]
Zhao 2013 45 7.5 (1.6) 46 8.8 (1.8) 51.54% -1.29[-1.99,-0.59]
   
Total *** 162   154   100% -0.52[-2.08,1.04]
Heterogeneity: Tau2=1.1; Chi2=7.53, df=1(P=0.01); I2=86.73%  
Test for overall effect: Z=0.65(P=0.51)  
Favours metformin + intensive diet and exercise 2010-20 -10 0 Favours intensive diet and exercise
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Analysis 6.7.   Comparison 6 Metformin + intensive diet and exercise
versus intensive diet and exercise, Outcome 7 Fasting plasma glucose.





Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
IDPP-1 2006 117 6.2 (1.8) 108 6.1 (1.4) 48.92% 0.1[-0.32,0.52]
Zhao 2013 45 5.6 (1.1) 46 6.2 (0.6) 51.08% -0.6[-0.97,-0.23]
   
Total *** 162   154   100% -0.26[-0.94,0.43]
Heterogeneity: Tau2=0.2; Chi2=6.04, df=1(P=0.01); I2=83.45%  
Test for overall effect: Z=0.74(P=0.46)  
Favours metformin + intensive diet and exercise 105-10 -5 0 Favours intensive diet and exercise
 
 
Analysis 6.8.   Comparison 6 Metformin + intensive diet and exercise versus intensive
diet and exercise, Outcome 8 Fasting plasma glucose (blinded vs open-label).





Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
6.8.1 Participants blinded  
Subtotal *** 0   0   Not estimable
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
6.8.2 Open-label  
IDPP-1 2006 117 6.2 (1.8) 108 6.1 (1.4) 48.92% 0.1[-0.32,0.52]
Zhao 2013 45 5.6 (1.1) 46 6.2 (0.6) 51.08% -0.6[-0.97,-0.23]
Subtotal *** 162   154   100% -0.26[-0.94,0.43]
Heterogeneity: Tau2=0.2; Chi2=6.04, df=1(P=0.01); I2=83.45%  
Test for overall effect: Z=0.74(P=0.46)  
   
Total *** 162   154   100% -0.26[-0.94,0.43]
Heterogeneity: Tau2=0.2; Chi2=6.04, df=1(P=0.01); I2=83.45%  
Test for overall effect: Z=0.74(P=0.46)  
Test for subgroup differences: Not applicable  
Favours metformin + intensive diet and exercise 10.5-1 -0.5 0 Favours intensive diet and exercise
 
 
Analysis 6.9.   Comparison 6 Metformin + intensive diet and exercise versus intensive
diet and exercise, Outcome 9 Fasting plasma glucose (duration of the intervention).





Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
6.9.1 Duration of the intervention less than 2 years  
Zhao 2013 45 5.6 (1.1) 46 6.2 (0.6) 51.08% -0.6[-0.97,-0.23]
Subtotal *** 45   46   51.08% -0.6[-0.97,-0.23]
Heterogeneity: Not applicable  
Favours metformin + intensive diet and exercise 42-4 -2 0 Favours intensive diet and exercise
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Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Test for overall effect: Z=3.2(P=0)  
   
6.9.2 Duration of the intervention 2 years or more  
IDPP-1 2006 117 6.2 (1.8) 108 6.1 (1.4) 48.92% 0.1[-0.32,0.52]
Subtotal *** 117   108   48.92% 0.1[-0.32,0.52]
Heterogeneity: Not applicable  
Test for overall effect: Z=0.47(P=0.64)  
   
Total *** 162   154   100% -0.26[-0.94,0.43]
Heterogeneity: Tau2=0.2; Chi2=6.04, df=1(P=0.01); I2=83.45%  
Test for overall effect: Z=0.74(P=0.46)  
Test for subgroup differences: Chi2=6.04, df=1 (P=0.01), I2=83.45%  
Favours metformin + intensive diet and exercise 42-4 -2 0 Favours intensive diet and exercise
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I: metformin 98 59 68 69.4
C1: intensive diet plus exercise 98 73 75 76.5
C2: standard care
— —





total: 294 217 237 80.6
1 year (1
year)
I1: metformin 29 27 27 93.1
C1: intensive diet plus exercise 33 30 30 90.9
C2: standard care
Quote: "Data from a previous
pilot study of the promoto-
ra-led ILI provided estimates
for participant retention at 12-
month follow-up (90%) and
12-month weight loss (4.9 kg,
SD 4.9 kg). Based on these as-
sumptions, the enrollment tar-
get was 30 participants per
study arm in order to retain 27
in each group at 12 months.
These assumptions allowed
for >80% power to detect a
mean weight loss difference of
at least 4.9 kg (SD=4.9 kg) be-
tween groups, which was low-
er than that observed in DPP, at
the overall 5% significance lev-
el. Power calculations adjusted
for three pairwise comparisons,
using a 1.7% significance level
for each"
441/197







total: 92 85 85 92.4
1 year (—)
I: metformin 68 68 68 100






70 70 70 100
2 years















































































































































total: 204 204 204 100
I: metformin plus intensive diet plus
exercise
46 45 45 97.8
C: intensive diet plus exercise
— —




total: 92 91 91 98.9
1 year
I1: metformin plus intensive diet and
exercise
95 85 85 89.5
C1: intensive diet and exercise 114 107 107 93.9
C2: standard care
Quote: "Mean and standard de-
viation were reported for con-
tinuous variables and inter-
group comparisons were test-
ed by two tailed ANOVA. Com-
parison of proportions was by
χ2 analysis. The proportion of
subjects developing diabetes
in each group and their com-
parison was by χ2 analysis. For
the intervention measures, the
absolute and relative risk re-
ductions, 95% CIs of the esti-
mates, and the number needed
to treat to prevent diabetes in
one person were calculated. A P
value <0.05 was considered sig-
nificant"
1739/317





total: 317 274 274 86.4
18 months
(—)
I: metformin 52 50 50 96.2
C: acarbose
— —




total: 104 101 101 97.1
1 year
I1: metformin 52 52 52 100
C1: intensive diet plus exercise 60 60 60 100
C2: standard care
— —




total: 176 176 176 100
2 years















































































































































I: metformin 117 115 96 82
C: standard care
— —




total: 234 226 196 83.8
2 years
S1 - I1: metformin 49 28 28 57.1
S1 - C1: placebo 52 36 36 69.2
S2 - I1: metformin 28 18 18 64.3
S2 - C1: placebo
Quote: "Given the number of
variable to be compared, the
required sample size fluctuate
between 200
and 500 per group, according to
the variable under considera-
tion and allowing for multiple





23 14 14 60.9






total S2: 51 32 32  
1 year (—)
I: metformin 49 44 44 89.8
C: standard care
— —




total: 101 90 90 89.1
2 years
I: metformin 48 45 45 93.8
C1: standard care 41 41 41 100
C2: rosiglitazone
— —




total: 133 127 127 95.5
3 years
I: metformin 77 77 74 96.1
C: intensive diet plus exercise
— —




total: 160 160 153 95.6
3 years
Wang 2009 I: metformin — — 32 30 30 93.8 1 year















































































































































C: standard care 32 32 32 100
(parallel
RCT)
total: 64 62 62 96.9
I1: metformin 133 128 128 96.2
I2: metformin plus intensive diet and
physical activity
129 121 121 93.8
C1: intensive exercise plus diet 133 120 120 90.2
C2: standard care
Quote: "It was assumed that
the cumulative incidence of di-
abetes in 3 years would be ap-
proximately 30% in the control
group and that there would be
a 50% reduction with the inter-
vention methods. The sample
size required in each of the four
subgroups was 134 with a type
1 error of 5%, 80% power, and
allowing for a dropout rate of
10%"
10,839/531





total: 531 502 502 94.5
3 years (—)
I1: metformin 48 — — —
C1: intensive lifestyle intervention 90 — — —
C2: rosiglitazone 48 — — —
C3: acarbose
— 234/234




total: 234 — — —
3 years (—)
I: metformin 48 44 44 91.7
C1: acarbose 50 45 45 90.0
C2: intensive exercise and diet 40 36 36 90.0
C3: standard care
— 1549/178




total: 178 160 160 89.9
5 years (—)




C1: intensive exercise and diet
Quote: "The principal analy-
ses of primary and secondary
outcomes will employ the "in-
tent-to-treat" approach (Pe-
153,183
1079 — — —
2.8 years
(15 years)
















































































































































duzzi, Wittes, et al., 1993). The
intent-to-treat analyses will in-
clude all randomized partici-
pants with all participants in-
cluded in their randomly as-
signed treatment group; treat-
ment group assignment will
not be altered based on the
participant’s adherence to the
assigned treatment regimen.
All statistical tests will be two-
sided. The overall significance
level of the primary outcome
will be α = 0.05. However, be-
cause interim analyses will be
conducted throughout the DPP,
the significance levels used in
the interim and final analyses
of the primary outcome will
be adjusted to account for the
multiplicity of interim analy-
ses." and "The study design
provided 90 percent power
to detect a 33 percent reduc-
tion from an incidence of 6.5
cases of diabetes per 100 per-
son-years, with a 10 percent
rate of loss to follow-up per
year"
1082 — — —
total: 3234 3234 — —
I1: metformin 80 75 75 93.8
C1: standard care 72 64 64 88.9
C2: standard care plus diet instruc-
tion every 6th month
57 51 51 89.5
C3: standard care plus fibre diet
— —




total: 293 270 270 92.2
3 years
Li 1999 I1: metformin — 29,938 45 33 33 73.3 1 year (—)















































































































































C1: placebo 45 37 37 82.2
(parallel
RCT)
total: 90 70 70 77.8
I1: metformin (plus placebo) 30 23 23 76.7
C1: glibenclamide plus placebo 28 22 22 78.6
C2: placebo
— —




total: 91 64 64 71
2 years (2
years)
All interventions 2426  
All comparators 4348  
Grand total






Table 1.   Overview of trial populations  (Continued)
—: denotes not reported
aFollow-up under randomised conditions until end of trial or if not available, duration of intervention; extended follow-up refers to follow-up of participants once the original
trial was terminated as specified in the power calculation
bFor BIGPRO1 we evaluated two subgroups available as secondary analyses (published in 2009) from the original trial (1996), which did not meet our inclusion criteria for the
population
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A P P E N D I C E S
Appendix 1. Search strategies
 
Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Register of Studies Online)
1. MESH DESCRIPTOR Prediabetic state
2. MESH DESCRIPTOR Glucose Intolerance
3. (prediabet* or pre diabet*):TI,AB,KY
4. (intermediate hyperglyc?emi*):TI,AB,KY
5. ((impaired fasting ADJ2 glucose) or IFG or impaired FPG):TI,AB,KY
6. glucose intolerance:TI,AB,KY
7. ((impaired glucose ADJ (tolerance or metabolism)) or IGT):TI,AB,KY
8. ((risk or progress* or prevent* or inciden* or conversion or develop* or delay*) ADJ4 (diabetes or T2D* or NIDDM or "type 2" or
"type II")):TI,AB,KY
9. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8
10. MESH DESCRIPTOR Metformin
11. metformin*:TI,AB,KY
12. #10 OR #11




3. (prediabet* or pre diabet*).tw.
4. intermediate hyperglyc?emi*.tw.
5. ((impaired fasting adj2 glucose) or IFG or impaired FPG).tw.
6. glucose intolerance.tw.
7. ((impaired glucose adj (tolerance or metabolism)) or IGT).tw.





12. 10 or 11
13. 9 and 12
[14-24: Cochrane Handbook 2008 RCT filter - sensitivity maximizing version]
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14. randomized controlled trial.pt.








23. exp animals/ not humans/
24. 22 not 23
25. 13 and 24
26. ..dedup 25
Scopus
1. KEY("prediabetic state" OR "glucose intolerance" OR "impaired glucose tolerance")
2. TITLE-ABS(prediabet* OR "pre diabet*" OR "intermediate hyperglyc?emi*")
3. TITLE-ABS(("impaired fasting" PRE/3 glucose) OR IFG OR "impaired FPG")
4. TITLE-ABS("glucose intolerance")
5. TITLE-ABS(("impaired glucose" PRE/0 (tolerance OR metabolism)) OR IGT)
6. TITLE-ABS((risk or progress* or prevent* or inciden* or conversion or develop* or delay*) W/4 (diabetes or T2D* or NIDDM or "type
2" or "type II"))
7. #1 OR #2 OR #3 OR #4 OR #5 OR #6
8. TITLE-ABS-KEY(Metformin)
9. #7 AND #8
10. TITLE-ABS-KEY(random* OR "clinical trial*" OR "double blind*" OR placebo*)
11. #9 AND #10
12. #11 AND (LIMIT-TO (DOCTYPE, "ar") OR LIMIT-TO (DOCTYPE, "ip")) [ar = article, ip = article in press]
ICTRP Search Portal (Standard search)
prediabet* AND metformin OR
pre diabet* AND metformin OR
impaired AND glucose* AND metformin OR
impaired AND fasting* AND metformin OR
glucose AND intoleran* AND metformin OR
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(prediabetes OR prediabetic OR "pre diabetes" OR "pre diabetic" OR "impaired glucose" OR "impaired fasting" OR "glucose intoler-
ance" OR IGT OR IFG OR ((diabetes OR "type 2" OR "type II" OR T2D OR T2DM) AND (risk OR progress OR progression OR progressed
OR incident OR incidence OR conversion OR developed OR development OR develop OR delay OR delayed OR prevention OR prevent
OR prevented))) [DISEASE] AND metformin [TREATMENT]
  (Continued)
 
Appendix 2. Assessment of risk of bias
 
Risk of bias domains
Random sequence generation (selection bias due to inadequate generation of a randomised sequence)
For each included study, we described the method used to generate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups.
• Low risk of bias: the study authors achieved sequence generation using computer-generated random numbers or a random num-
bers table. Drawing of lots, tossing a coin, shuffling cards or envelopes, and throwing dice are adequate if an independent person
performed this who was not otherwise involved in the study. We considered the use of the minimisation technique as equivalent
to being random.
• Unclear risk of bias: insufficient information about the sequence generation process.
• High risk of bias: the sequence generation method was non-random or quasi-random (e.g. sequence generated by odd or even date
of birth; sequence generated by some rule based on date (or day) of admission; sequence generated by some rule based on hospital
or clinic record number; allocation by judgment of the clinician; allocation by preference of the participant; allocation based on the
results of a laboratory test or a series of tests; or allocation by availability of the intervention).
Allocation concealment (selection bias due to inadequate concealment of allocation prior to assignment)
We described for each included study the method used to conceal allocation to interventions prior to assignment and we assessed
whether intervention allocation could have been foreseen in advance of or during recruitment, or changed after assignment.
• Low risk of bias: central allocation (including telephone, interactive voice-recorder, web-based and pharmacy-controlled randomi-
sation); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes.
• Unclear risk of bias: insufficient information about the allocation concealment.
• High risk of bias: used an open random allocation schedule (e.g. a list of random numbers); assignment envelopes used without
appropriate safeguards; alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.
We also evaluated study baseline data to incorporate assessment of baseline imbalance into the 'Risk of bias' judgment for selection
bias (Corbett 2014). Chance imbalances may also affect judgments on the risk of attrition bias. In the case of unadjusted analyses, we
distinguished between studies that we rated as being at low risk of bias on the basis of both randomisation methods and baseline
similarity, and studies that we judged as being at low risk of bias on the basis of baseline similarity alone (Corbett 2014). We reclassi-
fied judgements of unclear, low or high risk of selection bias as specified in Appendix 3.
Blinding of participants and study personnel (performance bias due to knowledge of the allocated interventions by partici-
pants and personnel during the study)
We evaluated the risk of detection bias separately for each outcome (Hróbjartsson 2013). We noted whether endpoints were self-re-
ported, investigator-assessed or adjudicated outcome measures (see below).
• Low risk of bias: blinding of participants and key study personnel was ensured, and it was unlikely that the blinding could have been
broken; no blinding or incomplete blinding, but we judge that the outcome is unlikely to have been influenced by lack of blinding.
• Unclear risk of bias: insufficient information about the blinding of participants and study personnel; the study does not address this
outcome.
• High risk of bias: no blinding or incomplete blinding, and the outcome is likely to have been influenced by lack of blinding; blinding
of study participants and key personnel attempted, but likely that the blinding could have been broken, and the outcome is likely
to be influenced by lack of blinding.
Blinding of outcome assessment (detection bias due to knowledge of the allocated interventions by outcome assessment
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We evaluated the risk of detection bias separately for each outcome (Hróbjartsson 2013). We noted whether endpoints were self-re-
ported, investigator-assessed or adjudicated outcome measures (see below).
• Low risk of bias: blinding of outcome assessment is ensured, and it is unlikely that the blinding could have been broken; no blinding
of outcome assessment, but we judge that the outcome measurement is unlikely to have been influenced by lack of blinding.
• Unclear risk of bias: insufficient information about the blinding of outcome assessors; the study did not address this outcome.
• High risk of bias: no blinding of outcome assessment, and the outcome measurement was likely to have been influenced by lack of
blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement was
likely to be influenced by lack of blinding.
Incomplete outcome data (attrition bias due to amount, nature or handling of incomplete outcome data)
For each included study and/or each outcome, we described the completeness of data, including attrition and exclusions from the
analyses. We stated whether the study reported attrition and exclusions, and reported the number of participants included in the
analysis at each stage (compared with the number of randomised participants per intervention/comparator groups). We also noted
if the study reported the reasons for attrition or exclusion and whether missing data were balanced across groups or were related to
outcomes. We considered the implications of missing outcome data per outcome such as high dropout rates (e.g. above 15%) or dis-
parate attrition rates (e.g. difference of 10% or more between study arms).
• Low risk of bias: no missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data,
censoring unlikely to introduce bias); missing outcome data balanced in numbers across intervention groups, with similar reasons
for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event
risk was not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible
effect size (mean difference or standardised mean difference) among missing outcomes was not enough to have a clinically relevant
impact on observed effect size; appropriate methods, such as multiple imputation, were used to handle missing data.
• Unclear risk of bias: insufficient information to assess whether missing data in combination with the method used to handle missing
data were likely to induce bias; the study did not address this outcome.
• High risk of bias: reason for missing outcome data was likely to be related to true outcome, with either imbalance in numbers or
reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared
with observed event risk enough to induce clinically relevant bias in the intervention effect estimate; for continuous outcome data,
plausible effect size (mean difference or standardised mean difference) among missing outcomes enough to induce clinically-rele-
vant bias in observed effect size; 'as-treated' or similar analysis done with substantial departure of the intervention received from
that assigned at randomisation; potentially inappropriate application of simple imputation.
Selective reporting (reporting bias due to selective outcome reporting)
We assessed outcome reporting bias by integrating the results of the appendix 'Matrix of study endpoints (publications and trial doc-
uments)' (Boutron 2014; Jones 2015; Mathieu 2009), with those of the appendix 'High risk of outcome reporting bias according to the
Outcome Reporting Bias In Trials (ORBIT) classification' (Kirkham 2010). This analysis formed the basis for the judgement of selective
reporting.
• Low risk of bias: the study protocol was available and all the studies' prespecified (primary and secondary) outcomes that were of
interest to this review were reported in the prespecified way; the study protocol was unavailable, but it was clear that the published
reports included all expected outcomes (ORBIT classification).
• Unclear risk of bias: insufficient information about selective reporting.
• High risk of bias: not all the studies' prespecified primary outcomes were reported; one or more primary outcomes were reported
using measurements, analysis methods or subsets of the data (e.g. subscales) that were not prespecified; one or more reported
primary outcomes were not prespecified (unless clear justification for their reporting was provided, such as an unexpected adverse
effect); one or more outcomes of interest in the Cochrane Review were reported incompletely so that we cannot enter them in a
meta-analysis; the study report failed to include results for a key outcome that we would expect to have been reported for such a
study (ORBIT classification).
Other bias
• Low risk of bias: the study appears to be free from other sources of bias.
• Unclear risk of bias: there was insufficient information to assess whether an important risk of bias existed; insufficient rationale or
evidence that an identified problem introduced bias.
• High risk of bias: the study had a potential source of bias related to the specific study design used; the study was claimed to be
fraudulent; or the study had some other serious problem.
  (Continued)
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Appendix 3. Selection bias decisions
 
Selection bias decisions for studies reporting unadjusted analyses: comparison of results obtained using method details alone















Baseline imbalances present for important prognostic variable(s) High risk
Groups appear similar at baseline for all important prognostic vari-
ables
Low risk
Unclear methods Unclear risk
Limited or no baseline details Unclear risk
Baseline imbalances present for important prognostic variable(s) Unclear riskb
Groups appear similar at baseline for all important prognostic vari-
ables
Low risk
Limited baseline details, showing balance in some important prognos-
tic variablesc
Low risk





No baseline details Unclear risk
Baseline imbalances present for important prognostic variable(s) High risk
Groups appear similar at baseline for all important prognostic vari-
ables
Low risk
Limited baseline details, showing balance in some important prognos-
tic variablesc
Unclear risk





No baseline details High risk
aTaken from Corbett 2014; judgements highlighted in bold indicate situations in which the addition of baseline assessments would
change the judgement about risk of selection bias, compared with using methods reporting alone.
bImbalance identified that appears likely to be due to chance.




Appendix 4. Description of interventions
 
Trial ID Intervention(s)
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C1: intensive diet and exerciseAlfawaz
2018
Metformin 500 mg twice a day
plus standard advice on diet plus
exercise
Yes
C2: diet plus exercise
Yes
C1: intensive diet and physical activityPRE-
VENT-DM
2017
Metformin 850 mg daily for the
first month, thereafter 850 mg
twice daily. If side effects, then
dose reduction. Titrated to the
highest tolerable dose with a
maximum of 850 mg three times
a day
Yes
C2: diet plus exercise
Yes
C1: diet plus exerciseZeng 2013 Metformin 38 mg once daily.
Diet plus exercise (no details)
Yes
C2: pioglitazone 38 mg once daily
Diet plus exercise
Yes
Zhao 2013 Metformin 500 mg twice daily
Education plus behaviour inter-
ventions, including diet control
and increased physical activity
(at least 30 minutes per day and
at least 5 days per week)
Yes Education plus behaviour interventions, including diet
control and increased physical activity (at least 30 min-
utes per day and at least 5 days per week)
Yes
C1: intensive diet plus physical activityIqbal Hy-
drie 2012
Metformin 500 mg twice daily
plus intensive diet and physical
activity
Yes
C2: standard medical advice
Yes
Liao 2012 Metformin from 250 mg, three
times daily, adjusting the dose
according to blood glucose, with
the maximum 1500 mg daily
Yes Acarbose from 50 mg three times daily with meals, ad-
justing the dose according to blood glucose, with the
maximum 300 mg daily
Yes
C1: Intesive diet plus exercise; based on individual di-
etary habits, calories are determined according to age,
height, actual weight, activity intensity and season. Pa-
tients were given a low-fat diet and a controlled diet.
Patients were instructed to have a balanced diet and
exercise (150 minutes per week).
Ji 2011 Metformin 500 mg, three times
daily, after meals.
Standard advice on diet plus ex-
ercise
Yes
C2: diet plus exercise
Yes
Lu 2010 Metformin 250 mg three times
daily, according to tolerance,
gradually reaching the target
dose of 500 mg three times daily
Lectures and leaflets were given
to inform the prognosis and haz-
ards of pre-diabetes, and scientif-
ic diet and exercise instructions
were provided for each follow-up
to promote a healthy lifestyle
Yes By giving lectures and sending out leaflets to inform
the prognosis and hazards of pre-diabetes, providing
healthy diet and lifestyle guidance, referring to the di-
etary nutrition guidelines of China, and adjusting diet
according to individual specific conditions to maintain
a balanced nutritional status.
The advice was:
(1) variety of food, mainly cereals, with a combination
of grains and grains;
Yes
  (Continued)
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(2) eat more vegetables, fruits and potatoes;
(3) daily intake of milk, beans and their preparation;
(4) eat adequate amount of fish, poultry, eggs and lean
meat;
(5) reduce the amount of cooking oil, eat light diet with
little salt, not too greasy and salty, including not too
much smoke and animal oil food, daily adult salt to 6
g, eat less pickles, monosodium glutamate and other
sodium-containing food;
(6) reasonable allocation of three meals, snacks should
be appropriate.
Reduce calorie intake to maintain the ideal weight.
Patients with a BMI < 25kg/m2 were advised 30 Kcal/
kg·day, with emphasis on alcohol and sugary soN
drinks: patients with a BMI ≥ 25kg/m2 were encour-
aged to lose 0.5 g to 1.0 kg per month until ideal body
weight. Initiate, encourage family members to care, su-
pervise the completion of dietary plan.
At each follow-up, the participants were informed of di-
etary compliance.
The exercise advice was as follows:
(1) exercise prescription should consider the patient's
individual factors such as gender, age, height, weight
and living habits comprehensively;
(2) principle of gradual progress and acting accord-
ing to ability.The formulation of exercise prescription
should be based on the patient's disease degree, physi-
cal condition to develop a long-term plan, step by step,
not subjective assumptions, eager for quick success
and instant benefit.
In the exercise prescription a clear purpose should be
stated, and use the degree of realisation of this pur-
pose to measure and modify the exercise prescription.
Patients are required to engage in continuous aerobic
exercise. Generally, after 30 minutes of exercise, blood
glucose starts to supply energy to tissues, thus caus-
ing a drop in blood glucose. Moreover, studies have
confirmed that the effect of moderate amount of ex-
ercise on blood glucose lasts for 12 months.17 hours,
so people with diabetes should exercise at least once a
day, no less than 30 minutes at a time. According to the
principles and contents of exercise prescription, the ex-
ercise group should take appropriate physical activities
and adopt various forms according to the specific con-
ditions of each person, such as walking, jogging, play-
ing ball games, aerobics, taijiquan, etc. It is required
that the exercise program should be 1 exercise unit per
day, lasting at least 30 minutes, and at least 5 days per
week.
  (Continued)
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At each follow-up, participants were informed about




Metformin, 850 mg tablet twice a
day; diet plus exercise
Yes Identical placebo tablet given twice a day; diet plus ex-
ercise
Yes
Chen 2009 Metformin 750 mg, three times
daily
All patients received behaviour
changing with reference to diet
and exercise therapy in the dia-
betes guidelines of China
Yes All patients received behaviour changing with refer-
ence to diet and exercise therapy in the diabetes guide-
lines of China.
Yes
C1: diet plus exercise (no details)Jin 2009 Metformin 1000 mg twice or three
times daily.
Diet plus exercise (no details)
Yes
C2: rosiglitazone 4 mg, orally, once daily.
Diet plus exercise (no details)
Yes
Li 2009 Metformin 500 mg once daily plus
diet and exercise
Yes Individualised diet and exercise and education Yes
Wang
2009
Metformin 250 mg twice daily,
with or after meals.
Plus standard advice on diet and
exercise
Yes Diet plus exercise Yes
C1: intensive diet and exerciseIDPP-1
2006
I1: Metformin, 500 mg twice a day
I2: Metformin, 500 mg twice a day





C1: intensive diet and physical activity
C2: rosiglitazone 2 mg daily plus diet and physical ac-
tivity
Maji 2005 Metformin 500 mg once daily plus
diet and physical activity
Yes
C3: acarbose 25 mg twice daily plus diet and physical
activity
Yes
C1: acarbose 75 mg to 150 mg three times a day
C2: intensive diet plus exercise
Fang 2004 Metformin 375 mg to 750 mg
three times a day
Yes
C3: diet and physical activity
Yes
C1: intensive diet plus exercise: consumption of a
healthy low-calorie, low-fat diet and to engage in phys-
ical activity of moderate intensity (such as brisk walk-
ing) for at least 150 minutes/week
DPP/DP-
POS 2002
Metformin 850 mg twice a day
plus standard diet and lifestyle
advice
Yes
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C1: health education (not described, assumed to be
standard care)
C2: diet instruction (every 6 months).
Health education
Lu 2002 Metformin 750 mg three times
daily.
Health education (not described,
assumed to be standard care)
Yes
C3: fibre diet, fibre (Litesse) 6 g, twice daily, take with
meal. Provide fibre once a month.
Health education
Yes
Li 1999 Metformin, 250 mg three times a
day
Yes C1: placebo administered with the same schedule as
metformin
Yes
C1: glibenclamide 2.0 mg, orally, twice daily and place-




Metformin 850 mg, twice daily
plus placebo, twice daily; over-
weight participants were recom-
mended calorie restriction
Yes
C2: placebo, orally, twice daily; overweight participants
were recommended calorie restriction
Yes
aThe term 'clinical practice setting' refers to the specification of the intervention/comparator as used in the course of a standard
medical treatment (such as dose, dose escalation, dosing scheme, provision for contraindications and other important features)
BMI: body mass index; C: comparator; I: intervention.
  (Continued)
 
Appendix 5. Baseline characteristics (I)
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January 2009 - March 2010
(recruitment period) 2012
























































































































































































IGT, Asian — Pakistan Outpa-
tient
Assume 100% Asian (Pakistini) —
I: met-
formin





IGT, Chinese August 2009 - July 2010 (re-




















September 2007 - August
2008 (recruitment period)




































































































































































































IFG patients January 2004 - May 2006 (re-

















2004 - 2005 (recruitment pe-














January - December 2008
(recruitment period) 2009


















35 years to 55
years
2001 - 2005 India Outpa-
tient




















































































































































Asian Indian: 100 —
C2: stan-
dard care
Asian Indian: 100 —
I1: met-
formin





Assume 100% Indian —
C2: rosigli-
tazone






IGT Initiated 2001 India Outpa-
tient
Assume 100% Indian —
I: met-
formin
Assume 100% Asian (Chinese) —
C1: acar-
bose





































July 2001 (end of treatment
period)

































































































































































































IGT, Chinese 1992-1994 China Outpa-
tient















Participants entered the tri-
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Appendix 6. Baseline characteristics (II)
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
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I: metformin 71 42.6 (6.9) 6.6 (0.5) — 5.6 (0.5) 32.1 (5.7) — —
C1: intensive diet plus
exercise
70 43.4 (7.8) 6.1 (0.4) — 5.8 (0.4) 31.3 (6.4) — —
Alfawaz
2018
C2: standard care 75 42.3 (11.2) 6.0 (0.4) — 5.6 (0.5) 32.6 (5.8) — —
I1: metformin 100 45.8 (11.7) 5.3 (0.6) — 6.0 (0.2) 33.2 (5.5) — —
C1: intensive diet plus
exercise




C2: standard care 100 44.0 (13.6) 5.3 (0.6) — 5.9 (0.2) 32.2 (5.7) — —
I: metformin 44 47.7 (5.8) 5.5 (0.4) 8.75 (0.57) — 25.2 (1.8) — —
C1: Standard care 42 48.6 (7.4) 5.6 (0.3) 8.9 (0.4) — 25.3 (2.6) — —
Zeng
2013
C2: pioglitazone 46 47.2 (4.4) 5.7 (0.2) 8.9 (0.6) — 25.2 (3.2) — —
I: metformin plus in-
tensive diet plus exer-
cise
43 — — 9.32 (1.51) — 28.61 (3.5) — —Zhao
2013
C: intensive diet plus
exercise
48 — — 9.13 (1.72) — 28.32 (3.7) — —
I1: metformin plus in-
tensive diet and physi-
cal activity




C1: intensive diet and
physical activity



















































































































































C2: standard care — 44.2 (10.9) — — — 27.0 (5.7) —
I: metformin 46 50.8 (9.3) 6.03 (0.5) 8.2 (0.84) — — — —Liao
2012
C: acarbose 48 50.5 (8.3) 6.05 (0.51) 8.28 (1.12) — — — —
I1: metformin 54 50.9 (2.7) 7.0 (1.4) 8.8 (1.3) — 24.6 (2.8) — —
C1: Intensive diet plus
exercise
47 52.1 (2.3) 7.2 (0.7) 9.0 (1.5) — 24.4 (1.4) — —
Ji 2011
C2: standard care 53 53.4 (3.8) 6.9 (1.8) 8.7 (1.3) — 24.6 (2.8) — —
I: metformin 43 41 (4.6) — — 5.87
(0.47)
25.1 (2.8) — —Lu 2010
C: standard care 41 41 (4.3) — — 5.89
(0.44)
25.5 (3.4) — —
I: metformin 76 52.6 (6.2) 5.8 (0.6) 8.3 (1.2) — 33.5 (5.9) Diet and exercise —BIGPRO1
2009a
C: placebo 58 48.9 (6.7) 5.6 (0.8) 8.5 (1.2) — 35.6 (7.5) Diet and exercise —
I: metformin 41 56.4 (2.1) 5.4 (0.6) 9.1 (0.8) — 127.2 (17.9) — —Chen
2009
C: standard care 44 56.3 (12.8) 5.3 (0.6) 9.0 (0.9) — 125.8 (18.0) — —
I: metformin — — 6.47 (0.18) 6.82 (0.45) — 23.95 (3.04) — —
C1: standard care — — 6.47 (0.18) 6.92 (0.41) — 24.8 (3.47) — —
Jin 2009
C2: rosiglitazone — — 6.5 (0.19) 6.88 (0.5) — 24.85 (3.97) — —
I: metformin — — 6.6 (0.4) 10.4 (0.3) — 28.1 (1.4) — —Li 2009
C: intensive diet plus
exercise
— — 6.6 (0.3) 10.3 (0.4) — 28.2 (1.7) — —
I: metformin — 49 (9) — 9.4 (1.6) — 25.0 (1.0) — —Wang
2009




















































































































































I2: metformin plus in-
tensive diet and physi-
cal activity





















5.6 (0.9) 8.5 (1.3) 7.4 (0.3) 28.6 (1.2) — —












5.3 (0.7) 8.8 (2.0) 7.4 (0.6) 28.1 (1.4) Information about healthy
diet and exercise
—
I: metformin 48 50 (1) 6.3 (2.1) 7.48 (1.9) — 25.2 (0.4) - —
C1: acarbose 50 50 (1) 6.5 (1.9) 8.38 (1.9) — 24.9 (0.3) - —
C2: intensive exercise
and diet
40 49 (1) 5.6 (2.4) 6.99 (2.1) — 25.3 (0.3) - —
Fang
2004




I: metformin 66.2 50.9 (10.3) 5.9 (0.5) 9.2 (0.9) 5.9 (0.5) 33.9 (6.6) 17% in all treatment
groups had antihyperten-





















































































































































68 50.6 (11.3) 5.90 (0.5) 9.1 (0.9) 5.91 (0.5) 33.9 (6.8)
C2: placebo 69 50.3 (10.4) 5.92 (0.5) 9.1 (1.0) 5.91 (0.5) 34.2 (6.8)
5.2% of participants re-
ported taking pharmaco-
logic therapy for dyslipi-




















I1: metformin 25 61 (9) — 9.0 (0.8) — 26.1 (2.7) — —
C1: standard care 16 65 (7) — 9.1 (1.0) — 25.9 (3.3) — —
C2: standard care plus
diet instruction every
6th month
35 63 (9) — 9.0 (0.9) — 26.0 (3.2) — —
Lu 2002
C3: standard care plus
fibre diet
29 64 (9) — 9.4 (0.9) — 26.2 (3.0) — —
I: metformin 27.2 49 (1.3) 6.9 (0.9) 9.1 (0.9) 7.4 (0.8) 26.0 (23) Information about healthy
diet and exercise
—Li 1999b







0 44 (5.5)c 6.7 (0.7)c,d,e 8.2 (1.7)c,d,e — — Overwieght participants
were prescribed calorie
restriction in order to ap-




















































































































































0 43 (10.6)c 6.7 (0.7)c,d,e 8.8 (2.0)c,d,e — — Overwieght participants
were prescribed calorie
restriction in order to ap-
proach their ideal body
weight
—
C2: placebo 0 45 (5.7)c 6.3 (0.7)c,d,e 8.3 (2.1)c,d,e — — Overwieght participants
were prescribed calorie
restriction in order to ap-
proach their ideal body
weight
—
—: denotes not reported
aBaseline data only available for the people with IGT/IFG who completed the trial
bBaseline data only available for the participants who completed the trial
cSD calculated from standard error
dGlucose concentrations were converted from mg/dL to mmol/L (diabetes.co.uk 2019a)
eBlood glucose concentrations were converted to plasma glucose values (diabetes.co.uk 2019b)
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Appendix 7. Matrix of study endpoints (publications and trial documents)
 
Trial ID
Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufactur-
er's website, published design paper)a,c
Source: N/T
Endpoints quoted in publication(s)b,c
Primary outcome measure(s): participants with metabolic syndrome
Secondary outcome measure(s): individual components of metabolic syndrome
Other outcome measure(s): total number of metabolic syndrome components; metabolic syn-
drome risk-score
Endpoints quoted in abstract of publication(s)b,c
Alfawaz 2018
Primary outcome measure(s): participants with metabolic syndrome
Secondary outcome measure(s): individual components of metabolic syndrome
Other outcome measure(s): —
Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufactur-
er's website, published design paper)a,c
Source: NCT02088034
Primary outcome measure(s): weight
Secondary outcome measure(s): cardiometabolic markers, physical activity, dietary intake, dia-
betes knowledge (assessed with Spanish-speaking Diabetes Knowledge Questionnaire)
Other outcome measure(s):
Trial results available in trial register: yes
Endpoints quoted in publication(s)b,c
Primary outcome measure(s): blood glucose, insulin levels
Secondary outcome measure(s): —
Other outcome measure(s): weight
Endpoints quoted in abstract of publication(s)b,c
PREVENT-DM 2017
Primary outcome measure(s): weight loss
Secondary outcome measure(s): HbA1c, waist circumference
Other outcome measure(s):
Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufactur-
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Primary outcome measure(s): —
Secondary outcome measure(s): —
Other outcome measure(s): —
Trial results available in trial register: —
Endpoints quoted in publication(s)b,c
Primary outcome measure(s): incidence of T2DM
Secondary outcome measure(s): fasting blood glucose, 2-hour plasma glucose
Other outcome measure(s): fasting insulin, 2-hour insulin, BMI, blood pressure, cholesterol, con-
version to normoglycaemia
Endpoints quoted in abstract of publication(s)b,c
Primary outcome measure(s): incidence of T2DM
Secondary outcome measure(s): fasting blood glucose, 2-hour plasma glucose
Other outcome measure(s): fasting insulin, 2-hour insulin, BMI, blood pressure, cholesterol, con-
version to normoglycaemia
Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufactur-
er's website, published design paper)a,c
Source: NT
Primary outcome measure(s): —
Secondary outcome measure(s): —
Other outcome measure(s): —
Trial results available in trial register: —
Endpoints quoted in publication(s)b,c
Primary outcome measure(s): incidence of T2DM
Secondary outcome measure(s): fasting blood glucose, 2-hour plasma glucose, non-serious ad-
verse events
Other outcome measure(s): fasting insulin, HOMA-IR, WHR, BMI
Endpoints quoted in abstract of publication(s)b,c
Zhao 2013
Primary outcome measure(s): — (NA)
Secondary outcome measure(s): —
Other outcome measure(s): —
Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufactur-
er's website, published design paper)a,c
Iqbal Hydrie 2012
Source: main publication
Primary outcome measure(s): —
  (Continued)
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Secondary outcome measure(s): —
Other outcome measure(s): —
Trial results available in trial register: —
Endpoints quoted in publication(s)b,c
Primary outcome measure(s): incidence of T2DM
Secondary outcome measure(s):
Other outcome measure(s): waist circumference, weight changes
Endpoints quoted in abstract of publication(s)b,c
Primary outcome measure(s): incidence of T2DM
Secondary outcome measure(s):
Other outcome measure(s):
Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufactur-
er's website, published design paper)a,c
Source: NT
Primary outcome measure(s): —
Secondary outcome measure(s): —
Other outcome measure(s): —
Trial results available in trial register: —
Endpoints quoted in publication(s)b,c
Primary outcome measure(s): incidence of T2DM, serious adverse events
Secondary outcome measure(s): fasting plasma glucose, 2-hour plasma glucose
Other outcome measure(s): fasting insulin, HOMA-IR, WHR, BMI, conversion to normoglycaemia
Endpoints quoted in abstract of publication(s)b,c
Liao 2012
Primary outcome measure(s): —
Secondary outcome measure(s): fasting plasma glucose, 2-hour plasma glucose
Other outcome measure(s): —
Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufactur-
er's website, published design paper)a,c
Ji 2011
Source: NT
Primary outcome measure(s): —
Secondary outcome measure(s): —
Other outcome measure(s): —
  (Continued)
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Trial results available in trial register: —
Endpoints quoted in publication(s)b,c
Primary outcome measure(s): incidence of T2DM
Secondary outcome measure(s): fasting plasma glucose, 2-hour plasma glucose, HbA1c
Other outcome measure(s): conversion to normoglycaemia, BMI, triglycerides, cholesterol, hs-
CRP, fasting insulin
Endpoints quoted in abstract of publication(s)b,c
Primary outcome measure(s): incidence of T2DM
Secondary outcome measure(s): fasting plasma glucose, 2-hour plasma glucose, HbA1c
Other outcome measure(s): conversion to normoglycaemia, BMI, triglycerides, cholesterol, hs-
CRP, fasting insulin
Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufactur-
er's website, published design paper)a,c
Source: NT
Primary outcome measure(s): —
Secondary outcome measure(s): —
Other outcome measure(s): —
Trial results available in trial register: —
Endpoints quoted in publication(s)b,c
Primary outcome measure(s): incidence of T2DM, serious adverse events
Secondary outcome measure(s): HbA1c (%), IGT, IFG, non-serious adverse events
Other outcome measure(s): BMI, compliance of treatment
Endpoints quoted in abstract of publication(s)b,c
Lu 2010
Primary outcome measure(s): incidence of T2DM, serious adverse events
Secondary outcome measure(s): HbA1c (%), IGT, IFG, non-serious adverse events
Other outcome measure(s): BMI, compliance of treatment
Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufactur-
er's website, published design paper)a,c
Source: design paper
Endpoints quoted in publication(s)b,c
BIGPRO1 2009
Primary outcome measure(s): —
Secondary outcome measure(s): —
  (Continued)
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Other outcome measure(s): not prioritised as primary or secondary: fasting plasma glucose; 2-
hour plasma glucose; plasma lipids: total cholesterol, LDL cholesterol, HDL cholesterol, and triglyc-
erides; fasting plasma insulin; 2-hour plasma insulin; blood pressure: systolic and diastolic blood
pressure; BMI and WHR
Endpoints quoted in abstract of publication(s)b,c
Primary outcome measure(s): —
Secondary outcome measure(s): —
Other outcome measure(s): not prioritised as primary or secondary: fasting plasma glucose; 2-
hour plasma glucose; plasma lipids: total cholesterol, LDL cholesterol, HDL cholesterol, and triglyc-
erides; fasting plasma insulin; 2-hour plasma insulin; blood pressure; BMI and WHR
Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufactur-
er's website, published design paper)a,c
Source: NT
Primary outcome measure(s): —
Secondary outcome measure(s): —
Other outcome measure(s): —
Trial results available in trial register: —
Endpoints quoted in publication(s)b,c
Primary outcome measure(s): incidence of T2DM
Secondary outcome measure(s): fasting plasma glucose, 2-hour plasma glucose
Other outcome measure(s): reversion to normoglycaemia
Endpoints quoted in abstract of publication(s)b,c
Chen 2009
Primary outcome measure(s): incidence of T2DM
Secondary outcome measure(s): fasting plasma glucose, 2-hour plasma glucose
Other outcome measure(s): —
Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufactur-
er's website, published design paper)a,c
Source: NT
Primary outcome measure(s): —
Secondary outcome measure(s): —
Other outcome measure(s): —
Trial results available in trial register: —
Endpoints quoted in publication(s)b,c
Jin 2009
Primary outcome measure(s): incidence of T2DM, serious adverse event
  (Continued)
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Secondary outcome measure(s): fasting plasma glucose, 2-hour plasma glucose, non-serious ad-
verse event
Other outcome measure(s): fasting plasma insulin, 2-hour plasma insulin, BMI, reversion to nor-
moglycaemia
Endpoints quoted in abstract of publication(s)b,c
Primary outcome measure(s): incidence of T2DM
Secondary outcome measure(s): fasting plasma glucose, 2-hour plasma glucose
Other outcome measure(s): fasting plasma insulin, 2-hour plasma insulin
Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufactur-
er's website, published design paper)a,c
Source: NT
Primary outcome measure(s): —
Secondary outcome measure(s): —
Other outcome measure(s): —
Trial results available in trial register: —
Endpoints quoted in publication(s)b,c
Primary outcome measure(s): incidence of T2DM
Secondary outcome measure(s): fasting plasma glucose, 2-hour plasma glucose
Other outcome measure(s): fasting insulin, BMI, leptin, triglycerides
Endpoints quoted in abstract of publication(s)b,c
Li 2009
Primary outcome measure(s): incidence of T2DM
Secondary outcome measure(s): fasting plasma glucose, 2-hour plasma glucose
Other outcome measure(s): fasting insulin, BMI, leptin, triglycerides
Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufactur-
er's website, published design paper)a,c
Source: NT
Primary outcome measure(s): —
Secondary outcome measure(s): —
Other outcome measure(s): —
Trial results available in trial register: —
Endpoints quoted in publication(s)b,c
Wang 2009
Primary outcome measure(s): incidence of T2DM
Secondary outcome measure(s): 2-hour plasma glucose, non-serious adverse events
  (Continued)
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Other outcome measure(s): fasting blood glucose
Endpoints quoted in abstract of publication(s)b,c
Primary outcome measure(s): — (NA)
Secondary outcome measure(s): —
Other outcome measure(s): —
Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufactur-
er's website, published design paper)a,c
Source: NCT00279240
Primary outcome measure: incidence of T2DM
Secondary outcome measure: benefits of the drug on anthropometric variables and biochemical
parameter
Other outcome measure(s): —
Trial results available in trial register: yes
Endpoints quoted in publication(s)b,c
Primary outcome measure(s): morbidity of T2DM
Secondary outcome measure(s): mortality; morbidity of cardiovascular disease; fasting and 2-
hour plasma glucose; plasma lipids: total cholesterol, LDL cholesterol and HDL cholesterol; blood
pressure; BMI; adverse events; costs
Other outcome measure(s): —
Endpoints quoted in abstract of publication(s)b,c
IDPP-1 2006
Primary outcome measure: incidence of T2DM
Secondary outcome measure(s): diabetes related morbidity, adverse events, all-cause mortality,
total cholesterol, LDL cholesterol and HDL cholesterol, blood pressure, BMI, socioeconomic effects
Other outcome measure(s): —
Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufactur-
er's website, published design paper)a,c
Source: main publication
Primary outcome measure(s): —
Secondary outcome measure(s): —
Other outcome measure(s): —
Trial results available in trial register: —
Endpoints quoted in publication(s)b,c
Maji 2005
Primary outcome measure(s): —
Secondary outcome measure(s): —
  (Continued)
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Other outcome measure(s): not described whether outcomes were primary or secondary: inci-
dence of T2DM, per cent change in glycaemic measures
Endpoints quoted in abstract of publication(s)b,c
Primary outcome measure(s): —
Secondary outcome measure(s): —
Other outcome measure(s): not described whether outcomes were primary or secondary: conver-
sion to normoglycaemia
Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufactur-
er's website, published design paper)a,c
Source: N/T
Endpoints quoted in publication(s)b,c
Primary outcome measure(s): incidence of T2DM, all-cause mortality, serious adverse events
Secondary outcome measure(s): fasting plasma glucose, 2-hour plasma glucose, non-serious ad-
verse events
Other outcome measure(s): BMI, total cholesterol, triglycerides, conversion to normoglycaemia
Endpoints quoted in abstract of publication(s)b,c
Fang 2004
Primary outcome measure(s): incidence of T2DM
Secondary outcome measure(s): fasting plasma glucose, 2-hour plasma glucose
Other outcome measure(s): conversion to normoglycaemia
Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufactur-
er's website, published design paper)a,c
DPP/DPPOS 2002
DPP: Source: NCT00004992; design article and protocol available from website (DPP/DPPOS 2002)
Primary outcome measure(s): incidence of T2DM
DPPOS: NCT00038727: design article and protocol available from website (DPP/DPPOS 2002)
Primary outcome measure(s): incidence of T2DM; aggregate microvascular complications
DPP: Secondary outcome measure(s): HbA1c; insulin and glucose; electrocardiogram; cardiovas-
cular symptom assessment; blood pressure; carotid ultrasound; lipoproteins; fibrinolysis and clot-
ting factors; albumin excretion; physical measurements; physical activity; nutrient intake; health-
related quality of life; resource utilisation; safety
DPPOS: Secondary outcome measure(s): microvascular and cardiovascular disease risk factors;
microvascular and cardiovascular disease risk factors; subclinical atherosclerosis; quality of life
and economic analyses, bone density, health aging index; pulmonary function, urinary inconti-
nence, amputation of lower extremity, hospitalisations; cardiovascular disease events
Other outcome measure(s): quote: "...comparing the incidence and determinants of these health
outcomes in participants with new-onset diabetes and IGT, as well as assessing subgroups of par-
ticipants in order to evaluate the effect of age, race/ethnicity, and sex on health outcomes"
Trial results available in trial register: no trial results available, but references to publications at
clinicaltrials.gov
  (Continued)
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Endpoints quoted in publication(s)b,c
DPP: Primary outcome measure(s): incidence of T2DM
DPPOS: Primary outcome measure(s): incidence of T2DM; aggregate microvascular complica-
tions
DPP: Secondary outcome measure(s): HbA1c; insulin and glucose; electrocardiogram; cardiovas-
cular symptom assessment; blood pressure; lipoproteins; fibrinolysis and clotting factors; albumin
excretion; physical measurements; physical activity; nutrient intake; health-related quality of life;
resource utilisation; safety
DPPOS: Secondary outcome measure(s): microvascular and cardiovascular disease risk factors;
economic analyses; health aging index; urinary incontinence
Other outcome measure(s): several subgroup analyses investigating the incidence of the primary
outcomes
Endpoints quoted in abstract of publication(s)b,c
DPP: Primary outcome measure(s): incidence of T2DM
DPPOS: Primary outcome measure(s): incidence of T2DM; aggregate microvascular complica-
tions
DPP: Secondary outcome measure(s): insulin; cardiovascular symptom assessment; blood pres-
sure; lipoproteins; fibrinolysis and clotting factors; albumin excretion; physical measurements; nu-
trient intake; health related quality of life; resource utilisation
DPPOS: Secondary outcome measure(s): microvascular and cardiovascular disease risk factors;
economic analyses; health aging index; urinary incontinence
Other outcome measure(s): several subgroup analyses investigating the incidence of the primary
outcomes
Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufactur-
er's website, published design paper)a,c
Source: NT
Primary outcome measure(s): —
Secondary outcome measure(s): —
Other outcome measure(s): —
Trial results available in trial register: —
Endpoints quoted in publication(s)b,c
Primary outcome measure(s): incidence of T2DM, serious adverse events
Secondary outcome measure(s): fasting plasma glucose, 2-hour plasma glucose
Other outcome measure(s): 1 hour PG
Endpoints quoted in abstract of publication(s)b,c
Lu 2002
Primary outcome measure(s): incidence of T2DM
Secondary outcome measure(s): fasting blood sugar, - hour plasma glucose
  (Continued)
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Other outcome measure(s): 1 hour plasma glucose
Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufactur-
er's website, published design paper)a,c
Source: main publication
Primary outcome measure(s): —
Secondary outcome measure(s): —
Other outcome measure(s): not described whether outcomes were primary or secondary: inci-
dence of T2DM, weight, lipids, risk factors for cardiovascular disease
Trial results available in trial register: no
Endpoints quoted in publication(s)b,c
Primary outcome measure(s): —
Secondary outcome measure(s): —
Other outcome measure(s): not described whether outcomes were primary or secondary: gly-
caemic control: fasting and 2-hour plasma glucose, HbA1c; plasma lipids: total cholesterol and
triglycerides; fasting and 2-hour plasma insulin; blood pressure: Systolic and diastolic blood pres-
sure; BMI and WHR; adverse events
Endpoints quoted in abstract of publication(s)b,c
Li 1999
Primary outcome measure(s): —
Secondary outcome measure(s): —
Other outcome measure(s): not described whether outcomes were primary or secondary: inci-
dence of T2DM, adverse events, HbA1c, total cholesterol and triglycerides, fasting plasma insulin,
blood pressure, weight change
Endpoints quoted in trial document(s) (ClinicalTrials.gov, FDA/EMA document, manufactur-
er's website, published design paper)a,c
Source: N/T
Endpoints quoted in publication(s)b,c
Primary outcome measure(s): blood glucose, insulin levels
Secondary outcome measure(s): —
Other outcome measure(s): weight
Endpoints quoted in abstract of publication(s)b,c
Papoz 1978
Primary outcome measure(s): blood glucose, insulin levels
Secondary outcome measure(s): —
Other outcome measure(s): weight
— denotes not reported
aTrial document(s) refers to all available information from published design papers and sources other than regular publications (e.g.
FDA/EMA documents, manufacturer's websites, trial registers).
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bPublication(s) refers to trial information published in scientific journals (primary reference, duplicate publications, companion doc-
uments or multiple reports of a primary trial)
cPrimary and secondary outcomes refer to verbatim specifications in publication/records. Unspecified outcome measures refer to all
outcomes not described as primary or secondary outcome measures
BMI: body mass index; CRP: C-reactive protein; EMA: European Medicines Agency; FDA: Food and Drug Administration (US); HDL:
high-density lipoprotein; HOMA-IR: homeostatic model assessment insulin resistance; hs-CRP: high sensitive C-reactive protein; IFG:
impaired fasting glucose; IGT: impaired glucose tolerance; LDL: low-density lipoprotein; NT: no trial document available; NA: no ab-
stract available; PG: plasma glucose; T2DM: type 2 diabetes mellitus; WHR: waist-to-hip ratio.
  (Continued)
 
Appendix 8. High risk of outcome reporting bias according to Outcome Reporting Bias In Trials (ORBIT) classification
 
 
















Incidence of T2DM No No No YesAlfawaz
2018




Hypoglycaemia No No Yes No
Incidence of T2DM No No No NoZeng 2013
Measures of blood glucose control No No No No
Incidence of T2DM No No No No
Non-serious adverse events No No Yes No
Zhao 2013
Measures of blood glucose control No No No No
Incidence of T2DM No No No No
Serious adverse events No No No No
Liao 2012
Measures of blood glucose control No No No No
Hypoglycaemia No Yes No NoIqbal Hy-
drie 2012
Adverse events No Yes No No
Incidence of T2DM No No No No
Serious adverse events No No No No
Ji 2011
Measures of blood glucose control No No No No
Lu 2010 Incidence of T2DM No No No No
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Serious adverse events No No No No
Non-serious adverse events No No No No
Measures of blood glucose control No No No No
Incidence of T2DM No Yes No No
Hypoglycaemia No Yes No No
BIGPRO1
2009
Adverse events No Yes No No
Incidence of T2DM No No No No
Non-serious adverse events No No Yes No
Chen 2009
Measures of blood glucose control No No No No
Incidence of T2DM No No No No
Serious adverse events No No No No
Non-serious adverse events No No No No
Jin 2009
Measures of blood glucose control No No No No
Incidence of T2DM No No No NoLi 2009
Measures of blood glucose control No No No No
Incidence of T2DM No No No No
Non-serious adverse events No No No No
Wang
2009
Measures of blood glucose control No No No No
Serious adverse events No Yes No No
Non-fatal myocardial infarction No Yes No No
Stroke No Yes No No
IDPP-1
2006
Non-serious adverse events No No Yes No
Hypoglycaemia No Yes No NoMaji 2005
Adverse events No Yes No No
All-cause mortality No No No No
Incidence of T2DM No No No No
Serious adverse events No No No No
Fang 2004
Non-serious adverse events No No No No
  (Continued)
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Measure of blood glucose control No No No No
Serious adverse events No Yes No No
Non-fatal myocardial infarction No No Yes No
Non-fatal stroke No No Yes No
Non-serious adverse events No Yes No No
DPP 2002
Hypoglycaemia No Yes No No
Incidence of T2DM No No No No
Serious adverse events No No No No
Lu 2002
Measures of blood glucose control No No No No
Li 1999 Hypoglycaemia No Yes No No
Papoz
1978
Adverse events No No No Yes
aClear that outcome was measured and analysed; trial report states that outcome was analysed but only reports that result was not
significant
(Classification 'A', table 2, Kirkham 2010)
bClear that outcome was measured and analysed; trial report states that outcome was analysed but no results reported
( Classification 'D', table 2, Kirkham 2010)
cClear that outcome was measured; clear that outcome was measured but not necessarily analysed; judgement says likely to have
been analysed but not reported because of non-significant results
(Classification 'E', table 2, Kirkham 2010)
dUnclear whether the outcome was measured; not mentioned but clinical judgement says likely to have been measured and
analysed but not reported on the basis of non-significant results
(Classification 'G', table 2, Kirkham 2010)
ORBIT: Outcome Reporting Bias In Trials
  (Continued)
 
Appendix 9. Definition of endpoint measurement (I)a
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
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NI Type 2 diabetes mellitus
IO
NI NI NI NI NI
Zeng 2013 NR ND
IO
NR NR NR NR NR
Zhao 2013 NR ND
IO
NR NR NR NR NR
Iqbal Hydrie
2012
NI Either fasting plasma glucose of > 125 mg/dL (6.9
mmol/L) and/or 2-hour plasma glucose of > 199 mg/
dL (11.1 mmol/L)
IO
NI NI NI NI NI
Liao 2012 NR ND
IO
NR NR NR NR NR
Ji 2011 NR ND
IO
NR NR NR NR NR
Lu 2010 NR American Diabetes Association 1997 criteria (any
glucose ≥ 11.1 mmol/L or fasting plasma glucose ≥
7.0 mmol/L).
Quote: "If the patient has diabetes symptoms such
as polydipsia, polyuria and polyphagy, if FPG≥
7.0mmol/L or 2hPG> 11.1mmol/L after meal, the sec-
ond FPG and/or 75 g OGTT were performed within 6
weeks. If the diabetes criteria were met, the prima-





















































































































































NI NI NI NI NI NI NI
Chen 2009 NR 75 g OGTT, and confirmed with a repeated test (no
other data)
Quote: "If the results of 75g OGTT for 2 times during
the observation were diabetic, they were considered
to have converted to diabetes, which was the end
point of the study."
IO
NR NR NR NR NR
Jin 2009 NR ND
IO
NR NR NR NR NR
Li 2009 NR ND
IO
NR NR NR NR NR
Wang 2009 NR ND
IO
NR NR NR NR NR
IDPP-1 2006 IO WHO 1999 (either a fasting plasma glucose ≥ 7.0
mmol/L
(≥ 126 mg/dL) and/or a 2-hour plasma glucose con-
centration
≥ 11.1 mmol/L (≥ 200 mg/dL), and confirmed with a
repeat test)
IO
IO NI NI NI NI
Maji 2005 NI Type 2 diabetes mellitus
IO
NI NI NI NI NI


















































































































































IO American Diabetes Association criteria (fasting plas-
ma glucose level ≥ 126 mg/dL [7.0 mmol/L] or 2-hour
plasma glucose ≥ 200 mg/dL [11.1 mmol/L] after a 75








that results in any







tion of existing hos-
pitalization
• A persistent or sig-
nificant disability/in-
capacity; or








Lu 2002 NR 75 g OGTT, and confirmed with a repeated test (no
other data)
Quote: "If the results of 75 g OGTT at one time dur-
ing the observation were diabetic, the patients were
still treated according to the original regimen; if
the patients were still diabetic at the next review,
the patients were judged to have converted to dia-
betes, which was the end point of the study. If it is
IGT or normal glucose tolerance, observation will be
continued, and final results of each subject will be
judged after review at the end of 3 years."
IO
NR NR NR NR NR
Li 1999 NI Not described, presumable WHO 1985 criteria (either
a fasting plasma glucose ≥ 140 mg/dL (7.8 mmol/L)
or higher or a 2-hour plasma glucose ≥ 200 mg/dL
(11.1 mmol/L) after a 75 g OGTT)
IO
















































































































































Papoz 1978 NI NI NI NI NI NI NI
aIn addition to definition of endpoint measurement, description who measured the outcome (AO: adjudicated outcome measurement;IO: investigator-assessed outcome
measurement; SO: self-reported outcome measurement)
2hPG: 2-hour plasma glucose; CVD: cardiovascular disease; FPG: fasting plasma glucose; IGT: impaired glucose tolerance; ND: not defined; NI: not investigated; NR: not re-



















































Cochrane Database of Systematic Reviews
Appendix 10. Definition of endpoint measurement (II)b
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
development of type 2 diabetes mellitus (Review)










































































































































NI NI NI HbA1c; fasting plasma glucose
IO
NI
Zeng 2013 NR NR NR NR NR NR Fasting plasma glucose, 2-hour plasma glucose;
Quote:" At the end, OGTT was used to judge the number
of cases of NGT, IGR and DM. Biochemical detection was
conducted by Olympus automatic biochemical instru-
ment, glucose detection by glucose oxidase method,














NI NI NI NI NI NI NI NI
Liao 2012 NR NR NR NR NR NR Fasting plasma glucose, 2-hour plasma glucose;
Quote:"At the initial visit, fasting 10-12h overnight, ve-
nous blood was taken and plasma glucose (i.e., FPG
and 2hPG) was measured after OGTT (75g glucose). The
above examination was repeated every 3 months. Blood
glucose was measured by hexokinase method (the bio-



















































































































































Ji 2011 NR NR NR NR NR NR Fasting plasma glucose, HbA1c, 2-hour plasma glucose
Quote:"All cases were followed for 2 years, outpatient
follow-up once every 2 months, patients with glucose
oxidase method is used to determination of FPG, 2h
postprandial blood glucose (2 HPG), treatment before
and after the treatment, test weight, height, and calcu-
late the BMI, waist circumference, hip circumference,
waist-to-hip ratio calculation, the determination of FPG,
FINS application of chemiluminescence analysis, appli-
cation of biochemical analyzer determination of TC, TG,
LDL cholesterol (LDL - C), immune turbidimetric method
is used to test the hs CRP, glycosylated hemoglobin
(HbA1c) levels, Meanwhile, ISI =1/ (determined value of
FINS ×FPG) was calculated. Review OGTT at the end of
treatment to determine if diabetes has developed."
IO
NR
















NR NR NR Fasting plasma glucose; 2-hour plasma glucose; HbA1c
Quote:"Venous blood was collected 8-12 hours after
fasting, and serum was isolated for determination of
blood glucose, total cholesterol, triglyceride HDL and
LDL. Blood at finger tips was used to determine glycosy-
lated hemoglobin (DS). 5 glycosylated hemoglobin ana-
lyzer).",
Quote:"Oral glucose tolerance test. On the morning of
fasting venous blood sampling, 300ml sugar water con-
taining 75g glucose was drunk within 5 minutes, and






NI NI NI NI NI NI 2-hour plasma glucose; fasting plasma glucose
IO
NI



















































































































































Jin 2009 NR NR NR NR NR NR Fasting plasma glucose, 2-hour plasma glucose;
ND














NI NI NI Hypogly-
caemia
SO, IO
NI NI 2-hour plasma glucose; fasting plasma glucose
IO
NI
Maji 2005 NI NI NI NI NI NI 2-hour plasma glucose; HbA1c; fasting plasma glucose
IO
NI






































































































































































































NI NI NI NI NI NI Fasting blood glucose, 2-hour glucose levels
IO
NI
aIn addition to definition of endpoint measurement, description who measured the outcome (AO: adjudicated outcome measurement; IO: investigator-assessed outcome
measurement; SO: self-reported outcome measurement)
BMI: body mass index; CRP: C-reactive protein; FINS: fasting insulin; FPG: fasting plasma glucose; HbA1c: glycosylated haemoglobin A1c; ISI: insulin sensitivity index; ND:
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Appendix 11. Adverse events (I)
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
development of type 2 diabetes mellitus (Review)















































































































































I: metformin 59 — — — — — —
C1: intensive diet plus exercise 73 — — — — — —
Alfawaz
2018
C2: standard care 85 — — — — — —
I1: metformin 29 0 0 10 34.4 0 0




C2: standard care 30 0 0 0 0 0 0
I: metformin 68 — — — — — —
C1: Standard care 66 — — — — — —
Zeng 2013
C2: pioglitazone 70 — — — — — —
I: metformin plus intensive diet plus ex-
ercise







Gastrointestinal symptoms: 2.2 — —Zhao 2013























































































































































I1: metformin plus intensive diet and
physical activity
95 0 0 — — — —
C1: intensive diet and physical activity 114 0 0 — — — —
Iqbal Hy-
drie 2012
C2: standard care 108 2 1.9 — — — —















I1: metformin 52 — — — — — —
C1: Intensive diet plus exercise 60 — — — — — —
Ji 2011
C2: standard care 64 — — — — — —

























abdominal discomfort and headache:
7.0
abnormal defecate: 13.9
low blood sugar: 3.5
muscle pain: 6.1
dizzy: 0.8
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abdominal discomfort and headache:
2.7
abnormal defecate: 3.6




















































Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
development of type 2 diabetes mellitus (Review)




































































































































































































































I: metformin 21 — — — — — —BIGPRO1
2009
C: placebo 36 — — — — — —
I: metformin 44 — — — — — —Chen 2009
C: standard care 46 — — — — — —



















Hypoglycaemia 0 — —
Jin 2009







































































































































































I: metformin 77 — — — — — —Li 2009
C: intensive diet plus exercise 83 — — — — — —







Gastrointestinal symptoms: 6.7 — —Wang 2009
C: standard care 32 — — — — — —
I1: metformin 128 0 0 — 0 — —
I2: metformin plus intensive diet and
physical activity
121 1 0.8 — — — —
C1: intensive exercise plus diet 120 1 0.8 — — — —
IDPP-1
2006
C2: standard care 133 1 0.8 — — — —
I1: metformin — — — — — — —
C1: intensive lifestyle intervention — — — — — — —
C2: rosiglitazone — — — — — — —
Maji 2005
C3: acarbose — — — — — — —
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I1: metformin 80 — — — — — —















C2: standard care plus diet instruction
every 6th month
64 — — — — — —
Lu 2002













(1) 9.1 — —Li 1999






























































































































































I1: metformin (plus placebo) — — — — — — —
C1: glibenclamide plus placebo — — — — — — —
Papoz
1978
C2: placebo — — — — — — —
—: denotes not reported
aAll adverse events from DPP are calculated from number of events/100 person years; some participants might have experienced more than one event. Therefore only the
number of participants with an event cannot be calculated
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I: metformin 59 — — — — — —
C1: intensive diet plus exercise 73 — — — — — —
Alfawaz
2018
C2: standard care 85 — — — — — —
I1: metformin 29 1 3.4 — — — —




C2: standard care 30 0 0 — — — —
I: metformin 68 — — — — — —
C1: Standard care 66 — — — — — —
Zeng 2013
C2: pioglitazone 70 — — — — — —
I: metformin plus intensive diet plus exercise 45 1 2.2 — — — —Zhao 2013
C: intensive diet plus exercise 46 — — — — — —
I1: metformin plus intensive diet and physical activity 95 5 5.3 — — — —
C1: intensive diet and physical activity 114 0 0 — — — —
Iqbal Hydrie
2012
C2: standard care 108 0 0 — — — —
I: metformin 51 1 2.0 — — — —Liao 2012
C: acarbose 50 2 4.0 — — — —
















































































































































C1: Intensive diet plus exercise 60 — — — — — —
C2: standard care 64 — — — — — —
I: metformin 115 21 18.3 — — — —Lu 2010
C: standard care 111 17 15.3 — — — —
I: metformin 21 — — — — — —BIGPRO1
2009
C: placebo 36 — — — — — —
I: metformin 44 — — — — — —Chen 2009
C: standard care 46 — — — — — —
I: metformin 45 3 6.7 — — — —
C1: standard care 41 — 6.7 — — — —
Jin 2009
C2: rosiglitazone 41 3 6.7 — — — —
I: metformin 77 — — — — — —Li 2009
C: intensive diet plus exercise 83 — — — — — —
I: metformin 30 2 6.7 — — — —Wang 2009
C: standard care 32 — — — — — —
I1: metformin 128 — — — — — —
I2: metformin plus intensive diet and physical activity 121 — — — — — —
C1: intensive exercise plus diet 120 — — — — — —
IDPP-1 2006
C2: standard care 133 — — — — — —
I1: metformin — — — — — — —Maji 2005
















































































































































C2: rosiglitazone — — — — — — —
C3: acarbose — — — — — — —
I: metformin 44 4 9.1 — — — —
C1: acarbose 45 5 11.1 — — — —
C2: intensive exercise and diet 36 0 0 — — — —
Fang 2004
C3: standard care 35 0 0 — — — —
I: metformin 1073 — — — — — —
C1: intensive exercise and diet 1079 — — — — — —
DPP/DPPOS
2002
C2: placebo 1082 — — — — — —
I1: metformin 80 — — — — — —
C1: standard care 75 1 1.3 — — — —
C2: standard care plus diet instruction every 6th month 64 — — — — — —
Lu 2002
C3: standard care plus fibre diet 51 1 2.0 — — — —
I: metformin 33 2 6.1 — — — —Li 1999
C: placebo 37 1 2.7 — — — —
I1: metformin (plus placebo) — — — — — — —
C1: glibenclamide plus placebo — — — — — — —
Papoz 1978
C2: placebo — — — — — — —
—: denotes not reported
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Appendix 13. Adverse events (III)
 


























I: metformin 59 — — —
C1: intensive diet plus exercise 73 — — —
Alfawaz
2018
C2: standard care 85 — — —













C2: standard care 30 0 0 0
I: metformin 68 — — —
C1: Standard care 66 — — —
Zeng 2013
C2: pioglitazone 70 — — —
I: metformin plus intensive diet
plus exercise
45 — — —Zhao 2013
C: intensive diet plus exercise 46 — — —
I1: metformin plus intensive diet
and physical activity
95 — — —
C1: intensive diet and physical
activity
114 — — —
Iqbal Hy-
drie 2012
C2: standard care 108 — — —
I: metformin 51 Cerebral haemorrhage 1 2.0Liao 2012






I1: metformin 52 — — —
C1: Intensive diet plus exercise 60 — — —
Ji 2011
C2: standard care 64 — — —
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I: metformin 115 Taste abnormalities 13 13 11.3Lu 2010
C: standard care 111 Taste abnormalities 1 1 0.9
I: metformin 21 — — —BIGPRO1
2009
C: placebo 36 — — —
I: metformin 44 — — —Chen 2009
C: standard care 46 — — —
I: metformin 45 Severe gastrointestinal reactions 3 6.7
C1: standard care 41 — — —
Jin 2009
C2: rosiglitazone 41 (1) facial oedema





I: metformin 77 — — —Li 2009
C: intensive diet plus exercise 83 — — —
I: metformin 30 — — —Wang
2009
C: standard care 32 — — —
I1: metformin 128 (1) Cardiovascular event













I2: metformin plus intensive diet
and physical activity
121 (1) Cardiovascular event








































Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
development of type 2 diabetes mellitus (Review)









Cochrane Database of Systematic Reviews
I1: metformin — — — —
C1: intensive diet plus exercise — — — —
C2: rosiglitazone — — — —
Maji 2005
C3: acarbose — — — —
I: metformin 44 (1) Diarrhea



























I: metformin 1073 — — —
C1: intensive exercise and diet 1079 — — —
DPP/DP-
POS 2002
C2: placebo 1082 — — —
I1: metformin 80 — — —
C1: standard care 75 Death (cerebral thrombosis with pul-
monary infection)
1 1.3
C2: standard care plus diet in-
struction every 6th month
64 — — —
Lu 2002
C3: standard care plus fibre diet 51 Stomach cancer 1 2.0
I: metformin 33 Mild diarrhoea and nausea 3 9.1Li 1999
C: placebo 37 (1) Mild nausea





I1: metformin (plus placebo) — — — —
C1: glibenclamide plus placebo — — — —
Papoz
1978
C2: placebo — — — —
—: denotes not reported
C: comparator; CVD: cardiovascular disease; I: intervention; N: number of participants.
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Appendix 14. Survey of authors providing information on included trials
 




















11th of August 2017 No reply Asked if they could provide additional information on the trial NA
Zeng 2013 No contact infor-
mation available
NA NA NA
Zhao 2013 5th of August 2019 NA No contact information provided in publication. Hospital was called





9th of August 2017 No reply Asked if they could provide additional information on the trial includ-
ing a trial protocol
NA
Liao 2012 5th of August 2019 NA No contact information provided in publication. Hospital was called
to get contact information on first author, no one answered the
phone.
NA
Ji 2011 5th of August 2019 No reply.0 Contacted through e-mail NA





14th of August 2017 14 August
2017



















Chen 2009 5th of June 2019 NA No contact information provided in publication. Hospital was called
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Jin 2009 No contact infor-
mation available
NA NA NA
Li 2009 5th of June 2019 NA No contact information provided in publication. Hospital was called





5th of June 2019 NA No contact information provided in publication. Hospital was called





14th of April 2015 No reply Asked for change of HbA1c and insulin level NA
Maji 2005 No contact infor-
mation available
NA NA NA









Asked for detailed number of diabetes, deaths, CVD and adverse
events.
NA
Lu 2002 5th of August 2019 NA No contact information provided in publication. Hospital was called
to get contact information on first author, colleague refused to for-
ward
NA
Li 1999 14th of April 2015 NA Asked for detailed number of CVD NA
Papoz
1978
4th of May 2016 No reply No contact information could be identified for the first author. Con-
tact information on one of the other authors was identified through
an Internet search (Dr Eschwege)
NA
CVD: cardiovascular disease; HbA1c: glycosylated haemoglobin A1c; NA: not applicable.
  (Continued)
 
Appendix 15. Checklist to aid consistency and reproducibility of GRADE assessments: metformin versus placebo or
diet and exercise
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Was random sequence generation used (i.e. no potential for
selection bias)?
Unclear Unclear Unclear Unclear Unclear Yes Unclear
Was allocation concealment used (i.e. no potential for se-
lection bias)?
Unclear Unclear Unclear Unclear Unclear Yes Unclear
Was there blinding of participants and personnel (i.e. no po-
tential for performance bias) or outcome not likely to be in-
fluenced by lack of blinding?
Yes Yes Yes Yes Yes No (↓) Yes
Was there blinding of outcome assessment (i.e. no potential
for detection bias) or was outcome measurement not likely
to be influenced by lack of blinding?
Yes Yes Yes Yes Yes No (↓) Yes
Was an objective outcome used? Yes Yes Yes Yes Yes No (↓) Yes
Were more than 80% of participants enrolled in trials in-
cluded in the analysis (i.e. no potential reporting bias)?e
Yes Yes Unclear Yes Yes Yes Yes
Were data reported consistently for the outcome of interest
(i.e. no potential selective reporting)?
Unclear Unclear No (↓) Unclear Unclear Unclear Yes





Did the trials end up as scheduled (i.e. not stopped early)? No (↓) No (↓) No (↓) No (↓) No (↓) No (↓) No (↓)
Point estimates did not vary widely? Yes Yes
To what extent did confidence intervals overlap (substan-
tial: all confidence intervals overlap at least one of the in-
cluded studies point estimate; some: confidence intervals
overlap but not all overlap at least one point estimate; no:
at least one outlier: where the confidence interval of some


































































































































































What was the magnitude of statistical heterogeneity (as
measured by I2) - low (I2< 40%), moderate (I2 40% to 60%),
high I2 > 60%)?
Low Moderate








































Was the included outcome not a surrogate outcome? Yes Yes Yes Yes Yes Yes Yes
Was the outcome timeframe sufficient? Sufficient Sufficient Sufficient Sufficient Sufficient Sufficient Sufficient
Indirect-
ness
Were the conclusions based on direct comparisons? Yes Yes Yes Yes Yes Yes Yes
Was the confidence interval for the pooled estimate not
consistent with benefit and harm?
No (↓) Yes N/A N/A
What is the magnitude of the median sample size (high: 300
participants, intermediate: 100 to 300 participants, low: <
100 participants)?e
High High High High
What was the magnitude of the number of included stud-
ies (large: >10 studies, moderate: 5 to 10 studies, small: < 5
studies)?e
Moderate Large Small (↓) Small (↓)
Impreci-
sionc













Was a comprehensive search conducted? Yes Yes Yes Yes Yes Yes Yes
Was grey literature searched? Yes Yes Yes Yes Yes Yes Yes
Were no restrictions applied to study selection on the basis
of language?
Yes Yes Yes Yes Yes Yes Yes
Publica-
tion biasd
There was no industry influence on studies included in the
review?




























































































































































There was no discrepancy in findings between published
and unpublished trials?
Unclear Unclear Unclear Unclear Unclear Unclear Unclear
aQuestions on risk of bias are answered in relation to the majority of the aggregated evidence in the meta-analysis rather than to individual trials
bQuestions on inconsistency are primarily based on visual assessment of forest plots and the statistical quantification of heterogeneity based on I2
cWhen judging the width of the confidence interval it is recommended to use a clinical decision threshold to assess whether the imprecision is clinically meaningful
dQuestions address comprehensiveness of the search strategy, industry influence, funnel plot asymmetry and discrepancies between published and unpublished trials
eDepends on the context of the systematic review area
(↓): key item for potential downgrading the quality of the evidence (GRADE) as shown in the footnotes of the 'Summary of finding' table(s); GRADE: Grading of Recommen-
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Appendix 16. Checklist to aid consistency and reproducibility of GRADE assessments: metformin versus intensive
diet plus exercise
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Was random sequence generation used (i.e. no potential for
selection bias)?
Unclear Unclear Yes Unclear Unclear Unclear
Was allocation concealment used (i.e. no potential for se-
lection bias)?
Unclear Unclear Unclear Unclear Unclear Unclear
Was there blinding of participants and personnel (i.e. no po-
tential for performance bias) or outcome not likely to be in-
fluenced by lack of blinding?
Yes Yes Yes Yes Yes Yes
Was there blinding of outcome assessment (i.e. no potential
for detection bias) or was outcome measurement not likely
to be influenced by lack of blinding?
Yes Yes Yes Yes Yes Yes
Was an objective outcome used? Yes Yes Yes Yes Yes Yes
Were more than 80% of participants enrolled in trials in-
cluded in the analysis (i.e. no potential reporting bias)?e
Yes Yes Unclear Yes Yes Yes
Were data reported consistently for the outcome of interest
(i.e. no potential selective reporting)?
Unclear Unclear No (↓) Unclear Unclear Yes





Did the trials end up as scheduled (i.e. not stopped early)? No (↓) No (↓) No (↓) No (↓) No (↓) No (↓)
Point estimates did not vary widely? Yes No (↓)
To what extent did confidence intervals overlap (substan-
tial: all confidence intervals overlap at least one of the in-
cluded studies point estimate;
some: confidence intervals overlap but not all overlap at
least one point estimate; no: at least one outlier: where the
confidence interval of some of the studies do not overlap
































































































































































What was the magnitude of statistical heterogeneity (as
measured by I2) - low (I2 < 40%), moderate (I2 40% to 60%),
high I2 > 60%)?
Low High (↓)




































Was the included outcome not a surrogate outcome? Yes Yes Yes Yes Yes Yes
Was the outcome timeframe sufficient? Sufficient Sufficient Sufficient Sufficient Sufficient Sufficient
Indirect-
ness
Were the conclusions based on direct comparisons? Yes Yes Yes Yes Yes Yes
Was the confidence interval for the pooled estimate not
consistent with benefit and harm?
No (↓) No (↓) N/A
What is the magnitude of the median sample size (high: 300
participants, intermediate: 100 to 300 participants, low: <
100 participants)?e
High High High
What was the magnitude of the number of included stud-
ies (large: >10 studies, moderate: 5 to 10 studies, small: < 5
studies)?e
Small (↓) Moderate Small (↓)
Impreci-
sionc











Was a comprehensive search conducted? Yes Yes Yes Yes Yes Yes
Was grey literature searched? Yes Yes Yes Yes Yes Yes
Were no restrictions applied to study selection on the basis
of language?
Yes Yes Yes Yes Yes Yes
Publica-
tion biasd
There was no industry influence on studies included in the
review?




























































































































































There was no discrepancy in findings between published
and unpublished trials?
Unclear Unclear Unclear Unclear Unclear Unclear
aQuestions on risk of bias are answered in relation to the majority of the aggregated evidence in the meta-analysis rather than to individual trials
bQuestions on inconsistency are primarily based on visual assessment of forest plots and the statistical quantification of heterogeneity based on I2
cWhen judging the width of the confidence interval it is recommended to use a clinical decision threshold to assess whether the imprecision is clinically meaningful
dQuestions address comprehensiveness of the search strategy, industry influence, funnel plot asymmetry and discrepancies between published and unpublished trials
eDepends on the context of the systematic review area
(↓): key item for potential downgrading the quality of the evidence (GRADE) as shown in the footnotes of the 'Summary of finding' table(s); GRADE: Grading of Recommen-



















































Cochrane Database of Systematic Reviews
Appendix 17. Checklist to aid consistency and reproducibility of GRADE assessments: metformin versus acarbose
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
development of type 2 diabetes mellitus (Review)





































































































































Was random sequence generation used (i.e. no potential for
selection bias)?
Yes Unclear Unclear
Was allocation concealment used (i.e. no potential for se-
lection bias)?
Unclear Unclear Unclear
Was there blinding of participants and personnel (i.e. no po-
tential for performance bias) or outcome not likely to be in-
fluenced by lack of blinding?
Yes Yes Yes
Was there blinding of outcome assessment (i.e. no potential
for detection bias) or was outcome measurement not likely
to be influenced by lack of blinding?
Yes Yes Yes
Was an objective outcome used? Yes Yes Yes
Were more than 80% of participants enrolled in trials in-
cluded in the analysis (i.e. no potential reporting bias)?e
Yes Yes Unclear
Were data reported consistently for the outcome of interest
(i.e. no potential selective reporting)?
Unclear Unclear No (↓)





Did the trials end up as scheduled (i.e. not stopped early)? Yes Yes Yes
Point estimates did not vary widely? Yes
To what extent did confidence intervals overlap (substan-
tial: all confidence intervals overlap at least one of the in-
cluded studies point estimate;
some: confidence intervals overlap but not all overlap at
least one point estimate; no: at least one outlier: where the
confidence interval of some of the studies do not overlap


































































































































































What was the magnitude of statistical heterogeneity (as
measured by I2) - low (I2 < 40%), moderate (I2 40% to 60%),
high I2 > 60%)?
Low





















Was the included outcome not a surrogate outcome? Yes Yes Yes
Was the outcome timeframe sufficient? Sufficient Sufficient Sufficient
Indirect-
ness
Were the conclusions based on direct comparisons? Yes Yes Yes
Was the confidence interval for the pooled estimate not





What is the magnitude of the median sample size (high: 300





What was the magnitude of the number of included stud-
ies (large: >10 studies, moderate: 5 to 10 studies, small: < 5
studies)?e
Small (↓) Small (↓) Small (↓)
Impreci-
sionc
Was the outcome a common event (e.g. occurs more than
1/100)?
No (↓) Yes Yes
Was a comprehensive search conducted? Yes Yes Yes
Was grey literature searched? Yes Yes Yes





There was no industry influence on studies included in the
review?






















































































































































There was no discrepancy in findings between published
and unpublished trials?
Unclear Unclear Unclear
aQuestions on risk of bias are answered in relation to the majority of the aggregated evidence in the meta-analysis rather than to individual trials
bQuestions on inconsistency are primarily based on visual assessment of forest plots and the statistical quantification of heterogeneity based on I2
cWhen judging the width of the confidence interval it is recommended to use a clinical decision threshold to assess whether the imprecision is clinically meaningful
dQuestions address comprehensiveness of the search strategy, industry influence, funnel plot asymmetry and discrepancies between published and unpublished trials
eDepends on the context of the systematic review area
(↓): key item for potential downgrading the quality of the evidence (GRADE) as shown in the footnotes of the 'Summary of finding' table(s); GRADE: Grading of Recommen-
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Appendix 18. Checklist to aid consistency and reproducibility of GRADE assessments: metformin versus
thiazolidinediones
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
development of type 2 diabetes mellitus (Review)





































































































































Was random sequence generation used (i.e. no potential for
selection bias)?
Unclear Unclear
Was allocation concealment used (i.e. no potential for se-
lection bias)?
Unclear Unclear
Was there blinding of participants and personnel (i.e. no po-
tential for performance bias) or outcome not likely to be in-
fluenced by lack of blinding?
Yes Yes
Was there blinding of outcome assessment (i.e. no potential
for detection bias) or was outcome measurement not likely
to be influenced by lack of blinding?
Yes Yes
Was an objective outcome used? Yes Yes
Were more than 80% of participants enrolled in trials in-
cluded in the analysis (i.e. no potential reporting bias)?e
Yes Unclear
Were data reported consistently for the outcome of interest
(i.e. no potential selective reporting)?
Unclear No (↓)





Did the trials end up as scheduled (i.e. not stopped early)? Yes Yes
Point estimates did not vary widely? Yes
To what extent did confidence intervals overlap (substan-
tial: all confidence intervals overlap at least one of the in-
cluded studies point estimate;
some: confidence intervals overlap but not all overlap at
least one point estimate; no: at least one outlier: where the
confidence interval of some of the studies do not overlap


































































































































































What was the magnitude of statistical heterogeneity (as
measured by I2) - low (I2 < 40%), moderate (I2 40% to 60%),
high I2 > 60%)?
Low

















Was the included outcome not a surrogate outcome? Yes Yes
Was the outcome timeframe sufficient? Sufficient Sufficient
Indirect-
ness
Were the conclusions based on direct comparisons? Yes Yes
Was the confidence interval for the pooled estimate not
consistent with benefit and harm?
Yes Not ap-
plicable
What is the magnitude of the median sample size (high: 300





What was the magnitude of the number of included stud-
ies (large: >10 studies, moderate: 5 to 10 studies, small: < 5
studies)?e
Small (↓) Small (↓)
Impreci-
sionc
Was the outcome a common event (e.g. occurs more than
1/100)?
Yes Yes
Was a comprehensive search conducted? Yes Yes
Was grey literature searched? Yes Yes
































































































































































aQuestions on risk of bias are answered in relation to the majority of the aggregated evidence in the meta-analysis rather than to individual trials
bQuestions on inconsistency are primarily based on visual assessment of forest plots and the statistical quantification of heterogeneity based on I2
cWhen judging the width of the confidence interval it is recommended to use a clinical decision threshold to assess whether the imprecision is clinically meaningful
dQuestions address comprehensiveness of the search strategy, industry influence, funnel plot asymmetry and discrepancies between published and unpublished trials
eDepends on the context of the systematic review area
(↓): key item for potential downgrading the quality of the evidence (GRADE) as shown in the footnotes of the 'Summary of finding' table(s); GRADE: Grading of Recommen-
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Appendix 19. Checklist to aid consistency and reproducibility of GRADE assessments: metformin plus intensive diet
and exercise versus intensive diet and exercise
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
development of type 2 diabetes mellitus (Review)





































































































































Was random sequence generation used (i.e. no potential for
selection bias)?
Unclear Unclear Unclear
Was allocation concealment used (i.e. no potential for se-
lection bias)?
Unclear Unclear Unclear
Was there blinding of participants and personnel (i.e. no po-
tential for performance bias) or outcome not likely to be in-
fluenced by lack of blinding?
Yes Yes Yes
Was there blinding of outcome assessment (i.e. no potential
for detection bias) or was outcome measurement not likely
to be influenced by lack of blinding?
Yes Yes Yes
Was an objective outcome used? Yes Yes Yes
Were more than 80% of participants enrolled in trials in-
cluded in the analysis (i.e. no potential reporting bias)?e
Yes Yes Yes
Were data reported consistently for the outcome of interest
(i.e. no potential selective reporting)?
Yes Yes Yes





Did the trials end up as scheduled (i.e. not stopped early)? No (↓) No (↓) No (↓)
Point estimates did not vary widely? No (↓)
To what extent did confidence intervals overlap (substan-
tial: all confidence intervals overlap at least one of the in-
cluded studies point estimate;
some: confidence intervals overlap but not all overlap at
least one point estimate; no: at least one outlier: where the
confidence interval of some of the studies do not overlap

































































































































































What was the magnitude of statistical heterogeneity (as
measured by I2) - low (I2 < 40%), moderate (I2 40% to 60%),
high I2 > 60%)?
High (↓)





















Was the included outcome not a surrogate outcome? Yes Yes Yes
Was the outcome timeframe sufficient? Sufficient Sufficient Sufficient
Indirect-
ness
Were the conclusions based on direct comparisons? Yes Yes Yes
Was the confidence interval for the pooled estimate not




What is the magnitude of the median sample size (high: 300







What was the magnitude of the number of included stud-
ies (large: >10 studies, moderate: 5 to 10 studies, small: < 5
studies)?e
Small (↓) Small (↓) Small (↓)
Impreci-
sionc
Was the outcome a common event (e.g. occurs more than
1/100)?
No Yes Not ap-
plicable
Was a comprehensive search conducted? Yes Yes Yes
Was grey literature searched? Yes Yes Yes




































































































































































aQuestions on risk of bias are answered in relation to the majority of the aggregated evidence in the meta-analysis rather than to individual trials
bQuestions on inconsistency are primarily based on visual assessment of forest plots and the statistical quantification of heterogeneity based on I2
cWhen judging the width of the confidence interval it is recommended to use a clinical decision threshold to assess whether the imprecision is clinically meaningful
dQuestions address comprehensiveness of the search strategy, industry influence, funnel plot asymmetry and discrepancies between published and unpublished trials
eDepends on the context of the systematic review area
(↓): key item for potential downgrading the quality of the evidence (GRADE) as shown in the footnotes of the 'Summary of finding' table(s); GRADE: Grading of Recommen-
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Appendix 20. Health-related quality of life: instruments
Metformin for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the
development of type 2 diabetes mellitus (Review)



































































































































SF-36 (G) Physical functioning (PF) (10)
Role-physical (RP) (4)
Bodily pain (BP) (2)
General health (GH) (5)
Vitality (VT) (4)
Social functioning (SF) (2)
Role-emotional (RE) (3)
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We changed the definition of the intervention "Metformin monotherapy" in our protocol to "Metformin monotherapy (with or without
diet, exercise or both)" because most trials included some element of diet, exercise or both in the intervention groups.
In our protocol, interventions in the control group did not comprise "no antidiabetic treatment". However, we found three trials comparing
metformin with this type of intervention after reading all publications. Therefore, we extracted and analysed the data from these trials.
In our protocol we stated that we planned to do subgroup analyses on 'type of comparator (active comparator or placebo/no interven-
tion)'. This subgroup analysis was changed to 'trials designed to blind participants and investigators versus open-labelled trials' to better
address issues of risk of bias.
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